Study Status,Study Results,Interventions,Sex,Age,Phases,Enrollment,Funder Type,Study Design,Start Date,Completion Date
COMPLETED,NO,"RADIATION: [14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)|DRUG: AZD9833 film-coated tablet A Dose 1|DRUG: AZD9833 Oral Solution|DRUG: AZD9833 film-coated tablet B Dose 1|DRUG: AZD9833 film-coated tablet A Dose 2|DRUG: AZD9833 film-coated tablet B Dose 2",FEMALE,"ADULT, OLDER_ADULT",PHASE1,32,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-17,2021-01-07
RECRUITING,NO,DRUG: Paclitaxel|DRUG: Nilotinib,ALL,"ADULT, OLDER_ADULT",PHASE2,70,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10-13,2031-12-30
NOT_YET_RECRUITING,NO,DRUG: chidamide combined with fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE2,23,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05-01,2024-11-01
RECRUITING,NO,OTHER: patient education,FEMALE,"ADULT, OLDER_ADULT",NA,52,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2022-07-01,2023-04-01
RECRUITING,NO,OTHER: rhomboid intercostal block|OTHER: serratus anterior plane block,FEMALE,ADULT,PHASE2|PHASE3,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-09-01,2022-12-30
RECRUITING,NO,BEHAVIORAL: Motivational Interviewing (MI)|BEHAVIORAL: Cognitive Behavioural Therapy (CBT)|BEHAVIORAL: Hypnotherapy|DRUG: Nicotine Replacement Therapy (NRT),ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-29,2023-09
NOT_YET_RECRUITING,NO,BIOLOGICAL: Fluzone Quadrivalent,ALL,"ADULT, OLDER_ADULT",PHASE1,18,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02-01,2025-12-31
RECRUITING,NO,PROCEDURE: RIB,FEMALE,"ADULT, OLDER_ADULT",NA,254,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-09-07,2025-01
WITHDRAWN,NO,BEHAVIORAL: Decision Making Support Tool,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: SCREENING,2022-01-04,2022-06-30
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody,ALL,"ADULT, OLDER_ADULT",PHASE1,9,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-18,2024-09-22
RECRUITING,NO,DRUG: Fenofibrate|OTHER: Placebo|DRUG: Doxorubicin|DRUG: Cyclophosphamide,FEMALE,"ADULT, OLDER_ADULT",PHASE4,44,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-12,2025-12
SUSPENDED,NO,BIOLOGICAL: chimeric antigen receptor (CAR) T cell therapy,ALL,"ADULT, OLDER_ADULT",PHASE1,220,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-07,2027-01-02
RECRUITING,NO,DIETARY_SUPPLEMENT: Nicotinamide Riboside|DIETARY_SUPPLEMENT: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-03-16,2035-09-30
TERMINATED,NO,DEVICE: TENS (transcutaneous electrical nerve stimulation)|DEVICE: TENS (transcutaneous electrical nerve stimulation) ECOMODYN,ALL,"ADULT, OLDER_ADULT",NA,5,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-01-05,2023-04-14
COMPLETED,NO,OTHER: Pecs block|OTHER: no Pecs block,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-08-01,2022-03-31
UNKNOWN,NO,DRUG: Recombinant L-IFN adenovirus injection,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,28,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-30,2023-12-31
RECRUITING,NO,DRUG: DB-1303/BNT323|DRUG: Capecitabine|DRUG: Paclitaxel|DRUG: Nab-paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE3,532,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-18,2028-05
RECRUITING,NO,DRUG: Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-15,2026-12-31
RECRUITING,NO,DIAGNOSTIC_TEST: 89Zr-DFO*-trastuzumab PET scan,ALL,"ADULT, OLDER_ADULT",PHASE1,6,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-06-26,2024-04-30
TERMINATED,NO,DRUG: LYT-100 MAD|OTHER: Matching Placebo for MAD|DRUG: LYT-100 Food Effect|DRUG: LYT-100 BCRL|DRUG: Placebo BCRL|DRUG: Placebo Food Effect,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,50,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-03-01,2022-09-09
ACTIVE_NOT_RECRUITING,NO,"COMBINATION_PRODUCT: Atezolizumab,Paclitaxel, Carboplatin",ALL,"ADULT, OLDER_ADULT",PHASE2,49,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-03,2024-07-03
RECRUITING,NO,PROCEDURE: Axilla dissection + Lymphovenous anastomosis,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-06-30,2025-12-27
ACTIVE_NOT_RECRUITING,NO,DRUG: Simvastatin 80mg,FEMALE,"ADULT, OLDER_ADULT",PHASE2,5,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-04,2030-12
COMPLETED,NO,OTHER: Stage of Decision Making|OTHER: Choice framing|OTHER: Opportunity Framing,FEMALE,ADULT,NA,3000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-06-22,2022-09-05
NOT_YET_RECRUITING,NO,PROCEDURE: Breast Surgery (BCS or mastectomy) with TAD/SNB|RADIATION: Adjuvant Radiation Therapy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,45,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02-28,2031-01
UNKNOWN,NO,DRUG: INT230-6|OTHER: Saline injection,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE2,90,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-25,2023-03-01
RECRUITING,NO,BIOLOGICAL: EGFR/B7H3 CAR-T,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-01,2025-05-01
UNKNOWN,NO,"DRUG: Eribulin,cisplatin|DRUG: Gemcitabine,cisplatin",FEMALE,"ADULT, OLDER_ADULT",PHASE2,160,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-08,2022-10-31
ENROLLING_BY_INVITATION,NO,DRUG: Camrelizumab+Fluzoparib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,94,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10-01,2026-12-31
UNKNOWN,NO,BEHAVIORAL: Education program on healthy habits,ALL,"ADULT, OLDER_ADULT",NA,58,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-06,2021-11
RECRUITING,NO,DRUG: Drug determined by treating oncologist based on recommendation from systems biology analysis.,ALL,"ADULT, OLDER_ADULT",PHASE2,74,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-08,2025-07
ACTIVE_NOT_RECRUITING,NO,DRUG: Erlotinib|DRUG: Trastuzumab|DRUG: Trastuzumab emtansine|DRUG: Pertuzumab|DRUG: Lapatinib|DRUG: Everolimus|DRUG: Vemurafenib|DRUG: Cobimetinib|DRUG: Alectinib|DRUG: Brigatinib|DRUG: Palbociclib|DRUG: Ponatinib|DRUG: Vismogedib|DRUG: Itacitinib|DRUG: Ipatasertib|DRUG: Entrectinib|DRUG: Atezolizumab|DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Pemigatinib|DRUG: Oncology Drugs|DRUG: Pralsetinib|DRUG: Selpercatinib|DRUG: Talazoparib|DRUG: Tepotinib|DRUG: Alpelisib,ALL,"ADULT, OLDER_ADULT",PHASE2,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-07,2025-06
RECRUITING,NO,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Biospecimen Collection|BIOLOGICAL: Sacituzumab Govitecan,ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-02,2028-10-01
NOT_YET_RECRUITING,NO,DEVICE: The RJBC-APP|OTHER: Routine post-surgical follow-up,FEMALE,"ADULT, OLDER_ADULT",NA,490,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-08-01,2026-08-01
RECRUITING,NO,DRUG: Neratinib|DRUG: Letrozole (L) or Anastrozole (A)|DRUG: Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-21,2024-02
ACTIVE_NOT_RECRUITING,NO,OTHER: Best Practice|OTHER: Informational Intervention|OTHER: Medical Device Usage and Evaluation|OTHER: Quality-of-Life Assessment|OTHER: Survey Administration,FEMALE,"ADULT, OLDER_ADULT",NA,33,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-10-22,2024-12-31
COMPLETED,NO,OTHER: Questionnaire,FEMALE,"ADULT, OLDER_ADULT",NA,102,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-10-06,2022-02-01
ACTIVE_NOT_RECRUITING,NO,DRUG: PY159 Single agent dose level 1|DRUG: PY159 Single agent dose level 2|DRUG: PY159 Single agent dose level 3|DRUG: PY159 Single agent dose level 4|DRUG: PY159 Single agent dose level 5|DRUG: PY159 Single agent dose level 6|DRUG: PY159 Single agent dose level 7|DRUG: PY159/Pembrolizumab Combination dose level 1|DRUG: PY159/Pembrolizumab Combination dose level 2|DRUG: PY159/Pembrolizumab Combination dose level 3|DRUG: PY159/Pembrolizumab Combination dose level 4|DRUG: PY159 Single agent dose expansion cohort|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 1|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 2|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 3|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 4|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 5|DRUG: PY159/Pembrolizumab Combination dose expansion cohort 6,ALL,"ADULT, OLDER_ADULT",PHASE1,343,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-10,2025-12
NOT_YET_RECRUITING,NO,DIAGNOSTIC_TEST: Dedicated breast CT(BCT),FEMALE,"ADULT, OLDER_ADULT",NA,600,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-01,2027-12
NOT_YET_RECRUITING,NO,OTHER: SOCIO-AESTHETICS care,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-03,2027-04
UNKNOWN,NO,COMBINATION_PRODUCT: ImmunicomAIAC,ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-24,2022-12-30
UNKNOWN,NO,DRUG: GB491+ Fulvestrant|DRUG: Placebo+Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE3,270,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-09-10,2024-01-31
NOT_YET_RECRUITING,NO,DRUG: Anlotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-01,2024-05-01
NOT_YET_RECRUITING,NO,DRUG: PLX038,ALL,"ADULT, OLDER_ADULT",PHASE2,44,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02-13,2026-02-15
RECRUITING,NO,DRUG: DS-1103a|DRUG: T-DXd,ALL,"ADULT, OLDER_ADULT",PHASE1,78,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-30,2026-06-30
RECRUITING,NO,DRUG: GSK4381562|DRUG: Dostarlimab|DRUG: GSK4428859A,ALL,"ADULT, OLDER_ADULT",PHASE1,162,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-22,2026-10-14
ACTIVE_NOT_RECRUITING,NO,DRUG: BI-1607|DRUG: BI-1607|DRUG: Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,18,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-28,2024-04
RECRUITING,NO,PROCEDURE: omission of SLNB,FEMALE,"ADULT, OLDER_ADULT",NA,350,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-13,2028-01
RECRUITING,NO,DRUG: Palbociclib 125mg,FEMALE,"ADULT, OLDER_ADULT",PHASE2,46,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-02,2031-09-01
RECRUITING,NO,DRUG: ipilimumab +pembrolizumab +durvalumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-01,2025-10-30
NOT_YET_RECRUITING,NO,OTHER: WCM app,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-01,2026-01
RECRUITING,NO,BEHAVIORAL: MIND Diet Intervention Group|BEHAVIORAL: General Health Curriculum (GHC) Group,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-08-01,2025-06
NOT_YET_RECRUITING,NO,DRUG: Calendula Ointment|OTHER: Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|OTHER: Polyethylene Glycol Hydrogel|DRUG: Silicone-based Film Forming Topical Gel|DRUG: Silver Sulfadiazine|DRUG: Topical Hydrocortisone,ALL,"ADULT, OLDER_ADULT",NA,92,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2024-01-01,2025-07-01
ACTIVE_NOT_RECRUITING,NO,DRUG: ZW25 (Zanidatamab)|DRUG: Palbociclib|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE2,51,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-10,2025-10-26
RECRUITING,NO,BEHAVIORAL: Genetic Testing and Counseling|BEHAVIORAL: Screening Form,FEMALE,"ADULT, OLDER_ADULT",NA,1000,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2022-11-18,2027-02-02
RECRUITING,NO,DRUG: SLN mapping using technetium-99m +/- isosulfan blue dye|DEVICE: SLN mapping with ICG fluorescence using the Asimov Platform,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-04-13,2024-03
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Mobile phone app + patient navigation,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2021-05-03,2025-06
COMPLETED,NO,BEHAVIORAL: Fasting,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-07-24,2022-07-05
NOT_YET_RECRUITING,NO,DRUG: LY4101174,ALL,"ADULT, OLDER_ADULT",PHASE1,280,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-29,2027-03-04
RECRUITING,NO,DRUG: ST316,ALL,"ADULT, OLDER_ADULT",PHASE1,156,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-05,2027-05-31
TERMINATED,NO,DRUG: Ribociclib,FEMALE,"ADULT, OLDER_ADULT",PHASE4,21,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-05-20,2023-10-30
RECRUITING,NO,DEVICE: Receives SCOUT at biopsy,FEMALE,"ADULT, OLDER_ADULT",NA,500,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04-01,2025-03
RECRUITING,NO,DRUG: Alpelisib 150 MG Oral Tablet [Piqray]|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE2,130,NETWORK,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-02,2028-03
RECRUITING,NO,DRUG: Abemaciclib|PROCEDURE: Therapeutic Conventional Surgery,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-10,2024-07-31
UNKNOWN,NO,DRUG: Lymphoseek|DRUG: Nanocoll,ALL,"ADULT, OLDER_ADULT",PHASE4,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-03,2021-08
RECRUITING,NO,DRUG: Pegylated liposomal doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamid|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Docetaxel,FEMALE,"ADULT, OLDER_ADULT",NA,204,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-07-01,2025-09
RECRUITING,NO,"DRUG: KK-LC-1 TCR-T cells|DRUG: Aldesleukin 720,000 IU/kg IV every eight hours",ALL,"ADULT, OLDER_ADULT",PHASE1,42,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-26,2028-12-31
RECRUITING,NO,OTHER: Assessment tool IA3-CP with SDoH|OTHER: Assessment tool IA3-CP without SDoH,ALL,OLDER_ADULT,NA,35,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2024-12,2026-12
NOT_YET_RECRUITING,NO,DRUG: Sintilimab,FEMALE,ADULT,PHASE2,49,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03,2024-03
RECRUITING,NO,COMBINATION_PRODUCT: radiation combined with pyrotinib and capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,362,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-01,2025-09-30
RECRUITING,NO,DRUG: AMXT1501|DRUG: DFMO,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,56,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-29,2024-09-30
TERMINATED,NO,DRUG: AC682,FEMALE,"ADULT, OLDER_ADULT",PHASE1,6,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10-01,2023-09-28
RECRUITING,NO,DRUG: SKB264|DRUG: KL-A167,ALL,"ADULT, OLDER_ADULT",PHASE2,175,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-17,2025-07
COMPLETED,NO,OTHER: Remedial exercise|OTHER: Compression bandage,FEMALE,"ADULT, OLDER_ADULT",NA,34,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-14,2023-02-28
RECRUITING,NO,RADIATION: internal mammary nodal irradiation|RADIATION: no internal mammary nodal irradiation,FEMALE,"ADULT, OLDER_ADULT",PHASE3,2000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-08,2024-05
NOT_YET_RECRUITING,NO,DRUG: Pyrotinib and Trastuzumab,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09-20,2026-11-30
RECRUITING,NO,RADIATION: Radiation Therapy to partial breast,FEMALE,"ADULT, OLDER_ADULT",NA,380,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-03,2028-12
RECRUITING,NO,RADIATION: Locoregional radiation treatment - Conventional fractionation|RADIATION: Locoregional radiation treatment - Hypofractionation,ALL,"ADULT, OLDER_ADULT",PHASE3,588,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-10,2030-12-31
COMPLETED,NO,PROCEDURE: Manual lymphatic drainage|PROCEDURE: Manual lymphatic drainage,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,28,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-03-01,2022-10-27
RECRUITING,NO,PROCEDURE: breast conservative surgery for post chemotherapy tumour size,FEMALE,ADULT,NA,1,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-01,2024-12-01
WITHDRAWN,NO,RADIATION: Partial Chest Wall Radiation Therapy,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-15,2029-08
NOT_YET_RECRUITING,NO,DRUG: Standard endocrine therapy plus Apatinib,FEMALE,"ADULT, OLDER_ADULT",PHASE3,916,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-01,2026-06-01
WITHDRAWN,NO,DRUG: GW572016,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-31,2023-07-31
NOT_YET_RECRUITING,NO,DRUG: Alkaline Glucosodiene Molecules,FEMALE,ADULT,PHASE1,2,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-01-01,2024-12-31
RECRUITING,NO,PROCEDURE: Biopsy|PROCEDURE: Contrast-Enhanced Mammography|OTHER: Questionnaire Administration|OTHER: Radioactive Iodine,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-04-08,2026-03-01
ACTIVE_NOT_RECRUITING,NO,OTHER: Breast Reconstruction Education and Support Tool (BREASTChoice)|OTHER: Attention Control Website|OTHER: Clinician Survey,FEMALE,"ADULT, OLDER_ADULT",NA,412,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-11-04,2023-06-30
RECRUITING,NO,DRUG: Monosialotetrahexosyl ganglioside (GM1)|DRUG: Control,ALL,"ADULT, OLDER_ADULT",PHASE3,204,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-05-15,2024-12-31
UNKNOWN,NO,OTHER: Manual lymph drainage.|PROCEDURE: Coban compression bandage..|DEVICE: Adjustable Compression Sleeve,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-10-30,2022-01-31
RECRUITING,NO,DEVICE: Colli-Pee UAS devices,ALL,"ADULT, OLDER_ADULT",NA,200,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-12-21,2024-04
RECRUITING,NO,PROCEDURE: Near infrared fluorescence navigated sentinel lymph node mapping,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-04-08,2023-04-07
NOT_YET_RECRUITING,NO,DRUG: M1774|DRUG: Fulvestrant injection,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,57,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-04-01,2027-09-15
RECRUITING,NO,DRUG: Olaparib tablet|DRUG: Navitoclax,FEMALE,"ADULT, OLDER_ADULT",PHASE1,36,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-09,2025-04-28
RECRUITING,NO,BIOLOGICAL: DB-1303|DRUG: Pertuzumab Injection|DRUG: Ritonavir|DRUG: Itraconazole,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,631,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-31,2025-10
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: IntelliCare|BEHAVIORAL: Psychoeducation|BEHAVIORAL: Coaching,FEMALE,"ADULT, OLDER_ADULT",NA,314,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-09-27,2024-11-30
NOT_YET_RECRUITING,NO,DRUG: Trastuzumab Emtansine for Injection|DRUG: Pyrotinib Maleate Tablets,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-30,2025-08-23
COMPLETED,NO,DRUG: Margetuximab Margetuximab-IV,ALL,"ADULT, OLDER_ADULT",PHASE1,16,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-25,2021-04-27
SUSPENDED,NO,OTHER: Fasting Mimicking diet program,ALL,"ADULT, OLDER_ADULT",PHASE3,10,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-17,2024-01-01
RECRUITING,NO,DRUG: Elacestrant,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05-19,2025-08
RECRUITING,NO,PROCEDURE: malignant fungating wounds care regimen,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-24,2024-07-30
NOT_YET_RECRUITING,NO,DRUG: Olaparib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-01,2024-09-01
RECRUITING,NO,BEHAVIORAL: Group 1|BEHAVIORAL: Group 2|BEHAVIORAL: Group 3,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,225,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-10-12,2028-12-31
RECRUITING,NO,OTHER: Online physiotherapy protocol based on pain neuroscience education and gradual exposure to movement.,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-01,2024-12-01
RECRUITING,NO,DRUG: Dato-DXd|DRUG: Durvalumab|DRUG: Pembrolizumab|DRUG: Doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Capecitabine|DRUG: Olaparib,ALL,"ADULT, OLDER_ADULT",PHASE3,1728,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-14,2030-08-28
RECRUITING,NO,BEHAVIORAL: DOULA-AC 1,FEMALE,"ADULT, OLDER_ADULT",NA,5,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-03-13,2024-06
RECRUITING,NO,PROCEDURE: Axillary lymph node dissection|RADIATION: Axillary radiotherapy|RADIATION: Breast or chest wall radiotherapy,ALL,"ADULT, OLDER_ADULT",NA,1900,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-26,2030-02-28
RECRUITING,NO,DRUG: Tobemstomig|DRUG: Pembrolizumab|DRUG: Nab-Paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE2,160,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-07-18,2026-02-27
COMPLETED,NO,OTHER: Hydrating emollient for acute radiodermatitis|OTHER: Standard institutional skin care,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-02-01,2023-06-13
RECRUITING,NO,BEHAVIORAL: Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-07-21,2024-06-30
RECRUITING,NO,BIOLOGICAL: Pembrolizumab|COMBINATION_PRODUCT: MK-0482 + Pembrolizumab|COMBINATION_PRODUCT: MK-4830 + Pembrolizumab,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,15,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-07-26,2031-12
RECRUITING,NO,DRUG: Minoxidil|DRUG: Minoxidil|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-03-01,2024-12-31
RECRUITING,NO,DRUG: trastuzumab-emtansine|DRUG: Trastuzumab SC|DRUG: Paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE2,500,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-16,2028-05-01
COMPLETED,NO,OTHER: The expert assessment of shoulder impairments and individualised treatment plan|OTHER: A minimal physiotherapeutic rehabilitation program delivered in a pamphlet,FEMALE,"ADULT, OLDER_ADULT",NA,31,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-04-04,2022-10-10
RECRUITING,NO,DRUG: Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet|DRUG: Goserelin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-01,2024-12-01
COMPLETED,NO,DIAGNOSTIC_TEST: Odour sampling,FEMALE,"ADULT, OLDER_ADULT",NA,196,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-02-03,2023-04-25
COMPLETED,NO,DEVICE: low level laser in addition to diet recommendations|OTHER: sham laser application in addition to diet recommendations,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2020-07-01,2023-04-01
NOT_YET_RECRUITING,NO,DRUG: Tenalisib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-26,2025-03
COMPLETED,NO,OTHER: Characterization of Neuromuscular Function and Fatigue,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-09-29,2021-09-06
NOT_YET_RECRUITING,NO,DRUG: chidamide|DRUG: camrelizumab|DRUG: carboplatin|DRUG: capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-10,2024-07-10
RECRUITING,NO,DRUG: Palbociclib|DRUG: Cetuximab|DRUG: Fulvestrant|DRUG: Letrozole,ALL,"ADULT, OLDER_ADULT",PHASE2,35,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-07,2026-04-19
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Navigation|OTHER: Information only,FEMALE,"ADULT, OLDER_ADULT",NA,540,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-10-16,2024-12
RECRUITING,NO,DEVICE: Paxman Scalp Cooling System|DRUG: Eribulin|DRUG: Sacituzumab govitecan|DRUG: Trastuzumab deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-10-07,2026-06-01
WITHDRAWN,NO,PROCEDURE: cryoablation,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-16,2023-09-01
RECRUITING,NO,COMBINATION_PRODUCT: PECS II combined with intercostal nerve blockade;|COMBINATION_PRODUCT: General anesthesia with laryngeal mask,FEMALE,"ADULT, OLDER_ADULT",NA,96,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-10-15,2024-02-28
RECRUITING,NO,DRUG: STX-478|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,220,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-17,2026-06-01
RECRUITING,NO,DEVICE: Robotic NSM|PROCEDURE: Open NSM,FEMALE,"ADULT, OLDER_ADULT",NA,204,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-08,2026-12
RECRUITING,NO,DRUG: [68Ga]Ga-NeoB|DRUG: [177Lu]Lu-NeoB|DRUG: Ribociclib|DRUG: fulvestrant|OTHER: Goserelin,FEMALE,"ADULT, OLDER_ADULT",PHASE1,42,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-13,2029-10-26
RECRUITING,NO,PROCEDURE: core needle biopsy|OTHER: blood draw,FEMALE,"ADULT, OLDER_ADULT",NA,42,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-11-06,2028-11
RECRUITING,NO,DRUG: Trastuzumab deruxtecan|DRUG: Valemetostat,ALL,"ADULT, OLDER_ADULT",PHASE1,37,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-09,2032-12-31
UNKNOWN,NO,DRUG: Eribulin|DRUG: Tislelizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,265,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-27,2023-06-01
ENROLLING_BY_INVITATION,NO,OTHER: Survivorship Care Plan|OTHER: Educational Intervention|OTHER: Questionnaire Administration,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2020-02-19,2025-12-31
RECRUITING,NO,DRUG: ST101|DRUG: Temozolomide|RADIATION: Radiation,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,162,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-01,2025-12
RECRUITING,NO,DEVICE: Magnetic seed localization,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-15,2028-12-31
RECRUITING,NO,DRUG: ELVN-002|DRUG: Fam-Trastuzumab Deruxtecan-Nxki|DRUG: Trastuzumab emtansine,ALL,"ADULT, OLDER_ADULT",PHASE1,178,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-20,2026-07
WITHDRAWN,NO,DRUG: Lorcaserin|DRUG: Lorcaserin Hydrochloride|OTHER: Questionnaire Administration,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-01,2021-12-31
RECRUITING,NO,DRUG: Paclitaxel Micelles for Injection|DRUG: Paclitaxel injection,ALL,"ADULT, OLDER_ADULT",PHASE1,98,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-04,2023-03-01
RECRUITING,NO,DRUG: Sacituzumab Govitecan|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05-23,2024-03-29
RECRUITING,NO,RADIATION: Entire supraclavicular lymph node radiotherapy|RADIATION: Medial supraclavicular lymph node radiotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1650,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-20,2027-08
RECRUITING,NO,DRUG: TFX06 tablet,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,74,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-17,2025-04-30
RECRUITING,NO,PROCEDURE: Omission of intraoperative frozen section biopsy for margin status|PROCEDURE: Frozen section biopsy for margin status,FEMALE,"ADULT, OLDER_ADULT",NA,1292,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-24,2026-06
NOT_YET_RECRUITING,NO,DRUG: TSL-1502 capsules(low dose)|DRUG: TSL-1502 capsules(high dose)|DRUG: Investigator's choice of chemotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,125,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-01,2026-06-30
NOT_YET_RECRUITING,NO,DRUG: HRS-8080; SHR-A1811|DRUG: HRS-8080; SHR-A2009|DRUG: SHR-A2009; SHR-1316,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,350,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01,2026-10-31
RECRUITING,NO,DRUG: IMM2902,ALL,"ADULT, OLDER_ADULT",PHASE1,135,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-20,2024-12
RECRUITING,NO,DRUG: ARV-471|DRUG: Abemaciclib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-23,2025-12-03
COMPLETED,NO,"OTHER: Equity Dashboard, Population Health Coordinator and Community Health Worker Support|OTHER: Equity Dashboard and Population Health Coordinator Support",ALL,"ADULT, OLDER_ADULT",NA,10766,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-03-24,2023-04-30
RECRUITING,NO,BIOLOGICAL: CEA-targeted CAR-T cells|BIOLOGICAL: CEA-targeted CAR-T cells,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-06,2026-12-31
COMPLETED,NO,DEVICE: HoloLens v2,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-08-02,2023-09-30
RECRUITING,NO,OTHER: Precision Medicine|OTHER: Physican Decision Making,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-16,2026-08
NOT_YET_RECRUITING,NO,DIETARY_SUPPLEMENT: Creatine supplementation|OTHER: Resistance training,ALL,ADULT,NA,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE,2024-01-08,2025-12-08
RECRUITING,NO,OTHER: Consultation of a Web Platform,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE,2022-06-22,2025-04-01
RECRUITING,NO,PROCEDURE: Near infrared fluorescence navigated sentinel lymph node mapping,ALL,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2022-04-08,2023-04-07
RECRUITING,NO,DRUG: IMT-009,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,119,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-28,2025-04
RECRUITING,NO,DRUG: Capecitabine|COMBINATION_PRODUCT: Sarilumab 150mg or 200 mg plus Capecitabine|COMBINATION_PRODUCT: Sarilumab 150mg plus Capecitabine,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,65,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-26,2026-11-03
ACTIVE_NOT_RECRUITING,NO,DRUG: NC762,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-30,2024-10
RECRUITING,NO,DEVICE: Selene,FEMALE,"ADULT, OLDER_ADULT",NA,333,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-12-01,2024-12
RECRUITING,NO,OTHER: DPD activity assessment|DRUG: Capecitabine,FEMALE,"ADULT, OLDER_ADULT",NA,155,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-07-20,2026-04
RECRUITING,NO,DRUG: Atezolizumab Injection|DRUG: Ipatasertib|DRUG: Bevacizumab|DRUG: Pertuzumab|DRUG: Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE2,210,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-24,2025-02
TERMINATED,NO,DRUG: Carelizumab|DRUG: Nab-paclitaxel|DRUG: Apatinib,FEMALE,"ADULT, OLDER_ADULT",PHASE3,80,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-14,2023-04-14
RECRUITING,NO,BIOLOGICAL: Double Recombinant Vaccinia Virus VV-GMCSF-Lact,FEMALE,"ADULT, OLDER_ADULT",PHASE1,73,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-11,2024-05-05
ACTIVE_NOT_RECRUITING,NO,OTHER: Supervised Training|OTHER: Individually tailored home program,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-07-01,2024-07
ACTIVE_NOT_RECRUITING,NO,DRUG: Margetuximab|DRUG: Trastuzumab|DRUG: Chosen Chemotherapy (Capecitabine)|DRUG: Chosen Chemotherapy (Vinorelbine )|DRUG: Chosen Chemotherapy (Gemcitabine ),ALL,"ADULT, OLDER_ADULT",PHASE2,123,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-13,2023-12
RECRUITING,NO,OTHER: Respiratory gating,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2023-03-02,2023-06-15
COMPLETED,NO,OTHER: Family History education|OTHER: Patient Ambassador,FEMALE,"ADULT, OLDER_ADULT",NA,196,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-04-01,2022-09-30
RECRUITING,NO,OTHER: WEB-Application|OTHER: Standard accompaniment,FEMALE,"ADULT, OLDER_ADULT",NA,438,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-09-03,2025-03-03
SUSPENDED,NO,DRUG: Pertuzumab and tratuzumab fixed dose combination|DRUG: Trastuzumab emtansine,ALL,"ADULT, OLDER_ADULT",PHASE2,1065,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-17,2029-03
NOT_YET_RECRUITING,NO,"DEVICE: SmartXIDE2V2LR, Monalisa Touch, DEKA, Florence, Italy",FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2024-03-01,2025-07-30
RECRUITING,NO,DRUG: Trastuzumab deruxtecan|DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Ribociclib|DRUG: Letrozole|DRUG: Epirubicin|DRUG: Cyclophosphamide,ALL,"ADULT, OLDER_ADULT",PHASE2,370,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-09,2031-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Abemaciclib|DRUG: Aromatase Inhibitors,FEMALE,"ADULT, OLDER_ADULT",PHASE2,31,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-07,2023-12
RECRUITING,NO,DRUG: (Z)-endoxifen|DRUG: exemestane|DRUG: goserelin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,180,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-14,2026-09
UNKNOWN,NO,PROCEDURE: Oncoplastic technique with a droplet-shaped glandular flap,FEMALE,"ADULT, OLDER_ADULT",NA,109,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-18,2022-11
RECRUITING,NO,DRUG: ARX788,ALL,"ADULT, OLDER_ADULT",PHASE2,71,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-26,2026-12
TERMINATED,NO,PROCEDURE: SpotTM Tattoo Ink,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-12-29,2023-04-13
RECRUITING,NO,DIAGNOSTIC_TEST: Drug: 68Ga-P16-093,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-11-15,2024-12-31
ACTIVE_NOT_RECRUITING,NO,DEVICE: Colli-Pee UAS devices,ALL,"ADULT, OLDER_ADULT",NA,105,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-06-18,2023-12
RECRUITING,NO,RADIATION: SBRT anticipated boost,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-01,2026-12-31
NOT_YET_RECRUITING,NO,OTHER: Acupuncture treatment|OTHER: Sham acupuncture treatment,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-12-01,2027-12-01
ACTIVE_NOT_RECRUITING,NO,DRUG: GQ1001+pyrotinib|DRUG: pyrotinib+capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,75,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-01,2024-01-01
RECRUITING,NO,DRUG: OP-1250|DRUG: Ribociclib|DRUG: Alpelisib,ALL,"ADULT, OLDER_ADULT",PHASE1,90,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-31,2024-08-31
RECRUITING,NO,DEVICE: Bilateral MARIA scan,FEMALE,"ADULT, OLDER_ADULT",NA,800,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-02-16,2022-10-31
NOT_YET_RECRUITING,NO,OTHER: Resistance Therapeutic Exercise,FEMALE,"ADULT, OLDER_ADULT",NA,170,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2024-08,2027-01-15
RECRUITING,NO,OTHER: MOve-ABC|OTHER: Enhanced Usual Care,FEMALE,"ADULT, OLDER_ADULT",PHASE1,75,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-11,2024-06
ENROLLING_BY_INVITATION,NO,DRUG: Silymarin|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,56,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-10-28,2024-10-28
RECRUITING,NO,RADIATION: Pencil Beam Scanning Proton Therapy,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-07-07,2027-07-07
ACTIVE_NOT_RECRUITING,NO,DRUG: Curcumin,ALL,"ADULT, OLDER_ADULT",PHASE1,22,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-29,2024-03-31
COMPLETED,NO,DRUG: Niraparib|DRUG: Aromatase Inhibitors,ALL,"ADULT, OLDER_ADULT",PHASE2,14,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-15,2023-11-17
NOT_YET_RECRUITING,NO,PROCEDURE: Biospecimen Collection|PROCEDURE: Mammography|DRUG: Omega-3-Acid Ethyl Esters|OTHER: Questionnaire Administration|PROCEDURE: Random Periareolar Fine-Needle Aspiration|DRUG: Tamoxifen,FEMALE,"ADULT, OLDER_ADULT",PHASE2,66,NIH,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2024-06-16,2027-01-01
COMPLETED,NO,OTHER: costotransverse block,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-01-06,2020-04-29
COMPLETED,NO,OTHER: Resource Matching|OTHER: Usual Care,ALL,"ADULT, OLDER_ADULT",NA,125,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-05-17,2023-04-01
RECRUITING,NO,OTHER: e-PRO Intervention|DRUG: Pravastatin,ALL,"ADULT, OLDER_ADULT",PHASE2,105,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-28,2025-06-30
COMPLETED,NO,OTHER: oral cryotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,54,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-07-21,2021-05-17
RECRUITING,NO,DEVICE: Tissue Marker Clip,FEMALE,"ADULT, OLDER_ADULT",NA,332,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-15,2025-07-15
RECRUITING,NO,BEHAVIORAL: Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN),FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-06-15,2025-03
RECRUITING,NO,DRUG: Sacituzumab Govitecan|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,260,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-14,2026-10
RECRUITING,NO,DRUG: B013+Nab-Paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,450,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-06,2026-12-31
NOT_YET_RECRUITING,NO,BEHAVIORAL: Aerobic Exercise Training|OTHER: Health Education (Active comparator)|PROCEDURE: Magnetic Resonance Imaging|OTHER: Medical Device Usage and Evaluation,FEMALE,"ADULT, OLDER_ADULT",NA,160,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2024-03-01,2027-07-31
RECRUITING,NO,BIOLOGICAL: α-lactalbumin vaccine|BIOLOGICAL: Zymosan,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,45,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-01,2024-09-01
RECRUITING,NO,PROCEDURE: Harmonic motion imaging,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-06-14,2024-01
RECRUITING,NO,DEVICE: Wavelia #2,FEMALE,"ADULT, OLDER_ADULT",NA,103,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-03-09,2024-11-30
RECRUITING,NO,DRUG: Ipatasertib 300mg|DRUG: Fulvestrant 500g|DRUG: Palbociclib 75mg-125mg|DRUG: CDK4/6 Inhibitor,ALL,"ADULT, OLDER_ADULT",PHASE2,324,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-28,2026-09
NOT_YET_RECRUITING,NO,DRUG: Disitamab Vedotin|DRUG: Toripalimab,ALL,"ADULT, OLDER_ADULT",PHASE2,80,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-20,2026-04-10
ACTIVE_NOT_RECRUITING,NO,DEVICE: Oncomfort® clinical virtual reality,FEMALE,"ADULT, OLDER_ADULT",NA,27,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-09-24,2024-01-30
NOT_YET_RECRUITING,NO,DRUG: Capecitabine，Pyrotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,1008,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-01,2028-07-01
NOT_YET_RECRUITING,NO,"DRUG: HLX10|DRUG: nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide|DRUG: Placebo",FEMALE,"ADULT, OLDER_ADULT",PHASE3,522,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-17,2027-04-09
NOT_YET_RECRUITING,NO,DRUG: Pentoxifylline Oral Tablet|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-12-15,2024-09-30
RECRUITING,NO,BIOLOGICAL: CCT303-406,ALL,"ADULT, OLDER_ADULT",PHASE1,15,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-09,2025-03-29
RECRUITING,NO,DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Aromatase inhibitor,ALL,"ADULT, OLDER_ADULT",PHASE2,44,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-12,2025-01
COMPLETED,YES,OTHER: Move Together app/Garmin Activity Tracker,ALL,"ADULT, OLDER_ADULT",NA,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-09-10,2022-01-21
RECRUITING,NO,DRUG: Pembrolizumab|DRUG: Olaparib|RADIATION: Radiation,FEMALE,"ADULT, OLDER_ADULT",PHASE2,34,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-21,2025-01
UNKNOWN,NO,DRUG: Pyrotinib Plus And|DRUG: Trastuzumab|DRUG: Abraxane,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-01,2022-03-01
COMPLETED,NO,OTHER: Web access,FEMALE,ADULT,NA,424,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2022-01-15,2022-06-26
RECRUITING,NO,DRUG: AB598|DRUG: Zimberelimab|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Fluorouracil|DRUG: Leucovorin|DRUG: Oxaliplatin,ALL,"ADULT, OLDER_ADULT",PHASE1,81,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-13,2025-08
NOT_YET_RECRUITING,NO,"BIOLOGICAL: PERT-IJS plus trastuzumab, carboplatin and docetaxel|BIOLOGICAL: Perjeta plus trastuzumab, carboplatin and docetaxel",FEMALE,"ADULT, OLDER_ADULT",PHASE3,382,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-03-15,2026-11-15
RECRUITING,NO,DRUG: Inavolisib|DRUG: Phesgo|DRUG: Placebo|DRUG: Taxane-based Chemotherapy|DRUG: Optional Endocrine Therapy of Investigator's Choice,ALL,"ADULT, OLDER_ADULT",PHASE3,230,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-07-28,2028-10-31
UNKNOWN,NO,BEHAVIORAL: Immediate Intervention Group|BEHAVIORAL: Delayed Intervention Group,FEMALE,"ADULT, OLDER_ADULT",NA,132,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2021-03-15,2023-12-31
RECRUITING,NO,RADIATION: External Beam Accelerated Partial Breast Irradiation,FEMALE,"ADULT, OLDER_ADULT",NA,130,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-12,2029-06-30
UNKNOWN,NO,DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Carboplatin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,42,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-29,2023-08
RECRUITING,NO,DRUG: SPC-flakes|DRUG: Salovum|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-06-07,2025-03-31
RECRUITING,NO,BIOLOGICAL: Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination,FEMALE,"ADULT, OLDER_ADULT",PHASE2,17,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-23,2026-12
RECRUITING,NO,OTHER: PRESIONA,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-01-01,2027-01-01
NOT_YET_RECRUITING,NO,COMBINATION_PRODUCT: Endocrine therapy|COMBINATION_PRODUCT: Endocrine therapy combined with the local treatment of FES-negative lesions|COMBINATION_PRODUCT: Chemotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE3,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-15,2029-08-15
RECRUITING,NO,DRUG: AndroGel,MALE,"ADULT, OLDER_ADULT",NA,6,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-10,2024-01-03
NOT_YET_RECRUITING,NO,DRUG: Niraparib,ALL,"ADULT, OLDER_ADULT",PHASE2,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05,2030-05
RECRUITING,NO,DRUG: Durvalumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-06,2026-06
UNKNOWN,NO,DRUG: Pitavastatin|DRUG: placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-01-15,2021-12-15
RECRUITING,NO,DRUG: BMS-986340|DRUG: BMS-936558-01|DRUG: Docetaxel,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,665,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-27,2026-09-15
WITHDRAWN,NO,DRUG: Wee1 Inhibitor ZN-c3,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-30,2025-07-31
NOT_YET_RECRUITING,NO,DRUG: Lutetium-177-DOTAGA-PEG-IAC,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,100,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-01-30,2024-08-30
NOT_YET_RECRUITING,NO,OTHER: Dance,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-02-01,2025-11-30
ENROLLING_BY_INVITATION,NO,"BEHAVIORAL: Culturally Targeted Narrative Video: ""Is My Cancer Hereditary? Rosa Visits a Genetic Counselor.""|BEHAVIORAL: FORCE Fact Sheet",FEMALE,"ADULT, OLDER_ADULT",NA,332,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-06-01,2025-12-31
RECRUITING,NO,RADIATION: Neoadjuvant radiotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2025-12
COMPLETED,NO,DIAGNOSTIC_TEST: Ultrasound and biyopsy,FEMALE,"ADULT, OLDER_ADULT",NA,102,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC,2021-04-01,2023-05-30
RECRUITING,NO,BEHAVIORAL: Digital Health Coaching Program|DEVICE: Fitbit,ALL,"ADULT, OLDER_ADULT",NA,660,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-06-23,2025-12
RECRUITING,NO,BEHAVIORAL: OPTIMISE,ALL,"ADULT, OLDER_ADULT",NA,340,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-04-01,2025-06
WITHDRAWN,NO,DRUG: SBT6290|DRUG: SBT6290|DRUG: pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03,2022-03-31
WITHDRAWN,NO,BEHAVIORAL: Exercise program,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09,2022-09
RECRUITING,NO,DRUG: Niraparib|DRUG: Dostarlimab|RADIATION: Radiation therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,32,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07-21,2029-12-01
COMPLETED,NO,DRUG: Octreotide Injection|OTHER: Sterile water,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE4,41,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-18,2021-12-02
RECRUITING,NO,DEVICE: LifeChamps Platform HCP|DEVICE: LifeChamps Platform,ALL,OLDER_ADULT,NA,200,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-01-15,2023-10-15
UNKNOWN,NO,DRUG: Pembrolizumab 200mg +Paclitaxel 80mg/m2,ALL,"ADULT, OLDER_ADULT",PHASE2,52,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07,2022-12
RECRUITING,NO,BIOLOGICAL: Pembrolizumab/Vibostolimab Co-Formulation|BIOLOGICAL: Pembrolizumab|DRUG: Lenvatinib|DRUG: 5-Fluorouracil|DRUG: Cisplatin|DRUG: Paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Bevacizumab|DRUG: Capecitabine|DRUG: Oxaliplatin,ALL,"ADULT, OLDER_ADULT",PHASE2,610,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-16,2027-02-22
TERMINATED,NO,DRUG: Sitravatinib,ALL,"ADULT, OLDER_ADULT",PHASE2,3,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-22,2023-01-03
RECRUITING,NO,DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Degarelix|DRUG: Abemaciclib,MALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-11,2036-04-01
RECRUITING,NO,RADIATION: Metastases-directed Radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,564,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-05,2025-06-30
NOT_YET_RECRUITING,NO,"DRUG: Trastuzumab deruxtecan|DRUG: Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection|DRUG: Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection",ALL,"ADULT, OLDER_ADULT",PHASE2,165,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-05,2029-05
WITHDRAWN,NO,DRUG: NUV-422|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-09,2026-09
RECRUITING,NO,DRUG: 18F-fluorofuranylnorprogesterone|DEVICE: Positron Emissions Tomography / Magnetic Resonance Imaging|DRUG: Anastrozole|OTHER: Blood Sampling|DRUG: Gadobenate dimeglumine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,53,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-02,2030-01
COMPLETED,YES,DEVICE: Flexitouch Plus with Cellular Connectivity (FT-CC),FEMALE,"ADULT, OLDER_ADULT",NA,29,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-13,2021-11-19
RECRUITING,NO,OTHER: Best Practice|DEVICE: Wound Dressing Material|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,ALL,"ADULT, OLDER_ADULT",PHASE3,216,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2022-06-15,2025-12-31
RECRUITING,NO,OTHER: CARE|OTHER: TARE|OTHER: Home-Based Stretching,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-08-13,2026-06-15
RECRUITING,NO,DRUG: PG2 Lyo. Injection 500mg|DRUG: Placebo 0.9% normal saline,FEMALE,"ADULT, OLDER_ADULT",PHASE2,36,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-06-15,2022-12
RECRUITING,NO,OTHER: Evaluation on skin toxicities,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-11-25,2024-07-25
RECRUITING,NO,DRUG: Talazoparib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-08,2025-11
RECRUITING,NO,DRUG: Dalcelli、Exemestane、Gosserine|DRUG: Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,119,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2023-04-11,2026-09-11
COMPLETED,NO,DRUG: GLR2007,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,19,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-15,2022-07-29
COMPLETED,NO,DEVICE: BNT103,FEMALE,ADULT,NA,15,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2021-09-01,2021-12-31
TERMINATED,NO,DEVICE: Epicutaneous cryoimmunotherapy|DRUG: Topical imiquimod|DRUG: Pembrolizumab|OTHER: Dermatologic Quality of Life Index|OTHER: Functional Assessment of Cancer Therapy|DRUG: Intra-lesional GM-CSF|DEVICE: Cry-AC|PROCEDURE: Cutaneous tumor biopsy|PROCEDURE: Peripheral blood draw for research,ALL,"ADULT, OLDER_ADULT",PHASE1,1,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-14,2021-03-03
ACTIVE_NOT_RECRUITING,NO,OTHER: Electronic Health Record Review|PROCEDURE: Ultrasound Microvessel Imaging,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-08-19,2024-04
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Computed Tomography|OTHER: Fludeoxyglucose F-18|PROCEDURE: Positron Emission Tomography,ALL,"ADULT, OLDER_ADULT",PHASE2,138,NETWORK,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-09-15,2027-08-31
RECRUITING,NO,DRUG: oral vinorelbine and capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-01,2023-06
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: NM21-1480,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,406,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-19,2024-01
RECRUITING,NO,DRUG: Ovarian Function Suppression + Aromatase Inhibitor|DRUG: Adjuvant Chemotherapy + Ovarian Function Suppression,FEMALE,ADULT,PHASE3,3960,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-31,2034-07
RECRUITING,NO,DRUG: Ribociclib|DRUG: Fulvestrant|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-13,2027-12
RECRUITING,NO,OTHER: Discontinuation of Anti-HER-2 Maintenance Treatment,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-07-17,2029-07-31
RECRUITING,NO,DRUG: TT-702,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,114,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-19,2025-09
RECRUITING,NO,DRUG: Letrozole 2.5mg|DRUG: Letrozole + vitamin D3 and calcium,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-01,2024-10
ACTIVE_NOT_RECRUITING,NO,DRUG: Trastuzumab deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE2,468,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-18,2027-07-30
RECRUITING,NO,BEHAVIORAL: Mediterranean diet supplemented with extra-virgin olive oil|BEHAVIORAL: Low-fat diet,FEMALE,"ADULT, OLDER_ADULT",NA,766,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2020-05-29,2024-12
RECRUITING,NO,DRUG: Ribociclib + Letrozole OR Fulvestrant|DRUG: Palbociclib + Letrozole OR Fulvestrant|DRUG: Paclitaxel +/- Tislelizumab,ALL,"ADULT, OLDER_ADULT",PHASE3,456,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-28,2027-03-01
RECRUITING,NO,RADIATION: Pencil Beam Scanning Proton Therapy,ALL,"ADULT, OLDER_ADULT",NA,1800,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-24,2027-01
RECRUITING,NO,DRUG: Take probiotics,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-04-12,2024-08
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Prepectoral reconstruction,FEMALE,"ADULT, OLDER_ADULT",NA,81,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-22,2026-12
TERMINATED,NO,BEHAVIORAL: Acute Exercise,FEMALE,"ADULT, OLDER_ADULT",NA,3,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-02-01,2023-06-29
RECRUITING,NO,DRUG: CBD-dominant|DRUG: THC dominant,ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-01,2025-04-01
RECRUITING,NO,OTHER: Aerobic Exercise Training|OTHER: Attention Control,FEMALE,"ADULT, OLDER_ADULT",NA,126,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2020-01-17,2025-08-31
COMPLETED,NO,BEHAVIORAL: Written Weight Loss Material|BEHAVIORAL: Weight Loss App|BEHAVIORAL: Behavioral Lifestyle Weight Loss Intervention (Coaching),ALL,"ADULT, OLDER_ADULT",NA,340,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-09-22,2023-06-30
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Serratus posterior superior intercostal plane block,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2024-01-01,2024-05-01
RECRUITING,NO,DRUG: Imlunestrant|DRUG: Exemestane|DRUG: Fulvestrant|DRUG: Abemaciclib,ALL,"ADULT, OLDER_ADULT",PHASE3,860,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-04,2027-08-31
NOT_YET_RECRUITING,NO,DRUG: capecitabine and trastuzumab|DRUG: vinorelbine and trastuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,356,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07-01,2026-06-30
COMPLETED,NO,PROCEDURE: serratus plane block|PROCEDURE: erector spinae block|DRUG: Morphine Sulfate,FEMALE,"ADULT, OLDER_ADULT",NA,75,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-01-28,2020-07-01
RECRUITING,NO,PROCEDURE: One-stage immediate breast reconstruction,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-11-02,2026-04-30
RECRUITING,NO,OTHER: assessment of UL function and prognostic factors,ALL,"ADULT, OLDER_ADULT",NA,250,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2022-04-26,2025-02
RECRUITING,NO,RADIATION: Stereotactic Radiation|DRUG: AGuIX gadolinium-based nanoparticles|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,134,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-09-15,2026-02
RECRUITING,NO,DRUG: Elacestrant|DRUG: Abemaciclib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,106,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-31,2025-12
UNKNOWN,NO,DRUG: CYH33|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Palbociclib,ALL,"ADULT, OLDER_ADULT",PHASE1,228,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-04,2022-12
UNKNOWN,NO,DEVICE: VABB Elite 10G|DEVICE: BARD 14G CNB,ALL,"ADULT, OLDER_ADULT",PHASE3,1470,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-11-01,2022-06-30
RECRUITING,NO,DRUG: capecitabine|DRUG: capecitabine + camrelizumab + apatinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,260,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-01,2033-09-01
RECRUITING,NO,OTHER: Questionnaire,FEMALE,"ADULT, OLDER_ADULT",NA,189,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-05-31,2032-04-01
UNKNOWN,NO,PROCEDURE: Blood sample collection,ALL,"ADULT, OLDER_ADULT",NA,76,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-03-11,2023-12
RECRUITING,NO,BEHAVIORAL: Mobile Health Pain Coping Skills Training (mPCST),FEMALE,"ADULT, OLDER_ADULT",NA,180,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-20,2025-01-31
RECRUITING,NO,"DRUG: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)|DRUG: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)|DRUG: traditional herbal medicine",ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-20,2023-07-01
RECRUITING,NO,BEHAVIORAL: Together After Cancer,ALL,"ADULT, OLDER_ADULT",NA,480,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-01-01,2026-03-01
NOT_YET_RECRUITING,NO,BEHAVIORAL: The home-based extremity exercise program,FEMALE,"ADULT, OLDER_ADULT",NA,88,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-12-01,2023-12-31
NOT_YET_RECRUITING,NO,DRUG: Dalpiciclib|DRUG: Pyrotinib|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05,2025-12
WITHDRAWN,NO,DIETARY_SUPPLEMENT: Dietary Intervention,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-06-15,2023-06-15
COMPLETED,NO,DEVICE: Constructive Shearwave Interference (CSI),ALL,"ADULT, OLDER_ADULT",NA,21,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-05-26,2023-08-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: TAEK-VAC-HerBy,ALL,"ADULT, OLDER_ADULT",PHASE1,55,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-10,2026-06
RECRUITING,NO,DRUG: Abemaciclib|DRUG: Abemaciclib|DRUG: Abemaciclib|DRUG: Abemaciclib,ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-28,2030-11
RECRUITING,NO,DEVICE: Photobiomodulation therapy (PBMT)|PROCEDURE: Manual Lymphatic drainage,FEMALE,"ADULT, OLDER_ADULT",NA,104,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-02-22,2028-02
RECRUITING,NO,RADIATION: Prophylactic contralateral breast irradiation,FEMALE,"ADULT, OLDER_ADULT",NA,323,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-01-01,2029-12-01
RECRUITING,NO,DRUG: oxybutynin ER|DRUG: Paroxetine CR,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE3,146,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-02-10,2023-12
RECRUITING,NO,BEHAVIORAL: Cancer Educational Materials|OTHER: Decision Aid|OTHER: Decision Aid|OTHER: Interview|OTHER: Questionnaire Administration,ALL,"CHILD, ADULT, OLDER_ADULT",NA,415,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-09-01,2028-06-01
COMPLETED,NO,BEHAVIORAL: Behavioural Message|BEHAVIORAL: Behavioural Message + Video|OTHER: Usual Care Message,FEMALE,"ADULT, OLDER_ADULT",NA,34047,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: SCREENING,2022-07-15,2023-01-15
UNKNOWN,NO,OTHER: music|OTHER: comprehensive in-patient education program,ALL,"ADULT, OLDER_ADULT",NA,130,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-01,2020-12-31
RECRUITING,NO,OTHER: Decision Aid iCanDecide - ESE website|OTHER: Decision Aid iCanDecide - S website|PROCEDURE: Therapeutic Conventional Surgery|OTHER: Interview|OTHER: Training|OTHER: Media Intervention|OTHER: Best Practice|OTHER: Survey Administration|OTHER: Quality-of-Life Assessment,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,700,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2021-01-15,2027-01
RECRUITING,NO,DRUG: Eribulin mesylate injection、Pertuzumab、Trastuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,78,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-02-25,2025-02-25
NOT_YET_RECRUITING,NO,OTHER: Expressive writing,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2024-02-12,2025-12-01
RECRUITING,NO,DEVICE: Electroacupuncture|DRUG: Standard antiemetic treatment|DEVICE: Sham electroacupuncture|DRUG: Standard antiemetic treatment,ALL,"ADULT, OLDER_ADULT",PHASE3,370,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-12-20,2026-12-31
NOT_YET_RECRUITING,NO,OTHER: Supportive care and education before surgery,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: SUPPORTIVE_CARE",2023-07-01,2023-12-30
RECRUITING,NO,DRUG: Placebo|DRUG: Fenofibrate 160mg,FEMALE,ADULT,NA,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-01-01,2024-02-01
COMPLETED,NO,BEHAVIORAL: Noom Healthy Weight Program,FEMALE,"ADULT, OLDER_ADULT",NA,30,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-03-24,2021-10-01
RECRUITING,NO,OTHER: Correlative Studies (Survey)|OTHER: Correlative Studies (Interview)|BEHAVIORAL: GeneSHARE|BEHAVIORAL: LivingLabReport|BEHAVIORAL: Standard-of-care & Adaptive Intervention|OTHER: Access to Education Materials,ALL,"ADULT, OLDER_ADULT",NA,720,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-08-05,2028-12
ACTIVE_NOT_RECRUITING,NO,OTHER: Quality of Life Questionnaires,ALL,"ADULT, OLDER_ADULT",NA,109,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2020-08-13,2024-08
COMPLETED,NO,DRUG: Bintrafusp Alfa|DRUG: Pimasertib|OTHER: Quality-of-Life Assessment,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,8,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-15,2023-12-08
ACTIVE_NOT_RECRUITING,NO,DRUG: RP12146,ALL,"ADULT, OLDER_ADULT",PHASE1,23,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-05,2024-02
RECRUITING,NO,DRUG: Azacitidine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-10,2024-05
RECRUITING,NO,RADIATION: 1 week RT|RADIATION: 2 week RT,FEMALE,"ADULT, OLDER_ADULT",NA,1018,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-30,2028-08-20
COMPLETED,NO,DRUG: MetFORMIN 500 Mg Oral Tablet|DRUG: Chemotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE4,107,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2021-07-31
RECRUITING,NO,DEVICE: Breast Tomosynthesis,FEMALE,"ADULT, OLDER_ADULT",NA,150,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-02-15,2024-02
RECRUITING,NO,DRUG: AZD5305|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: T- Dxd|DRUG: Dato-DXd|DRUG: Camizestrant,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,804,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-12,2026-12-15
RECRUITING,NO,BEHAVIORAL: Exercise Programme|BEHAVIORAL: Control,FEMALE,"ADULT, OLDER_ADULT",NA,2156,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-01,2033-05-31
RECRUITING,NO,DRUG: Tucatinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,28,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-09,2028-05-09
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: No SLNB|PROCEDURE: SLNB,FEMALE,"ADULT, OLDER_ADULT",NA,1734,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-15,2027-12-31
RECRUITING,NO,DRUG: Lenvatinib|DRUG: Pembrolizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE1,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-09,2026-07
RECRUITING,NO,DRUG: Lenvatinib|DRUG: Pembrolizuma|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,43,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-29,2026-11
RECRUITING,NO,DRUG: Losartan,FEMALE,"ADULT, OLDER_ADULT",PHASE2,84,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2023-12-12,2024-06-30
RECRUITING,NO,PROCEDURE: Home-based cardiac rehabilitation,ALL,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-01-15,2025-03-31
RECRUITING,NO,DRUG: Giredestrant|DRUG: Tamoxifen,FEMALE,"ADULT, OLDER_ADULT",PHASE2,92,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-20,2024-12
RECRUITING,NO,DRUG: pegylated liposomal doxorubicin (PLD)|DRUG: cyclophosphamide (C)|DRUG: trastuzumab (H)|DRUG: pertuzumab (P)|DRUG: docetaxel (T)|DRUG: docetaxel (T)|DRUG: carboplatin (Cb)|DRUG: trastuzumab (H)|DRUG: pertuzumab (P),FEMALE,"ADULT, OLDER_ADULT",PHASE3,372,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-20,2028-01-31
RECRUITING,NO,DRUG: Ribociclib Oral Tablet,FEMALE,OLDER_ADULT,PHASE1|PHASE2,85,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-26,2032-03
COMPLETED,NO,DRUG: Lithium Carbonate,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-08-01,2022-06-01
RECRUITING,NO,DRUG: magnesium sulphate|DRUG: bupivicaine,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2022-01-01,2022-09
WITHDRAWN,NO,DRUG: Tucatinib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-15,2023-06-19
ACTIVE_NOT_RECRUITING,NO,GENETIC: PIK3CA analysis,FEMALE,"ADULT, OLDER_ADULT",NA,58,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-02,2023-09-01
RECRUITING,NO,DRUG: Gemcitabine|DEVICE: Focused Ultrasound|OTHER: Gemcitabine and Focused Ultrasound,ALL,"ADULT, OLDER_ADULT",PHASE1,48,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-27,2025-01
NOT_YET_RECRUITING,NO,DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: KRAS TCR-Transduced PBL|BIOLOGICAL: GRT-C903/GRT-R904,ALL,"ADULT, OLDER_ADULT",PHASE1,210,NIH,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-03-15,2033-06-15
RECRUITING,NO,DRUG: Sevoflurane|DRUG: Propofol,FEMALE,"ADULT, OLDER_ADULT",NA,130,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-03-29,2028-04-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Pembrolizumab|DRUG: TAK-676|RADIATION: Image-guided radiation therapy,ALL,"ADULT, OLDER_ADULT",PHASE1,65,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-09,2024-02-18
ENROLLING_BY_INVITATION,NO,DRUG: Olaparib,ALL,"ADULT, OLDER_ADULT",PHASE3,292,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-04,2025-04-30
COMPLETED,NO,PROCEDURE: Erector Spinae Plane Block with Bubivacaine|PROCEDURE: Standard General Anaesthesia,ALL,ADULT,NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-11-25,2022-01-21
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Lifestyle intervention to reduce breast cancer risk,FEMALE,ADULT,NA,240,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-09-16,2023-12
RECRUITING,NO,DRUG: 18F Fluoroestradiol Radiopharmaceutical with PET/CT,FEMALE,"ADULT, OLDER_ADULT",PHASE4,152,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-02-08,2025-06
RECRUITING,NO,DIAGNOSTIC_TEST: [68Ga]Ga-ABY-025 PET|DIAGNOSTIC_TEST: Biopsy and analysis of HER2 expression,ALL,"ADULT, OLDER_ADULT",PHASE2,72,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-11-23,2025-12-31
COMPLETED,NO,DEVICE: The Breast Cancer Self-Care App,ALL,"ADULT, OLDER_ADULT",NA,73,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: OTHER,2020-09-18,2022-08-15
RECRUITING,NO,DRUG: inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-01,2023-12-01
COMPLETED,NO,BEHAVIORAL: One Diet and Physical Activity Session|OTHER: Electronic (e) Health (eHealth) Communication Intervention|BEHAVIORAL: Twelve Diet and Physical Activity Group Sessions|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment,FEMALE,"ADULT, OLDER_ADULT",PHASE2,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-02-21,2021-10-28
RECRUITING,NO,DRUG: Cemiplimab|DRUG: Paclitaxel|DRUG: Carboplatin (not mandatory)|DRUG: Doxorubicin|DRUG: Cyclophosphamide,FEMALE,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-05,2026-01-01
WITHDRAWN,NO,BIOLOGICAL: rVV-740CTA,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03,2021-09
TERMINATED,NO,BIOLOGICAL: ONCR-177|BIOLOGICAL: pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,66,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-20,2023-05-31
WITHDRAWN,NO,DRUG: POL6326|DRUG: Eribulin|DRUG: Nab paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-16,2022-03-16
TERMINATED,YES,DRUG: Amcenestrant (SAR439859)|DRUG: Letrozole,FEMALE,"ADULT, OLDER_ADULT",PHASE2,105,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-02-04,2021-05-28
UNKNOWN,NO,OTHER: Shared decision making support tool,FEMALE,"ADULT, OLDER_ADULT",NA,264,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2020-05-05,2021-05-05
RECRUITING,NO,PROCEDURE: Axillary surgery based on lymphedema prediction nomogram,FEMALE,"ADULT, OLDER_ADULT",NA,600,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-12-11,2027-12-31
NOT_YET_RECRUITING,NO,DRUG: dalpiciclib plus letrozole,FEMALE,"ADULT, OLDER_ADULT",PHASE2,35,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08,2024-05
RECRUITING,NO,DEVICE: Cool-tip electrode for Radiofrequency Ablation,FEMALE,OLDER_ADULT,NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-01,2024-12-15
RECRUITING,NO,BIOLOGICAL: Dendritic Cell Vaccine,ALL,"ADULT, OLDER_ADULT",PHASE1,18,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-28,2026-03
TERMINATED,NO,BIOLOGICAL: ATRC-101|BIOLOGICAL: Pembrolizumab|DRUG: Pegylated liposomal doxorubicin (PLD),ALL,"ADULT, OLDER_ADULT",PHASE1,87,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-11,2023-11-01
COMPLETED,NO,OTHER: Morning administration of endocrine therapy|OTHER: Evening administration of endocrine therapy,ALL,"ADULT, OLDER_ADULT",PHASE4,247,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-30,2023-07-29
COMPLETED,NO,BEHAVIORAL: Dragon Boat|BEHAVIORAL: Home-based Exercise,FEMALE,"ADULT, OLDER_ADULT",NA,32,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-05-15,2021-09-30
RECRUITING,NO,BEHAVIORAL: Value Affirmation|BEHAVIORAL: Reflective Journaling,FEMALE,"ADULT, OLDER_ADULT",NA,250,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-02-01,2025-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: AZD9833|DRUG: Anastrozole|DRUG: Anastrozole placebo|DRUG: AZD9833 placebo|DRUG: Palbociclib|DRUG: Luteinizing hormone-releasing hormone (LHRH) agonist,ALL,"ADULT, OLDER_ADULT",PHASE3,1370,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-01-28,2029-02-01
RECRUITING,NO,BEHAVIORAL: Digitally distributed yoga,FEMALE,"ADULT, OLDER_ADULT",NA,250,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-10-01,2028-10-01
NOT_YET_RECRUITING,NO,DEVICE: Photobiomodulation through LED board,FEMALE,"ADULT, OLDER_ADULT",NA,148,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-02-06,2025-02-06
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Behavioral Weight-loss Program Via Telehealth|BEHAVIORAL: Behavioral Weight-Loss Program Via Telehealth - Weight Measures|BEHAVIORAL: Validated Surveys of Patient-Reported Outcomes,FEMALE,"ADULT, OLDER_ADULT",NA,22,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07-19,2025-12
RECRUITING,NO,RADIATION: Radiotherapy|PROCEDURE: Surgery|OTHER: Radiofrequency ablation,FEMALE,"ADULT, OLDER_ADULT",PHASE2,74,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-01,2031-04-01
UNKNOWN,NO,DRUG: Zoledronic Acid 4 MG,FEMALE,"ADULT, OLDER_ADULT",PHASE3,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-30,2023-09-30
UNKNOWN,NO,BEHAVIORAL: Mindfulness Based Intervention|BEHAVIORAL: Cognitive Behavioral Therapy,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-01,2022-12-31
COMPLETED,NO,PROCEDURE: Erector spinae plane block,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-01,2024-01-02
ACTIVE_NOT_RECRUITING,NO,DRUG: BCD-178|DRUG: Perjeta,MALE,ADULT,PHASE1,100,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-08,2024-01-31
RECRUITING,NO,OTHER: PASCA intervention,ALL,"ADULT, OLDER_ADULT",NA,858,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-12-24,2028-04-24
NOT_YET_RECRUITING,NO,DRUG: SYHX2011 and Abraxane®,FEMALE,"ADULT, OLDER_ADULT",PHASE1,28,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2022-03-31,2022-10-30
RECRUITING,NO,RADIATION: Ultra-hypofractionated whole breast radiotherapy|RADIATION: Standard Radiation,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-18,2030-12-31
RECRUITING,NO,BEHAVIORAL: Online mindfulness and acceptance intervention,FEMALE,"ADULT, OLDER_ADULT",NA,244,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-09-30,2023-12-30
RECRUITING,NO,DRUG: Losartan 25 milligram capsule|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-08-17,2027-08-17
RECRUITING,NO,DRUG: Talazoparib|DRUG: Selinexor,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,63,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2025-11
RECRUITING,NO,BIOLOGICAL: Placebo|BIOLOGICAL: GLSI-100,ALL,"ADULT, OLDER_ADULT",PHASE3,598,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-08-11,2026-12
NOT_YET_RECRUITING,NO,PROCEDURE: Biospecimen Collection|OTHER: Educational Intervention|OTHER: Exercise Intervention|DRUG: Fisetin|OTHER: Physical Performance Testing|DRUG: Placebo Administration|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE2,164,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2024-09-30,2027-10-31
RECRUITING,NO,BIOLOGICAL: Sacituzumab Govitecan,ALL,"ADULT, OLDER_ADULT",PHASE2,44,NETWORK,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-08,2026-12
RECRUITING,NO,DRUG: BLU-222|DRUG: Carboplatin|DRUG: Ribociclib|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,366,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-07,2026-09-30
COMPLETED,NO,DRUG: GSK3326595,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-08,2022-08-15
RECRUITING,NO,RADIATION: Whole Breast Irradiation (WBI)|RADIATION: Partial Breast Irradiation (PBI),FEMALE,"ADULT, OLDER_ADULT",PHASE3,910,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-11-20,2031-11
COMPLETED,NO,BEHAVIORAL: Mindful compassion based on behavioural change taxonomy experimental group,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-01,2023-09-13
COMPLETED,NO,"DEVICE: MYOVOLT (MyovoltTM, Myovolt Limited, Christchurch, New Zealand ) wearable vibration therapy device|OTHER: Home based exercise",FEMALE,"ADULT, OLDER_ADULT",NA,38,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2023-02-01,2023-06-15
RECRUITING,NO,DIAGNOSTIC_TEST: high-resolution PET-CT specimen imaging.,FEMALE,"ADULT, OLDER_ADULT",NA,160,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-06-17,2024-04-30
RECRUITING,NO,DRUG: Anti-aromatase inhibitor,FEMALE,"ADULT, OLDER_ADULT",PHASE2,696,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10-12,2034-11
RECRUITING,NO,"DRUG: Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)|DRUG: Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)",FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2022-09-02,2024-04-02
RECRUITING,NO,DRUG: EP0062,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,128,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-11,2025-03
RECRUITING,NO,DRUG: Losartan|RADIATION: Radiation Therapy,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-01-01,2024-12-01
ACTIVE_NOT_RECRUITING,NO,OTHER: Pain Neuroscience Education|OTHER: Behavioural Graded Activity|OTHER: Usual care,FEMALE,"ADULT, OLDER_ADULT",NA,122,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-12,2024-04
SUSPENDED,NO,PROCEDURE: Aspiration of seroma fluid,FEMALE,"CHILD, ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-08-17,2026-08-30
ENROLLING_BY_INVITATION,NO,DRUG: HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus,FEMALE,"ADULT, OLDER_ADULT",PHASE1,156,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-02-17,2025-07-31
SUSPENDED,NO,DRUG: XMT-2056,ALL,"ADULT, OLDER_ADULT",PHASE1,171,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-01-24,2025-11
RECRUITING,NO,DRUG: metronomic oral vinorelbine plus anlotinib,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10-05,2026-01
RECRUITING,NO,DRUG: Lasofoxifene in combination with abemaciclib|DRUG: Fulvestrant in combination with abemaciclib,ALL,"ADULT, OLDER_ADULT",PHASE3,400,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-31,2026-06
RECRUITING,NO,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Magrolimab|DRUG: Olaparib,ALL,"ADULT, OLDER_ADULT",PHASE1,33,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-03-05,2026-12-06
NOT_YET_RECRUITING,NO,BIOLOGICAL: Novel probiotic|OTHER: Placebo,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2024-06-01,2026-01-01
NOT_YET_RECRUITING,NO,PROCEDURE: Biopsy|PROCEDURE: Blood samples|BEHAVIORAL: Questionnaires,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-10,2033-04
RECRUITING,NO,DRUG: ALX148|DRUG: Fam-Trastuzumab Deruxtecan-Nxki|DRUG: Zanidatamab|DRUG: Tucatinib,ALL,"ADULT, OLDER_ADULT",PHASE1,54,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-22,2027-12-30
NOT_YET_RECRUITING,NO,DRUG: Disitamab Vedotin Injection （18 weeks）|DRUG: Toripalimab （18weeks）|DRUG: Carboplatin|DRUG: Disitamab Vedotin Injection （12 weeks）|DRUG: Sequential Epirubicin|DRUG: Sequential CTX|DRUG: Toripalimab （12weeks）,ALL,"ADULT, OLDER_ADULT",PHASE2,160,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01,2026-12
RECRUITING,NO,BEHAVIORAL: Exercise|BEHAVIORAL: Motor-cognitive Training|BEHAVIORAL: Health and Wellness,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2024-03,2025-02
RECRUITING,NO,RADIATION: 68Ga/131I-SGMIB-5F7,FEMALE,"ADULT, OLDER_ADULT",NA,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-05-15,2024-05-14
ACTIVE_NOT_RECRUITING,NO,DRUG: SHR6390|DRUG: famitinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,35,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-05-26,2023-09-30
COMPLETED,NO,DRUG: SY-5609|DRUG: Fulvestrant|DRUG: Gemcitabine|DRUG: Nab-paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE1,105,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-23,2023-03-30
ENROLLING_BY_INVITATION,NO,DRUG: SHR6390|DRUG: placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE3,4350,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-30,2031-10-31
WITHDRAWN,NO,DRUG: Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07-28,2021-11-17
RECRUITING,NO,DEVICE: Hyaluronique Acid Gel|DEVICE: Laser CO2|DEVICE: Hyaluronique Acid Injection,FEMALE,"ADULT, OLDER_ADULT",NA,330,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-02-21,2024-02-01
RECRUITING,NO,DRUG: enfortumab vedotin|DRUG: pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,320,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-09,2026-09-30
TERMINATED,NO,DRUG: SHR6390、Famitinib,FEMALE,"ADULT, OLDER_ADULT",PHASE1,3,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-25,2023-06-15
UNKNOWN,NO,DRUG: X4P-001,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,24,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07-21,2023-05-21
RECRUITING,NO,"DRUG: pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel",FEMALE,"ADULT, OLDER_ADULT",PHASE2,62,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05-11,2028-05-11
COMPLETED,NO,DRUG: Rhomboid Intercostal and Subserratus Plane Block with local anesthetic,FEMALE,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-31,2021-03-01
RECRUITING,NO,DRUG: fluzoparib+chidamide|DRUG: fluzoparib+camrelizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-08,2024-12-31
ENROLLING_BY_INVITATION,NO,PROCEDURE: PECS BLOCK 2|PROCEDURE: ESP BLOCK,FEMALE,"ADULT, OLDER_ADULT",NA,160,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-09-07,2023-11-07
RECRUITING,NO,DRUG: ONC-392|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,914,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-16,2024-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: OP-1250,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,153,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-13,2024-07
COMPLETED,NO,BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|DRUG: Nab-paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-22,2022-08-15
RECRUITING,NO,DRUG: RC48-ADC,FEMALE,"ADULT, OLDER_ADULT",PHASE2,64,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04,2024-08
RECRUITING,NO,DRUG: SYSA1901|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Docetaxel,ALL,"ADULT, OLDER_ADULT",PHASE3,560,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-09,2026-02-21
RECRUITING,NO,DRUG: utidelone|DRUG: Bevacizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-29,2024-05
RECRUITING,NO,OTHER: ConquerFear Intervention|OTHER: Active control: Basic Cancer Care,ALL,"ADULT, OLDER_ADULT",NA,174,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-07-21,2024-12-31
RECRUITING,NO,DRUG: Capecitabine,ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-03,2026-02
TERMINATED,YES,"PROCEDURE: Digital Mammography|DRUG: Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml",ALL,"ADULT, OLDER_ADULT",PHASE4,6,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-01-22,2022-06-15
COMPLETED,NO,DRUG: AZD5462|DRUG: Midazolam|DRUG: Rosuvastatin|DRUG: Digoxin,ALL,ADULT,PHASE1,32,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-30,2022-09-12
RECRUITING,NO,DRUG: TAS2940|DRUG: TAS2940,ALL,"ADULT, OLDER_ADULT",PHASE1,42,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-16,2025-06
UNKNOWN,NO,DRUG: All trans-retinoic acid|DRUG: 13-Cis Retinoic Acid plus Tocopherol|DRUG: Mifepristone|DRUG: Cannabidiol|DRUG: 9 cis retinoic acid|DRUG: Tamoxifen|DRUG: Standard therapy,FEMALE,"ADULT, OLDER_ADULT",PHASE3,160,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08,2021-12
COMPLETED,NO,PROCEDURE: Adjuncts to levobupivacaine in Erector Spinae Plane Block,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-12-15,2022-03-15
NOT_YET_RECRUITING,NO,DRUG: Suvorexant Tablets|OTHER: Placebo Control,FEMALE,"ADULT, OLDER_ADULT",PHASE4,44,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2024-01,2026-03
NOT_YET_RECRUITING,NO,DRUG: Camrelizumab Plus Chemotherapy and Famitinib|DRUG: Camrelizumab Plus Chemotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE3,424,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-01,2027-08-30
COMPLETED,NO,DRUG: Saline|DRUG: Ropivacaine,FEMALE,"ADULT, OLDER_ADULT",PHASE3,182,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-04,2022-01-28
RECRUITING,NO,RADIATION: Neoadjuvant radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-02,2025-08
ACTIVE_NOT_RECRUITING,NO,DRUG: Fruquintinib|DRUG: Tislelizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,112,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-09,2024-11
UNKNOWN,NO,PROCEDURE: Serratus Anterior Plane Block|PROCEDURE: Erector Spinae Plane Block,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-11-01,2022-12-30
UNKNOWN,NO,PROCEDURE: Vacuum-assisted breast biopsy,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-01,2022-12
TERMINATED,NO,DRUG: Citalopram|BEHAVIORAL: Psychotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-10,2022-06-29
NOT_YET_RECRUITING,NO,PROCEDURE: Endocrine Therapy|PROCEDURE: Biopsy of breast|DRUG: Neratinib|PROCEDURE: Biospecimen Collection|PROCEDURE: Mammogram|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Breast Surgery|PROCEDURE: Ultrasound,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-04-30,2030-01-30
WITHDRAWN,NO,DRUG: Letrozole|DRUG: Palbociclib|DRUG: Onapristone ER,FEMALE,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-09,2023-04-25
NOT_YET_RECRUITING,NO,DRUG: doxorubicin|DRUG: epirubicin|DRUG: pirarubicin|DRUG: cyclophosphamide|DRUG: albumin-bound paclitaxel|DRUG: paclitaxel|DRUG: docetaxel,FEMALE,"ADULT, OLDER_ADULT",NA,500,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03,2027-09
COMPLETED,NO,BEHAVIORAL: walking exercise,FEMALE,"ADULT, OLDER_ADULT",NA,82,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-07-20,2023-10-06
NOT_YET_RECRUITING,NO,DRUG: Abiraterone acetate|DRUG: Prednisolone|DRUG: Goserelin,MALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-05,2024-12
WITHDRAWN,NO,DRUG: Metformin Extended Release Oral Tablet,FEMALE,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09,2022-09
COMPLETED,NO,BEHAVIORAL: MBCT-S|BEHAVIORAL: SexEd,FEMALE,"ADULT, OLDER_ADULT",NA,118,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-01-06,2023-04-01
RECRUITING,NO,OTHER: 18F-FDG PET/CT,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2023-02-16,2032-12-31
COMPLETED,NO,OTHER: Low glycemic load|OTHER: High glycemic load,FEMALE,"ADULT, OLDER_ADULT",NA,121,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2020-09-21,2022-12-19
NOT_YET_RECRUITING,NO,PROCEDURE: Quilting|PROCEDURE: Conventional wound closure,ALL,"ADULT, OLDER_ADULT",NA,113,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-08-01,2023-07-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Giredestrant|DRUG: Giredestrant-matched Placebo|DRUG: Letrozole|DRUG: Letrozole-matched Placebo|DRUG: Palbociclib|DRUG: LHRH Agonist,ALL,"ADULT, OLDER_ADULT",PHASE3,992,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-09,2027-03-18
RECRUITING,NO,DEVICE: non invasive auricular vagal stimulation|DRUG: usual medical treatment|DEVICE: sham stimulation,ALL,"ADULT, OLDER_ADULT",NA,338,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-06-24,2024-05-01
RECRUITING,NO,DRUG: TQB3909 tablets,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,65,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-02,2023-12
RECRUITING,NO,BEHAVIORAL: BAC-Enhanced Letter|BEHAVIORAL: Waitlist Control,FEMALE,"ADULT, OLDER_ADULT",NA,14875,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING",2021-09-29,2026-03-31
NOT_YET_RECRUITING,NO,DRUG: Elacestrant dihydrochloride,ALL,"ADULT, OLDER_ADULT",PHASE1,16,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2024-01-24,2024-12-30
COMPLETED,NO,DRUG: Desflurane Inhalation,FEMALE,"ADULT, OLDER_ADULT",NA,118,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-10-21,2023-03-10
RECRUITING,NO,DRUG: Giredestrant|DRUG: Abemaciclib|DRUG: Ipatasertib|DRUG: Inavolisib|DRUG: Ribociclib|DRUG: Everolimus|DRUG: Samuraciclib|DRUG: PH FDC SC|DRUG: Palbociclib|DRUG: Atezolizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,510,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-20,2026-10-31
COMPLETED,NO,DRUG: ZN-c5|DRUG: Abemaciclib,ALL,"ADULT, OLDER_ADULT",PHASE1,14,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-12,2022-10-24
RECRUITING,NO,DRUG: Pregabalin|DRUG: Tianeptine,FEMALE,ADULT,NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-06-21,2024-01
RECRUITING,NO,DRUG: Personalized treatment guided by mini-PDX and RNA sequencing|DRUG: Nab paclitaxel|DRUG: Eribulin|DRUG: Vinorelbine|DRUG: Gemcitabine|DRUG: Capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-01,2023-01
RECRUITING,NO,GENETIC: Automated program (ChatBot)|GENETIC: Genetics counselor|OTHER: BCGCKQ Survey|OTHER: Satisfaction Survey|DEVICE: Genetic testing,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-06-29,2025-06-01
RECRUITING,NO,DRUG: Trastuzumab deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE2,41,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09-28,2029-03-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Filgrastim|DRUG: Pegfilgrastim,ALL,"ADULT, OLDER_ADULT",PHASE4,233,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-09,2023-12
RECRUITING,NO,DRUG: Piflufolastat F18,ALL,"ADULT, OLDER_ADULT",PHASE1,36,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-10-28,2025-01-01
RECRUITING,NO,BEHAVIORAL: Lifestyle Intervention|BEHAVIORAL: Attention Control,FEMALE,"ADULT, OLDER_ADULT",NA,176,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-11-01,2027-02-01
RECRUITING,NO,DRUG: surufatinib + fulvestrant + chidamide,FEMALE,"ADULT, OLDER_ADULT",PHASE2,63,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-01,2025-07
RECRUITING,NO,DRUG: Olaparib|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,23,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-31,2026-01
NOT_YET_RECRUITING,NO,DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,46,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-01,2023-12-01
RECRUITING,NO,OTHER: Best Practice|OTHER: Internet-Based Intervention|OTHER: Questionnaire Administration|OTHER: Survey Administration,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-03-21,2025-03-30
RECRUITING,NO,DRUG: Trastuzumab Deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE3,250,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-30,2027-10-01
RECRUITING,NO,DRUG: Nilotinib|DRUG: Nilotinib Hydrochloride Monohydrate|DRUG: Paclitaxel|OTHER: Placebo|OTHER: Questionnaire Administration,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-11,2024-01-02
RECRUITING,NO,DRUG: HS-10502,ALL,"ADULT, OLDER_ADULT",PHASE1,318,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-09,2026-10-01
NOT_YET_RECRUITING,NO,DRUG: Combination use of SRT with T-DXd,FEMALE,"ADULT, OLDER_ADULT",PHASE2,17,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11,2026-07
COMPLETED,YES,OTHER: Breast Cancer Screening Decision Support Tool|OTHER: National Cancer Institute Breast Cancer Screening PDQ,FEMALE,ADULT,NA,1277,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-04-19,2021-08-30
COMPLETED,NO,DEVICE: Uincare Homeplus|OTHER: Brochure,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2020-04-01,2021-11-17
COMPLETED,NO,DEVICE: MRI scan,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-02-11,2023-08-15
RECRUITING,NO,DRUG: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer|DRUG: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,46,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-02,2026-12-31
NOT_YET_RECRUITING,NO,PROCEDURE: Sentinel lymph Node Biopsy,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-01,2028-05-31
RECRUITING,NO,OTHER: Short-Term Fasting,ALL,"ADULT, OLDER_ADULT",NA,55,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-07-28,2024-05-01
NOT_YET_RECRUITING,NO,DRUG: Dalpiciclib in combination with endocrine therapy by Physicians choice,FEMALE,"ADULT, OLDER_ADULT",PHASE2,53,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06,2027-12
RECRUITING,NO,BEHAVIORAL: Patient-centered teleprehabilitation,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-01-30,2024-08-31
RECRUITING,NO,RADIATION: Radiotherapy,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,72,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-24,2024-11
NOT_YET_RECRUITING,NO,DRUG: Xiaopi granules|DRUG: Xiaopi decoction|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,90,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-25,2026-03-30
RECRUITING,NO,OTHER: Routine Assessment of HRQoL coupled with Therapeutic Information,FEMALE,"ADULT, OLDER_ADULT",NA,342,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-05-14,2025-10
UNKNOWN,NO,BEHAVIORAL: Resistance Training,FEMALE,"ADULT, OLDER_ADULT",NA,106,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-01,2023-06
COMPLETED,NO,DEVICE: Adjustable Compression Wrap|DEVICE: Compression Sleeve,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-06-01,2023-03-31
RECRUITING,NO,OTHER: Aerobic exercises|OTHER: Diet protocol,FEMALE,ADULT,NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-05-20,2023-03-28
NOT_YET_RECRUITING,NO,GENETIC: blood sample for BRCA2 mutation detection,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-08-22,2026-03-22
RECRUITING,NO,DRUG: Denosumab|DRUG: Placebo|OTHER: Quality-of-Life Assessment,FEMALE,ADULT,PHASE3,300,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-02-23,2033-12
RECRUITING,NO,OTHER: Main study:|OTHER: Sub-study:,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-06-23,2025-06
NOT_YET_RECRUITING,NO,"BEHAVIORAL: Time restricted eating, nutrition education, and sedentary time reduction strategies",FEMALE,"ADULT, OLDER_ADULT",NA,65,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2024-02-05,2027-06
RECRUITING,NO,"DRUG: pyrotinib combined with trastuzumab, dalpiciclib and letrozole",FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-04,2025-07-30
RECRUITING,NO,"DRUG: Pyrotinib, trastuzumab, paclitaxel-albumin",FEMALE,"ADULT, OLDER_ADULT",PHASE2,65,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-29,2024-07
RECRUITING,NO,DRUG: Tamoxifen|DRUG: Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,104,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-07-26,2026-12-31
UNKNOWN,NO,RADIATION: SBRT,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-04,2023-01-01
RECRUITING,NO,DRUG: Epidiferphane|DRUG: Taxane Chemotherapy,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,74,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-22,2026-01
RECRUITING,NO,PROCEDURE: LYMPHA|PROCEDURE: control,ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-02-01,2027-12-31
RECRUITING,NO,DEVICE: Extracorporeal shock waves,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-10-01,2023-06
UNKNOWN,NO,OTHER: Bacterial cellulose-monolaurin hydrogel|OTHER: Placebo cream,FEMALE,"ADULT, OLDER_ADULT",PHASE2,54,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-09-01,2022-12
RECRUITING,NO,DRUG: Ganglioside-Monosialic Acid|DRUG: 250ml normal saline (NS),ALL,"ADULT, OLDER_ADULT",PHASE3,306,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-02-08,2024-02-08
RECRUITING,NO,OTHER: ASCAPE-based follow-up strategy,ALL,"ADULT, OLDER_ADULT",PHASE2,500,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-02-01,2023-12-31
RECRUITING,NO,PROCEDURE: Computed Tomography|RADIATION: Fluorine F 18 Fluorthanatrace|PROCEDURE: Positron Emission Tomography,ALL,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-02-27,2026-08-20
RECRUITING,NO,DRUG: Capivasertib|DRUG: Fulvestrant|DRUG: Palbociclib|DRUG: Ribociclib|DRUG: Abemaciclib,ALL,"ADULT, OLDER_ADULT",PHASE3,895,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-10,2029-08-14
RECRUITING,NO,DEVICE: Acupuncture|OTHER: Nature scenery with a relaxation exercise,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-09-08,2025-02-28
NOT_YET_RECRUITING,NO,OTHER: Individualized exercise program|OTHER: Control Arm,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-04,2026-10
RECRUITING,NO,DEVICE: MEAVANTI prothesis|DEVICE: Standard prothesis,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2021-01-28,2024-05
TERMINATED,NO,OTHER: Carbohydrate restricted dietary intervention|DRUG: standard of care aromatase inhibitors,FEMALE,"ADULT, OLDER_ADULT",PHASE2,6,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-02-04,2023-03-30
RECRUITING,NO,DRUG: Maxigesic|DRUG: 0.9% saline solution,FEMALE,"ADULT, OLDER_ADULT",NA,84,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2023-04-03,2025-02-26
RECRUITING,NO,BEHAVIORAL: Exercise training,FEMALE,"ADULT, OLDER_ADULT",NA,68,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2023-11,2024-05-31
RECRUITING,NO,DRUG: Camrelizumab|RADIATION: radiotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-14,2026-10-01
RECRUITING,NO,RADIATION: Radiation Therapy|DRUG: Pertuzumab|DRUG: Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,39,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-10,2024-11-01
ACTIVE_NOT_RECRUITING,NO,OTHER: Educational Video and QPL List|OTHER: Usual Care,ALL,"ADULT, OLDER_ADULT",NA,210,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-01-23,2024-04
ENROLLING_BY_INVITATION,NO,OTHER: e-PRO monitoring,ALL,"ADULT, OLDER_ADULT",NA,500,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-26,2027-03-31
NOT_YET_RECRUITING,NO,PROCEDURE: Axillary sentinal lymph node biopsy,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-10-20,2024-01-15
UNKNOWN,NO,RADIATION: Stereotactic Body Radiation Therapy (SBRT),FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-10,2023-04-10
NOT_YET_RECRUITING,NO,DRUG: Disitamab Vedotin|DRUG: Penpulimab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-01,2024-08-31
RECRUITING,NO,DRUG: Epirubicin|DRUG: CTX|DRUG: Paclitaxel|DRUG: ddEpirubicin|DRUG: ddCTX|DRUG: Paclitaxel(with carbo)|DRUG: Carboplatin,FEMALE,"ADULT, OLDER_ADULT",PHASE3,808,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-05,2025-06
RECRUITING,NO,DRUG: Chidamide Plus Toripalimab Plus Paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE2,28,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02,2024-08
RECRUITING,NO,DIAGNOSTIC_TEST: Dual-Energy Contrast-Enhanced Spectral Mammography (CESM),FEMALE,"ADULT, OLDER_ADULT",NA,2032,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-03-24,2027-01-01
RECRUITING,NO,DRUG: Pembrolizumab Injection [Keytruda]|DRUG: Olaparib Oral Tablet [Lynparza],ALL,"ADULT, OLDER_ADULT",PHASE2,89,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-30,2026-02
RECRUITING,NO,DIAGNOSTIC_TEST: Blood samples,ALL,"ADULT, OLDER_ADULT",NA,1000,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-01-20,2030-09
RECRUITING,NO,DRUG: Farletuzumab ecteribulin|DRUG: Prednisone|DRUG: Prednisolone|DRUG: Dexamethasone,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,142,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-06,2025-03-31
ENROLLING_BY_INVITATION,NO,OTHER: comprehensive educational program for reduction of Pre-Operative Anxiety,FEMALE,"ADULT, OLDER_ADULT",NA,400,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-06-01,2024-03-30
RECRUITING,NO,BEHAVIORAL: Group 2: The DISCO App|BEHAVIORAL: Group 1: Usual Care|BEHAVIORAL: Group 3: The DISCO App + Booster,ALL,"ADULT, OLDER_ADULT",NA,260,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-02-10,2025-08-31
RECRUITING,NO,DRUG: NUV-868|DRUG: Olaparib|DRUG: Enzalutamide,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,657,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-29,2026-11
NOT_YET_RECRUITING,NO,BEHAVIORAL: The-Optimal-Lymph-Flow (TOLF) Program,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-12-01,2025-12-31
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Educational mobile app,FEMALE,"ADULT, OLDER_ADULT",NA,142,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-10-03,2024-12-31
NOT_YET_RECRUITING,NO,DRUG: Pyrotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,27,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-01,2025-02-01
NOT_YET_RECRUITING,NO,BEHAVIORAL: Music therapy,FEMALE,"ADULT, OLDER_ADULT",NA,27,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-09,2025-09
RECRUITING,NO,DRUG: BB-1701,ALL,"ADULT, OLDER_ADULT",PHASE2,135,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-03-15,2026-10-26
NOT_YET_RECRUITING,NO,DRUG: SKB264|DRUG: Eribulin|DRUG: Capecitabine|DRUG: Gemcitabine|DRUG: Vinorelbine,ALL,"ADULT, OLDER_ADULT",PHASE3,376,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-30,2027-12-31
TERMINATED,NO,DRUG: Part 1|DRUG: Part 2|DRUG: Part 3,ALL,"ADULT, OLDER_ADULT",PHASE1,9,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-20,2023-02-28
UNKNOWN,NO,DEVICE: MAMMOT2,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-01-27,2023-01-27
RECRUITING,NO,RADIATION: Phase I|RADIATION: Phase II,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,79,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07-31,2029-03
WITHDRAWN,NO,BIOLOGICAL: Injections Subcutaneously Talazoparib|DRUG: Oral capsules Talazoparib,FEMALE,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-10,2024-01-10
RECRUITING,NO,DIAGNOSTIC_TEST: SOLUS examination,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-11-11,2023-12
NOT_YET_RECRUITING,NO,PROCEDURE: Intra-arterial chemoinfusion of breast cancer,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-04,2025-05
RECRUITING,NO,DRUG: Abemaciclib 50 MG; 150mg 1-0-1 per os,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1250,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-02,2027-12
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Mindfulness|BEHAVIORAL: Control group,ALL,"ADULT, OLDER_ADULT",NA,31,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-03-15,2026-10-31
RECRUITING,NO,DRUG: SHR-A1811|DRUG: Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE3,530,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-30,2026-06-30
RECRUITING,NO,DRUG: Romiplostim|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,162,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-02-26,2027-02-13
ACTIVE_NOT_RECRUITING,NO,DRUG: tusamitamab ravtansine|DRUG: Gemcitabine,ALL,"ADULT, OLDER_ADULT",PHASE2,50,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-29,2024-10-01
RECRUITING,NO,OTHER: intermittent fasting,FEMALE,"ADULT, OLDER_ADULT",NA,66,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-01,2025-06-01
RECRUITING,NO,OTHER: Questionnaires|OTHER: Interviews|OTHER: 30-minute telephone or videoconference sessions,ALL,OLDER_ADULT,NA,130,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-09-07,2026-09
NOT_YET_RECRUITING,NO,DEVICE: HyperSight Imaging,ALL,"ADULT, OLDER_ADULT",NA,40,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2024-02,2025-01
RECRUITING,NO,DRUG: Tucatinib|DRUG: Trastuzumab|DRUG: Pertuzumab,ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-18,2036-05
RECRUITING,NO,DRUG: Imlunestrant|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane,ALL,"ADULT, OLDER_ADULT",PHASE3,6000,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-04,2032-03-15
UNKNOWN,NO,DRUG: A|DRUG: B|DRUG: CL1|DRUG: CL2|DRUG: CLH1|DRUG: CLH2|DRUG: CH1|DRUG: CH2|DRUG: CT1,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-20,2021-12-31
RECRUITING,NO,BEHAVIORAL: Intake Session|BEHAVIORAL: Individual Sessions|BEHAVIORAL: Group Sessions|BEHAVIORAL: Graduation|BEHAVIORAL: Exercise,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-11-07,2025-12-31
UNKNOWN,NO,DEVICE: Crossover Device (PCD or Dayspring - alternate to first group),ALL,"ADULT, OLDER_ADULT",NA,50,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2021-06-01,2021-12-31
TERMINATED,NO,DRUG: SAR443216 IV|DRUG: SAR443216 SC,ALL,"ADULT, OLDER_ADULT",PHASE1,44,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-16,2024-01-15
ACTIVE_NOT_RECRUITING,NO,DRUG: epirubicin hydrochloride|DRUG: Cyclophosphamide|DRUG: Albumin bound paclitaxel|DRUG: Toripalimab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-09,2023-12-31
UNKNOWN,NO,DRUG: Palbociclib|DRUG: AI,FEMALE,"ADULT, OLDER_ADULT",PHASE2,150,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-22,2023-06-30
UNKNOWN,NO,DIETARY_SUPPLEMENT: Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd)|DIETARY_SUPPLEMENT: Low Fat Strawberry Yogurt Drinks (Morrisons Ltd),FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-02-10,2021-12-31
RECRUITING,NO,RADIATION: Stereotactic body radiotherapy|RADIATION: Lattice Radiation Therapy,ALL,"ADULT, OLDER_ADULT",NA,26,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-24,2026-07-24
RECRUITING,NO,RADIATION: Stereotactic Radiosurgery,ALL,"ADULT, OLDER_ADULT",PHASE3,98,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-31,2024-03-31
NOT_YET_RECRUITING,NO,DEVICE: Cryoablation,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-15,2024-07-15
TERMINATED,NO,DRUG: RAIN-32,ALL,"ADULT, OLDER_ADULT",PHASE2,40,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-01,2023-10-15
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Computed Tomography|DRUG: 18F-FMAU|PROCEDURE: Multiparametric Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-02-15,2025-02-15
RECRUITING,NO,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|PROCEDURE: Computed Tomography|BIOLOGICAL: Durvalumab|DRUG: Gemcitabine Hydrochloride|PROCEDURE: Magnetic Resonance Imaging|DRUG: Nab-paclitaxel|BIOLOGICAL: Personalized Synthetic Long Peptide Vaccine|DRUG: Poly ICLC|BIOLOGICAL: Tremelimumab,ALL,"ADULT, OLDER_ADULT",PHASE2,70,NIH,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-13,2024-12-31
UNKNOWN,NO,BEHAVIORAL: Online integrated and stepped psychosocial care|BEHAVIORAL: Usual psychosocial care,FEMALE,"ADULT, OLDER_ADULT",NA,193,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-01,2022-06-30
RECRUITING,NO,DEVICE: A digital health program for patients with Breast Cancer,FEMALE,"ADULT, OLDER_ADULT",NA,66,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-07-15,2024-02-01
COMPLETED,NO,DEVICE: Multi-waved Locked System Laser|DEVICE: Cold Compression therapy|OTHER: complete decongestive therapy,FEMALE,"ADULT, OLDER_ADULT",NA,66,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-21,2023-06-05
RECRUITING,NO,BIOLOGICAL: NI-1801,ALL,"ADULT, OLDER_ADULT",PHASE1,40,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04-29,2025-09-30
COMPLETED,NO,OTHER: Kinesiology taping technique with exercise therapy|OTHER: Compression decongestive therapy,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-04-04,2023-01-17
RECRUITING,NO,OTHER: Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-02-12,2024-02
RECRUITING,NO,OTHER: Cardiac Rehab,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-03,2025-08
RECRUITING,NO,BIOLOGICAL: CEA-targeted CAR-T cells|BIOLOGICAL: CEA-targeted CAR-T cells,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-07,2026-08-31
COMPLETED,NO,DRUG: Tucidinostat|DRUG: Exemestane|DRUG: Ovarian function suppression,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-08,2023-10-01
NOT_YET_RECRUITING,NO,OTHER: AI assisted mammography screening interpretation|OTHER: Standard mammography screening interpretation,FEMALE,"ADULT, OLDER_ADULT",NA,150000,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: SCREENING",2024-01,2033-06
RECRUITING,NO,DEVICE: Low energy ESWT,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-13,2024-08-31
RECRUITING,NO,BIOLOGICAL: Camrelizumab|DRUG: Nab paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-20,2024-02-28
WITHDRAWN,NO,DRUG: Atezolizumab|PROCEDURE: Cryosurgery|DRUG: Nab-paclitaxel,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-23,2021-11-17
RECRUITING,NO,DRUG: Patritumab deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-24,2026-10
RECRUITING,NO,BEHAVIORAL: Clinical trial match-list|BEHAVIORAL: Match-list intervention,ALL,"ADULT, OLDER_ADULT",NA,1200,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-12-24,2025-04
COMPLETED,NO,DRUG: monosialic gangliosides|OTHER: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,159,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-08-28,2022-04-21
UNKNOWN,NO,PROCEDURE: prepectoral implant-based reconstruction|PROCEDURE: subpectoral implant-based reconstruction,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-01,2022-11-30
NOT_YET_RECRUITING,NO,OTHER: Standard Physiotherapy Exercise Group|OTHER: Telerehabilitation Based Supervised Exercise Group|OTHER: Mobile Application Supported Exercise Group,FEMALE,"ADULT, OLDER_ADULT",NA,45,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-30,2024-02-15
RECRUITING,NO,DRUG: Samuraciclib|DRUG: Elacestrant Dihydrochloride,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,48,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-09,2025-06-16
NOT_YET_RECRUITING,NO,OTHER: Patients in the intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS),FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-01-15,2024-10-30
COMPLETED,NO,OTHER: LIBERATE website,FEMALE,"ADULT, OLDER_ADULT",NA,41,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-06-06,2021-03-31
RECRUITING,NO,DRUG: Anhydrous Enol-oxaloacetate|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",PHASE2,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-09-29,2025-11-01
RECRUITING,NO,"DRUG: comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival",ALL,"ADULT, OLDER_ADULT",PHASE3,116,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-01,2023-12-15
TERMINATED,YES,BIOLOGICAL: Pembrolizumab|DRUG: Tamoxifen|DRUG: Vorinostat,ALL,"ADULT, OLDER_ADULT",PHASE2,1,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-11,2023-06-15
ACTIVE_NOT_RECRUITING,NO,DRUG: SBT6050|DRUG: pembrolizumab|DRUG: Cemiplimab,ALL,"ADULT, OLDER_ADULT",PHASE1,58,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-27,2022-12
RECRUITING,NO,DIAGNOSTIC_TEST: Relational Agent|OTHER: Clinical Letter,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,56,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2023-10-26,2025-01-31
RECRUITING,NO,DRUG: LS301|DEVICE: Cancer Vision Goggles and standard fluorescence imaging systems|PROCEDURE: Surgery,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,97,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-02-18,2024-01-31
RECRUITING,NO,BIOLOGICAL: P-MUC1C-ALLO1 CAR-T cells|DRUG: Rimiducid,ALL,"ADULT, OLDER_ADULT",PHASE1,100,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-15,2039-04
RECRUITING,NO,RADIATION: Radiation Therapy (RT),FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-08,2027-09
NOT_YET_RECRUITING,NO,DEVICE: Endocare SlimLine Cryoprobe|PROCEDURE: Lumpectomy,FEMALE,"ADULT, OLDER_ADULT",NA,256,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-28,2031-08-31
RECRUITING,NO,DRUG: Enituzumab injection+Abesili tablets+Anastrozole tablets,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-23,2024-08-23
NOT_YET_RECRUITING,NO,DRUG: Niraparib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-01,2025-06-30
UNKNOWN,NO,BEHAVIORAL: Online Group Therapy for PTG|BEHAVIORAL: Online Support Group,FEMALE,"ADULT, OLDER_ADULT",NA,51,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-15,2022-10
RECRUITING,NO,DRUG: AT regimen|DRUG: Tislelizumab|DRUG: Anlotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,32,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09-15,2025-09-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Abemaciclib|DRUG: Fulvestrant|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,368,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-03-11,2026-02-16
RECRUITING,NO,DRUG: Cediranib|DRUG: Ceralasertib|DRUG: Olaparib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-28,2025-03-31
RECRUITING,NO,BEHAVIORAL: Iyengar Yoga|BEHAVIORAL: Meditative Yoga,FEMALE,"ADULT, OLDER_ADULT",NA,138,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-05-09,2024-12
COMPLETED,NO,"DRUG: Docetaxel, trastuzumab|DRUG: Pyrotinib",FEMALE,"ADULT, OLDER_ADULT",PHASE1,97,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-28,2023-05-24
RECRUITING,NO,DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Nab paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Nab paclitaxel|DRUG: Cyclophosphamide,FEMALE,"ADULT, OLDER_ADULT",PHASE4,2413,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-10,2027-12-20
NOT_YET_RECRUITING,NO,OTHER: Best Practice|BEHAVIORAL: Internet-Based Intervention|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-02-11,2024-12-31
RECRUITING,NO,PROCEDURE: Biospecimen Collection|DRUG: Extended Release Metformin Hydrochloride|OTHER: Monitoring|OTHER: Nutritional Assessment|OTHER: Short-Term Fasting,FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-04-04,2025-11-20
NOT_YET_RECRUITING,NO,DRUG: Adebrelimab|DRUG: Vinorelbine|DRUG: Cyclophosphamide (tablet)|DRUG: Capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,182,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-19,2027-01-19
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Standardized TRE Protocol|BEHAVIORAL: Personalized TRE Protocol|BEHAVIORAL: External Support for TRE|BEHAVIORAL: Peer Support for TRE,FEMALE,"ADULT, OLDER_ADULT",NA,178,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-07-07,2023-12-06
WITHDRAWN,NO,OTHER: Mainstream Genetic Testing Model|OTHER: Enhanced Standard of Care Model,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-08,2027-12
TERMINATED,NO,DRUG: Milademetan|BEHAVIORAL: Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL),ALL,"ADULT, OLDER_ADULT",PHASE2,1,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-10-12,2023-11-30
COMPLETED,NO,OTHER: Telerehabilitation-based relaxation exercise group (EG),FEMALE,"ADULT, OLDER_ADULT",NA,52,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-01-20,2022-12-01
COMPLETED,NO,"DIETARY_SUPPLEMENT: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)|DRUG: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo|DRUG: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).",ALL,"ADULT, OLDER_ADULT",PHASE2,90,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-20,2023-05-25
WITHDRAWN,NO,DRUG: 177Lu-DOTATOC,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-04,2021-07-15
RECRUITING,NO,DEVICE: ZetaFuse™ Bone Graft,FEMALE,"ADULT, OLDER_ADULT",NA,10,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2022-09-01,2024-09
COMPLETED,NO,BEHAVIORAL: Exercise,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-07-07,2023-03-30
UNKNOWN,NO,OTHER: Physical exercise program,FEMALE,"ADULT, OLDER_ADULT",NA,90,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-09-13,2022-09-20
RECRUITING,NO,DRUG: ARV-471 (PF-07850327)|COMBINATION_PRODUCT: Palbociclib|DRUG: Letrozole|COMBINATION_PRODUCT: Palbociclib,ALL,"ADULT, OLDER_ADULT",PHASE3,1180,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-09,2030-07-26
RECRUITING,NO,DEVICE: Mobile device as a support tool for the treatment of women with breast cancer undergoing chemotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-05-16,2023-12-31
RECRUITING,NO,BEHAVIORAL: Center-Based Walking Exercise|BEHAVIORAL: Home-Based Walking Exercise,FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-29,2025-08
RECRUITING,NO,OTHER: Eurythmy therapy|OTHER: CoordiFit,FEMALE,"ADULT, OLDER_ADULT",NA,196,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-03-10,2024-11-30
COMPLETED,NO,BEHAVIORAL: character strengths-based intervention|BEHAVIORAL: early memories,FEMALE,"ADULT, OLDER_ADULT",NA,122,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2020-05-04,2020-12-20
RECRUITING,NO,DRUG: TMP-SMX DS|DEVICE: ciNPT dressing,FEMALE,"ADULT, OLDER_ADULT",NA,105,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-26,2025-12-31
COMPLETED,NO,DRUG: Diphenhydramine|DRUG: Cetirizine|DRUG: Lactose pill|DRUG: Sodium chloride 0.9%,ALL,"ADULT, OLDER_ADULT",PHASE3,27,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-02-14,2020-09-04
RECRUITING,NO,"DRUG: TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen|DRUG: Placebo capsules, Letrozole, Anastrozole, Tamoxifen",FEMALE,"ADULT, OLDER_ADULT",PHASE3,1946,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-03-30,2027-01
UNKNOWN,NO,DIETARY_SUPPLEMENT: tahini|OTHER: control,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-05-08,2021-07-15
WITHDRAWN,NO,BIOLOGICAL: SNK01|DRUG: Trastuzumab|DRUG: Cetuximab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03,2023-02
RECRUITING,NO,DRUG: [68Ga]Ga-OncoFAP administration,ALL,"ADULT, OLDER_ADULT",PHASE1,20,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-04-27,2024-01
NOT_YET_RECRUITING,NO,DRUG: U-13C-glucose,ALL,"ADULT, OLDER_ADULT",NA,16,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2024-04-15,2028-06-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Paclitaxel|DRUG: Carboplatin|BIOLOGICAL: Nivolumab|BIOLOGICAL: Cabiralizumab|PROCEDURE: Tumor biopsy|PROCEDURE: Bone marrow|PROCEDURE: Blood draw,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,15,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-19,2026-05-31
RECRUITING,NO,BIOLOGICAL: CEA CAR-T cells,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-20,2024-04-30
RECRUITING,NO,PROCEDURE: Lymphovenous anastomosis,FEMALE,"ADULT, OLDER_ADULT",NA,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-11,2024-01-31
RECRUITING,NO,OTHER: Triage of clinical breast examination positive women using handheld ultrasound by non-radiologists.,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2022-05-09,2024-05-31
RECRUITING,NO,BEHAVIORAL: Adapted Intimacy Enhancement|BEHAVIORAL: Intimacy Facts and Resources,ALL,"ADULT, OLDER_ADULT",NA,112,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-01-01,2024-08-31
NOT_YET_RECRUITING,NO,OTHER: resistive training|OTHER: kinesiotaping,ALL,ADULT,NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2023-02-20,2023-06-20
RECRUITING,NO,DRUG: BDC-1001|DRUG: Pertuzumab,ALL,"ADULT, OLDER_ADULT",PHASE2,66,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-30,2025-03
COMPLETED,NO,BEHAVIORAL: FOLLOW UP VISIT-TELEMEDICINE|BEHAVIORAL: FOLLOW UP VISIT-FACE TO FACE,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-08-01,2022-11-01
NOT_YET_RECRUITING,NO,DRUG: Mitoquinone|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",NA,44,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-06-02,2023-12-02
NOT_YET_RECRUITING,NO,DRUG: OKI-219|DRUG: Fulvestrant|DRUG: Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE1,150,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-22,2027-08-01
COMPLETED,NO,OTHER: PECS block|OTHER: Rhomboid intercostal block,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-03-23,2021-02-20
RECRUITING,NO,DRUG: Everolimus|DRUG: Chidamide|DRUG: Endocrine therapy|DRUG: Ovarian function suppression(OFS),FEMALE,"ADULT, OLDER_ADULT",PHASE2,102,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-20,2027-07-15
RECRUITING,NO,DRUG: IL-2 (Aldesleukin)|DRUG: Cyclophosphamide|BIOLOGICAL: KK-LC-1 TCR|DRUG: Fludarabine,ALL,"ADULT, OLDER_ADULT",PHASE1,100,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-08,2026-04-05
ENROLLING_BY_INVITATION,NO,BEHAVIORAL: Web + Streamlined Telephone Genetic Counseling,ALL,"ADULT, OLDER_ADULT",NA,426,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-05-01,2025-06-30
WITHDRAWN,NO,DRUG: Eftilagimod Alpha|DRUG: Paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06,2026-02
RECRUITING,NO,DEVICE: Sirius Pintution|DEVICE: HydroMARK (C) Clip,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-08-01,2025-01
UNKNOWN,NO,OTHER: Kinesiotherapy protocol|OTHER: Usual orientations,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-08-01,2021-12
RECRUITING,NO,BEHAVIORAL: Progressive combine training (PCT)|BEHAVIORAL: Attention Control (AC),FEMALE,"ADULT, OLDER_ADULT",NA,160,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-08-12,2026-06-15
RECRUITING,NO,DRUG: KVA12123 - Dose Escalation|DRUG: KVA12123 Plus Pembrolizumab - Dose Escalation|DRUG: KVA12123 - Dose Expansion|DRUG: KVA12123 Plus Pembrolizumab - Dose Expansion,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,314,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-03,2024-12-31
RECRUITING,NO,DRUG: Tucatinib Oral Tablet|DRUG: Capecitabine tablets|DRUG: Trastuzumab Injection,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-18,2027-06
UNKNOWN,NO,"OTHER: Treatment modalities of Traditional Chinese Medicine (Acupuncture, Chinese herbal medicine, Tunia, Chinese dietetics)|OTHER: Standard care",ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-02,2022-07
RECRUITING,NO,DRUG: Dexmedetomidine|DRUG: placebo,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-04-20,2025-07-01
COMPLETED,NO,BEHAVIORAL: Virtual group based physical activity (BurnAlong) and Social Media Discussion Board,ALL,ADULT,NA,8,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-01-10,2023-08-21
RECRUITING,NO,DRUG: 600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib|DRUG: RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,29,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-12,2024-12-31
RECRUITING,NO,DEVICE: Transcranial Direct Current Stimulation|DEVICE: Transcranial Alternating Current Stimulation|DEVICE: tES sham|DEVICE: Online Cognitive Training,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-09-27,2025-09
RECRUITING,NO,OTHER: Complementary and alternative medicine (CAM),FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-07-01,2024-12-31
COMPLETED,NO,DRUG: Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes,FEMALE,"ADULT, OLDER_ADULT",NA,159,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-09-24,2023-05-24
COMPLETED,NO,DRUG: Eribulin Mesylate|DRUG: Anlotinib,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-09,2022-07-20
NOT_YET_RECRUITING,NO,DRUG: Pyrotinib|DRUG: Trastuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2030-05-31
RECRUITING,NO,OTHER: traditional physical therapy session|OTHER: wii console based exercise,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-11-01,2023-12
ACTIVE_NOT_RECRUITING,NO,DRUG: TT-00420|COMBINATION_PRODUCT: Nab-Paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,225,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-14,2024-02-01
RECRUITING,NO,OTHER: Best Practice|OTHER: Educational Intervention|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,FEMALE,ADULT,NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-06-01,2024-12-31
ACTIVE_NOT_RECRUITING,NO,OTHER: AI screening modality|OTHER: Conventional screening modality,FEMALE,"ADULT, OLDER_ADULT",NA,100000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SCREENING,2021-04-12,2025-04-12
COMPLETED,NO,BEHAVIORAL: Yoga Intervention,ALL,"ADULT, OLDER_ADULT",NA,18,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-12-13,2022-07-27
COMPLETED,NO,DRUG: LX-039 tablets,FEMALE,"ADULT, OLDER_ADULT",PHASE1,44,INDUSTRY,"Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-01-07,2023-02-07
NOT_YET_RECRUITING,NO,DRUG: Abemaciclib|DRUG: Anastrozole|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Diagnostic Imaging|DRUG: Exemestane|OTHER: Fludeoxyglucose F-18|DRUG: Fluorine F 18 Fluoro Furanyl Norprogesterone|DRUG: Fulvestrant|BIOLOGICAL: Gonadotropin-releasing Hormone Analog|DRUG: Letrozole|PROCEDURE: Positron Emission Tomography|DRUG: Tamoxifen|DRUG: Therapeutic Estradiol,ALL,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-06-01,2025-03-01
COMPLETED,NO,BEHAVIORAL: Bulk Order|BEHAVIORAL: Texting|BEHAVIORAL: Clinician Endorsement|BEHAVIORAL: No Bulk Order|BEHAVIORAL: Standard Endorsement,FEMALE,"ADULT, OLDER_ADULT",NA,24680,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SCREENING",2021-10-25,2022-04-25
RECRUITING,NO,DRUG: HX008，Niraparib|DRUG: HX008，Niraparib|DRUG: HX008，Niraparib，Trastuzumab|DRUG: HX008，Niraparib，Pyrrolitinib,ALL,"ADULT, OLDER_ADULT",PHASE2,37,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-14,2022-12-28
NOT_YET_RECRUITING,NO,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Mammography|OTHER: Questionnaire Administration|DRUG: Tamoxifen,FEMALE,ADULT,PHASE2,200,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2024-06-10,2027-07-30
COMPLETED,NO,OTHER: Analgesia management; group ESPB and RIB,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-16,2021-12-20
UNKNOWN,NO,DRUG: LTLD|PROCEDURE: MR-HIFU induced hyperthermia|DRUG: Cyclophosphamide,FEMALE,"ADULT, OLDER_ADULT",PHASE1,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03,2022-11
WITHDRAWN,NO,DEVICE: Microablative Fractional CO2 Laser Therapy,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-09-01,2022-07-01
COMPLETED,NO,BEHAVIORAL: Exercise Counselling|BEHAVIORAL: Partner Matching|BEHAVIORAL: Resistance training sessions led by a QEP,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-05-10,2022-01-30
NOT_YET_RECRUITING,NO,PROCEDURE: erector spinae block|PROCEDURE: retrolaminar block|PROCEDURE: serratus anterior block|PROCEDURE: pectoral nerve block,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2024-02-01,2025-07-25
COMPLETED,NO,DRUG: CX-2009|DRUG: CX-072,ALL,"ADULT, OLDER_ADULT",PHASE2,125,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-29,2023-06-02
NOT_YET_RECRUITING,NO,DEVICE: CPAP,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07,2023-07
RECRUITING,NO,OTHER: Questionnaire: SPIRIT|OTHER: Questionnaire: HADS|OTHER: Questionnaire: QSC-R23|OTHER: General questions|OTHER: Clinical data collected,ALL,"ADULT, OLDER_ADULT",NA,600,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-06-16,2025-06-30
RECRUITING,NO,OTHER: exercise and training,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-04-18,2024-05-30
ACTIVE_NOT_RECRUITING,NO,DRUG: bazedoxifene plus conjugated estrogens,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,16,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-12-02,2024-12-31
RECRUITING,NO,PROCEDURE: Biopsy of Breast|OTHER: Medical Device Usage and Evaluation|RADIATION: Scintimammography|OTHER: Technetium Tc-99m Sestamibi,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-08-26,2026-08-26
UNKNOWN,NO,DEVICE: Dayspring Active Wearable Compression System,ALL,"ADULT, OLDER_ADULT",NA,20,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-01,2021-12-31
RECRUITING,NO,OTHER: Therapeutic Education and Nursing Support Program for Supportive Care,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-08-09,2025-08
COMPLETED,NO,OTHER: REASSURE,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-08-24,2022-07-28
NOT_YET_RECRUITING,NO,DRUG: capecitabine and trastuzumab|DRUG: endocrine therapy and trastuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,356,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-15,2027-05-15
NOT_YET_RECRUITING,NO,DRUG: XZP-3287+ Letrozole/Anastrozole|DRUG: Placebo + Letrozole/Anastrozole,FEMALE,"ADULT, OLDER_ADULT",PHASE3,372,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-02,2025-12
WITHDRAWN,NO,PROCEDURE: TAP block|PROCEDURE: QL Block,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-04,2023-03
RECRUITING,NO,DRUG: TOL2506|DRUG: Tamoxifen|DRUG: Letrozole Tablets|DRUG: Anastrozole Tablets|DRUG: Exemestane Tablets,ALL,ADULT,PHASE3,250,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07-01,2025-04-30
RECRUITING,NO,OTHER: Prolonged resistance-type exercise training,FEMALE,ADULT,NA,52,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-03-22,2024-08
ACTIVE_NOT_RECRUITING,NO,DRUG: SGN-STNV,ALL,"ADULT, OLDER_ADULT",PHASE1,111,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-18,2026-03-31
RECRUITING,NO,DEVICE: Motiva Flora® Tissue Expander,FEMALE,"ADULT, OLDER_ADULT",NA,66,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-08-18,2027-04
RECRUITING,NO,DRUG: ²¹²Pb-DOTAM-GRPR1,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-22,2025-01
COMPLETED,NO,OTHER: progressive muscle relaxation|OTHER: Listening to relaxing music once/day,FEMALE,"ADULT, OLDER_ADULT",NA,84,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2022-03-08,2022-08-10
RECRUITING,NO,COMBINATION_PRODUCT: Palliative Radiation and Pembrolizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-02,2031-07-01
NOT_YET_RECRUITING,NO,RADIATION: Stereotactic Radiation|DRUG: Zimberelimab|DRUG: Sacituzumab govitecan,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,31,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-02,2027-02
COMPLETED,NO,BEHAVIORAL: Narrative breast health education,FEMALE,"ADULT, OLDER_ADULT",NA,99,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2021-07-01,2022-12-13
RECRUITING,NO,PROCEDURE: Thoracic paravertebral block multiple (3) injections|PROCEDURE: Thoracic paravertebral block single injection,FEMALE,"ADULT, OLDER_ADULT",NA,68,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-11-04,2023-12-01
COMPLETED,NO,OTHER: Attention-restorative therapy (ART)-based virtual reality (VR),FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-10-26,2022-05-16
RECRUITING,NO,DRUG: Chiauranib|DRUG: capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,38,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-05,2024-08-09
RECRUITING,NO,DRUG: 18F-DCFPyL,ALL,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-05-24,2025-11
RECRUITING,NO,DRUG: The combination of Dalpiciclib with physician-selected endocrine therapy|DRUG: Chemotherapy selected by the physician,ALL,"ADULT, OLDER_ADULT",PHASE3,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-15,2026-06-30
COMPLETED,NO,DRUG: [18F]-DPA-714 PET/CT scan,FEMALE,"ADULT, OLDER_ADULT",PHASE2,13,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-06-11,2021-07-21
RECRUITING,NO,OTHER: Exercise,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-01,2024-03-01
RECRUITING,NO,"RADIATION: Accelerated Partial Breast Irradiation (APBI)|DRUG: tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene",FEMALE,OLDER_ADULT,PHASE2,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-17,2025-05-17
UNKNOWN,NO,DRUG: Metformin|DRUG: Placebo oral tablet,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-05,2023-05-01
UNKNOWN,NO,OTHER: Augmented Reality|OTHER: Traditional leaflet,ALL,"CHILD, ADULT, OLDER_ADULT",NA,20,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2020-11-30,2022-03-30
COMPLETED,NO,OTHER: White tea|OTHER: Salt water with soda,FEMALE,"ADULT, OLDER_ADULT",NA,88,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-09-02,2023-04-30
RECRUITING,NO,OTHER: Intervention plus 12 months maintenance|OTHER: Intervention plus 10 months maintenance|OTHER: Intervention plus 8 months maintenance|OTHER: Intervention plus 6 months maintenance|OTHER: Intervention plus 4 months maintenance,FEMALE,ADULT,NA,500,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2022-03-09,2024-08
COMPLETED,NO,DRUG: Ropivacaïne Hydrochloride by Erector Spinae block|DRUG: Ropivacaïne Hydrochloride by Paravertebral block,FEMALE,"ADULT, OLDER_ADULT",PHASE4,292,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-28,2023-07-14
COMPLETED,NO,DRUG: 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg|DRUG: 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg|DRUG: 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg,ALL,ADULT,EARLY_PHASE1,6,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-11-12,2022-09-19
COMPLETED,NO,BEHAVIORAL: Lymphedema prevention protocols,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2020-03-01,2020-12-08
RECRUITING,NO,BEHAVIORAL: Brain Training A|BEHAVIORAL: Brain Training B|BEHAVIORAL: Brain Training C,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2022-06-01,2025-06-01
RECRUITING,NO,BEHAVIORAL: Preparation in Self-Hypnosis by anchoring|BEHAVIORAL: Conversational Hypnosis|BEHAVIORAL: Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: OTHER,2022-10-11,2024-07
ENROLLING_BY_INVITATION,NO,PROCEDURE: NOL monitor,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-01-01,2025-03
RECRUITING,NO,"BIOLOGICAL: TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3",ALL,"ADULT, OLDER_ADULT",PHASE1,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-01,2035-01-01
RECRUITING,NO,DRUG: Trastuzumab and nelatinib|DRUG: Trastuzumab and Parstuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE3,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-16,2028-11-01
RECRUITING,NO,DRUG: Trastuzumab|DRUG: Trastuzumab Emtansine (T-DM1)|DRUG: Pertuzumab|DRUG: Tucatinib,ALL,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-23,2025-04
COMPLETED,NO,"OTHER: Patients with breast cancer (stage I, II III or IV)",FEMALE,"ADULT, OLDER_ADULT",NA,61,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-03-31,2022-07-29
NOT_YET_RECRUITING,NO,BIOLOGICAL: HS-IT101,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10-08,2027-03-31
RECRUITING,NO,OTHER: Aerobic Exercise three time a week,FEMALE,ADULT,NA,28,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-10,2024-01
RECRUITING,NO,BIOLOGICAL: navicixizumab+paclitaxel|BIOLOGICAL: navicixizumab+irinotecan|BIOLOGICAL: navicixizumab monotherapy,ALL,"ADULT, OLDER_ADULT",PHASE2,180,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-05,2024-12-15
COMPLETED,NO,"OTHER: Microbiopsy sample|OTHER: Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level",FEMALE,"ADULT, OLDER_ADULT",NA,13,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-09-16,2021-05-20
WITHDRAWN,NO,PROCEDURE: Omission of axillary lymph node dissection|RADIATION: Omission of regional irradiation,ALL,"ADULT, OLDER_ADULT",PHASE3,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-01,2029-12-31
COMPLETED,NO,OTHER: Practice-Level Implementation Strategies,ALL,"ADULT, OLDER_ADULT",NA,8,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2023-07-25,2024-01-04
RECRUITING,NO,DIAGNOSTIC_TEST: Pre-neoadjuvant radiotherapy (NART) biopsy|RADIATION: Neoadjuvant radiotherapy|PROCEDURE: Unilateral total mastectomy with axillary lymph node dissection,FEMALE,"ADULT, OLDER_ADULT",PHASE1,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-06,2025-06-06
NOT_YET_RECRUITING,NO,"OTHER: Rehabilitation, exercise",FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2023-05-20,2025-12-30
NOT_YET_RECRUITING,NO,DRUG: 6.0 mg/kg of TQB2102 for injection|DRUG: 7.5 mg/kg of TQB2102 for injection,ALL,"ADULT, OLDER_ADULT",PHASE2,104,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02,2026-02
COMPLETED,NO,"DRUG: [14C]AZD9833 Oral Solution, 75 mg",FEMALE,"ADULT, OLDER_ADULT",PHASE1,6,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-10,2022-06-20
UNKNOWN,NO,BEHAVIORAL: Adherence Improving self-Management Strategy|OTHER: Regular care,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-12-13,2022-12-31
TERMINATED,NO,DRUG: NUV-422,ALL,"ADULT, OLDER_ADULT",PHASE1,74,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-08,2022-08-31
UNKNOWN,NO,DIETARY_SUPPLEMENT: FADA (active fraction of Ficus septica leaf) 800 mg/day|DIETARY_SUPPLEMENT: FADA (active fraction of Ficus septica leaf) 2000 mg/day|OTHER: Placebo capsule,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,324,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-09-07,2023-12-30
RECRUITING,NO,DEVICE: MARIA,FEMALE,"ADULT, OLDER_ADULT",NA,400,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-01-27,2023-03-31
RECRUITING,NO,RADIATION: Hypofractionated radiotherapy VS Standard/Conventional fractionation radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,132,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-01,2027-12-31
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,178,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-27,2028-12-31
RECRUITING,NO,BIOLOGICAL: SV-BR-1-GM|DRUG: Cyclophosphamide|DRUG: Interferon infiltration of the inoculation site|DRUG: Retifanlimab|DRUG: Treatment of Physician's Choice,ALL,"ADULT, OLDER_ADULT",PHASE3,404,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-20,2025-12
UNKNOWN,NO,PROCEDURE: Regional anesthesia,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-01,2021-11-30
RECRUITING,NO,BIOLOGICAL: pING-hHER3FL,ALL,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-07-13,2025-03-01
RECRUITING,NO,DRUG: Pioglitazone 15mg|DRUG: Pioglitazone 30 mg,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-23,2023-04
ENROLLING_BY_INVITATION,NO,BEHAVIORAL: Reimbursement,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-07-01,2026-04-01
RECRUITING,NO,DRUG: Dato-DXd|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Carboplatin|DRUG: Capecitabine|DRUG: Eribulin mesylate,ALL,"ADULT, OLDER_ADULT",PHASE3,600,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-16,2025-12-03
WITHDRAWN,NO,DRUG: Tilmanocept|DRUG: Nanocolloid,FEMALE,"ADULT, OLDER_ADULT",PHASE4,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: DIAGNOSTIC",2020-11-24,2021-05-01
RECRUITING,NO,DRUG: Eribulin Mesylate|DRUG: Lobaplatin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2023-12-31
RECRUITING,NO,OTHER: tele nursing,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-09-01,2024-05
RECRUITING,NO,DRUG: GM103 (Part A)|DRUG: GM103 (Part B)|DRUG: GM103 and Pembrolizumab (Part C),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,125,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-29,2028-10-30
NOT_YET_RECRUITING,NO,OTHER: Exercise Intervention|PROCEDURE: Biospecimen Collection|OTHER: Educational Intervention,ALL,"ADULT, OLDER_ADULT",PHASE2,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2024-01-01,2028-09-01
COMPLETED,NO,BEHAVIORAL: Survey questionnaire,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-01-20,2021-10-12
NOT_YET_RECRUITING,NO,BEHAVIORAL: RealRisks,FEMALE,"ADULT, OLDER_ADULT",NA,55,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-05,2024-07
ACTIVE_NOT_RECRUITING,NO,DRUG: Trastuzumab deruxtecan|DRUG: Capecitabine|DRUG: Paclitaxel|DRUG: Nab-Paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE3,866,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-24,2026-06-19
ACTIVE_NOT_RECRUITING,NO,DRUG: Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment,FEMALE,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07-13,2028-03-31
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Digital information tool,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-09-01,2023-12-31
RECRUITING,NO,BEHAVIORAL: Gait/balance & resistive exercise,FEMALE,"ADULT, OLDER_ADULT",NA,312,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-08-14,2024-09-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Palbociclib|DRUG: Olaparib|DRUG: Fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE1,54,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-15,2024-04
RECRUITING,NO,DRUG: disitamab vedotin|DRUG: tucatinib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,198,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-29,2030-01-31
ENROLLING_BY_INVITATION,NO,DRUG: Axitinib,ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-11,2024-11-09
RECRUITING,NO,DRUG: HRS8807|DRUG: HRS8807|DEVICE: HRS8807、SHR6390|DRUG: HRS8807、SHR6390,FEMALE,"ADULT, OLDER_ADULT",PHASE1,90,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-26,2024-12-31
RECRUITING,NO,PROCEDURE: Stained region Lymph Node Biopsy (SrLNB)|RADIATION: Regional lymph node radiotherapy (RNI) including the axilla,FEMALE,"ADULT, OLDER_ADULT",NA,92,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09-11,2026-07
WITHDRAWN,NO,DRUG: Abemaciclib|BIOLOGICAL: Trastuzumab Emtansine,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-11,2022-02-16
RECRUITING,NO,DRUG: U3-1402,ALL,"ADULT, OLDER_ADULT",PHASE2,121,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-03,2025-11
RECRUITING,NO,BEHAVIORAL: Brief Physical Activity Counselling|BEHAVIORAL: Structured Exercise Program,FEMALE,"ADULT, OLDER_ADULT",NA,122,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-01-05,2025-02
RECRUITING,NO,DRUG: Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788),FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-01,2027-08-15
ACTIVE_NOT_RECRUITING,NO,DEVICE: MOLLI Localization,FEMALE,"ADULT, OLDER_ADULT",NA,41,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-16,2024-06-30
TERMINATED,NO,DRUG: Onapristone|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE2,11,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-05,2023-05-15
ACTIVE_NOT_RECRUITING,NO,OTHER: On-demand personalized follow-up care|OTHER: Guideline-based follow-up care (standard of care),FEMALE,"ADULT, OLDER_ADULT",PHASE4,264,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-08-19,2026-07
COMPLETED,NO,OTHER: White Wine|OTHER: Grape Juice,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE,2022-09-01,2023-07-31
RECRUITING,NO,"DRUG: Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant",FEMALE,"ADULT, OLDER_ADULT",PHASE2,34,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-04,2024-12-31
RECRUITING,NO,DEVICE: BioBridge® Collagen Matrix|PROCEDURE: Vascularized Lymph Node Transfer (VLNT),ALL,"ADULT, OLDER_ADULT",NA,60,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-10-26,2024-02-15
TERMINATED,NO,"OTHER: Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract",ALL,"ADULT, OLDER_ADULT",NA,12,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-08-30,2023-02-18
RECRUITING,NO,DEVICE: cryo-ablation,FEMALE,"ADULT, OLDER_ADULT",NA,186,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-01,2025-05-01
ACTIVE_NOT_RECRUITING,NO,DEVICE: CO2 LASER|DEVICE: CO2 SHAM LASER,FEMALE,"ADULT, OLDER_ADULT",NA,84,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-30,2022-08-30
RECRUITING,NO,BIOLOGICAL: Multi-epitope HER2 Peptide Vaccine TPIV100|BIOLOGICAL: Pertuzumab|OTHER: Placebo Administration|BIOLOGICAL: Sargramostim|BIOLOGICAL: Trastuzumab|BIOLOGICAL: Trastuzumab Emtansine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,480,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2020-02-20,2025-01-15
RECRUITING,NO,DRUG: YH32367,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,110,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-26,2026-10-06
COMPLETED,NO,BEHAVIORAL: Medical hypnosis|BEHAVIORAL: Internet-based Acceptance and Commitment Therapy (iACT)|BEHAVIORAL: Mindfulness session|BEHAVIORAL: Treatment as Usual (TAU),FEMALE,"ADULT, OLDER_ADULT",NA,203,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-10-01,2023-11-01
RECRUITING,NO,OTHER: Exercise training|OTHER: Control,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2020-01-01,2024-12-01
NOT_YET_RECRUITING,NO,BEHAVIORAL: Education program on healthy habits|BEHAVIORAL: Habitual,ALL,"ADULT, OLDER_ADULT",NA,78,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-06,2025-09
RECRUITING,NO,PROCEDURE: Cold dissection|PROCEDURE: Electrocautery Dissection,FEMALE,"ADULT, OLDER_ADULT",NA,234,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-01,2024-05-31
RECRUITING,NO,OTHER: Control Arm ACSM Guidelines|OTHER: Experimental Arm 6-12-25 repetitions per set,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2024-01-09,2027-01
RECRUITING,NO,RADIATION: hypofractionated radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,57,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-08,2025-04-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Magrolimab|DRUG: Nab-Paclitaxel|DRUG: Paclitaxel|DRUG: Sacituzumab Govitecan-hziy,ALL,"ADULT, OLDER_ADULT",PHASE2,90,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-14,2025-01
RECRUITING,NO,BEHAVIORAL: Diabetes Prevention Program-based lifestyle change intervention (DPP)|BEHAVIORAL: Highly Microbiota-Accessible Foods (HMAFs) intervention,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-04-01,2023-06
RECRUITING,NO,OTHER: Home_Based Digital Mindful Dance Program,FEMALE,"ADULT, OLDER_ADULT",NA,104,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-07-01,2024-12-30
RECRUITING,NO,"OTHER: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|DRUG: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)",ALL,"ADULT, OLDER_ADULT",PHASE3,1670,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-07,2041-07
COMPLETED,NO,DRUG: LUT014 Gel|DRUG: Placebo for LUT014 Gel,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,28,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-30,2022-07-15
RECRUITING,NO,DRUG: Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI,FEMALE,"ADULT, OLDER_ADULT",PHASE2,78,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-25,2025-07-01
COMPLETED,NO,PROCEDURE: Serratus Anterior Plane Block|PROCEDURE: Erector spinae plane block,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE,2020-01-10,2020-05-20
ACTIVE_NOT_RECRUITING,NO,DRUG: TQB2440 injection + Trastuzumab + Docetaxel|DRUG: Perjeta + Trastuzumab + Docetaxel,ALL,"ADULT, OLDER_ADULT",PHASE3,412,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-20,2023-12
ACTIVE_NOT_RECRUITING,NO,DRUG: inetetamab and PD-1 inhibitor combined with chemotherapy.,FEMALE,"ADULT, OLDER_ADULT",PHASE2,46,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-23,2024-12-30
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Behavioral Symptom Management for Young Adult Cancer Survivors,ALL,ADULT,NA,120,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-01-22,2024-05-30
RECRUITING,NO,BEHAVIORAL: Structured Hypnotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,62,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-07-31,2024-12-30
TERMINATED,NO,DRUG: FT516|DRUG: Avelumab|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: IL-2,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-07,2023-08-11
RECRUITING,NO,DRUG: Dato-DXd|DRUG: Durvalumab|DRUG: Capecitabine|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE3,1075,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-28,2030-03-27
UNKNOWN,NO,PROCEDURE: General anesthesia|PROCEDURE: Regional anesthesia,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-03-01,2022-03-01
RECRUITING,NO,PROCEDURE: Axillary mapping reverse,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-06-01,2023-12-01
UNKNOWN,NO,DRUG: Tacrolimus ointment,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-02-26,2022-09
UNKNOWN,NO,COMBINATION_PRODUCT: bupivacaine and triamcinolone,FEMALE,"ADULT, OLDER_ADULT",NA,22,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-07,2020-04
RECRUITING,NO,"DRUG: anlotinib, fulvestrant",FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-01,2026-08-31
RECRUITING,NO,DIAGNOSTIC_TEST: HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment,ALL,"ADULT, OLDER_ADULT",NA,22,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-02-01,2026-02-01
RECRUITING,NO,"OTHER: Behavioral, Psychological or Informational Intervention|OTHER: Behavioral, Psychological or Informational Intervention|OTHER: Best Practice|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration",FEMALE,"ADULT, OLDER_ADULT",NA,240,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-07-23,2026-04-01
ACTIVE_NOT_RECRUITING,YES,DRUG: Giredestrant|DRUG: Fulvestrant or an Aromatase Inhibitor (Physician Choice)|DRUG: LHRH Agonist,ALL,"ADULT, OLDER_ADULT",PHASE2,303,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-27,2024-06-27
RECRUITING,NO,DRUG: Fulvestrant plus AI plus ribociclib|DRUG: AI plus ribociclib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,202,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-31,2029-06-30
RECRUITING,NO,DRUG: Neoadjuvant Olaparib monotherapy group|COMBINATION_PRODUCT: Neoadjuvant combination therapy with olaparib plus durvalumab,ALL,"ADULT, OLDER_ADULT",PHASE2,50,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-07,2026-12-07
NOT_YET_RECRUITING,NO,DRUG: Tusamitamab ravtansine,ALL,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02,2025-05
RECRUITING,NO,DRUG: BCD-178|DRUG: Perjeta,FEMALE,"ADULT, OLDER_ADULT",PHASE3,374,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-30,2026-01-31
RECRUITING,NO,OTHER: Exercise Intervention|OTHER: Informational Intervention|OTHER: Nutritional Assessment|OTHER: Physical Performance Testing|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,ALL,OLDER_ADULT,NA,70,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-08-28,2025-05-15
ACTIVE_NOT_RECRUITING,NO,DRUG: SHR-A1811|DRUG: TROP2 ADC,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,56,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-14,2026-10-10
RECRUITING,NO,RADIATION: Regional lymph node radiotherapy|RADIATION: chest/whole breast irradiation,FEMALE,"ADULT, OLDER_ADULT",NA,1355,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-28,2031-05-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Niraparib|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,40,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-06-28,2029-08-28
ACTIVE_NOT_RECRUITING,NO,OTHER: Clinical Breast exam (CBE)|DEVICE: iBreastExam device|DIAGNOSTIC_TEST: mammogram,FEMALE,"ADULT, OLDER_ADULT",NA,310,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-01-29,2025-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Berzosertib|PROCEDURE: Biospecimen Collection|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|RADIATION: Radiation Therapy,ALL,"ADULT, OLDER_ADULT",PHASE1,42,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-24,2024-11-20
RECRUITING,NO,DRUG: Esketamine|DRUG: Saline Solution,FEMALE,"ADULT, OLDER_ADULT",PHASE4,36,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-10-08,2023-12-30
NOT_YET_RECRUITING,NO,DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Carboplatin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,82,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-01,2024-04-30
NOT_YET_RECRUITING,NO,OTHER: Very low calorie ketogenic diet (VLCKD)|BEHAVIORAL: Group educational intervention program (IGOBE),FEMALE,"ADULT, OLDER_ADULT",NA,220,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-10-15,2025-12-21
RECRUITING,NO,PROCEDURE: PVB group|PROCEDURE: MTP block group|PROCEDURE: Control Group,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-01-01,2023-12-31
TERMINATED,NO,BEHAVIORAL: Cognitive Behavior Therapy|OTHER: Interview|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,ALL,"ADULT, OLDER_ADULT",NA,5,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-04-08,2023-03-30
UNKNOWN,NO,DEVICE: mChemotherapy,ALL,"ADULT, OLDER_ADULT",NA,76,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-06-07,2023-02-28
COMPLETED,NO,DEVICE: Medical Device Usage and Evaluation|OTHER: Questionnaire Administration,ALL,"ADULT, OLDER_ADULT",NA,94,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-03-10,2023-01-18
UNKNOWN,NO,DRUG: Chidamide in combination with chemotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-30,2022-12
RECRUITING,NO,BEHAVIORAL: pre-trained guided slow paced breathing (~6 breaths per minute),FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-11-29,2025-11-02
COMPLETED,NO,DRUG: Tiragolumab|DRUG: Atezolizumab|DRUG: Nab-paclitaxel|DRUG: Tiragolumab|DRUG: Atezolizumab|DRUG: Nab-paclitaxel|DRUG: Carboplatin|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Granulocyte colony-stimulating factor (G-CSF)|DRUG: Granulocyte-macrophage colony-stimulating factor (GM-CSF),ALL,"ADULT, OLDER_ADULT",PHASE1,83,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-28,2023-03-08
RECRUITING,NO,DRUG: CFI-402257|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,44,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-27,2025-08
RECRUITING,NO,RADIATION: Ultra-fractionated radiation therapy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,65,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10-25,2030-10-25
RECRUITING,NO,PROCEDURE: reSLNB arm,FEMALE,"ADULT, OLDER_ADULT",NA,532,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-01,2029-01-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Inetetamab plus pyrotiniband and capecitabine,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-20,2023-08-31
RECRUITING,NO,RADIATION: Single dose ablative radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-24,2035-03
RECRUITING,NO,DRUG: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,46,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-28,2026-12-31
RECRUITING,NO,DEVICE: cryotherapy|OTHER: education,FEMALE,"ADULT, OLDER_ADULT",NA,94,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2023-05-01,2024-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Cannabis capsules,ALL,"ADULT, OLDER_ADULT",PHASE1,12,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-08,2023-12-31
TERMINATED,YES,DRUG: Rucaparib,ALL,"ADULT, OLDER_ADULT",PHASE2,83,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-16,2022-07-15
RECRUITING,NO,DIETARY_SUPPLEMENT: Mushroom|DRUG: Placebo Administration|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2023-10-18,2025-10
RECRUITING,NO,DRUG: Injection of 99mTc-NM-02|DRUG: Injection of 188Re-NM-02,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-24,2024-09-30
NOT_YET_RECRUITING,NO,DEVICE: REBECCA system (smartwatch + mobile app use),FEMALE,"ADULT, OLDER_ADULT",NA,110,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-09-01,2025-12-31
RECRUITING,NO,DRUG: TAK-500|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,313,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-14,2026-08-11
RECRUITING,NO,DRUG: Cimetidine|DRUG: Dexamethasone|DRUG: Diphenhydramine|DRUG: Famotidine|DRUG: Paclitaxel|OTHER: Quality-of-Life Assessment|DRUG: Ranitidine,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-10-07,2024-12-31
RECRUITING,NO,OTHER: Pain Neuroscience Education|OTHER: Biomedical Pain Education|OTHER: Standard Physiotherapy Program,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-02-15,2025-02-15
UNKNOWN,NO,PROCEDURE: subcutaneous mastectomy|PROCEDURE: endoscopic subcutaneous mastectomy,FEMALE,"ADULT, OLDER_ADULT",NA,287,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-01,2022-12-31
NOT_YET_RECRUITING,NO,OTHER: Motivational Interviewing,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-04-30,2022-10-30
RECRUITING,NO,DRUG: SHR-A1811|DRUG: Pyrotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,61,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-16,2029-02-28
WITHDRAWN,NO,DEVICE: Y-90 SIR-Spheres|PROCEDURE: Yttrium-90 Microsphere Radioembolization|OTHER: Systemic Therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-17,2025-07-31
RECRUITING,NO,DEVICE: Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics,ALL,"ADULT, OLDER_ADULT",NA,224,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-03-02,2025-06-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Niraparib,ALL,"ADULT, OLDER_ADULT",PHASE2,26,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-16,2025-11-13
RECRUITING,NO,DRUG: FES,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-10-11,2023-10
WITHDRAWN,NO,DRUG: Carboplatin|BIOLOGICAL: Pembrolizumab|GENETIC: Transferrin Receptor-Targeted Liposomal p53 cDNA,FEMALE,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-10,2022-11-10
RECRUITING,NO,RADIATION: IMRT/VMAT-Based Accelerated Partial Breast Irradiation,FEMALE,"ADULT, OLDER_ADULT",NA,91,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-01,2027-03-31
RECRUITING,NO,DEVICE: hyperbaric oxygen chamber,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-06,2024-12-31
RECRUITING,NO,PROCEDURE: Cryotherapy treatment,FEMALE,"ADULT, OLDER_ADULT",NA,5,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-02-16,2023-12
RECRUITING,NO,DRUG: Chidamide,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-16,2026-10-01
RECRUITING,NO,DRUG: IDE-161,ALL,"ADULT, OLDER_ADULT",PHASE1,68,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-05,2025-09
RECRUITING,NO,DRUG: Tucatinib 150 MG|DRUG: Trastuzumab|DRUG: Capecitabine|RADIATION: Brain & Spinal Radiation,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-25,2028-10-05
RECRUITING,NO,OTHER: fasting diet,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-07-01,2024-07
RECRUITING,NO,COMBINATION_PRODUCT: Pertuzumab+TRASTUZUMAB|DRUG: ADJUVANT ENDOCRINE THERAPY,ALL,"ADULT, OLDER_ADULT",PHASE2,375,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-11,2030-09-01
COMPLETED,NO,"OTHER: Written, Oral and Visual Education|OTHER: Written, Oral and Visual Education|OTHER: Written, Oral and Visual Education",FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-08-01,2020-10-30
COMPLETED,NO,PROCEDURE: Sentinel lymph node biopsy|PROCEDURE: Breast massage|PROCEDURE: Blue dye injection,ALL,"ADULT, OLDER_ADULT",NA,77,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-12-06,2023-07-06
RECRUITING,NO,DRUG: FWD1802|DRUG: palbocilib,FEMALE,"ADULT, OLDER_ADULT",PHASE1,99,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-12,2026-02
COMPLETED,NO,OTHER: Customizable support material|OTHER: Non-customizable support material,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,125,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2021-05-21,2022-03-13
RECRUITING,NO,DEVICE: Ommaya reservoir|DRUG: Systematic chemotherapy,ALL,"ADULT, OLDER_ADULT",PHASE4,48,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-03-01,2027-01-01
TERMINATED,YES,DRUG: Talazoparib|DRUG: Atezolizumab|RADIATION: Radiation,ALL,"ADULT, OLDER_ADULT",PHASE2,1,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-04,2022-12-20
RECRUITING,NO,BIOLOGICAL: UCMYM802 Injection,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-01-01,2025-04
UNKNOWN,NO,BEHAVIORAL: iACT-BC: Oncovox,FEMALE,"ADULT, OLDER_ADULT",NA,140,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-11-15,2022-05
RECRUITING,NO,DRUG: Niraparib|DRUG: Dostarlimab,ALL,"ADULT, OLDER_ADULT",PHASE2,62,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-18,2029-07-17
COMPLETED,NO,BEHAVIORAL: Combined Exercise + Behavioural Counselling|BEHAVIORAL: Active Control,FEMALE,"ADULT, OLDER_ADULT",NA,21,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2023-02-01,2023-09-30
RECRUITING,NO,BEHAVIORAL: Postcard|BEHAVIORAL: Letter|BEHAVIORAL: Auto-dialer|BEHAVIORAL: Live call,FEMALE,"ADULT, OLDER_ADULT",NA,17650,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2023-05-10,2024-06
RECRUITING,NO,BIOLOGICAL: LYL797,ALL,"ADULT, OLDER_ADULT",PHASE1,54,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-29,2026-09
RECRUITING,NO,OTHER: Acupuncture,FEMALE,"ADULT, OLDER_ADULT",NA,66,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-11-01,2025-05-31
RECRUITING,NO,"DRUG: Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole",FEMALE,"ADULT, OLDER_ADULT",PHASE2,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-02-10,2027-12-31
RECRUITING,NO,DRUG: Adenosine Stress Cardiac Magnetic Resonance Imaging|DIAGNOSTIC_TEST: Electrocardiogram|DIAGNOSTIC_TEST: Computed Tomography Angiogram|OTHER: Laboratory Testing|BEHAVIORAL: Quality of Life Survey,FEMALE,ADULT,EARLY_PHASE1,90,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-02,2027-12
RECRUITING,NO,BEHAVIORAL: Decision aid video|BEHAVIORAL: Genetic counseling informational brochure,FEMALE,"ADULT, OLDER_ADULT",NA,106,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-06-06,2024-12-31
RECRUITING,NO,DRUG: Trastuzumab Deruxtecan|DRUG: Paclitaxel|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Doxorubicin|DRUG: cyclophosphamide,ALL,"ADULT, OLDER_ADULT",PHASE3,900,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-25,2027-04-30
RECRUITING,NO,DEVICE: da Vinci SP Surgical System,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-08,2024-02
NOT_YET_RECRUITING,NO,BEHAVIORAL: A multimodal prehabilitation programme,ALL,"ADULT, OLDER_ADULT",NA,11,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2024-03-01,2025-03-01
COMPLETED,NO,DRUG: Lidocaine in Saline|DRUG: Duloxetine 30 MG|DRUG: Normal saline,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-01-15,2022-07-05
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Robot-assisted Nipple Sparing Mastectomy|OTHER: Survey Administration|DEVICE: RNSM,ALL,"ADULT, OLDER_ADULT",NA,4,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-11-17,2023-12-31
COMPLETED,NO,OTHER: Meaning Centered Coping Program,FEMALE,"ADULT, OLDER_ADULT",NA,44,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-30,2022-12-30
WITHDRAWN,NO,DRUG: SM-88,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10,2023-10
NOT_YET_RECRUITING,NO,DRUG: Fluzoparib|DRUG: Apatinib Mesylate|DRUG: Capecitabine tablets|DRUG: Vinorelbine Tartrate Oral|DRUG: Eribulin mesylate injection|DRUG: Gemcitabine Hydrochloride|DRUG: Paclitaxel-albumin,FEMALE,"ADULT, OLDER_ADULT",PHASE3,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02,2031-03
NOT_YET_RECRUITING,NO,DIAGNOSTIC_TEST: Contrast-enhanced CT lymphography with the periareolar injection of iopamidol,FEMALE,"ADULT, OLDER_ADULT",NA,31,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-10-01,2023-08-01
RECRUITING,NO,BEHAVIORAL: Interpersonal Psychotherapy|DRUG: Venlafaxine HCl ER,ALL,"ADULT, OLDER_ADULT",PHASE3,20,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-03-01,2024-12-31
UNKNOWN,NO,OTHER: Optical and infrared imaging,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-07-01,2022-12
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: exosome and ctDNA evaluation,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2021-05-01,2028-07-01
RECRUITING,NO,RADIATION: stereotactic body radiotherapy|DRUG: CMP-001,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-08,2025-12
COMPLETED,NO,BEHAVIORAL: Educational Intervention,FEMALE,"ADULT, OLDER_ADULT",NA,46,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-03-31,2022-06-03
RECRUITING,NO,RADIATION: Stereotactic Ablative Breast Radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,18,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-05,2026-05
ACTIVE_NOT_RECRUITING,NO,DEVICE: Contrast-enhanced mammography|DRUG: Iodinated Contrast Media (ICM),FEMALE,"ADULT, OLDER_ADULT",PHASE4,600,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2021-02-15,2024-01-31
RECRUITING,NO,DRUG: Adebrelimab|DRUG: dalpiciclib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,82,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-30,2026-11-30
RECRUITING,NO,DEVICE: Activity tracker,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-09-20,2025-09
TERMINATED,NO,DRUG: Neratinib + endocrine therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-23,2021-11-29
COMPLETED,NO,BEHAVIORAL: Support,ALL,"ADULT, OLDER_ADULT",NA,63,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-05-05,2023-06-10
UNKNOWN,NO,DRUG: SC10914,ALL,"ADULT, OLDER_ADULT",PHASE2,78,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-12,2022-08-30
RECRUITING,NO,DRUG: Docetaxel or Paclitaxel|DRUG: Cyclophosphamide + Doxorrubicin,FEMALE,"ADULT, OLDER_ADULT",PHASE3,494,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-12,2029-08-23
NOT_YET_RECRUITING,NO,BEHAVIORAL: the Bone@BC app,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-12-01,2024-10-30
RECRUITING,NO,DIAGNOSTIC_TEST: Delayed SLND|DIAGNOSTIC_TEST: Late SLND,FEMALE,"ADULT, OLDER_ADULT",PHASE3,500,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-01,2027-12-30
COMPLETED,NO,"COMBINATION_PRODUCT: Cosmetic cream (Alantel (R): aloe vera, chamomile and thime)|COMBINATION_PRODUCT: Usual treatment",ALL,"CHILD, ADULT, OLDER_ADULT",NA,78,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2022-07-19,2023-07-30
RECRUITING,NO,"DIETARY_SUPPLEMENT: Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)",FEMALE,"ADULT, OLDER_ADULT",PHASE2,145,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-15,2026-05-15
NOT_YET_RECRUITING,NO,BEHAVIORAL: Digital Cognitive Behavioral Therapy for Insomnia,FEMALE,"ADULT, OLDER_ADULT",NA,264,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-16,2025-08
RECRUITING,NO,BEHAVIORAL: THRIVE|BEHAVIORAL: Health Education Support Program,FEMALE,OLDER_ADULT,NA,270,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-03-20,2027-02-01
NOT_YET_RECRUITING,NO,DRUG: Palbociclib|DRUG: Paclitaxel|DRUG: Carboplatin,ALL,"ADULT, OLDER_ADULT",PHASE2,126,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-01,2026-12-06
RECRUITING,NO,DRUG: TNG260|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,126,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-12,2025-06
RECRUITING,NO,BEHAVIORAL: Cognitively-Based Compassion Training for Survivors|BEHAVIORAL: Cognitively-Based Compassion Training for Dyads|BEHAVIORAL: Health Education,ALL,"ADULT, OLDER_ADULT",PHASE2,452,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-03-20,2027-06
RECRUITING,NO,DRUG: [18F]-FDG,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2025-03-01,2028-06-30
RECRUITING,NO,OTHER: Digital Photography|PROCEDURE: Lumbar Puncture|PROCEDURE: Magnetic Resonance Imaging|DEVICE: Medical Device Usage and Evaluation,ALL,"ADULT, OLDER_ADULT",NA,5,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-04-07,2027-03-01
RECRUITING,NO,BIOLOGICAL: T3011|BIOLOGICAL: T3011|BIOLOGICAL: T3011|BIOLOGICAL: T3011|BIOLOGICAL: T3011|BIOLOGICAL: T3011|BIOLOGICAL: T3011,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,233,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-21,2024-01
NOT_YET_RECRUITING,NO,DRUG: Tamoxifen 10 Mg Tablet|OTHER: Intermittent caloric restriction|BEHAVIORAL: Step counter Device,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-09-01,2026-07-31
RECRUITING,NO,DRUG: MDNA11|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,115,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-27,2026-12-30
NOT_YET_RECRUITING,NO,OTHER: Thermal cure with a primary dermatological indication,FEMALE,"ADULT, OLDER_ADULT",NA,110,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: OTHER,2023-09,2026-04
NOT_YET_RECRUITING,NO,DRUG: Taxane and Carboplatin|DRUG: Short-term Sintilimab|PROCEDURE: Surgery,FEMALE,"ADULT, OLDER_ADULT",PHASE4,48,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-01,2034-12-31
NOT_YET_RECRUITING,NO,PROCEDURE: Radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,1380,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-01,2025-06-30
RECRUITING,NO,OTHER: Digitized support,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-10-25,2024-12
ENROLLING_BY_INVITATION,NO,BEHAVIORAL: Stick Together,FEMALE,ADULT,NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-02-01,2024-05-31
RECRUITING,NO,OTHER: Reminder message,FEMALE,"ADULT, OLDER_ADULT",NA,160,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-04-01,2024-03-01
TERMINATED,NO,BIOLOGICAL: REMD-477,ALL,"ADULT, OLDER_ADULT",PHASE1,1,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-13,2021-05-05
COMPLETED,NO,DRUG: Anastrozole|DRUG: Letrozole,FEMALE,"ADULT, OLDER_ADULT",PHASE2,161,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-28,2022-12-12
RECRUITING,NO,DRUG: Camrelizumab plus Famitinib with/without nab-Palitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE2,46,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-01,2023-09-01
RECRUITING,NO,OTHER: Comprehensive Geriatric Assessment|BEHAVIORAL: Health Education|OTHER: Medical Device Usage and Evaluation|OTHER: Supportive Care,ALL,OLDER_ADULT,NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-06-17,2024-12-31
RECRUITING,NO,OTHER: standard cold cap|OTHER: scalp-cooling technique,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,196,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2023-08-03,2026-09-03
COMPLETED,NO,DRUG: Onapristone,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-06,2021-04-30
COMPLETED,NO,OTHER: Using mobile information application about before and after surgery,FEMALE,"ADULT, OLDER_ADULT",NA,82,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-04-01,2021-08-30
RECRUITING,NO,DRUG: Vaginal Dehydroepiandrosterone|COMBINATION_PRODUCT: Vaginal Polycarbophil Moisturizer,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-06-07,2025-06
WITHDRAWN,NO,DRUG: Niraparib|DRUG: M4344|DRUG: Niraparib|DRUG: M4344|DRUG: Niraparib|DRUG: Niraparib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-01,2023-09-01
NOT_YET_RECRUITING,NO,DRUG: Disitamab Vedotin+Anlotinib,ALL,"ADULT, OLDER_ADULT",PHASE2,35,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-08-10,2025-12-31
RECRUITING,NO,DRUG: Pembrolizumab & ADG106 (Phase Ib)|DRUG: Pembrolizumab & ADG106 (Phase II),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,51,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-12,2026-12-31
RECRUITING,NO,DRUG: L-NMMA,ALL,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-01-12,2028-12-02
TERMINATED,NO,DRUG: EXPERIMENTAL ARM|OTHER: CONTROL GROUP|RADIATION: Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions),FEMALE,"ADULT, OLDER_ADULT",PHASE3,15,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-04,2023-04-27
RECRUITING,NO,DRUG: BGB-43395|DRUG: Fulvestrant|DRUG: Letrozole,ALL,"ADULT, OLDER_ADULT",PHASE1,79,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-01,2026-05
ACTIVE_NOT_RECRUITING,NO,OTHER: Early Diagnosis on BSE,FEMALE,ADULT,NA,76,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-04-04,2023-09-04
WITHDRAWN,NO,DRUG: Carvedilol|DRUG: Lisinopril|DRUG: Pravastatin|DRUG: Spironolactone,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2020-09-01,2023-04-18
RECRUITING,NO,RADIATION: Genomically Guided Radiation Therapy|RADIATION: Genomically Guided Radiation Therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,86,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-04,2026-11-01
RECRUITING,NO,DRUG: Aminolevulinic Acid Hydrochloride|DEVICE: Eagle V1.2 Imaging System|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE3,370,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-27,2026-06
NOT_YET_RECRUITING,NO,DRUG: Chimeric receptor T-cells + Trastuzumab|DRUG: Fludarabine and Cyclophosphosphamide,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,36,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-01,2027-12-31
RECRUITING,NO,DRUG: 153-Sm-DOTMP (Samarium-153-DOTMP),ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,17,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-05,2024-11-01
NOT_YET_RECRUITING,NO,DEVICE: FR-101 Chest Dressing,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-09-18,2024-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Abemaciclib|DRUG: Paclitaxel|DRUG: Letrozole|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE2,162,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-02,2024-05
TERMINATED,NO,DRUG: Venetoclax|DRUG: Capecitabine,ALL,"ADULT, OLDER_ADULT",PHASE1,4,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-21,2020-10-08
ACTIVE_NOT_RECRUITING,NO,DRUG: alpelisib|DRUG: placebo|DRUG: nab-paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE3,137,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-08,2024-09-02
NOT_YET_RECRUITING,NO,DIETARY_SUPPLEMENT: APPOPRTAL®|OTHER: Placebo,FEMALE,"ADULT, OLDER_ADULT",NA,92,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2023-11-27,2024-12-27
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: 68Ga-FAPI PET/CT scan,ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-05-01,2024-02-01
RECRUITING,NO,PROCEDURE: PECS Block|OTHER: Control Group,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-01-01,2024-08-30
TERMINATED,NO,"BEHAVIORAL: Online-delivered physical activity intervention.|BEHAVIORAL: Printed, individualized resistance-based physical activity program.",FEMALE,"ADULT, OLDER_ADULT",NA,56,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-12-01,2023-08-24
RECRUITING,NO,DRUG: Fermented Wheat Germ Extract,ALL,"ADULT, OLDER_ADULT",PHASE1,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-02,2025-12
RECRUITING,NO,DRUG: Bone modifying agent,ALL,"ADULT, OLDER_ADULT",PHASE4,240,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-09,2025-11
RECRUITING,NO,BIOLOGICAL: Pembrolizumab|OTHER: Patient Observation|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment,ALL,"ADULT, OLDER_ADULT",PHASE3,1295,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-10,2033-05-31
COMPLETED,NO,OTHER: Music intervention,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-06-05,2022-03-27
UNKNOWN,NO,OTHER: Decision aid (DA) for breast cancer screening|OTHER: Standarised information for breast cancer screening,FEMALE,"ADULT, OLDER_ADULT",NA,3269,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-07-01,2022-10-31
RECRUITING,NO,DRUG: Lenvatinib + Letrozole|DRUG: Fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-27,2025-08
NOT_YET_RECRUITING,NO,DIAGNOSTIC_TEST: CEDM|DIAGNOSTIC_TEST: CDBT,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-01,2026-08
RECRUITING,NO,BEHAVIORAL: Cognitive-Behavioral Therapy for Insomnia (CBT-I)|BEHAVIORAL: Sleep Education Control (EDU),FEMALE,"ADULT, OLDER_ADULT",NA,250,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-02-01,2028-12-31
RECRUITING,NO,DRUG: Tucidinostat|DRUG: nab-paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE2,90,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-07,2025-12-01
RECRUITING,NO,RADIATION: Neoadjuvant radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-04-01,2024-03-01
RECRUITING,NO,BEHAVIORAL: Proactive nurse-led telephone follow-up,ALL,"ADULT, OLDER_ADULT",NA,512,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2024-01-20,2025-12
RECRUITING,NO,DRUG: BBI-355,ALL,"ADULT, OLDER_ADULT",PHASE1,47,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-24,2026-01-31
RECRUITING,NO,DRUG: Systemic therapy for 12 weeks after primary registration|PROCEDURE: Radiation therapy (SBRT/conventional RT)|PROCEDURE: Surgery|DRUG: Same systemic therapy after secondary registration,ALL,"ADULT, OLDER_ADULT",PHASE3,340,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-08,2032-10-31
RECRUITING,NO,DRUG: INCB0123667,ALL,"ADULT, OLDER_ADULT",PHASE1,340,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-05,2026-07-30
RECRUITING,NO,"COMBINATION_PRODUCT: Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine",ALL,"ADULT, OLDER_ADULT",PHASE1,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09-18,2025-11-01
UNKNOWN,NO,DRUG: Chidamide+ Fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE4,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-02-07,2022-12-30
UNKNOWN,NO,DIAGNOSTIC_TEST: Breast MRI|DIAGNOSTIC_TEST: Contrast Enhanced Mammography,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-01-19,2023-01
COMPLETED,NO,DRUG: Etoricoxib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,144,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-03-01,2021-06-28
COMPLETED,NO,DRUG: Rosuvastatin|DRUG: Rosuvastatin + BAY1817080,ALL,ADULT,PHASE1,14,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-03-02,2020-12-07
COMPLETED,NO,DRUG: Utidelone Injection; capecitabine|DRUG: Utidelone,FEMALE,"ADULT, OLDER_ADULT",PHASE1,16,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-10-15,2021-02-19
UNKNOWN,NO,OTHER: Adapted Physical Activity,FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-11-10,2022-11
RECRUITING,NO,DRUG: Huaier granule,ALL,"ADULT, OLDER_ADULT",PHASE4,379,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05-08,2025-08
RECRUITING,NO,DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07104091 + PF-07220060 + fulvestrant dose expansion|DRUG: PF-07104091 + PF-07220060 + fulvestrant dose expansion|DRUG: PF-07104091 + PF-07220060 + letrozole dose expansion|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,240,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-14,2026-09-13
RECRUITING,NO,BEHAVIORAL: High Intensity Interval Exercise|BEHAVIORAL: Moderate Intensity Walking,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2023-04-01,2025-03-15
RECRUITING,NO,PROCEDURE: No axillary surgery,FEMALE,"ADULT, OLDER_ADULT",NA,136,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-03,2028-09
NOT_YET_RECRUITING,NO,DRUG: Nanoxel M|DRUG: Taxotere|DRUG: Doxorubicin|DRUG: Cyclophosphamide,FEMALE,"ADULT, OLDER_ADULT",PHASE3,320,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-01,2024-12
COMPLETED,NO,DRUG: Tenalisib|DRUG: Tenalisib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-13,2023-03-31
RECRUITING,NO,DRUG: Anti-PD-1 monoclonal antibody|DRUG: VEGFR2 Tyrosine Kinase Inhibitor,FEMALE,"ADULT, OLDER_ADULT",PHASE2,58,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-01,2025-09-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Sacituzumab Govitecan-hziy,ALL,"ADULT, OLDER_ADULT",PHASE2,80,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-23,2024-12
RECRUITING,NO,BEHAVIORAL: Mind Programme|BEHAVIORAL: Support Group,FEMALE,"ADULT, OLDER_ADULT",NA,153,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-10-01,2025-12
TERMINATED,YES,DRUG: AL101,ALL,"ADULT, OLDER_ADULT",PHASE2,18,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-14,2022-10-11
UNKNOWN,NO,DEVICE: MUST device,FEMALE,"ADULT, OLDER_ADULT",NA,1333,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-01-14,2021-11
NOT_YET_RECRUITING,NO,DRUG: NTQ1062 with Fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE1,42,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-20,2025-07
RECRUITING,NO,DRUG: GB491 combined with Letrozole|DRUG: Placebo combined with Letrozole,ALL,"ADULT, OLDER_ADULT",PHASE3,350,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-14,2027-01-30
RECRUITING,NO,DRUG: SHR-1316|DRUG: SHR6390|DRUG: Nab paclitaxel|DRUG: SERD|DRUG: AI,FEMALE,"ADULT, OLDER_ADULT",PHASE2,338,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-06,2026-08-01
RECRUITING,NO,BEHAVIORAL: Community Health Worker support,ALL,"ADULT, OLDER_ADULT",NA,1116,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-05-05,2026-09-30
TERMINATED,NO,DEVICE: OCT- based investigational imaging device,FEMALE,"ADULT, OLDER_ADULT",NA,58,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2020-02-11,2021-12-07
RECRUITING,NO,DRUG: Anlotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-30,2025-07-30
RECRUITING,NO,OTHER: Pre-consultation electronic patient decision aid|OTHER: In-consultation paper-based patient decision aid,ALL,"ADULT, OLDER_ADULT",NA,274,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-11-15,2024-12
RECRUITING,NO,BEHAVIORAL: PSAI|BEHAVIORAL: One day seminar,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-01-04,2024-01
RECRUITING,NO,DEVICE: Acupuncture|DEVICE: Sham acupuncture,FEMALE,"ADULT, OLDER_ADULT",NA,264,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-10-20,2025-06
NOT_YET_RECRUITING,NO,DRUG: Paclitaxel + Trastuzumab|DRUG: Trastuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE3,800,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-15,2030-12-15
RECRUITING,NO,OTHER: Best Practice|OTHER: Internet-Based Intervention|OTHER: Survey Administration,FEMALE,"CHILD, ADULT",NA,360,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-06-28,2025-08-31
NOT_YET_RECRUITING,NO,DRUG: Pentoxifylline|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-12-25,2024-04-05
UNKNOWN,NO,DRUG: Eribulin|DRUG: anti-PD-1 antibody,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-01,2023-06-30
RECRUITING,NO,DRUG: pyrotinib+capecitabine+bevacizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-30,2025-11-30
RECRUITING,NO,DRUG: Ribociclib|RADIATION: Postoperative Radiation Therapy,FEMALE,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-03,2030-03-01
COMPLETED,NO,"DRUG: Prasterone (DHEA), Micronized",FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE4,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-09-01,2021-12-01
NOT_YET_RECRUITING,NO,BEHAVIORAL: Behavioral Dietary Intervention|BEHAVIORAL: Behavioral Intervention|PROCEDURE: Biospecimen Collection|OTHER: Dietary Intervention|OTHER: Educational Intervention|OTHER: Exercise Intervention|OTHER: Health Promotion and Education|OTHER: Internet-Based Intervention|OTHER: Interview|BEHAVIORAL: Lifestyle Counseling|OTHER: Medical Device Usage and Evaluation|OTHER: Medical Device Usage and Evaluation|OTHER: Nutritional Intervention|OTHER: Questionnaire Administration|BEHAVIORAL: Telephone-Based Intervention,FEMALE,"ADULT, OLDER_ADULT",NA,620,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2024-05-15,2027-06-01
NOT_YET_RECRUITING,NO,DRUG: Abemaciclib|DRUG: Letrozole,FEMALE,"ADULT, OLDER_ADULT",PHASE1,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-21,2032-09-30
WITHDRAWN,NO,DRUG: monosialic gangliosides|OTHER: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-09-09,2022-08-22
RECRUITING,NO,DEVICE: CAPABLE cohort,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-05-16,2024-01-31
RECRUITING,NO,DRUG: PF-07104091 monotherapy dose escalation|DRUG: PF-07104091 + palbociclib + fulvestrant|DRUG: PF-07104091 + palbociclib + letrozole|DRUG: PF-07104091 monotherapy dose expansion (ovarian)|DRUG: PF-07104091 monotherapy dose expansion (SCLC)|DRUG: PF-07104091 + Fulvestrant (post CDK4/6)|DRUG: PF-0704091 + Fulvestrant (post CDK4/6),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,320,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-16,2026-01-07
ACTIVE_NOT_RECRUITING,NO,DRUG: Niraparib,ALL,"ADULT, OLDER_ADULT",PHASE2,22,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-15,2025-01-01
NOT_YET_RECRUITING,NO,OTHER: Automated message|OTHER: Opt-out scheduling,FEMALE,"ADULT, OLDER_ADULT",NA,871,FED,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: SCREENING",2022-04-18,2022-08-31
COMPLETED,NO,DEVICE: Diagnostic microprobe (inPROBE) medical device,FEMALE,"ADULT, OLDER_ADULT",NA,18,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-08-24,2023-03-02
RECRUITING,NO,DRUG: Abemaciclib|DRUG: Bicalutamide,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-29,2024-09
RECRUITING,NO,DRUG: LCB84|DRUG: Anti-PD-1 monoclonal antibody,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,300,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-05,2027-05
RECRUITING,NO,OTHER: Empowerment and Navigation|OTHER: SOC,FEMALE,"ADULT, OLDER_ADULT",NA,600,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2023-01-18,2027-09
NOT_YET_RECRUITING,NO,PROCEDURE: Axillary Lymph Node Dissection|PROCEDURE: Axillary Reverse Mapping|PROCEDURE: Lymphaticovenous Bypass,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-04-01,2028-09-01
COMPLETED,NO,OTHER: Yoga|OTHER: Clinical Pilates|OTHER: An educational booklet,FEMALE,"ADULT, OLDER_ADULT",NA,28,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-10-29,2023-02-14
NOT_YET_RECRUITING,NO,DRUG: Eflapegrastim,FEMALE,"ADULT, OLDER_ADULT",PHASE4,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-08,2025-01
NOT_YET_RECRUITING,NO,DRUG: utidelone,FEMALE,"ADULT, OLDER_ADULT",PHASE2,61,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-10,2025-03-09
UNKNOWN,NO,"DIETARY_SUPPLEMENT: Flax ""milk""|DIETARY_SUPPLEMENT: Oat fibre ""milk""",FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-10-21,2022-12-31
NOT_YET_RECRUITING,NO,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|DRUG: F-18 16 Alpha-Fluoroestradiol|PROCEDURE: Positron Emission Tomography|OTHER: Questionnaire Administration|RADIATION: Stereotactic Body Radiation Therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,18,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-06-11,2025-12-11
RECRUITING,NO,PROCEDURE: robot assisted nipple sparing mastectomy(RNSM)|PROCEDURE: Conventional nipple sparing mastectomy(CNSM),FEMALE,"ADULT, OLDER_ADULT",NA,790,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-10-26,2030-06
RECRUITING,NO,PROCEDURE: Single level serratus anterior plane block|PROCEDURE: Single level serratus anterior plane block with dexmedetomidine|PROCEDURE: Bilevel serratus anterior plane block|PROCEDURE: Bilevel serratus anterior plane block with dexmedetomidine,FEMALE,"ADULT, OLDER_ADULT",NA,172,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-05-10,2024-04-25
RECRUITING,NO,DRUG: lidocaine 2% and 10%|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE4,4300,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-07-27,2028-07
COMPLETED,NO,OTHER: Menthol Application,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-07-01,2023-04-01
NOT_YET_RECRUITING,NO,OTHER: Energy Resonance by Cutaneous Stimulation,ALL,"ADULT, OLDER_ADULT",NA,57,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-10-02,2023-10-09
COMPLETED,NO,DEVICE: mp-BUS data collection,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-11-15,2021-12-13
RECRUITING,NO,DIAGNOSTIC_TEST: ctDNA,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-06-05,2028-12-05
WITHDRAWN,NO,DRUG: Tucatinib|DRUG: Abemaciclib|DRUG: Trastuzumab|DRUG: Aromatase Inhibitor,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-28,2020-09-22
RECRUITING,NO,DIAGNOSTIC_TEST: Nanomechanical Phenotype Test,ALL,"ADULT, OLDER_ADULT",NA,2706,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-11-02,2035-11
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Contrast-Enhanced Mammography|PROCEDURE: Digital Tomosynthesis Mammography|OTHER: Electronic Health Record Review|DRUG: Iodinated Contrast Agent,FEMALE,"ADULT, OLDER_ADULT",NA,89,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-03-19,2024-12-31
RECRUITING,NO,DEVICE: Ultrasound Imaging,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-02-14,2025-04-01
RECRUITING,NO,DEVICE: Physical activity intervention with connected devices,FEMALE,"ADULT, OLDER_ADULT",NA,244,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-06-24,2025-06
RECRUITING,NO,DRUG: Albumin binding paclitaxel+ trastuzumab+ patuzumab|DRUG: Docetaxel+ carboplatin+ trastuzumab + patuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE3,686,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-18,2023-12-31
RECRUITING,NO,"DRUG: pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage",FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-01,2023-12-31
NOT_YET_RECRUITING,NO,OTHER: APA Program|OTHER: Recommendations for physical activity,FEMALE,"ADULT, OLDER_ADULT",NA,866,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2024-01-01,2026-01-01
RECRUITING,NO,DEVICE: Muse MRgFUS System,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,34,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-02,2027-08-01
NOT_YET_RECRUITING,NO,DRUG: JSKN003|DRUG: Capecitabine tablets|DRUG: Gemcitabine hydrochloride for injection|DRUG: Vinorelbine tartrate injection|DRUG: Paclitaxel for injection (albumin-bound type)|DRUG: Docetaxel injection|DRUG: Eribulin mesylate injection,ALL,"ADULT, OLDER_ADULT",PHASE3,400,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-01,2029-03-01
RECRUITING,NO,RADIATION: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|DRUG: Letrozole 2.5Mg Tab|DRUG: Palbociclib 125mg,FEMALE,"ADULT, OLDER_ADULT",PHASE2,102,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-12,2025-10-31
RECRUITING,NO,BIOLOGICAL: DNX-2440,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-15,2023-12-31
UNKNOWN,NO,PROCEDURE: cryotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-15,2022-10-15
COMPLETED,NO,BEHAVIORAL: Aerobic Exercise,FEMALE,"ADULT, OLDER_ADULT",NA,210,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-09-08,2023-03-02
RECRUITING,NO,DIETARY_SUPPLEMENT: Omega-3 FA|DIETARY_SUPPLEMENT: Vitamin D|COMBINATION_PRODUCT: Combined Omega-3 and Vitamin D Supplementation,FEMALE,ADULT,EARLY_PHASE1,88,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-04-20,2022-12-30
RECRUITING,NO,DRUG: IMM2520,ALL,"ADULT, OLDER_ADULT",PHASE1,48,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-23,2025-10-26
COMPLETED,NO,OTHER: Art therapy,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2021-09-01,2022-10-07
TERMINATED,NO,DRUG: SEA-TGT|DRUG: sasanlimab|DRUG: brentuximab vedotin,ALL,"ADULT, OLDER_ADULT",PHASE1,132,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-29,2023-12-01
RECRUITING,NO,PROCEDURE: Contrast-Enhanced Ultrasound|DRUG: Perflutren Lipid Microspheres|DRUG: Sulfur Hexafluoride Lipid Microspheres,FEMALE,"ADULT, OLDER_ADULT",PHASE1,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-11-05,2025-11-05
COMPLETED,NO,PROCEDURE: Contrast Enhanced Digital Mammography,FEMALE,"ADULT, OLDER_ADULT",NA,107,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-06-23,2023-01-27
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: TJ107 +Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,133,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-22,2024-12-31
RECRUITING,NO,BIOLOGICAL: HER2 - primed Dendritic cells|BIOLOGICAL: HER3 - primed Dendritic cells,ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-26,2025-04
RECRUITING,NO,DEVICE: Ekstracorporeal Shock Wave Therapy (ESWT)|OTHER: complex decongestive therapy,FEMALE,"ADULT, OLDER_ADULT",NA,44,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-01,2024-01-15
RECRUITING,NO,DRUG: adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)|DRUG: adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin),FEMALE,"ADULT, OLDER_ADULT",PHASE2,136,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-26,2028-12-15
COMPLETED,NO,OTHER: Education,FEMALE,"ADULT, OLDER_ADULT",NA,165,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-08-15,2023-07-15
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: 18F-fluoroestradiol PET/CT,FEMALE,"ADULT, OLDER_ADULT",PHASE2,124,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-01-15,2023-12-15
NOT_YET_RECRUITING,NO,OTHER: Face to face and telephonic interviews,FEMALE,"ADULT, OLDER_ADULT",NA,56,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-09,2027-09
RECRUITING,NO,PROCEDURE: Standardization of the sentinel node detection procedure,ALL,"ADULT, OLDER_ADULT",NA,350,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-12-05,2024-07-15
RECRUITING,NO,BEHAVIORAL: YES portal,FEMALE,ADULT,NA,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2020-09-16,2028-03-01
RECRUITING,NO,DRUG: Pertuzumab|DRUG: Trastuzumab|OTHER: Circulating tumor cells,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2028-04-30
COMPLETED,NO,BEHAVIORAL: Online training group|BEHAVIORAL: Face-to-face training group,FEMALE,"ADULT, OLDER_ADULT",NA,126,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2023-03-09,2023-05-26
NOT_YET_RECRUITING,NO,BIOLOGICAL: Pertuzumab (ZRC-3277)|BIOLOGICAL: Pertuzumab (Perjeta®),FEMALE,"ADULT, OLDER_ADULT",PHASE3,268,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-09-17,2024-12-31
RECRUITING,NO,DRUG: Pentoxifylline|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-10-30,2024-06-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Pyrotinib|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Nab-paclitaxel|DRUG: EC chemotherapy|DRUG: Physician's choice|DRUG: T-DM1|PROCEDURE: Surgery,ALL,"ADULT, OLDER_ADULT",PHASE2,216,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-30,2027-12-30
COMPLETED,NO,DRUG: LY3475070|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,52,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-16,2022-06-20
RECRUITING,NO,OTHER: No endocrine therapy|OTHER: Endocrine therapy,ALL,OLDER_ADULT,PHASE4,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-19,2024-09
ACTIVE_NOT_RECRUITING,NO,DRUG: Alpelisib|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE2,24,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-20,2025-01-31
UNKNOWN,NO,DRUG: Capecitabine|DRUG: Letrozole 2.5mg,FEMALE,"ADULT, OLDER_ADULT",PHASE2,204,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-01,2022-04-30
COMPLETED,NO,DRUG: Esketamine|DRUG: normal saline,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-02-10,2022-05-10
ACTIVE_NOT_RECRUITING,NO,OTHER: Breast Cancer Education,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING,2023-02-15,2023-12-30
RECRUITING,NO,PROCEDURE: Sentinel Lymph Node Biopsy (SLNB)|DRUG: Doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Tumor-draining lymph node-derived lymphocyte (LNL)|BIOLOGICAL: Interleukin-2|DRUG: Nab-paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,196,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-01,2035-05-31
NOT_YET_RECRUITING,NO,DEVICE: MRI scan,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-05,2025-05-31
RECRUITING,NO,DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Inetetamab|DRUG: Pyrotinib,FEMALE,"ADULT, OLDER_ADULT",NA,154,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-27,2031-08-01
NOT_YET_RECRUITING,NO,DRUG: vepdegestrant|DRUG: PF-07220060,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,65,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-29,2026-11-17
RECRUITING,NO,DIAGNOSTIC_TEST: 4FMFES-PET,ALL,"ADULT, OLDER_ADULT",PHASE2,150,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-11-01,2025-12-31
ENROLLING_BY_INVITATION,NO,DEVICE: Histolog Scanner,FEMALE,"ADULT, OLDER_ADULT",NA,90,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-10-10,2024-05
RECRUITING,NO,DRUG: 18F-fluorofuranylnorprogesterone|DEVICE: Liquid Biopsy|DEVICE: Positron Emission Tomography/Computed Tomography,ALL,"ADULT, OLDER_ADULT",PHASE2,8,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-02,2026-01
RECRUITING,NO,DRUG: [18F]Fluoroestradiol (FES) PET/CT,ALL,"ADULT, OLDER_ADULT",PHASE2,79,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-12-11,2024-06-30
RECRUITING,NO,DRUG: Sacituzumab govitecan-hziy (SG)|DRUG: Pembrolizumab|DRUG: Capecitabine,ALL,"ADULT, OLDER_ADULT",PHASE3,1514,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-12,2031-08
ACTIVE_NOT_RECRUITING,NO,DRUG: Lasofoxifene and abemaciclib (VERZENIO (R)).,FEMALE,"ADULT, OLDER_ADULT",PHASE2,29,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-29,2024-05-31
COMPLETED,NO,DEVICE: Novel CBCT Imaging,ALL,"ADULT, OLDER_ADULT",NA,40,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-03-20,2023-08-18
COMPLETED,NO,DRUG: Folic Acid Tablet,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,10,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-21,2023-06-01
COMPLETED,NO,DRUG: Tocilizumab|DRUG: traditional Covid -19 therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-26,2022-08-26
COMPLETED,NO,OTHER: questionnaires,FEMALE,"ADULT, OLDER_ADULT",NA,10,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-03-03,2022-04-04
RECRUITING,NO,OTHER: Stressproffen cognitive based stress management|OTHER: Stressproffen mindfulness based intervention|OTHER: Control,FEMALE,"ADULT, OLDER_ADULT",NA,390,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-01-15,2035-12-31
RECRUITING,NO,PROCEDURE: Wire-guided localization and marker clip localization|PROCEDURE: Wire-guided localization,FEMALE,"ADULT, OLDER_ADULT",NA,170,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-16,2025-12-01
WITHDRAWN,NO,DRUG: Parsaclisib,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-06-01,2020-09-07
NOT_YET_RECRUITING,NO,DEVICE: High Intensity Focused Ultrasound (HIFU) to the Breast Cancer,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-01,2022-11-01
COMPLETED,NO,OTHER: mHealth psychoeducational intervention,FEMALE,"ADULT, OLDER_ADULT",NA,126,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2022-09-01,2023-06-30
COMPLETED,NO,OTHER: LifeChamps Platform,ALL,OLDER_ADULT,NA,27,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-07-31,2023-04-10
COMPLETED,NO,DRUG: Trastuzumab deruxtecan,FEMALE,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-28,2023-05-01
RECRUITING,NO,DRUG: Capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE3,400,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-15,2029-12
RECRUITING,NO,BEHAVIORAL: Genetic Testing and Counseling|BEHAVIORAL: Screening Form,ALL,"ADULT, OLDER_ADULT",NA,1000,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2022-11-23,2027-02-02
ACTIVE_NOT_RECRUITING,NO,OTHER: Embedded primary care in cancer survivorship model,ALL,"ADULT, OLDER_ADULT",NA,2450,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-09-21,2025-05-31
COMPLETED,NO,DRUG: Pelareorep,FEMALE,"ADULT, OLDER_ADULT",PHASE1,15,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-11,2023-05-30
RECRUITING,NO,DRUG: Fulvestrant combined with Pyrotinib|DRUG: Capecitabine combined with Pyrotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE3,516,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-14,2030-12-14
RECRUITING,NO,DRUG: Morphine|OTHER: Ultrasound-guided erector spinae plane block,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-06-01,2022-12-31
RECRUITING,NO,DRUG: AMT-151,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-01-25,2024-10-30
COMPLETED,NO,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Probiotic|PROCEDURE: Therapeutic Conventional Surgery,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,6,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-07-01,2023-03-08
RECRUITING,NO,PROCEDURE: No drain|PROCEDURE: With drain,FEMALE,"ADULT, OLDER_ADULT",NA,250,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-26,2023-12
COMPLETED,NO,DRUG: Protopic 0.1 % Topical Ointment,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-22,2022-01-06
RECRUITING,NO,DEVICE: GILUPI CellCollector®,FEMALE,"ADULT, OLDER_ADULT",NA,484,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2022-09-14,2029-06
NOT_YET_RECRUITING,NO,RADIATION: 68Ga-FAPI-46 PET/CT|BIOLOGICAL: Tumor samples analysis|BIOLOGICAL: Blood samples analysis: Circulating Tumor DNA,FEMALE,"ADULT, OLDER_ADULT",PHASE2,160,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-15,2029-02-15
UNKNOWN,NO,DRUG: Apatinib Mesylate|DRUG: Albumin-Bound Paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-01,2023-12-31
RECRUITING,NO,DRUG: Pyrotinib dose escalation|DRUG: Pyrotinib dose normal,FEMALE,"ADULT, OLDER_ADULT",PHASE2,102,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-01,2026-12-01
COMPLETED,NO,DRUG: Camizestrant|DRUG: Itraconazole,FEMALE,"ADULT, OLDER_ADULT",PHASE1,14,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-10-04,2022-12-28
RECRUITING,NO,BEHAVIORAL: Cognitive behavioural therapy for insomnia,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-03-23,2023-12-23
RECRUITING,NO,RADIATION: Partial breast re-irradiation,FEMALE,"ADULT, OLDER_ADULT",PHASE2,68,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-31,2032-03
ACTIVE_NOT_RECRUITING,NO,DRUG: LY3484356,ALL,"ADULT, OLDER_ADULT",PHASE1,17,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-09,2025-04-01
RECRUITING,NO,DRUG: CBP-1019,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,260,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-14,2025-09-30
RECRUITING,NO,DRUG: Docetaxel + Carboplatin + Trastuzumab + Pertuzumab|DRUG: (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab),FEMALE,"ADULT, OLDER_ADULT",PHASE3,456,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-11,2024-09-30
RECRUITING,NO,DRUG: Alpelisib|DRUG: Metformin|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Exemestane|DRUG: Vildagliptin|DRUG: Tamoxifen,ALL,"ADULT, OLDER_ADULT",PHASE2,88,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-23,2026-06-30
COMPLETED,NO,OTHER: CANUT support|OTHER: Anthropometric measures|OTHER: Prehension strength measurement|BEHAVIORAL: QVA Questionnaire|BEHAVIORAL: QLQ C30 Questionnaire|BEHAVIORAL: Scratch & Snif Test|BEHAVIORAL: Taste Strip Test|BEHAVIORAL: 24 H feed back questionnaire|BEHAVIORAL: Condiment questionnaire|BEHAVIORAL: Tobacco questionnaire|OTHER: Nutrition interview,ALL,"ADULT, OLDER_ADULT",NA,209,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-01-27,2023-09-21
WITHDRAWN,NO,DRUG: MB1707,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12,2024-12
COMPLETED,YES,DRUG: Lidocaine patch|DEVICE: Buzzy(R)|OTHER: Ice pack,FEMALE,"ADULT, OLDER_ADULT",PHASE3,167,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-04-23,2022-05-09
RECRUITING,NO,BEHAVIORAL: Mind|BEHAVIORAL: Support Group,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-02,2025-08-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Abemaciclib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Copanlisib Hydrochloride|PROCEDURE: Diagnostic Imaging|PROCEDURE: Echocardiography|DRUG: Fulvestrant|PROCEDURE: Multigated Acquisition Scan,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,204,NIH,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-17,2024-11-01
ACTIVE_NOT_RECRUITING,NO,"DRUG: SHR-1316 at a dose 20mg/kg q3w|DRUG: SHR6390 at a dose of 150mg orally, daily|RADIATION: SBRT",FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-25,2028-12-31
UNKNOWN,NO,DEVICE: ultrasound guided Nerve Block procedure,FEMALE,ADULT,NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2021-05-20,2023-08-20
RECRUITING,NO,DRUG: Imtenan Oil|DRUG: Baraka Capsules,FEMALE,"ADULT, OLDER_ADULT",PHASE2,132,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-01-24,2024-04
RECRUITING,NO,DRUG: Camrelizumab with vinorelbine and cisplatin,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-20,2024-12-31
NOT_YET_RECRUITING,NO,BIOLOGICAL: MUC1 Peptide Vaccine|DRUG: Hiltonol®|DRUG: Aromatase Inhibitor,FEMALE,"ADULT, OLDER_ADULT",PHASE1,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-31,2027-07-31
RECRUITING,NO,DRUG: Insulin,FEMALE,ADULT,NA,24,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-08,2026-09
RECRUITING,NO,OTHER: Respiratory training and relaxation techniques under adjuvant radiation therapy in DIBH in breast cancer,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-22,2025-12-31
UNKNOWN,NO,OTHER: Oxygen inhalation treatment group|OTHER: Control group,FEMALE,"ADULT, OLDER_ADULT",NA,102,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-03-01,2022-12-31
RECRUITING,NO,DEVICE: Oncotherm EHY-2030|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Cyclophosphamide/Doxorubicin|PROCEDURE: Breast cancer removal surgery,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-20,2025-04-30
COMPLETED,NO,DRUG: SPECT,FEMALE,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2021-12-22,2023-03-01
RECRUITING,NO,DRUG: NM1F Injection|DRUG: Pembrolizumab injection,ALL,"ADULT, OLDER_ADULT",PHASE1,38,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-04-13,2027-09-30
COMPLETED,NO,BEHAVIORAL: Supervised exercise,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-01-06,2022-07-25
UNKNOWN,NO,PROCEDURE: Exercise,ALL,"ADULT, OLDER_ADULT",NA,28,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-08-10,2022-12-31
RECRUITING,NO,DEVICE: BPET/DBT imaging|DRUG: 18F-FES,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-10-02,2026-01
UNKNOWN,NO,DEVICE: Hilotherm Chemo Care,FEMALE,"ADULT, OLDER_ADULT",NA,196,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-02-03,2024-02-03
RECRUITING,NO,BEHAVIORAL: Gamification and Social Support|BEHAVIORAL: Attention control,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2022-04-14,2024-02-01
ENROLLING_BY_INVITATION,NO,OTHER: Standard care encouraging family-mediated disclosure of hereditary cancer risk|OTHER: Offer of health-care assisted disclosure by sending direct letters to at-risk relatives,ALL,"ADULT, OLDER_ADULT",NA,490,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2020-02-06,2025-12-31
COMPLETED,NO,DRUG: AZD9833|DRUG: Midazolam|DRUG: Omeprazole|DRUG: Dabigatran Etexilate|DRUG: Celecoxib,FEMALE,"ADULT, OLDER_ADULT",PHASE1,59,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-06-13,2022-12-13
ACTIVE_NOT_RECRUITING,YES,DRUG: F-18 16 Alpha-Fluoroestradiol|PROCEDURE: Positron Emission Tomography|PROCEDURE: Computed Tomography|DRUG: Fludeoxyglucose F-18|PROCEDURE: Positron Emission Tomography|PROCEDURE: Computed Tomography|OTHER: Laboratory Biomarker Analysis,ALL,"ADULT, OLDER_ADULT",PHASE2,2,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-07-10,2041-04-30
COMPLETED,NO,DRUG: MW05|DRUG: PEG-rhG-CSF,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,586,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-09-21,2022-11-05
RECRUITING,NO,OTHER: blood sample,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-05-26,2030-05-26
RECRUITING,NO,BIOLOGICAL: CAdVEC,ALL,"ADULT, OLDER_ADULT",PHASE1,45,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-14,2038-12-30
UNKNOWN,NO,PROCEDURE: Same-day NSM or SSM,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-04,2022-02-04
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Supine MRI,FEMALE,"ADULT, OLDER_ADULT",NA,45,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-03-17,2024-03-31
RECRUITING,NO,DIAGNOSTIC_TEST: Brain Imaging with 18F-FES,FEMALE,"ADULT, OLDER_ADULT",PHASE4,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-27,2026-12
NOT_YET_RECRUITING,NO,OTHER: the Remote Intervention|OTHER: the Traditional Intervention,FEMALE,ADULT,NA,1250,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2024-01,2027-12
RECRUITING,NO,COMBINATION_PRODUCT: Contrast Enhanced Mammography,FEMALE,"ADULT, OLDER_ADULT",NA,420,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-10-01,2024-05-31
COMPLETED,NO,DEVICE: Oculus Go Virtual Reality Goggles,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-01-13,2022-01-07
TERMINATED,NO,DRUG: Alpelisib|DRUG: fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE2,2,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-08,2022-09-19
COMPLETED,NO,BEHAVIORAL: Nurse-led supportive care,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2022-04-18,2023-01-13
RECRUITING,NO,DIETARY_SUPPLEMENT: Phenylalanine intake,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-04-26,2025-12-31
NOT_YET_RECRUITING,NO,DRUG: Huaier Granule,ALL,"ADULT, OLDER_ADULT",PHASE4,384,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10,2027-10
RECRUITING,NO,OTHER: combination of mobilization with movement and muscle energy techniques|OTHER: muscle energy techniques Interventions:|OTHER: mobilization with movement,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-01,2023-09-30
RECRUITING,NO,DRUG: CNSI-Fe(II) 30 mg|DRUG: CNSI-Fe(II) 60 mg|DRUG: CNSI-Fe(II) 90 mg,ALL,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-14,2024-02-29
RECRUITING,NO,DRUG: Pyrotinib|DRUG: Epirubicin|DRUG: Doxorubicin Hydrochloride Liposome Injection|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Nab paclitaxel|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,140,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-20,2028-12-31
RECRUITING,NO,DEVICE: Questionnaire,ALL,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-10-17,2024-12-31
NOT_YET_RECRUITING,NO,DIAGNOSTIC_TEST: Ga-68-PEG-Αvβ3-IAC PET/CT,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,25,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-08-30,2024-08-30
RECRUITING,NO,RADIATION: omit of IMI group|RADIATION: IMI group,FEMALE,"ADULT, OLDER_ADULT",NA,214,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2030-10-30
NOT_YET_RECRUITING,NO,PROCEDURE: Subpectoral plexus block (low dose)|PROCEDURE: Subpectoral plexus block (High dose),ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-12-01,2025-12-31
RECRUITING,NO,OTHER: Personalized cognitive stimulation|OTHER: Sham cognitive stimulation,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-06-03,2023-12
NOT_YET_RECRUITING,NO,OTHER: Acupuncture treatment|OTHER: Sham Acupuncture treatment,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-01,2027-07-31
RECRUITING,NO,DRUG: Giredestrant|DRUG: Triptorelin|DRUG: Anastrozole,FEMALE,"ADULT, OLDER_ADULT",PHASE2,220,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-23,2026-06-01
RECRUITING,NO,RADIATION: External Beam radiotherapy using IMRT technique,FEMALE,"ADULT, OLDER_ADULT",NA,217,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-23,2026-12-10
RECRUITING,NO,"DRUG: Checkpoint Blockade, Immune",ALL,"ADULT, OLDER_ADULT",PHASE2,441,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-09-01,2024-12-01
COMPLETED,NO,BEHAVIORAL: Precision grip training|BEHAVIORAL: Use maximum strength grip training|BEHAVIORAL: Health education on routine grip strength training,ALL,ADULT,NA,270,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2022-07-10,2023-01-10
RECRUITING,NO,"BIOLOGICAL: Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)|BIOLOGICAL: Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)",ALL,"ADULT, OLDER_ADULT",PHASE3,314,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-28,2026-01-31
WITHDRAWN,NO,PROCEDURE: Radiation therapy,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05,2022-11
NOT_YET_RECRUITING,NO,DRUG: Pyrotinib|DRUG: Trastuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE3,450,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-01,2027-08-01
RECRUITING,NO,OTHER: Tilia tomentosa Concentrated - Glycerine macerate (C-GM) vs Placebo (1 gtt/10 kg/day before bedtime for 15 days),FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-06-01,2024-06-30
WITHDRAWN,NO,RADIATION: Proton Accelerated Partial Breast Irradiation,FEMALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-01,2021-07-08
RECRUITING,NO,DRUG: Camizestrant|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane,ALL,"ADULT, OLDER_ADULT",PHASE3,4300,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-31,2036-05-29
COMPLETED,NO,DRUG: enzalutamide|DRUG: enzalutamide Placebo|DRUG: digoxin|DRUG: rosuvastatin,MALE,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-27,2020-12-27
RECRUITING,NO,RADIATION: Radiation: Single Pre-Operative Radiation Therapy,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-08,2030-12-31
RECRUITING,NO,DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Olaparib|PROCEDURE: Definitive Surgery,ALL,"ADULT, OLDER_ADULT",PHASE2,23,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02-29,2027-09-30
RECRUITING,NO,DRUG: Trilaciclib|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab,ALL,"ADULT, OLDER_ADULT",PHASE2,116,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09-20,2027-12-31
NOT_YET_RECRUITING,NO,DRUG: Pyrotinib Maleate Tablets,FEMALE,"ADULT, OLDER_ADULT",PHASE4,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-05,2027-09-20
NOT_YET_RECRUITING,NO,BEHAVIORAL: Promoting Resilience in Stress Management Intervention,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2024-01-22,2025-12
NOT_YET_RECRUITING,NO,OTHER: manual treatment with osteopathic techniques and nutritional treatment|OTHER: manual treatment with osteopathic techniques|OTHER: nutritional treatment,FEMALE,"ADULT, OLDER_ADULT",NA,600,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-12,2025-12
RECRUITING,NO,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Celecoxib|PROCEDURE: Computed Tomography|BIOLOGICAL: Interferon Alpha-2|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|DRUG: Rintatolimod,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,12,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-28,2025-12-30
UNKNOWN,NO,DIETARY_SUPPLEMENT: Bromelain/Boswellia Serrata Casperome|DIETARY_SUPPLEMENT: Centella Asiatica/Vitamins|DIETARY_SUPPLEMENT: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE4,120,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-31,2022-01-31
RECRUITING,NO,DEVICE: Telerehabilitation Experimental Group|OTHER: Telerehabilitation Sham Control Group,FEMALE,"ADULT, OLDER_ADULT",NA,40,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-02-09,2022-09-30
RECRUITING,NO,DRUG: U3-1402,ALL,"ADULT, OLDER_ADULT",PHASE2,170,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-05-11,2026-06-11
NOT_YET_RECRUITING,NO,PROCEDURE: Targeted axillary lymph node dissection,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE4,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-01,2025-08-01
RECRUITING,NO,BIOLOGICAL: Anti-CD40 Agonist Monoclonal Antibody CDX-1140|DRUG: Poly ICLC|RADIATION: Radiation Therapy|BIOLOGICAL: Recombinant Flt3 Ligand,ALL,"ADULT, OLDER_ADULT",PHASE1,18,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-09,2026-01-09
RECRUITING,NO,DRUG: Atezolizumab + Trastuzumab + Vinorelbine,ALL,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-15,2025-02-24
TERMINATED,NO,DRUG: CB-103,FEMALE,"ADULT, OLDER_ADULT",PHASE2,2,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-05-06,2022-04-26
RECRUITING,NO,DRUG: Pirfenidone/Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,214,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-03-16,2024-05-31
UNKNOWN,NO,DRUG: Nab paclitaxel|DRUG: Docetaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-04-20,2023-06-30
COMPLETED,YES,BEHAVIORAL: iShare,ALL,"CHILD, ADULT, OLDER_ADULT",NA,32,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-02-07,2020-10-12
RECRUITING,NO,PROCEDURE: Fecal Microbiota Transplantation|DRUG: Loperamide,ALL,"ADULT, OLDER_ADULT",PHASE1,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-01,2025-04-30
TERMINATED,YES,DRUG: Amcenestrant-matching placebo|DRUG: SAR439859|DRUG: Palbociclib|DRUG: Letrozole|DRUG: Goserelin|DRUG: Letrozole-matching placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1068,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-14,2023-05-26
RECRUITING,NO,DRUG: Evexomostat,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,52,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-26,2026-09
RECRUITING,NO,PROCEDURE: Ultrasonsgraphy|DRUG: Perflutren Lipid Microcpheres|PROCEDURE: Contrast - Enhanced Ultrasound,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-11-24,2025-01-01
SUSPENDED,NO,DIETARY_SUPPLEMENT: Vitamin B12|OTHER: Blood collection|OTHER: Brief Pain Inventory - Short Form survey|OTHER: FACT-ES Trial Outcome Index (Version 4)|OTHER: Questionnaire to Assess Adherence to Aromatase Inhibitors|OTHER: Demographics Questionnaire,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-08-12,2025-06-01
RECRUITING,NO,DRUG: JAB-3312,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-10,2023-12
RECRUITING,NO,DIAGNOSTIC_TEST: 99mTc-MY6349 SPECT/CT scan,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-09-13,2026-12-31
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: Personalized screening protocol,FEMALE,ADULT,NA,10269,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-01-20,2026-01-31
RECRUITING,NO,OTHER: Myofascial Massage|OTHER: Light Touch,FEMALE,"ADULT, OLDER_ADULT",NA,202,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-02-04,2025-04-30
RECRUITING,NO,DRUG: Pyrotinib|DRUG: Trastuzumab|DRUG: Taxanes|DRUG: Capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE4,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-01-02,2027-06-30
RECRUITING,NO,DEVICE: Virtual reality software,ALL,"ADULT, OLDER_ADULT",NA,256,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2022-10-05,2024-08-01
NOT_YET_RECRUITING,NO,DEVICE: Cryoablation|COMBINATION_PRODUCT: Cryoablation combined with PD1 Inhibitor,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,36,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-01,2027-06
RECRUITING,NO,RADIATION: GammaPod Radiation,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-15,2028-12
COMPLETED,NO,DRUG: LY3484356,FEMALE,"ADULT, OLDER_ADULT",PHASE1,86,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-04-21,2022-11-11
COMPLETED,NO,OTHER: standard 12-week rehabilitation program|OTHER: extra session hydrotherapy|OTHER: extra session ground exercises,ALL,"ADULT, OLDER_ADULT",NA,62,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2021-06-05,2022-01-31
RECRUITING,NO,OTHER: Outcomes4Me|OTHER: Semi-structured interview,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-10-03,2024-10-03
RECRUITING,NO,DRUG: Pembrolizumab|DRUG: Sacituzumab Govitecan,ALL,"ADULT, OLDER_ADULT",PHASE2,110,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-23,2027-06-01
NOT_YET_RECRUITING,NO,RADIATION: Preoperative radiotherapy|RADIATION: Postmastectomy radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-01,2027-10-01
RECRUITING,NO,DRUG: ARX788|DRUG: Pyrotinib maleate|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Docetaxel|DRUG: Carboplatin,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-23,2026-12-30
RECRUITING,NO,BIOLOGICAL: Trastuzumab|DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Vinorelbine|DRUG: Capecitabine|DRUG: Eribulin,ALL,"ADULT, OLDER_ADULT",PHASE3,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-14,2026-09
RECRUITING,NO,DRUG: PRO1184,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,134,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-07,2025-09
RECRUITING,NO,RADIATION: Intraoperative Radiotherapy|PROCEDURE: Oncoplastic partial mastectomy,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-16,2026-02
RECRUITING,NO,DRUG: Bemarituzumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,303,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-23,2026-07-27
WITHDRAWN,NO,DRUG: Pembrolizumab|DRUG: Liposomal Irinotecan,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-31,2030-01-31
RECRUITING,NO,DRUG: Giredestrant|DRUG: Fulvestrant|DRUG: Abemaciclib|DRUG: Palbociclib|DRUG: Ribociclib|DRUG: LHRH Agonist|DIAGNOSTIC_TEST: FoundationOne Liquid CDx Assay (F1LCDx),ALL,"ADULT, OLDER_ADULT",PHASE3,1050,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-11,2028-12-30
NOT_YET_RECRUITING,NO,DRUG: KN026|DRUG: HB1801|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Docetaxel,ALL,"ADULT, OLDER_ADULT",PHASE3,880,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07,2027-12
RECRUITING,NO,DRUG: Chidamide combined with Zimberelimab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,47,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-15,2025-12-31
NOT_YET_RECRUITING,NO,DRUG: Camrelizumab|DRUG: Liposomal Doxorubicin|DRUG: Losartan,FEMALE,"ADULT, OLDER_ADULT",PHASE2,52,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10,2024-10
UNKNOWN,NO,DIAGNOSTIC_TEST: Ultrasonographical tattooing of suspicious axillary lymph nodes.|PROCEDURE: Sentinel lymph node biopsy|DIAGNOSTIC_TEST: Histopathological examination of the axillary nodes|PROCEDURE: Further axillary management,FEMALE,"ADULT, OLDER_ADULT",NA,75,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-12-15,2022-04
RECRUITING,NO,OTHER: Active Comparator: Group 1. Conventional treatment|OTHER: Experimental: Group 2. Experimental treatment.,ALL,"ADULT, OLDER_ADULT",NA,92,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-08-02,2024-05-01
RECRUITING,NO,OTHER: Cessation of anti-HER2 treatment,ALL,"ADULT, OLDER_ADULT",PHASE2,82,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-19,2036-02
WITHDRAWN,NO,DRUG: Cyclophosphamide|BIOLOGICAL: Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Recombinant Interferon Alpha 2b-like Protein|OTHER: Questionnaire Administration|OTHER: Quality of Life Assessment,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-21,2024-01-01
RECRUITING,NO,DEVICE: Anodal tDCS|DEVICE: Sham tDCS|BEHAVIORAL: Intensive cognitive training,FEMALE,ADULT,NA,52,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-11-02,2024-08
COMPLETED,NO,OTHER: Session (a)|OTHER: Session (b)|OTHER: Session (c),FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-11-22,2022-04-28
RECRUITING,NO,DRUG: trastuzumab deruxtecan (T-DXd) (IV),ALL,"ADULT, OLDER_ADULT",PHASE2,80,NETWORK,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-10-26,2028-03-30
UNKNOWN,NO,DRUG: Chidamide|DRUG: Fulvestrant,FEMALE,"ADULT, OLDER_ADULT",NA,82,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-18,2023-09-18
RECRUITING,NO,BIOLOGICAL: Dostarlimab|DRUG: Niraparib,ALL,"ADULT, OLDER_ADULT",PHASE1,18,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-18,2026-03-30
RECRUITING,NO,DRUG: BL-B01D1,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-11,2024-08
RECRUITING,NO,BEHAVIORAL: Free genetic testing and counseling group|BEHAVIORAL: IGNITE-TX Group|BEHAVIORAL: IGNITE-TX and free genetic testing and counseling group,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-04-14,2027-10-31
RECRUITING,NO,RADIATION: Radiation Therapy Boost|DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Capecitabine,ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-16,2024-12
UNKNOWN,NO,DEVICE: Acupuncture,FEMALE,"ADULT, OLDER_ADULT",NA,52,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-10-20,2023-06-01
RECRUITING,NO,OTHER: Prospective surveillance,ALL,"ADULT, OLDER_ADULT",NA,250,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-01-04,2026-12
COMPLETED,NO,DRUG: 420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection|DRUG: Perjeta (EU origin) 420 mg in 14 mL Injection|DRUG: Perjeta (US origin) 420 mg in 14 mL Injection,MALE,ADULT,PHASE1,135,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-16,2023-01-24
COMPLETED,NO,BEHAVIORAL: Behavioral Intervention,ALL,"ADULT, OLDER_ADULT",NA,81,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-08-25,2022-08-31
RECRUITING,NO,BEHAVIORAL: Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)|BEHAVIORAL: Active control comparator,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-05-08,2027-08-01
RECRUITING,NO,DEVICE: Brass Mesh Bolus,ALL,"CHILD, ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-01-18,2023-11-21
RECRUITING,NO,BEHAVIORAL: Multi-component oncofertility care intervention,FEMALE,ADULT,NA,135,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-10-15,2024-04-30
RECRUITING,NO,OTHER: Educational Intervention|OTHER: Genetic Counseling|OTHER: Survey Administration,FEMALE,ADULT,NA,1000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-06-13,2025-10-31
RECRUITING,NO,DRUG: Definity|DEVICE: Acoustic Angiography,ALL,"ADULT, OLDER_ADULT",PHASE2,45,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-05-26,2024-10
RECRUITING,NO,OTHER: the laughter therapy group|OTHER: the mindfulness therapy group,FEMALE,ADULT,NA,105,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-01-01,2024-04-01
NOT_YET_RECRUITING,NO,DEVICE: VENTANA MIB-1 Ki67 assay|DEVICE: Oncotype DX® Recurrence Score|DEVICE: PAM50-based Prosigna breast cancer gene signature assay|DRUG: Anastrozole|DRUG: Combination anthracycline and/or taxane based treatment,FEMALE,"ADULT, OLDER_ADULT",PHASE2,81,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2024-02-28,2027-08-31
RECRUITING,NO,OTHER: Educate|OTHER: Empower,FEMALE,"ADULT, OLDER_ADULT",NA,400,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING",2023-03-14,2027-08-31
RECRUITING,NO,DRUG: ARV-471|DRUG: Ribociclib,ALL,"ADULT, OLDER_ADULT",PHASE2,35,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-01,2027-10-06
WITHDRAWN,NO,PROCEDURE: Acupuncture Point Injection|PROCEDURE: Massage Therapy|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-23,2022-03-23
ACTIVE_NOT_RECRUITING,NO,DRUG: Dato-DXd|DRUG: Capecitabine|DRUG: Gemcitabine|DRUG: Eribulin|DRUG: Vinorelbine,ALL,"ADULT, OLDER_ADULT",PHASE3,732,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-18,2025-08-15
RECRUITING,NO,PROCEDURE: Harvesting method and Fat graft preparation method,FEMALE,ADULT,NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-12-19,2024-09-01
RECRUITING,NO,BIOLOGICAL: CEA-targeted CAR-T cells,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-11,2027-12-31
NOT_YET_RECRUITING,NO,DRUG: Chidamide combined with exemestane (+/- goserelin)|DRUG: Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician),FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,130,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-25,2025-01-31
WITHDRAWN,NO,OTHER: Virtual Reality Session,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-09,2025-09
COMPLETED,NO,BEHAVIORAL: Nurse AMIE (Addressing Metastatic Individuals Every day),FEMALE,"ADULT, OLDER_ADULT",NA,42,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-02-02,2022-02-28
RECRUITING,NO,DRUG: IMC-F106C|DRUG: IMC-F106C and atezolizumab and pembrolizumab|DRUG: IMC-F106C and chemotherapy|DRUG: IMC-F106C and tebentafusp,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,170,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-25,2026-02
COMPLETED,NO,PROCEDURE: MagSeed and MagTrace in breast cancer patiënts,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-01,2022-02-09
RECRUITING,NO,DRUG: Capecitabine|OTHER: Endocrine-therapy|OTHER: MammoPrint ® and BluePrint assays,ALL,"ADULT, OLDER_ADULT",PHASE2,64,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-11,2037-08-31
COMPLETED,NO,DRUG: BAY2701439|DRUG: BAY2701439,ALL,"ADULT, OLDER_ADULT",PHASE1,14,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-02,2023-09-26
NOT_YET_RECRUITING,NO,BEHAVIORAL: psychoeduc/self-care/self-hypnosis group,ALL,"ADULT, OLDER_ADULT",NA,500,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-07-01,2026-12-31
NOT_YET_RECRUITING,NO,DRUG: Avelumab|DRUG: Aspirin|DRUG: Lansoprazole,FEMALE,"ADULT, OLDER_ADULT",PHASE2,42,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-12-01,2025-05-31
NOT_YET_RECRUITING,NO,DRUG: Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC),FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-26,2025-09-30
COMPLETED,NO,BEHAVIORAL: Pinkwashed Advertisements|BEHAVIORAL: Control - Standard Advertisements,ALL,"ADULT, OLDER_ADULT",NA,602,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-01-11,2023-01-19
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Time restricted feeding|BEHAVIORAL: Control,FEMALE,"ADULT, OLDER_ADULT",NA,29,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-05-04,2024-05-01
ACTIVE_NOT_RECRUITING,NO,OTHER: FHAMe Intervention,ALL,"ADULT, OLDER_ADULT",NA,627,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-09-20,2024-12
ACTIVE_NOT_RECRUITING,NO,DRUG: TTI-101|DRUG: Palbociclib|DRUG: Aromatase inhibitor (AI)|DRUG: fulvestrant|DRUG: ribociclib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,6,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-09,2024-06-28
RECRUITING,NO,DRUG: Ribociclib|DRUG: Belinostat,ALL,"ADULT, OLDER_ADULT",PHASE1,34,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-05-03,2026-08
COMPLETED,NO,PROCEDURE: Serratus anterior plane block,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-03-01,2021-09-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Superparamagnetic Iron Oxide,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,50,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-01,2024-04-30
RECRUITING,NO,DRUG: Palbociclib,ALL,"ADULT, OLDER_ADULT",PHASE2,578,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-11,2025-02
RECRUITING,NO,DRUG: PM8002|DRUG: nab-paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-01,2026-10-30
RECRUITING,NO,DRUG: NGM707|DRUG: NGM707 plus pembrolizumab|DRUG: NGM707|DRUG: NGM707|DRUG: NGM707|DRUG: NGM707 plus pembrolizumab|DRUG: NGM707 plus pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,179,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-09,2025-07
RECRUITING,NO,OTHER: Communication model,FEMALE,"ADULT, OLDER_ADULT",NA,94,OTHER,"Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2023-05-17,2025-06
RECRUITING,NO,DRUG: eutidrone etoposide bevacizumab,FEMALE,"ADULT, OLDER_ADULT",NA,43,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-20,2025-07-20
COMPLETED,NO,OTHER: functional compressive bandage,FEMALE,"ADULT, OLDER_ADULT",NA,23,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-01-01,2021-12-30
RECRUITING,NO,DRUG: Goserelin acetate 3.6 mg Injection|DRUG: ZOLADEX® 3.6mg Injection,FEMALE,ADULT,PHASE3,68,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-30,2025-01-30
RECRUITING,NO,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Decitabine and Cedazuridine|PROCEDURE: Magnetic Resonance Imaging|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,24,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09-25,2027-02-23
ENROLLING_BY_INVITATION,NO,DIAGNOSTIC_TEST: Digital Breast Tomosynthesis,FEMALE,"ADULT, OLDER_ADULT",NA,18200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2023-07-17,2028-07-01
COMPLETED,NO,OTHER: Ipsilateral peripheral IV insertion,ALL,"ADULT, OLDER_ADULT",NA,3,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-09-20,2023-01-09
RECRUITING,NO,DRUG: Pyrotinib combined with albumin-bound paclitaxel and trastuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,216,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-01,2023-12-31
COMPLETED,NO,DIAGNOSTIC_TEST: CT scan and blood sample collection,FEMALE,ADULT,NA,92,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2022-03-24,2024-01-31
RECRUITING,NO,BEHAVIORAL: Faster Asleep Smart Speaker Program|BEHAVIORAL: Faster Asleep Website,FEMALE,"ADULT, OLDER_ADULT",NA,76,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-04-05,2024-03
RECRUITING,NO,BEHAVIORAL: Exercise prehabilitation,FEMALE,"ADULT, OLDER_ADULT",NA,48,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2022-05-26,2024-01-01
ACTIVE_NOT_RECRUITING,NO,OTHER: Best Practice|OTHER: Questionnaire Administration|DRUG: Rifaximin,ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-18,2024-12-01
TERMINATED,NO,DEVICE: Mepitel Film®,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-01-15,2023-11-06
RECRUITING,NO,DRUG: Paclitaxel|DRUG: Trastuzumab|DRUG: Docetaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,190,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-31,2025-06-30
NOT_YET_RECRUITING,NO,"DRUG: Pabociclib, Endocrine, Talazoparib, Atezolizumab|DRUG: Pabociclib, Endocrine, Talazoparib,",FEMALE,"ADULT, OLDER_ADULT",PHASE2,178,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-01,2027-12-31
RECRUITING,NO,PROCEDURE: Radical resection|RADIATION: Radical radiotherapy|OTHER: Palliative treatment,FEMALE,"ADULT, OLDER_ADULT",NA,183,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-09,2026-12-31
WITHDRAWN,NO,DEVICE: AMMA Portalbe Scalp Cooling System,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-08-15,2023-09-30
RECRUITING,NO,DRUG: Bevacizumab,ALL,"ADULT, OLDER_ADULT",PHASE4,75,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-31,2025-12-31
UNKNOWN,NO,PROCEDURE: Systemic therapy followed by surgery if the disease is not progressive,FEMALE,"ADULT, OLDER_ADULT",NA,212,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-20,2021-12-20
TERMINATED,NO,DRUG: Dasatinib|DIETARY_SUPPLEMENT: Icosapent Ethyl,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,1,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-08,2023-12-20
NOT_YET_RECRUITING,NO,OTHER: Experimental session,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-01-15,2024-06-15
RECRUITING,NO,DRUG: Olive oil cream|DRUG: Betamethasone Valerate Cream|OTHER: Base Cream,FEMALE,"ADULT, OLDER_ADULT",PHASE4,132,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2021-11-04,2023-06
NOT_YET_RECRUITING,NO,DRUG: Sacituzumab govitecan,ALL,"ADULT, OLDER_ADULT",PHASE2,75,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-04,2026-10
UNKNOWN,NO,OTHER: Virtual reality,FEMALE,ADULT,NA,196,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-03-13,2021-10
RECRUITING,NO,DRUG: Epirubicin|DRUG: Cyclophosphamid|DRUG: Docetaxel|DRUG: Paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,260,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-20,2027-09-20
RECRUITING,NO,DIAGNOSTIC_TEST: PET/MRI,ALL,"ADULT, OLDER_ADULT",NA,247,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-07-03,2025-02-14
ACTIVE_NOT_RECRUITING,NO,DRUG: LY3410738|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Durvalumab,ALL,"ADULT, OLDER_ADULT",PHASE1,200,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-16,2024-05
RECRUITING,NO,DEVICE: Application,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-01-16,2023-12-31
RECRUITING,NO,DRUG: Gedatolisib|DRUG: Palbociclib|DRUG: Fulvestrant|DRUG: Alpelisib,ALL,"ADULT, OLDER_ADULT",PHASE3,701,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-30,2026-09-30
RECRUITING,NO,RADIATION: SBRT to the spine,ALL,"ADULT, OLDER_ADULT",PHASE2,26,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-14,2026-05-31
COMPLETED,NO,OTHER: Collection of postoperative information|OTHER: Analysis of postoperative information collected from patients,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-04-01,2022-06-30
NOT_YET_RECRUITING,NO,RADIATION: Treatment ETHOS radiotherapy|RADIATION: Conventional IMRT,FEMALE,"ADULT, OLDER_ADULT",NA,500,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10,2028-10
UNKNOWN,NO,DRUG: HS627|DRUG: Pertuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE3,408,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-30,2021-11-20
RECRUITING,NO,DRUG: Eribulin and Tucidinostat,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,87,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-13,2025-11-01
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: ONCOTYPE DX DCIS test,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,78,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-07-07,2023-12-31
COMPLETED,NO,BEHAVIORAL: African Immigrant Breast Cancer Education Program,ALL,"ADULT, OLDER_ADULT",NA,155,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-02-05,2023-06-29
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: DPX-Survivac|DRUG: Letrozole 2.5mg|DRUG: Cyclophosphamide 50mg|RADIATION: XRT 10Gy x2,FEMALE,"ADULT, OLDER_ADULT",PHASE1,6,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-10,2026-09-01
NOT_YET_RECRUITING,NO,PROCEDURE: Vaginal laser treatment|DEVICE: sham|DEVICE: laser system,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,160,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2022-10-01,2026-12-31
COMPLETED,NO,DEVICE: Endermologie|DEVICE: Negative pressure therapy,FEMALE,ADULT,NA,68,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-29,2023-10-30
RECRUITING,NO,PROCEDURE: Immediate Lymphatic Reconstruction|DIAGNOSTIC_TEST: Volumetric arm measurements|OTHER: Lymphatic massage|OTHER: Range of motion exercises|OTHER: Compression garment use,FEMALE,"ADULT, OLDER_ADULT",PHASE3,285,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-11-16,2030-03-16
RECRUITING,NO,PROCEDURE: Axillary clearance,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-01-21,2025-12-31
NOT_YET_RECRUITING,NO,OTHER: digital technology-supported education,ALL,"ADULT, OLDER_ADULT",NA,38,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-12-11,2025-12-30
RECRUITING,NO,OTHER: Standard follow-up|OTHER: Learning workshops,FEMALE,"ADULT, OLDER_ADULT",NA,144,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-01-13,2025-08-31
NOT_YET_RECRUITING,NO,DRUG: BG-68501|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE1,108,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-19,2026-10-12
RECRUITING,NO,BIOLOGICAL: Dendritic Cell (DC1) Vaccine|DRUG: Trastuzumab|DRUG: Pepinemab|BIOLOGICAL: T-Cell therapy,ALL,"ADULT, OLDER_ADULT",PHASE1,28,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-31,2026-05
RECRUITING,NO,DRUG: TQB3616 capsules|DRUG: TQB3616-matching placebo|DRUG: Fluvestrin injection,FEMALE,"ADULT, OLDER_ADULT",PHASE3,287,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-18,2023-12
RECRUITING,NO,DRUG: Dexmedetomidine|DRUG: Esketamine|DRUG: Normal saline,FEMALE,"ADULT, OLDER_ADULT",PHASE4,180,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-05-22,2024-07
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Physical activity adoption|BEHAVIORAL: Self monitoring,FEMALE,"ADULT, OLDER_ADULT",NA,68,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2022-11-10,2025-01-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Trastuzumab Deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE3,506,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-22,2024-02-08
RECRUITING,NO,BEHAVIORAL: Intervention Arm|BEHAVIORAL: Control Group,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-10-01,2023-12-31
RECRUITING,NO,PROCEDURE: Motor Tests|PROCEDURE: Cognitive Tests|PROCEDURE: Unenhanced-MRI of the brain|PROCEDURE: Gadolinium Measurements|DRUG: Gadoxetate disodium|DRUG: Gadobenate dimeglumine|DRUG: Gadodiamide|DRUG: Gadoterate meglumine|DRUG: Gadobutrol|DRUG: Gadoteridol,ALL,ADULT,PHASE4,2076,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-03-24,2028-12-31
RECRUITING,NO,DEVICE: DiviTum® TKa assay|OTHER: Study Care Plans,ALL,"ADULT, OLDER_ADULT",NA,55,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-03-07,2027-03-31
UNKNOWN,NO,PROCEDURE: Ultrasound (US) bi-level erector spinae block|DRUG: levobupivacaine|DRUG: Ketamine|DRUG: Magnesium Sulfate,FEMALE,ADULT,PHASE2,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2020-08-01,2022-04
UNKNOWN,NO,BEHAVIORAL: Motivational enhancement therapy|BEHAVIORAL: Attention Control,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,128,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-10,2023-01
NOT_YET_RECRUITING,NO,BEHAVIORAL: Online psychological care program to reduce psychological distress in women who attend a breast clinic|BEHAVIORAL: Psychological care program to reduce psychological distress in women who attend a breast clinic,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2023-10-19,2024-08
RECRUITING,NO,DRUG: Ceralasertib|BIOLOGICAL: Trastuzumab Deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE1,15,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-09,2026-03-31
RECRUITING,NO,DRUG: Atezolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-17,2026-10
RECRUITING,NO,DRUG: Eribulin|DRUG: SDX-7320|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-10-03,2027-10
RECRUITING,NO,DRUG: Pyrotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,188,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-04-08,2028-12-31
RECRUITING,NO,BIOLOGICAL: Atezolizumab|DRUG: Cabozantinib S-malate|DRUG: Nab-paclitaxel|PROCEDURE: Tumor Treating Fields Therapy,ALL,"ADULT, OLDER_ADULT",PHASE1,36,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-29,2026-09-01
RECRUITING,NO,OTHER: Questionnaire Administration|DRUG: White Button Mushroom Extract,FEMALE,"ADULT, OLDER_ADULT",NA,26,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-07-27,2024-07-12
RECRUITING,NO,DRUG: Dato-DXd|DRUG: Durvalumab|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE3,625,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-23,2029-04-23
RECRUITING,NO,PROCEDURE: Physical Characteristics|PROCEDURE: Muscular Sympathetic Nervous Activity|DIAGNOSTIC_TEST: Cardiac Function|DIAGNOSTIC_TEST: Heart rate|DIAGNOSTIC_TEST: Blood pressure|DIAGNOSTIC_TEST: Blood Assessments|DIAGNOSTIC_TEST: Muscle blood flow|DIAGNOSTIC_TEST: Endothelium-dependent vascular function|DIAGNOSTIC_TEST: Vascular intima-media thickness|DIAGNOSTIC_TEST: Physical Capacity|DRUG: Anthracycline & Cyclophosphamide treatment scheme,FEMALE,ADULT,NA,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-08-03,2024-03-03
COMPLETED,NO,DEVICE: hemopatch|PROCEDURE: Aspirative drainage,FEMALE,"ADULT, OLDER_ADULT",NA,228,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2020-03-01,2023-02-14
TERMINATED,YES,DRUG: Amcenestrant|DRUG: Tamoxifen|DRUG: Amcenestrant-matching placebo|DRUG: Tamoxifen-matching placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,3,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-02-17,2022-10-13
RECRUITING,NO,OTHER: Families Accelerating Cascade Testing Toolkit,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-04-09,2024-10-31
RECRUITING,NO,DRUG: Fosifloxuridine Nafalbenamide|DRUG: Leucovorin|DRUG: Pembrolizumab|DRUG: Docetaxel,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,91,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-08,2025-01
RECRUITING,NO,BEHAVIORAL: Acupuncture,FEMALE,"ADULT, OLDER_ADULT",PHASE1,62,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-01-12,2025-05-31
RECRUITING,NO,DRUG: Abemaciclib + Aromatase Inhibitor|DRUG: Abemaciclib + Fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE4,300,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-27,2029-04
RECRUITING,NO,OTHER: Phased withdrawal of heart failure medications,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-14,2025-09
RECRUITING,NO,OTHER: Nutrition and resistance training exercise intervention,FEMALE,"ADULT, OLDER_ADULT",NA,44,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-05-20,2024-08-20
RECRUITING,NO,BEHAVIORAL: CARE|BEHAVIORAL: CARE + COACH,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,350,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SCREENING,2023-06-06,2025-12
COMPLETED,NO,OTHER: SCOPE-Chinese Women,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-07-20,2021-12-30
RECRUITING,NO,DRUG: Letrozole|DRUG: Abemaciclib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-04-15,2025-04-15
RECRUITING,NO,DRUG: EG017,FEMALE,"ADULT, OLDER_ADULT",PHASE1,70,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-08,2026-01-02
RECRUITING,NO,RADIATION: Hypofractionation with simultaneous integrated boost,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-22,2025-07-31
RECRUITING,NO,DRUG: Pyrotinib|DRUG: Trastuzumab|DRUG: Dalpiciclib|DRUG: Letrozole|DRUG: Pertuzumab|DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Gonadotropin-releasing hormone agonist,FEMALE,"ADULT, OLDER_ADULT",PHASE2,236,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-20,2027-12-10
COMPLETED,NO,DRUG: AZD9833|DRUG: AZD9833|DRUG: AZD9833 with palbociclib|DRUG: AZD9833 with everolimus,FEMALE,"ADULT, OLDER_ADULT",PHASE1,28,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-12,2023-09-07
NOT_YET_RECRUITING,NO,BEHAVIORAL: Stand-alone Research Portal|BEHAVIORAL: Portal with Virtual Community Health Educator (vCHE),ALL,"ADULT, OLDER_ADULT",NA,350,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2023-12-20,2027-08-31
RECRUITING,NO,RADIATION: external beams radiotherapy|RADIATION: brachytherapy,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-01-09,2029-12
RECRUITING,NO,DRUG: AC699,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-29,2024-12-31
RECRUITING,NO,DRUG: Pyrotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,209,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-01,2024-10-30
COMPLETED,NO,OTHER: Educational Brochure,ALL,"ADULT, OLDER_ADULT",NA,36,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-03-24,2023-08-21
RECRUITING,NO,DRUG: Talazoparib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-18,2024-07-31
RECRUITING,NO,DRUG: Sacituzumab Govitecan-hziy,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,143,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-20,2026-05
COMPLETED,NO,OTHER: Virtual Reality Glasses,FEMALE,"ADULT, OLDER_ADULT",NA,66,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2022-04-04,2022-11-30
RECRUITING,NO,DRUG: Tucatinib|DRUG: Pembrolizumab|DRUG: Trastuzumab|DRUG: Capecitabine,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-07,2025-09
NOT_YET_RECRUITING,NO,DRUG: BGB-43395|DRUG: Fulvestrant|DRUG: Letrozole,ALL,"ADULT, OLDER_ADULT",PHASE1,78,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-04-11,2026-10-26
RECRUITING,NO,DRUG: AsiDNA|DRUG: Olaparib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,115,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-20,2027-04
ACTIVE_NOT_RECRUITING,NO,DRUG: Pembrolizumab|DRUG: Paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE2,46,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-21,2024-11-01
RECRUITING,NO,DEVICE: Artificial Intelligence and Digital Health Arm,ALL,"ADULT, OLDER_ADULT",NA,1030,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-08-08,2025-12
RECRUITING,NO,RADIATION: Neoadjuvant radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-08,2025-10-31
RECRUITING,NO,DRUG: IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB,ALL,"ADULT, OLDER_ADULT",PHASE1,27,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-21,2025-02
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: AI CAD|DIAGNOSTIC_TEST: Radiologist reading,FEMALE,"ADULT, OLDER_ADULT",NA,55579,OTHER,"Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: DIAGNOSTIC",2021-04-01,2024-12
RECRUITING,NO,DRUG: Sacituzumab Govitecan-hziy|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Capecitabine,ALL,"ADULT, OLDER_ADULT",PHASE3,654,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-08,2028-12
RECRUITING,NO,BEHAVIORAL: Behavioral Intervention|OTHER: Best Practice|DEVICE: FitBit|BEHAVIORAL: Nutrition Education|OTHER: Physical Activity|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-05-21,2027-02-02
COMPLETED,NO,DRUG: Cilostazol|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,71,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-03-28,2022-12-30
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Computed Tomography|DRUG: Copper Cu-64-DOTA-alendronate|OTHER: Pharmacokinetic Study|PROCEDURE: Positron Emission Tomography,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,1,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-11-03,2025-02-20
RECRUITING,NO,DRUG: Paclitaxel Polymeric Micelles for Injection,ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-28,2025-11
RECRUITING,NO,DIETARY_SUPPLEMENT: iso-caloric ketogenic diet|DIETARY_SUPPLEMENT: protein restricted diet,FEMALE,"ADULT, OLDER_ADULT",NA,75,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-05-18,2025-03
RECRUITING,NO,DRUG: vitamin C group|OTHER: placebo group,FEMALE,"ADULT, OLDER_ADULT",NA,204,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-04-01,2024-12-01
RECRUITING,NO,BEHAVIORAL: Breast Cancer Survivor Education Program,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-02-28,2023-12-31
WITHDRAWN,NO,DRUG: Nab-paclitaxel|DRUG: Paclitaxel|RADIATION: Radiation Therapy|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-04,2022-12-01
RECRUITING,NO,DRUG: RC48-ADC|DRUG: Paclitaxel Injection|DRUG: Docetaxel Injection|DRUG: Vinorelbine Tartrate Injection|DRUG: Capecitabine Tablets,ALL,"ADULT, OLDER_ADULT",PHASE3,366,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-29,2024-12-30
ACTIVE_NOT_RECRUITING,NO,DRUG: E7090|DRUG: Fulvestrant|DRUG: Exemestane,FEMALE,"ADULT, OLDER_ADULT",PHASE1,72,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-09,2024-12-31
RECRUITING,NO,PROCEDURE: Harmonic motion imaging guided focused ultrasound (HMIgFUS),FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-01-19,2025-05
ACTIVE_NOT_RECRUITING,NO,"DRUG: DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C",ALL,"ADULT, OLDER_ADULT",PHASE1,23,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-21,2024-05
RECRUITING,NO,DRUG: PIK3CA inhibitor|DRUG: AKT inhibitor|DRUG: Carrelizumab|DRUG: Famitinib|DRUG: Fluzoparib|DRUG: Dalpiciclib|DRUG: SHR-A1811|DRUG: TROP2 ADC|DRUG: Everolimus|DRUG: Aromatase Inhibitors or Fulvestrant|DRUG: Goserelin|DRUG: TPC|DRUG: RTK Inhibitor,FEMALE,"ADULT, OLDER_ADULT",PHASE2,140,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-30,2026-12-01
RECRUITING,NO,"DRUG: MDK-703|DRUG: Checkpoint Inhibitor, Immune",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,150,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-08,2025-09
RECRUITING,NO,"DRUG: Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)",ALL,"ADULT, OLDER_ADULT",PHASE3,276,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2024-01-20,2030-12-01
RECRUITING,NO,BEHAVIORAL: REBECCA-assisted intervention,FEMALE,"ADULT, OLDER_ADULT",NA,110,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-01,2025-05-01
RECRUITING,NO,DRUG: IKS014,ALL,"ADULT, OLDER_ADULT",PHASE1,165,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-14,2027-09
RECRUITING,NO,DRUG: Alpelisib|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE4,100,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-09,2024-11-15
WITHDRAWN,NO,DIAGNOSTIC_TEST: Fluoro-D-glucose-positron Emission Tomography|BIOLOGICAL: 2-deoxy-2-[18F]fluoro-D-glucose (FDG)|DIAGNOSTIC_TEST: Echocardiogram,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-12,2022-12
RECRUITING,NO,DRUG: Fulvestrant plus Anlotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,61,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-16,2025-06-01
NOT_YET_RECRUITING,NO,DRUG: Pyrotinib|DRUG: Vinorelbine|DRUG: Inetetamab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-01,2024-07-31
RECRUITING,NO,BEHAVIORAL: SIS TALK Back Intervention,FEMALE,"ADULT, OLDER_ADULT",NA,460,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-03-01,2025-01-31
COMPLETED,NO,BEHAVIORAL: Nurse-led Supportive Care,FEMALE,"ADULT, OLDER_ADULT",NA,42,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2022-01-03,2022-06-10
RECRUITING,NO,"OTHER: Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)|OTHER: Multimodal rehabilitation program + traditional biomedical information|OTHER: Control group",ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2022-04-04,2024-04
UNKNOWN,NO,DEVICE: Acupuncture group,FEMALE,"ADULT, OLDER_ADULT",NA,59,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-25,2023-11-30
ACTIVE_NOT_RECRUITING,NO,DRUG: ARV-471 in combination with Everolimus,ALL,"ADULT, OLDER_ADULT",PHASE1,32,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-08,2024-11-30
RECRUITING,NO,OTHER: REASSURE,FEMALE,"ADULT, OLDER_ADULT",NA,110,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-11-16,2025-11
NOT_YET_RECRUITING,NO,DRUG: Giredestrant|DRUG: Abemaciclib|DRUG: Inavolisib,ALL,"ADULT, OLDER_ADULT",PHASE2,1260,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-03-01,2028-12-30
COMPLETED,NO,DRUG: Pentoxifylline|DRUG: Paclitaxel|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,66,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-10-03,2023-09-28
RECRUITING,NO,DRUG: Sulindac Pill|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-11-20,2025-02-28
RECRUITING,NO,DEVICE: intravaginal laser,FEMALE,"ADULT, OLDER_ADULT",NA,162,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-12-27,2025-12
RECRUITING,NO,BEHAVIORAL: educational yoga program|OTHER: no intervention,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-02-11,2025-08
RECRUITING,NO,OTHER: Carbon Black Tattoo,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-02-07,2024-03-01
RECRUITING,NO,DRUG: Entrectinib|DRUG: Letrozole|DRUG: Goserelin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,65,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-14,2024-07
RECRUITING,NO,DRUG: Onvansertib|DRUG: Paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,50,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-30,2029-02-15
RECRUITING,NO,OTHER: Accessing personal medical records online via online portals,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-04-30,2025-06
ACTIVE_NOT_RECRUITING,NO,DRUG: SKL27969,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,96,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-12,2024-09
RECRUITING,NO,DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Alpelisib-matching placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,234,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-11-29,2026-09-23
RECRUITING,NO,DRUG: AVA6000,ALL,"ADULT, OLDER_ADULT",PHASE1,80,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-07-16,2023-06-30
RECRUITING,NO,DRUG: Palbociclib|DRUG: trastuzumab|DRUG: pyrotinib|DRUG: fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE2,37,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-15,2024-10-15
RECRUITING,NO,DRUG: Cyclophosphamide|DRUG: Docetaxel|OTHER: Medical Chart Review|OTHER: Questionnaire Administration,ALL,OLDER_ADULT,PHASE2,174,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2024-04-28,2027-03-20
RECRUITING,NO,DIAGNOSTIC_TEST: Polygenic risk score (PRS),ALL,"ADULT, OLDER_ADULT",NA,1076,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING,2020-07-17,2025-09-30
RECRUITING,NO,DEVICE: Carbon-Fibre Adjustable Reuseable Accessory (CARA),ALL,"ADULT, OLDER_ADULT",NA,220,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2020-06-11,2024-12-31
WITHDRAWN,NO,DRUG: Ociperlimab|DRUG: Tislelizumab|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Carboplatin|DRUG: Placebo|DRUG: Pembrolizumab|DRUG: Gemcitabine,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-09-15,2029-07-18
RECRUITING,NO,RADIATION: Hypofractionation Radiotherapy.|RADIATION: Ultra-hypofractionation radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-01,2023-10-01
COMPLETED,NO,DRUG: Capivasertib|DRUG: Itraconazole,ALL,ADULT,PHASE1,11,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-02-01,2021-03-25
COMPLETED,NO,OTHER: Mobile Lymphedema Self-Care Support Program|OTHER: standart lymphedema education,FEMALE,ADULT,NA,98,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-09-01,2021-12-01
RECRUITING,NO,DRUG: Ribociclib|DRUG: Letrozole|DRUG: Anastrozole|DRUG: Goserelin|DRUG: Tamoxifen|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE4,137,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-07,2029-09-03
WITHDRAWN,NO,DRUG: Carboplatin|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Paclitaxel|BIOLOGICAL: Panitumumab|BIOLOGICAL: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-11,2023-07-26
RECRUITING,NO,RADIATION: Hypofractionation,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-27,2029-05-01
ENROLLING_BY_INVITATION,NO,BEHAVIORAL: Post-visit patient text messaging|BEHAVIORAL: Default pended order|BEHAVIORAL: High risk bidirectional post-visit text messaging,FEMALE,"ADULT, OLDER_ADULT",NA,21416,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2023-12-18,2024-12-18
RECRUITING,NO,OTHER: Acute Exercise,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-23,2024-10
RECRUITING,NO,PROCEDURE: Targeted Axillary Dissection|DIAGNOSTIC_TEST: Ultrasound of the axilla,FEMALE,"ADULT, OLDER_ADULT",NA,98,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-30,2025-05
RECRUITING,NO,OTHER: Counseling|OTHER: Educational Intervention|BEHAVIORAL: Questionnaire,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-03-18,2024-09-30
RECRUITING,NO,DIAGNOSTIC_TEST: Ga-PSMA PET/CT,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-05-30,2024-09
RECRUITING,NO,DRUG: Triptorelin Embonate|DRUG: Sodium Chloride solution 0.9%,FEMALE,"CHILD, ADULT",PHASE3,500,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-03-31,2032-01-31
RECRUITING,NO,BEHAVIORAL: Supportive Care (Fitbit),FEMALE,ADULT,NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-10-20,2024-12-31
NOT_YET_RECRUITING,NO,DRUG: 68Ga labeled HER2 Affibody,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,56,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-06-01,2023-12-01
RECRUITING,NO,OTHER: Vaginal Moisturizer|DEVICE: Vaginal Dilator,FEMALE,"ADULT, OLDER_ADULT",NA,59,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-08-03,2024-02-29
COMPLETED,NO,OTHER: Dedicated and coordinated monitoring,FEMALE,"ADULT, OLDER_ADULT",NA,45,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-02-28,2021-07-21
ACTIVE_NOT_RECRUITING,NO,DRUG: XL102|DRUG: Fulvestrant|DRUG: Abiraterone|DRUG: Prednisone,ALL,"ADULT, OLDER_ADULT",PHASE1,373,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-10,2024-10
RECRUITING,NO,BIOLOGICAL: HER-2 pulsed DC1|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Paclitaxel|PROCEDURE: Resection surgery,ALL,"ADULT, OLDER_ADULT",PHASE2,53,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-28,2025-01-31
RECRUITING,NO,OTHER: Aerobic Training|OTHER: Aerobic Training|OTHER: Aerobic Training|OTHER: Aerobic Training,FEMALE,"ADULT, OLDER_ADULT",NA,152,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-08,2025-07
NOT_YET_RECRUITING,NO,DRUG: PF-07220060|DRUG: Fulvestrant|DRUG: Everolimus|DRUG: Exemestane,ALL,"ADULT, OLDER_ADULT",PHASE3,510,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-15,2028-11-13
NOT_YET_RECRUITING,NO,PROCEDURE: Breast conserving surgery|PROCEDURE: Radical modified mastectomy,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-03-01,2028-01-01
RECRUITING,NO,BIOLOGICAL: Trastuzumab Emtansine|DRUG: Placebo Administration|DRUG: Tucatinib|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment,ALL,"ADULT, OLDER_ADULT",PHASE3,1031,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-01-06,2035-05
NOT_YET_RECRUITING,NO,"PROCEDURE: Arm I (Prepectoral), Arm II (Subpectoral)",FEMALE,"ADULT, OLDER_ADULT",NA,114,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2025-06-30
RECRUITING,NO,OTHER: Electronic Tumour-Specific Patient-Reported Outcomes (ePRO) questionnaires,ALL,"ADULT, OLDER_ADULT",PHASE3,128,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-03-30,2024-10-01
RECRUITING,NO,DEVICE: Use of the WeCancer app combined with the smartwatch.,FEMALE,"ADULT, OLDER_ADULT",NA,68,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-04-22,2024-05-31
NOT_YET_RECRUITING,NO,DRUG: FES|PROCEDURE: PET/MRI A|PROCEDURE: PET/MRI B|PROCEDURE: PET/MRI C|PROCEDURE: PET/MRI D|GENETIC: Translational analysis,FEMALE,"ADULT, OLDER_ADULT",NA,221,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-10-15,2028-11-01
UNKNOWN,NO,BIOLOGICAL: 4SCAR T cells,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2023-12-31
WITHDRAWN,NO,RADIATION: Simultaneous integrated boost,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-16,2025-08-31
RECRUITING,NO,DEVICE: EVEBRA device,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-07-12,2026-10
RECRUITING,NO,OTHER: Physical activity,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-04-08,2023-08
NOT_YET_RECRUITING,NO,OTHER: inspiratory muscle training,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-12-01,2024-09-01
RECRUITING,NO,DRUG: Giredestrant|DRUG: Endocrine Therapy of Physician's Choice|DRUG: LHRH Agonist|DRUG: Abemaciclib,ALL,"ADULT, OLDER_ADULT",PHASE3,4200,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-27,2033-11-21
COMPLETED,NO,DRUG: Lansoprazole|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE3,66,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-06-10,2022-11-05
RECRUITING,NO,DRUG: Disitamab Vedotin combined with Tislelizumab,ALL,"ADULT, OLDER_ADULT",PHASE4,42,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-01,2026-02-01
RECRUITING,NO,OTHER: Aerobic Exercise|OTHER: Dietary Intervention|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|OTHER: Resistance Training,FEMALE,"ADULT, OLDER_ADULT",NA,62,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-11-22,2025-04-30
RECRUITING,NO,PROCEDURE: Blood draw|PROCEDURE: Post-mortem tissue collection,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-11-30,2035-09
UNKNOWN,NO,DRUG: Cyclodynon|BEHAVIORAL: Lifestyl modification,FEMALE,ADULT,PHASE4,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-22,2022-05-01
RECRUITING,NO,DRUG: MRG002,ALL,"ADULT, OLDER_ADULT",PHASE2,99,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-23,2023-10
NOT_YET_RECRUITING,NO,DRUG: Vinorelbine|RADIATION: Radiotherapy|DRUG: PD-1/PD-L1 inhibitor|DRUG: GM-CSF|DRUG: IL-2,ALL,"ADULT, OLDER_ADULT",PHASE2,45,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10-30,2024-10-17
COMPLETED,NO,DRUG: DAN-222|DRUG: Niraparib,FEMALE,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-02,2023-10-11
UNKNOWN,NO,DRUG: Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,34,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-01,2023-01-31
RECRUITING,NO,DRUG: TOS-358,ALL,"ADULT, OLDER_ADULT",PHASE1,241,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-15,2025-12
RECRUITING,NO,OTHER: Whole Body Vibration exercise - WBV,FEMALE,"ADULT, OLDER_ADULT",NA,44,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-10-17,2024-04-25
RECRUITING,NO,DRUG: Camrelizumab|DRUG: Apatinib|DRUG: Nab-paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide,FEMALE,"ADULT, OLDER_ADULT",PHASE2,35,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-01,2026-12-31
RECRUITING,NO,DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001+ RT|DRUG: Association atezolizumab + BDB001+ RT|DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001 + RT|DRUG: Association atezolizumab + BDB001 + RT,ALL,"ADULT, OLDER_ADULT",PHASE2,247,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-31,2026-03
ACTIVE_NOT_RECRUITING,NO,OTHER: Oncological physical exercise intervention|OTHER: Active Physical Activities intervention,FEMALE,"ADULT, OLDER_ADULT",NA,76,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-01-12,2023-07-31
TERMINATED,NO,DRUG: RTX-224,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,7,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-12,2022-11-30
RECRUITING,NO,RADIATION: Preoperative MRI-guided tumor-bed boost and postopreative ultra-hypofractionated radiotherapy (26 Gy/5.2Gy/5),FEMALE,"CHILD, ADULT",NA,102,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-21,2028-07
RECRUITING,NO,DRUG: Cisplatin|DRUG: Nab-paclitaxel|DRUG: Pembrolizumab|DRUG: Olaparib,ALL,"ADULT, OLDER_ADULT",PHASE2,136,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-07,2025-03-01
COMPLETED,NO,PROCEDURE: RIB+SAP blocks,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-09-21,2023-04-14
RECRUITING,NO,DIAGNOSTIC_TEST: 68Ga-FAPI-46 PET scan,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-11-16,2026-04
RECRUITING,NO,BEHAVIORAL: HEALTH FAITH MODEL GUIDED IN CANCER FREQUENTLY SEEN IN WOMEN EARLY DIAGNOSIS AND SCREENING METHODS EDUCATION|BEHAVIORAL: STANDART CANCER EDUCATİON,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING",2023-01-01,2023-07-01
COMPLETED,NO,DRUG: Atezolizumab|DRUG: Paclitaxel|DRUG: Bevacizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-05,2023-12-07
COMPLETED,NO,DRUG: PRT2527,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-14,2023-12-06
RECRUITING,NO,OTHER: Copper Cu 64-DOTA-Trastuzumab|PROCEDURE: Magnetic Resonance Imaging|DEVICE: Positron Emission Tomography|BIOLOGICAL: Trastuzumab|BIOLOGICAL: Trastuzumab Deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE4,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-12-21,2026-02-25
RECRUITING,NO,PROCEDURE: axillary surgery de-escalation after NAT,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-18,2025-12-01
COMPLETED,NO,BEHAVIORAL: mindfulness-based stress reduction program,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-09-29,2022-06-30
COMPLETED,NO,BIOLOGICAL: Imprime PGG|BIOLOGICAL: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,26,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-09,2023-04-12
RECRUITING,NO,DRUG: GQ1001,ALL,"ADULT, OLDER_ADULT",PHASE1,96,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-07,2024-05-01
RECRUITING,NO,DRUG: Paclitaxel|DRUG: Pertuzumab|DRUG: Margetuximab|DRUG: Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE2,171,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-13,2027-07-01
ACTIVE_NOT_RECRUITING,NO,RADIATION: Breast Irradiation after Breast-Conserving Surgery,FEMALE,"ADULT, OLDER_ADULT",NA,147,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-01,2025-12-31
NOT_YET_RECRUITING,NO,"DRUG: Capecitabine and Pyrotinib|DRUG: Capecitabine,Trastuzumab, and Pertuzumab",FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-01,2024-12
ENROLLING_BY_INVITATION,NO,DRUG: 18F-FDG|DRUG: Injection of hyperpolarized [1-13C]Pyruvate|PROCEDURE: PET/MR/MRS/MRSI scanning,ALL,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-05-18,2024-12
NOT_YET_RECRUITING,NO,PROCEDURE: PECs block during mastectomy|PROCEDURE: Sham block,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04-01,2024-12-30
RECRUITING,NO,DRUG: TQB2102 for injection,ALL,"ADULT, OLDER_ADULT",PHASE1,150,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-17,2026-12
COMPLETED,NO,BEHAVIORAL: REx Condition First|BEHAVIORAL: Sedentary Control Condition First,FEMALE,ADULT,NA,21,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-02-07,2022-02-05
RECRUITING,NO,DRUG: Dalpiciclib combined with aromatase inhibitors,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10-01,2025-10-31
RECRUITING,NO,DEVICE: QPOP,FEMALE,"ADULT, OLDER_ADULT",PHASE1,26,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-06,2025-12-31
NOT_YET_RECRUITING,NO,BIOLOGICAL: Peptide pulsed autologous Dendritic cell,FEMALE,"ADULT, OLDER_ADULT",PHASE1,8,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-07-01,2026-06-01
NOT_YET_RECRUITING,NO,DRUG: Pembrolizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04,2023-05
RECRUITING,NO,DRUG: OC-001|DRUG: OC-001 in Combination,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,80,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-06,2026-09-30
NOT_YET_RECRUITING,NO,BEHAVIORAL: MyMammogram decision aid,FEMALE,ADULT,NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2024-04,2024-09
RECRUITING,NO,BEHAVIORAL: PACHA Program,ALL,"ADULT, OLDER_ADULT",NA,66,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2023-06-07,2024-12
TERMINATED,NO,DRUG: Lerociclib + Letrozole or Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE2,100,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-21,2023-11-29
WITHDRAWN,NO,DRUG: Tremelimumab|DRUG: Durvalumab,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09,2024-12-05
RECRUITING,NO,DRUG: APG-2575|DRUG: Palbociclib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,65,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-13,2024-10-01
COMPLETED,NO,OTHER: Compass Course,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-03-01,2023-11-07
RECRUITING,NO,"DRUG: Abemaciclib|DRUG: Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)",FEMALE,"ADULT, OLDER_ADULT",PHASE3,2032,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-23,2032-03-31
RECRUITING,NO,DRUG: Disitamab vedotin|OTHER: Endocrine therapy,ALL,"ADULT, OLDER_ADULT",PHASE3,288,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-01,2030-03-01
NOT_YET_RECRUITING,NO,COMBINATION_PRODUCT: Atezolizumab + RP1,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,51,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-30,2031-04-30
RECRUITING,NO,DRUG: TQB2930 for injection|DRUG: Docetaxel injection,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,89,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-13,2025-10
ACTIVE_NOT_RECRUITING,NO,DEVICE: Group wearing a radiotherapy bra,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,38,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-01,2024-10-20
RECRUITING,NO,PROCEDURE: Latissimus dorsi flap|PROCEDURE: Thoracodorsal artery perforator flap to breast|PROCEDURE: Deep inferior epigastric perforator flap,FEMALE,"ADULT, OLDER_ADULT",NA,550,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-01,2025-12-31
RECRUITING,NO,DRUG: Lipitor 40mg Tablet,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-19,2027-03-01
UNKNOWN,NO,DRUG: Trastuzumab and Pyrotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,68,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-20,2023-09-01
COMPLETED,NO,OTHER: Standard of care treatments,ALL,"ADULT, OLDER_ADULT",PHASE4,56,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-02-25,2022-09-22
RECRUITING,NO,RADIATION: proton plus carbon ion radiotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-01-10,2026-01-10
RECRUITING,NO,DEVICE: Hemopatch|OTHER: Control group,FEMALE,"ADULT, OLDER_ADULT",PHASE4,118,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2021-11-08,2022-11
NOT_YET_RECRUITING,NO,BEHAVIORAL: Intervention,FEMALE,"ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-11,2025-06
COMPLETED,NO,DEVICE: CBCT Imaging,ALL,"ADULT, OLDER_ADULT",NA,30,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-12-20,2023-07-30
RECRUITING,NO,OTHER: group serratus plan block|OTHER: group serratus and parasternal plan block,ALL,"ADULT, OLDER_ADULT",NA,64,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-06-21,2024-01-15
RECRUITING,NO,OTHER: Pulsed electromagnetic field|OTHER: traditional skin care,FEMALE,ADULT,NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-11-01,2024-03-30
COMPLETED,NO,BEHAVIORAL: Social Contact Reminder,FEMALE,"ADULT, OLDER_ADULT",NA,156,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-03-18,2022-06-30
RECRUITING,NO,DRUG: SHR-A1811：Pyrotinib|DRUG: SHR-A1811；Pertuzumab|DRUG: SHR-A1811；Adebrelimab|DRUG: SHR-A1811；Albumin paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE2,402,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-23,2025-12-31
RECRUITING,NO,DRUG: Ipatasertib|DRUG: Trastuzumab|DRUG: Pertuzumab,ALL,"ADULT, OLDER_ADULT",PHASE1,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-25,2025-08-25
UNKNOWN,NO,OTHER: use of a smartphone app for adverse event management|OTHER: conventional adverse event management,FEMALE,"ADULT, OLDER_ADULT",NA,108,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-03-07,2022-12-07
RECRUITING,NO,DRUG: Paclitaxel Polymeric Micelles for Injection|DRUG: Eribulin Mesilate injection|DRUG: Capecitabine Tablets|DRUG: Gemcitabine Hydrochloride for Injection|DRUG: Vinorelbine Tartrate Injection|DRUG: Paclitaxel (albumin-bound),ALL,"ADULT, OLDER_ADULT",PHASE3,168,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-30,2025-07
NOT_YET_RECRUITING,NO,"DRUG: Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel|DRUG: Epirubicin, Cyclophosphamide, Docetaxel",FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-01,2025-06-01
RECRUITING,NO,DIAGNOSTIC_TEST: screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice,FEMALE,ADULT,NA,60000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-02-06,2026-02
RECRUITING,NO,OTHER: Questionnaire Administration|BEHAVIORAL: Tonation Breathing Technique,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-02-22,2026-03-15
RECRUITING,NO,DRUG: AI+CDK4/6i|DRUG: SERD+CDK4/6i|DRUG: mTOR inhibitor + AI|DRUG: mTOR inhibitor + SERD|DRUG: mTOR inhibitor + Selective estrogen receptor modulator|DRUG: PI3K inhibitor + SERD|DRUG: PI3K inhibitor + AI|DRUG: Chemotherapy|DRUG: Oral SERD,ALL,"ADULT, OLDER_ADULT",PHASE2,500,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-12,2029-07-31
RECRUITING,NO,DRUG: Capecitabine|DRUG: Talazoparib|DRUG: Pembrolizumab|DRUG: Inavolisib,ALL,"ADULT, OLDER_ADULT",PHASE2,197,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-24,2034-01-31
NOT_YET_RECRUITING,NO,DRUG: CTX-8371,ALL,"ADULT, OLDER_ADULT",PHASE1,55,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-01,2026-04
RECRUITING,NO,DRUG: standard of care|RADIATION: radiotherapy + standard of care,FEMALE,"ADULT, OLDER_ADULT",PHASE3,170,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-06,2026-04-30
NOT_YET_RECRUITING,NO,RADIATION: Omission of radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,595,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07,2037-05
RECRUITING,NO,DRUG: Tamoxifen 20 mg|DRUG: Anastrozole 1Mg Tab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,262,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-03,2033-08-01
RECRUITING,NO,DRUG: Tamoxifen|DRUG: Exemestane|DRUG: Letrozole|DRUG: Anastrazole|DRUG: Testosterone + Anastrazole|DRUG: Elacestrant|DRUG: Z-endoxifen,FEMALE,"ADULT, OLDER_ADULT",PHASE2,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-30,2033-11
RECRUITING,NO,BIOLOGICAL: MEM-288 Intratumoral Injection|BIOLOGICAL: Nivolumab,ALL,"ADULT, OLDER_ADULT",PHASE1,61,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-02-23,2026-11
NOT_YET_RECRUITING,NO,OTHER: CUMACA-M Program,FEMALE,"ADULT, OLDER_ADULT",NA,182,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-01,2024-06
RECRUITING,NO,PROCEDURE: Ultrasonography|PROCEDURE: Automated Breast Ultrasound,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2022-11-18,2024-12
RECRUITING,NO,"DRUG: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|DRUG: nab-paclitaxel, with maintenance of capecitabine|DRUG: Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1|DRUG: VEGFR and TPC",FEMALE,"ADULT, OLDER_ADULT",PHASE3,192,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-25,2026-02-28
UNKNOWN,NO,OTHER: customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images,ALL,"CHILD, ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-03-01,2021-04-20
RECRUITING,NO,DRUG: Alpelisib|DRUG: Sacituzumab govitecan,ALL,"ADULT, OLDER_ADULT",PHASE1,18,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-28,2025-12
COMPLETED,YES,DEVICE: Affirm Contrast Biopsy procedure,FEMALE,"ADULT, OLDER_ADULT",NA,67,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-03-05,2022-08-18
UNKNOWN,NO,OTHER: Contrast enhanced mammography guided biopsy (diagnostic procedure)|OTHER: Mammography guided biopsy (diagnostic procedure),FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC,2021-07-24,2022-12
RECRUITING,NO,"DRUG: TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg",ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-07,2023-12
RECRUITING,NO,DRUG: investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)|DRUG: investigator-selected taxane/trastuzumab/pertuzumab (THP),FEMALE,"ADULT, OLDER_ADULT",PHASE3,774,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-30,2025-04-30
UNKNOWN,NO,"DRUG: Ribocyclib, fulvestrant, triptorelin|DRUG: Doxorubicin, cyclophosphamide, paclitaxel",FEMALE,ADULT,PHASE2|PHASE3,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-28,2024-01-28
RECRUITING,NO,OTHER: Internet Mobile Technology|OTHER: Internet-Based Intervention|OTHER: Questionnaire Administration|PROCEDURE: Supportive Care|OTHER: Informational Intervention,ALL,"ADULT, OLDER_ADULT",NA,700,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-10-23,2025-12-31
RECRUITING,NO,DRUG: ZN-A-1041 50mg BID|DRUG: ZN-A-1041 100mg BID|DRUG: ZN-A-1041 200mg BID|DRUG: ZN-A-1041 400mg BID|DRUG: ZN-A-1041 600mg BID|DRUG: ZN-A-1041 800mg BID|DRUG: ZN-A-1041 1000mg BID|DRUG: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b|DRUG: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b|DRUG: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b|DRUG: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c|DRUG: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c|DRUG: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c,ALL,"ADULT, OLDER_ADULT",PHASE1,210,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-15,2024-10-30
COMPLETED,NO,DRUG: Olanzapine|DRUG: Netupitant|DRUG: Palonesetron,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-12-17,2022-01-17
RECRUITING,NO,OTHER: Education with pecha kucha method,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2023-04-10,2023-06-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Tucatinib|BIOLOGICAL: Trastuzumab|DRUG: Capecitabine,ALL,"ADULT, OLDER_ADULT",PHASE2,66,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-08,2028-12-06
RECRUITING,NO,DRUG: BET Bromodomain Inhibitor ZEN-3694|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Nab-paclitaxel|BIOLOGICAL: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,57,NIH,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-18,2025-12-31
NOT_YET_RECRUITING,NO,DRUG: Oxybutynin|DRUG: Venlafaxine,FEMALE,"ADULT, OLDER_ADULT",PHASE3,260,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2024-01-08,2029-01-01
RECRUITING,NO,"DEVICE: Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA",ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-01-15,2026-11-30
RECRUITING,NO,DRUG: AZD9574|DRUG: Temozolomide|DRUG: [11C]AZ1419 3391|DRUG: Datopotamab Deruxtecan (Dato-DXd)|DRUG: Trastuzumab Deruxtecan (T-DXd),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,490,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-24,2026-01-12
RECRUITING,NO,DRUG: anlotinib and vinorelbine|DRUG: Vinorelbine injection,FEMALE,"ADULT, OLDER_ADULT",PHASE2,134,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-22,2024-12-01
RECRUITING,NO,DRUG: T-DM1|DRUG: Capecitabine|RADIATION: External Beam Radiation Therapy 0|RADIATION: External Beam Radiation Therapy 1,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,45,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-07-11,2026-10
UNKNOWN,NO,DRUG: Lidocaine mucilage-ICG,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-20,2024-01
RECRUITING,NO,BIOLOGICAL: Chemotherapy monitoring by circulating tumor DNA analysis,FEMALE,"ADULT, OLDER_ADULT",PHASE2,214,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-23,2025-06
RECRUITING,NO,OTHER: Counseling|OTHER: Educational Intervention|BEHAVIORAL: Health Education|OTHER: Health Promotion and Education - Direct Text Messaging|OTHER: Health Promotion and Education - Digital health tool kit|OTHER: Questionnaires,ALL,"ADULT, OLDER_ADULT",NA,1000,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-10-21,2027-12-31
COMPLETED,NO,BEHAVIORAL: follow the WeChat public platform to watch the education videos|BEHAVIORAL: regular preoperative visits and education by ward nurses.,FEMALE,"ADULT, OLDER_ADULT",NA,392,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-02-01,2022-03-31
COMPLETED,NO,DRUG: PRT1419,ALL,"ADULT, OLDER_ADULT",PHASE1,26,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-11,2023-02-06
NOT_YET_RECRUITING,NO,DRUG: [18F]FMISO-PET with contrast-enhanced MRI,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2025-06-01,2027-08-02
RECRUITING,NO,DRUG: HRS-8080; Dalpiciclib Isethionate Tablets,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,146,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-20,2025-12-31
NOT_YET_RECRUITING,NO,DEVICE: AMMA Portalbe Scalp Cooling System,FEMALE,"ADULT, OLDER_ADULT",NA,99,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-10-01,2025-03-01
RECRUITING,NO,PROCEDURE: Surgical Intervention|PROCEDURE: Conservative Complex Physical Decongestion Therapy,ALL,"ADULT, OLDER_ADULT",NA,280,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-14,2035-12
COMPLETED,NO,BEHAVIORAL: Virtual reality exposure,ALL,"ADULT, OLDER_ADULT",NA,41,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-06-07,2022-06-16
ENROLLING_BY_INVITATION,NO,PROCEDURE: Prepectoral implant-based immediate breast reconstruction,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-11-01,2025-02-01
RECRUITING,NO,BIOLOGICAL: eftilagimod alpha|DRUG: Paclitaxel|OTHER: placebo,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,849,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-05-22,2027-07-31
ACTIVE_NOT_RECRUITING,NO,OTHER: AI selection for supplemental breast MRI,FEMALE,"ADULT, OLDER_ADULT",NA,2500,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-04-01,2025-07-01
RECRUITING,NO,DRUG: AND019 PO QD,FEMALE,"ADULT, OLDER_ADULT",PHASE1,61,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-05,2025-05
NOT_YET_RECRUITING,NO,DRUG: Placebo|DRUG: famotidine and loratadine,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2024-02,2024-08
RECRUITING,NO,DRUG: Hemay022+AI|DRUG: Lapatinib+Capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE3,339,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-19,2024-06
COMPLETED,NO,DRUG: AMG 650,ALL,"ADULT, OLDER_ADULT",PHASE1,66,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-11,2023-02-15
COMPLETED,NO,BEHAVIORAL: Mindfulness-based Meditation and Yoga program,FEMALE,ADULT,NA,41,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2023-05-11,2023-12-31
COMPLETED,NO,BEHAVIORAL: Exercise|BEHAVIORAL: Art Sculpting Class,FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-01-01,2020-08-31
SUSPENDED,NO,DRUG: Atezolizumab|DRUG: Tivozanib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,29,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-03,2024-06
RECRUITING,NO,BIOLOGICAL: TBio-4101|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-17,2025-06-30
RECRUITING,NO,PROCEDURE: Biospecimen Collection|DRUG: Low-Dose Aspirin|OTHER: Questionnaire Administration|PROCEDURE: Ultrasound-Guided Biopsy,FEMALE,ADULT,PHASE2,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-02-14,2027-01-30
RECRUITING,NO,DRUG: KN026,ALL,"ADULT, OLDER_ADULT",PHASE2,30,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-09,2023-02-15
RECRUITING,NO,BIOLOGICAL: blood samples collection,FEMALE,"ADULT, OLDER_ADULT",NA,85,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-11-19,2026-05-31
UNKNOWN,NO,BEHAVIORAL: Group life-coaching|BEHAVIORAL: Individual life-coaching,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-09-15,2023-09-01
RECRUITING,NO,BEHAVIORAL: Multicomponent Adherence Intervention,ALL,"ADULT, OLDER_ADULT",NA,35,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-11-01,2026-12-10
RECRUITING,NO,DRUG: NT-I7|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,238,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-10,2024-06-20
RECRUITING,NO,DIETARY_SUPPLEMENT: FSMP|OTHER: Nutritional counseling,FEMALE,"ADULT, OLDER_ADULT",NA,60,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2023-08-04,2025-08
NOT_YET_RECRUITING,NO,DRUG: Utidelone|DRUG: Carboplatin|DRUG: Epirubicin|DRUG: Trastuzumab|DRUG: Pertuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,181,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-01,2027-09-01
RECRUITING,NO,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Talazoparib,ALL,"ADULT, OLDER_ADULT",PHASE2,36,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-26,2024-12-01
RECRUITING,NO,BEHAVIORAL: PFMT educational intervention,FEMALE,"ADULT, OLDER_ADULT",NA,42,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-02,2023-04-10
RECRUITING,NO,PROCEDURE: Biospecimen Collection|DRUG: Cyclophosphamide|DRUG: Doxorubicin|BIOLOGICAL: Durvalumab|OTHER: Genetic Testing|PROCEDURE: Mammography|DRUG: Paclitaxel|OTHER: Quality-of-Life Assessment,FEMALE,"ADULT, OLDER_ADULT",PHASE3,3680,NIH,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-27,2026-05-31
RECRUITING,NO,DRUG: Utidelone Injection in combination with AC|DRUG: Docetaxel Injection in combination with AC,FEMALE,"ADULT, OLDER_ADULT",PHASE3,552,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-30,2025-12-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Blood sampling,FEMALE,"ADULT, OLDER_ADULT",NA,165,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-05-27,2025-06
COMPLETED,NO,BEHAVIORAL: Integrated Intervention for Breast Cancer Survivors with Diabetes|BEHAVIORAL: Attention Control,FEMALE,"ADULT, OLDER_ADULT",NA,59,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-01-27,2023-07-24
RECRUITING,NO,OTHER: At-home Breast Oncology care Delivered with E-health solutions - ABODE,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-06-22,2026-06-22
NOT_YET_RECRUITING,NO,RADIATION: Proton Therapy,FEMALE,"ADULT, OLDER_ADULT",PHASE3,276,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02,2041-02
RECRUITING,NO,DEVICE: Open-tip pulsed needle biopsy (NeoNavia Biopsy System)|DEVICE: Core needle biopsy (CNB),FEMALE,"ADULT, OLDER_ADULT",NA,479,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-07-13,2025-03-31
ACTIVE_NOT_RECRUITING,NO,OTHER: Survivorship Clinic Assessments|OTHER: Survivorship Clinic Nurse Resource|OTHER: Survivorship Clinic Dietitian Resource,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-03-13,2024-04
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: OMO-103,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,22,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-28,2024-12
RECRUITING,NO,OTHER: Pre-Test Intervention|OTHER: Standard of Care|OTHER: Post-Test Intervention,ALL,"ADULT, OLDER_ADULT",NA,560,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-08-17,2024-12-31
COMPLETED,NO,DEVICE: User of Dayspring device,ALL,"ADULT, OLDER_ADULT",NA,40,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-05,2021-05-28
COMPLETED,NO,PROCEDURE: precision breast conserving surgery guided by wire guided localization combined with MDCT guided 3D reconstruction,FEMALE,"ADULT, OLDER_ADULT",NA,92,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-01,2023-01-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Datopotamab Deruxtecan (Dato-DXd),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,119,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-11,2024-06-23
NOT_YET_RECRUITING,NO,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|BIOLOGICAL: Pembrolizumab|DRUG: Propranolol|OTHER: Questionnaire Administration,ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02-15,2027-12-15
NOT_YET_RECRUITING,NO,DRUG: Mitoxantrone hydrochloride liposome|DRUG: Capecitabine|DRUG: Mitoxantrone hydrochloride liposome|DRUG: Capecitabine,FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-28,2025-04
NOT_YET_RECRUITING,NO,DRUG: Utidelone Combined with Bevacizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,71,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-01,2024-12-30
RECRUITING,NO,DRUG: BET Bromodomain Inhibitor ZEN-3694|DRUG: Binimetinib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging,ALL,"ADULT, OLDER_ADULT",PHASE1,42,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-02,2024-03-14
NOT_YET_RECRUITING,NO,"DRUG: epirubicin,cyclophosphamide,paclitaxel,Carrelizumab|DRUG: epirubicin,cyclophosphamide,paclitaxel",FEMALE,"ADULT, OLDER_ADULT",PHASE3,606,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-01,2028-07-01
COMPLETED,NO,OTHER: Erector spina plane block before general anaesthesia|OTHER: Thoracic epidural block before general anaesthesia,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-11,2021-03-31
RECRUITING,NO,BEHAVIORAL: Acceptance and Commitment Therapy|OTHER: Waitlist Control Group,FEMALE,"ADULT, OLDER_ADULT",NA,88,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-20,2025-06-30
WITHDRAWN,NO,DRUG: Tucatinib|DRUG: Pembrolizumab|DRUG: Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-01,2024-06-01
NOT_YET_RECRUITING,NO,DRUG: Datopotamab Deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE2,58,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-05,2029-01-01
RECRUITING,NO,DRUG: Atezolizumab 1200 mg in 20 ML Injection|DRUG: Inavolisib|DRUG: Ipatasertib|DRUG: Olaparib|DRUG: Sacituzumab govitecan|DRUG: Trastuzumab/pertuzumab,ALL,"ADULT, OLDER_ADULT",PHASE2,240,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-29,2030-12
RECRUITING,NO,DEVICE: Clinical investigation medical device class IIa marked CE,FEMALE,"ADULT, OLDER_ADULT",NA,600,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2023-01-07,2024-05-31
RECRUITING,NO,DRUG: Capecitabine and Neratinib.,ALL,"ADULT, OLDER_ADULT",PHASE2,22,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-23,2025-09-01
RECRUITING,NO,DRUG: Alpelisib|DRUG: Tamoxifen|DRUG: Zotatifin|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE2,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-20,2026-12
RECRUITING,NO,"OTHER: Cases for patients diagnosed with breast cancer, colonrectal cancer, ovarian cancer and endometrial cancer",ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-05-18,2023-07-31
RECRUITING,NO,DRUG: CYCLOPHOSPHAMIDE and FLUDARABIN|DRUG: Cyclophosphamide|BIOLOGICAL: HBI 0201-ESO TCRT|DRUG: Aldesleukin,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,3,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04-01,2027-12-30
RECRUITING,NO,DRUG: Sacituzumab Govitecan|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,110,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-20,2027-04-01
RECRUITING,NO,OTHER: Mindfulness: Awareness-Based Stress Reduction Program,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2023-12-29,2024-08-29
RECRUITING,NO,DRUG: SIM0270|DRUG: Palbociclib|DRUG: everolimus,ALL,"ADULT, OLDER_ADULT",PHASE1,210,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-18,2025-09-08
RECRUITING,NO,DRUG: Trastuzumab plus chemotherapy|DRUG: Trastuzumab in combination with pyrotinib plus chemotherapy,ALL,"ADULT, OLDER_ADULT",PHASE3,240,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-15,2024-10-31
NOT_YET_RECRUITING,NO,DRUG: Pertuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,125,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07,2026-12
NOT_YET_RECRUITING,NO,DRUG: Pembrolizumab injection|DRUG: Capecitabine tablets|RADIATION: Local radiotherapy,ALL,"ADULT, OLDER_ADULT",PHASE3,418,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01,2029-01
ACTIVE_NOT_RECRUITING,NO,RADIATION: Stereotactic Body Radiation Therapy (SBRT),ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-19,2027-08-31
NOT_YET_RECRUITING,NO,BIOLOGICAL: ConvitVax,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-04-01,2027-03-31
RECRUITING,NO,DEVICE: Photobiomodulation therapy,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-06-17,2022-12-31
RECRUITING,NO,DRUG: BL-B01D1|DRUG: SI-B003,FEMALE,"ADULT, OLDER_ADULT",PHASE2,58,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-12,2025-12
RECRUITING,NO,DRUG: ONM-501|DRUG: Cemiplimab,ALL,"ADULT, OLDER_ADULT",PHASE1,168,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-13,2026-08-29
RECRUITING,NO,DEVICE: Negative pressure wound therapy,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05-01,2023-12-01
UNKNOWN,NO,DRUG: Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine|DRUG: Capecitabine/eribulin/gemcitabine/vinorelbine,FEMALE,"ADULT, OLDER_ADULT",PHASE3,104,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-30,2023-04-30
COMPLETED,NO,DRUG: Drug omission|OTHER: Control group,ALL,"ADULT, OLDER_ADULT",NA,86,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-27,2022-06-20
UNKNOWN,NO,OTHER: True acupuncture|OTHER: Sham acupuncture,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2020-01-30,2022-02-28
NOT_YET_RECRUITING,NO,DRUG: Toripalimab|DRUG: Epirubicin|PROCEDURE: High Intensity Focused Ultrasoun|DRUG: Cyclophosphamide|DRUG: Carboplatin|DRUG: Nab-paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-01,2024-12-30
UNKNOWN,NO,DRUG: cicaderma + simple hygiene rules|OTHER: Simple hygiene rules and a maximum of one topical treatment,FEMALE,"ADULT, OLDER_ADULT",PHASE3,248,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-06,2022-10-09
COMPLETED,NO,DRUG: TQB3616 Capsule,ALL,"ADULT, OLDER_ADULT",PHASE1,16,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2021-07-06,2021-08-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Gallium-68 DOTATATE|DRUG: Copper-64 DOTATATE,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-01-10,2024-07-31
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: Monalizumab|BIOLOGICAL: Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE2,38,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-23,2030-05-01
NOT_YET_RECRUITING,NO,DRUG: MDX2001,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,115,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-05,2029-02
RECRUITING,NO,DRUG: Traditional Chinese Medicine Formulation|DRUG: Placebo Formulation,FEMALE,"ADULT, OLDER_ADULT",PHASE3,200,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-05-25,2024-05-31
RECRUITING,NO,BIOLOGICAL: CT-0508|BIOLOGICAL: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,48,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-02,2024-12
NOT_YET_RECRUITING,NO,BEHAVIORAL: Intermittent Fasting,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-03-15,2027-07-15
RECRUITING,NO,BEHAVIORAL: Acceptance and Commitment Therapy,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2022-10-20,2024-11-20
COMPLETED,NO,DRUG: Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine),FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-07-13,2023-06-30
RECRUITING,NO,DEVICE: a high-intensity focused ultrasound tumor treatment system (Super Knife),FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-01,2024-12-31
RECRUITING,NO,DRUG: ADG106|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,66,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-19,2030-02
RECRUITING,NO,DRUG: SPECT,FEMALE,"ADULT, OLDER_ADULT",PHASE1,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-09-01,2024-09-01
RECRUITING,NO,DRUG: Bexarotene|DRUG: Capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE1,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-01,2025-09-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Tamoxifen|DRUG: Tamoxifen,ALL,"ADULT, OLDER_ADULT",PHASE1,75,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-23,2025-11
SUSPENDED,NO,RADIATION: Viewray MRIdian® Linac,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-01,2024-06-18
COMPLETED,NO,DRUG: Sodium Fluoride F-18 Injection|DRUG: Technetium[99mTc] Methylenediphosphonate Injection,ALL,"ADULT, OLDER_ADULT",PHASE3,280,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-03-29,2022-06-02
RECRUITING,NO,BEHAVIORAL: Group-based Nordic Walking Exercise Program,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-11-01,2023-11-01
TERMINATED,NO,DRUG: Vesatolimod|DRUG: Cobicistat|DRUG: Voriconazole|DRUG: Rifabutin,ALL,"ADULT, OLDER_ADULT",PHASE1,18,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-19,2023-10-13
RECRUITING,NO,DRUG: Datopotamab deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-01,2026-05-23
COMPLETED,NO,OTHER: Water-based Exercise Group|OTHER: Land-based Exercise Group,FEMALE,"ADULT, OLDER_ADULT",NA,28,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-09-01,2023-04-30
RECRUITING,NO,DRUG: Granulocyte Colony-Stimulating Factor (G-CSF)|DRUG: Omission of Granulocyte Colony-Stimulating Factor (G-CSF),ALL,"ADULT, OLDER_ADULT",PHASE4,240,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-17,2025-10
UNKNOWN,NO,DRUG: AT regimen|DRUG: TP regimen,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08,2021-08
RECRUITING,NO,PROCEDURE: Biospecimen Collection|OTHER: Medical Chart Review|PROCEDURE: Stress Management Therapy|OTHER: Survey Administration,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-12-14,2024-12-31
RECRUITING,NO,PROCEDURE: Erector spinae plane block|PROCEDURE: Control group,ALL,"ADULT, OLDER_ADULT",NA,1206,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-05-23,2027-07
RECRUITING,NO,DRUG: sigvotatug vedotin|DRUG: pembrolizumab|DRUG: cisplatin|DRUG: carboplatin,ALL,"ADULT, OLDER_ADULT",PHASE1,1006,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-08,2024-10-31
RECRUITING,NO,DRUG: RLY-2608|DRUG: Fulvestrant|DRUG: Palbociclib 125mg|DRUG: Ribociclib 400mg|DRUG: Ribociclib 600mg,ALL,"ADULT, OLDER_ADULT",PHASE1,400,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-08,2025-08-31
COMPLETED,NO,BEHAVIORAL: TOPS,FEMALE,"ADULT, OLDER_ADULT",NA,26,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-06-11,2022-08-30
RECRUITING,NO,BIOLOGICAL: Modi-1/Modi-1v|BIOLOGICAL: Pembrolizumab|DEVICE: MicronJet600™ microneedle device (NanoPass),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,144,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-07,2026-06-30
ACTIVE_NOT_RECRUITING,NO,DIETARY_SUPPLEMENT: Dietary Supplement: N-111|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE1,160,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-10-12,2024-06-14
RECRUITING,NO,DRUG: vidutolimod|DRUG: cemiplimab,ALL,"ADULT, OLDER_ADULT",PHASE2,225,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-30,2027-07-29
ENROLLING_BY_INVITATION,NO,OTHER: e-OTCAT program|OTHER: Educational handbook and standard care,FEMALE,"ADULT, OLDER_ADULT",NA,98,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-10-31,2024-12-30
ACTIVE_NOT_RECRUITING,NO,DRUG: H3B-6545|DRUG: Antihistamine,FEMALE,"ADULT, OLDER_ADULT",PHASE1,33,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-30,2024-08-31
RECRUITING,NO,DRUG: Estrogen|DRUG: dehydroepiandrosterone|DRUG: Estrogen + probiotics|DRUG: Moisturizer,FEMALE,"ADULT, OLDER_ADULT",PHASE4,160,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-03-21,2027-03-01
COMPLETED,NO,OTHER: Experimental,ALL,OLDER_ADULT,PHASE1,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-07-28,2023-03-15
RECRUITING,NO,DRUG: [18F]Fluoroestradiol (FES) PET/CT,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,6,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-03-31,2025-04-30
NOT_YET_RECRUITING,NO,DEVICE: MammoScreen,FEMALE,"ADULT, OLDER_ADULT",NA,5000,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SCREENING,2023-05,2027-05
ACTIVE_NOT_RECRUITING,NO,DRUG: Tamoxifen,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,150,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-01,2024-06-30
RECRUITING,NO,DRUG: Inetetamab|DRUG: Pyrotinib|DRUG: Oral Vinorelbine Tartrate,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-02-13,2025-12
ACTIVE_NOT_RECRUITING,NO,DRUG: Alpelisib|DRUG: Alpelisib matching Placebo|DRUG: Trastuzumab|DRUG: Pertuzumab,ALL,"ADULT, OLDER_ADULT",PHASE3,20,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-16,2024-04-02
RECRUITING,NO,DRUG: Deferoxamine Plus Chemotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-21,2024-10-01
RECRUITING,NO,RADIATION: Accelerated Partial Breast Irradiation,FEMALE,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-09-29,2025-11-17
UNKNOWN,NO,OTHER: erector spinae block,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-12-12,2022-09-01
RECRUITING,NO,OTHER: Aerobic exercise,FEMALE,"ADULT, OLDER_ADULT",NA,69,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-10-20,2023-12-30
RECRUITING,NO,BIOLOGICAL: AST-301(pNGVL3-hICD)|DRUG: rhuGM-CSF|DRUG: Placebo|DRUG: Pembrolizumab|DRUG: Capecitabine,ALL,"ADULT, OLDER_ADULT",PHASE2,146,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-02-28,2025-12
RECRUITING,NO,DEVICE: compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg),FEMALE,"ADULT, OLDER_ADULT",NA,480,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-16,2025-10-16
RECRUITING,NO,PROCEDURE: PECs block|OTHER: Not receiving PECs Block,FEMALE,"ADULT, OLDER_ADULT",NA,156,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-02-23,2025-03-24
RECRUITING,NO,DRUG: SHR-A1811 for injection,FEMALE,"ADULT, OLDER_ADULT",PHASE2,66,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-05,2029-05-31
UNKNOWN,NO,DIAGNOSTIC_TEST: Diffusion Spectrum Imaging,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-08-20,2022-08-19
COMPLETED,NO,PROCEDURE: Erector spinae plane block|PROCEDURE: Sham block|PROCEDURE: General anesthesia|PROCEDURE: Patient-controlled analgesia|DRUG: Oxycodone|DRUG: paracetamol,FEMALE,"ADULT, OLDER_ADULT",PHASE4,75,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-01,2021-08-17
RECRUITING,NO,DIETARY_SUPPLEMENT: Ketogenic Diet|DIETARY_SUPPLEMENT: Low Carbohydrate Diet|DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Canagliflozin,ALL,"ADULT, OLDER_ADULT",PHASE2,106,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-08,2024-10-08
RECRUITING,NO,DRUG: Gemcitabine and carboplatin plus antibiotic (moxifloxacin)|DRUG: Gemcitabine combined with carboplatin plus placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE3,228,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-20,2025-02
COMPLETED,NO,DEVICE: Co'moon (online website to support women with AET),FEMALE,"ADULT, OLDER_ADULT",NA,77,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-12-01,2022-12-31
NOT_YET_RECRUITING,NO,DRUG: CDK 4/6 inhibitors|DRUG: Endocrine therapy,ALL,OLDER_ADULT,PHASE3,495,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11,2031-04
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Ayurvedic lifestyle protocol,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-09-01,2023-06-01
COMPLETED,NO,BEHAVIORAL: Behavioral: Sit Less,FEMALE,"ADULT, OLDER_ADULT",NA,21,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-03-29,2023-05-07
RECRUITING,NO,BEHAVIORAL: Neuropsychological treatment|BEHAVIORAL: Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).|BEHAVIORAL: Waitlist group,ALL,"ADULT, OLDER_ADULT",NA,123,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-25,2025-12-31
NOT_YET_RECRUITING,NO,PROCEDURE: Omission of sentinel lymph node biopsy,FEMALE,"ADULT, OLDER_ADULT",NA,340,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01,2027-07
RECRUITING,NO,DRUG: SHR7390|DRUG: Famitinib|DRUG: SHR3162|DRUG: Pyrotinib|DRUG: Capecitabine|DRUG: SHR1210|DRUG: Everolimus|DRUG: Nab paclitaxel|DRUG: SHR2554|DRUG: SHR3680|DRUG: SHR6390|DRUG: SHR1701|DRUG: SERD|DRUG: AI|DRUG: VEGFi,FEMALE,"ADULT, OLDER_ADULT",PHASE2,319,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-01,2025-04-01
UNKNOWN,NO,DEVICE: RadiaAce gel|DEVICE: Biafine,FEMALE,"ADULT, OLDER_ADULT",NA,120,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-07-14,2022-10
RECRUITING,NO,DIAGNOSTIC_TEST: Contrast Enhanced Mammography (CEM),FEMALE,"ADULT, OLDER_ADULT",NA,440,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-11-02,2023-12-31
COMPLETED,NO,OTHER: Carevive PROmpt™,ALL,"ADULT, OLDER_ADULT",NA,51,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-02-16,2021-11-01
WITHDRAWN,NO,BIOLOGICAL: MVC-101|BIOLOGICAL: Nivolumab|COMBINATION_PRODUCT: MVC-101 + Nivolumab,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-09-15,2022-06-05
RECRUITING,NO,DRUG: Nivolumab|DRUG: Cisplatin|DRUG: Low dose doxorubicin,ALL,"ADULT, OLDER_ADULT",PHASE2,52,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-21,2026-12-15
RECRUITING,NO,DIAGNOSTIC_TEST: GE Logiq E10 clinical ultrasound scanner|DIAGNOSTIC_TEST: Verasonics research scanner,FEMALE,"ADULT, OLDER_ADULT",NA,125,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-11-19,2025-12-31
RECRUITING,NO,DRUG: TCbHP VS ddEC-THP,FEMALE,"ADULT, OLDER_ADULT",PHASE3,832,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-08,2023-12-31
COMPLETED,NO,DRUG: tomivosertib|DRUG: paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE1,19,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-25,2022-07-04
RECRUITING,NO,DRUG: NGM438|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,71,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-11,2024-06
NOT_YET_RECRUITING,NO,DRUG: 18F-FDG|DEVICE: Breast-dedicated PET camera,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2024-05,2024-12
UNKNOWN,NO,DEVICE: Outcomes4Me Mobile App,ALL,"ADULT, OLDER_ADULT",NA,125,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-06-01,2020-10
NOT_YET_RECRUITING,NO,OTHER: Cognitive exercises with supervision|OTHER: Cognitive exercises without supervision,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2023-09,2029-03
NOT_YET_RECRUITING,NO,DRUG: Taxane plus Intermittent Capecitabine|DRUG: Utidelone plus Intermittent Capecitabine|DRUG: Taxane plus Metronomic Capecitabine|DRUG: Utidelone plus Metronomic Capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE3,512,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-01,2030-03-01
TERMINATED,YES,DRUG: Placebo|DRUG: Venetoclax|DRUG: Trastuzumab emtansine,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,1,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-09-23,2021-02-04
RECRUITING,NO,PROCEDURE: Patient sampling.,ALL,"ADULT, OLDER_ADULT",NA,132,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-02-14,2024-12-14
NOT_YET_RECRUITING,NO,PROCEDURE: surgical treatment 1|PROCEDURE: surgical treatment 2|DRUG: Systemic therapy,FEMALE,"ADULT, OLDER_ADULT",NA,362,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-01,2031-05-01
NOT_YET_RECRUITING,NO,BEHAVIORAL: NAVAH,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-06-01,2028-07-11
RECRUITING,NO,RADIATION: Stereotactic Body Radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2026-06-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Abemaciclib|DRUG: Standard Adjuvant ET|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,2450,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-05-10,2024-02-09
COMPLETED,NO,BEHAVIORAL: Time-restricted eating,FEMALE,"ADULT, OLDER_ADULT",NA,22,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-08-05,2021-07-28
RECRUITING,NO,DEVICE: Medical compression stocking (medical device name: mediven Harmony 734 (compression class1 AG armsleeve or with wide(735)),ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-03-12,2025-12-30
UNKNOWN,NO,OTHER: Multicomponent exercise intervention plus health education|OTHER: Health Education,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2021-02,2023-03
COMPLETED,NO,BEHAVIORAL: Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS),FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-06-01,2022-02-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Abemaciclib|DRUG: Fulvestrant|DRUG: Aromatase Inhibitors,FEMALE,"ADULT, OLDER_ADULT",PHASE2,18,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-14,2024-12-30
RECRUITING,NO,DRUG: Alpelisib|DRUG: Binimetinib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography|DRUG: Fluorouracil|DRUG: Fulvestrant|DRUG: Ipatasertib|DRUG: Leucovorin|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Mutation Carrier Screening|DRUG: Neratinib Maleate|DRUG: Nilotinib Hydrochloride Monohydrate|DRUG: Olaparib|DRUG: Oxaliplatin|DRUG: Paclitaxel|DRUG: Palbociclib|BIOLOGICAL: Panitumumab|PROCEDURE: Positron Emission Tomography|DRUG: Selumetinib Sulfate|DRUG: Sotorasib,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,2900,NIH,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2023-04-07,2030-07-01
RECRUITING,NO,OTHER: Osteopathic treatment|OTHER: Capsaicin QUTENZA Patch (TAU),ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2023-01-11,2024-12-08
NOT_YET_RECRUITING,NO,DRUG: Trastuzumab deruxtecan|DRUG: Standard-of-Care,FEMALE,"ADULT, OLDER_ADULT",PHASE2,402,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2023-12,2028-06
COMPLETED,NO,OTHER: Online exercise,FEMALE,"ADULT, OLDER_ADULT",NA,198,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-01-05,2022-07-29
RECRUITING,NO,DRUG: Triptorelin 3.75 MG Injection|PROCEDURE: Transvaginal oocyte retrieval|DRUG: Triptorelin Injection,FEMALE,ADULT,PHASE1|PHASE2,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-01,2025-12-31
UNKNOWN,NO,DIAGNOSTIC_TEST: Serum Autotaxin|RADIATION: chest x-ray|DIAGNOSTIC_TEST: Breast ultrasound or mammography|DIAGNOSTIC_TEST: Histopathological examination of breast mass specimens|RADIATION: Magnetic Resonance Imaging ( MRI) and Bone scan|DIAGNOSTIC_TEST: Peripheral haemogram|DIAGNOSTIC_TEST: Renal and liver functions|DIAGNOSTIC_TEST: Prothrombin time and concentration|DIAGNOSTIC_TEST: Cancer Antigen 15-3 (CA15-3).|OTHER: Full medical history|OTHER: Full clinical examination,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-05-01,2022-11-01
RECRUITING,NO,PROCEDURE: Identification and preservation of arm lymphatics (DEPART),FEMALE,"ADULT, OLDER_ADULT",NA,1200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-06-20,2025-09-30
RECRUITING,NO,DRUG: Trastuzumab combined with Pyrotinib and chemotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,104,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07,2026-12
RECRUITING,NO,OTHER: questionnaires|OTHER: moisturizers|OTHER: moisturizers,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-06-01,2027-06
RECRUITING,NO,DRUG: Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole),FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-20,2026-06
NOT_YET_RECRUITING,NO,BIOLOGICAL: Tumor-infiltrating lymphocytes|DRUG: IL-2,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-01,2026-05
RECRUITING,NO,DRUG: Antivascular therapy|DRUG: Chemotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE3,548,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-20,2031-05-30
UNKNOWN,NO,PROCEDURE: CEUS|PROCEDURE: blue dye,FEMALE,"ADULT, OLDER_ADULT",NA,350,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-06-15,2023-08-15
NOT_YET_RECRUITING,NO,DRUG: [68Ga]Ga-NeoB|DRUG: [177Lu]Lu-NeoB|DRUG: Capecitabine,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,58,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-05-16,2031-09-09
NOT_YET_RECRUITING,NO,DEVICE: DiviTum® TKa assay|DRUG: CDK4/6 + Endocrine therapy,ALL,"ADULT, OLDER_ADULT",NA,65,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-28,2034-02-28
NOT_YET_RECRUITING,NO,"DRUG: Inetetamab, pyrotinib, chemotherapy",FEMALE,"ADULT, OLDER_ADULT",PHASE2,63,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-10,2025-12-10
RECRUITING,NO,PROCEDURE: Vacuum assisted biopsy|PROCEDURE: conventional lumpectomy,FEMALE,"ADULT, OLDER_ADULT",NA,170,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-02,2023-12
UNKNOWN,NO,DRUG: TQB3616 capsules|DRUG: Fulvestrant injection,FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-04,2023-01-31
RECRUITING,NO,DRUG: 99mTc-MIRC213,FEMALE,"CHILD, ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-09-07,2023-12-31
COMPLETED,NO,DRUG: E7766,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-24,2022-07-26
RECRUITING,NO,DRUG: SV-101,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-01,2023-12-31
COMPLETED,NO,PROCEDURE: Biospecimen Collection|OTHER: Genetic Counseling|OTHER: Genetic Testing|OTHER: Survey Administration,ALL,"ADULT, OLDER_ADULT",PHASE1,230,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-06-29,2021-09-21
RECRUITING,NO,DRUG: Pyrotinib Maleate|DRUG: Dalpiciclib Isethionate Tablets|DRUG: Inetetamab|DRUG: Fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-20,2026-01-01
RECRUITING,NO,PROCEDURE: Breast MRI,FEMALE,"ADULT, OLDER_ADULT",NA,500,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2023-12-15,2025-01-01
RECRUITING,NO,OTHER: Proactive Cost of Care (P-COC) intervention|OTHER: Usual Care,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2022-06-01,2024-05-31
TERMINATED,NO,PROCEDURE: Mechanical Stimulation|PROCEDURE: Massages,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-05-27,2023-12-07
RECRUITING,NO,DIAGNOSTIC_TEST: Identification rate of sentinel lymph node for each dual method,FEMALE,"ADULT, OLDER_ADULT",NA,348,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-05-04,2026-06-30
RECRUITING,NO,DRUG: BAY3375968|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,270,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-11,2027-05-04
TERMINATED,YES,DRUG: Bintrafusp alfa,ALL,"ADULT, OLDER_ADULT",PHASE2,11,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-12,2022-07-08
NOT_YET_RECRUITING,NO,BEHAVIORAL: CAI|BEHAVIORAL: CAPA,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2024-04-15,2028-08-31
NOT_YET_RECRUITING,NO,BEHAVIORAL: 12-week Intervention Period|BEHAVIORAL: 12-week Observation Period,FEMALE,"ADULT, OLDER_ADULT",NA,158,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2023-11,2025-05-25
RECRUITING,NO,BEHAVIORAL: iGuide Intervention (Self-guided)|BEHAVIORAL: iGuide 2 Intervention (Tailored/Targeted)|BEHAVIORAL: Control,ALL,"ADULT, OLDER_ADULT",NA,800,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-06-14,2024-03-31
NOT_YET_RECRUITING,NO,BIOLOGICAL: Granulokine|BIOLOGICAL: Filgrastine,FEMALE,"ADULT, OLDER_ADULT",PHASE3,60,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05,2024-12
RECRUITING,NO,DEVICE: Black-Eye Ink,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-02,2023-08
RECRUITING,NO,BEHAVIORAL: hyperbaric oxygen therapy,ALL,"ADULT, OLDER_ADULT",NA,380,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-03-01,2024-12-31
RECRUITING,NO,PROCEDURE: Left stellate ganglion block,ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2023-08-08,2024-03-01
WITHDRAWN,NO,RADIATION: Intra-operative Radiation Therapy - IORT,FEMALE,"ADULT, OLDER_ADULT",NA,0,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-30,2034-06-30
RECRUITING,NO,DRUG: Ribociclib,FEMALE,"ADULT, OLDER_ADULT",PHASE4,1000,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10-12,2026-10
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Copanlisib Hydrochloride|DRUG: Eribulin Mesylate|PROCEDURE: Magnetic Resonance Imaging,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,106,NIH,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2024-12-31
RECRUITING,NO,DEVICE: Wrist cooling device with cooling plate|DEVICE: Wrist fan activating device without cooling plate|OTHER: Hot Flash Diary,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-03-05,2024-07
NOT_YET_RECRUITING,NO,DRUG: Sacituzumab Govitecan,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-02-20,2027-02-20
RECRUITING,NO,DEVICE: Ablative local therapy,ALL,"ADULT, OLDER_ADULT",NA,250,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-10-05,2031-01-05
RECRUITING,NO,DRUG: CYH33,ALL,"ADULT, OLDER_ADULT",PHASE1,350,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-28,2024-01-28
RECRUITING,NO,OTHER: Non-contrast MRA in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|OTHER: CTA with iodine contrast in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.,FEMALE,"ADULT, OLDER_ADULT",NA,135,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-05-06,2024-07-30
NOT_YET_RECRUITING,NO,DRUG: Neratinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-01,2024-12-31
RECRUITING,NO,RADIATION: single fraction stereotactic radiosurgery (SSRS)|RADIATION: fractionated stereotactic radiosurgery (FSRS),ALL,"ADULT, OLDER_ADULT",NA,244,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-07-11,2028-03-31
RECRUITING,NO,DRUG: Ivermectin|DRUG: Balstilmab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,41,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-10-13,2026-10
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: PEPRR|BEHAVIORAL: Pep-Pal,ALL,ADULT,NA,510,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-05,2024-09-30
RECRUITING,NO,DRUG: Olaparib,ALL,"ADULT, OLDER_ADULT",PHASE2,63,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-03-25,2024-06
WITHDRAWN,NO,DRUG: Abemaciclib|DRUG: Hydroxychloroquine 200 mg|DRUG: Faslodex|DRUG: Anastrazole|DRUG: Letrozole|DRUG: Hydroxychloroquine 400 mg|DRUG: Hydroxychloroquine 600 mg,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-21,2028-01
RECRUITING,NO,DIAGNOSTIC_TEST: Biomarkers: Troponins and natriuretic peptides,FEMALE,"ADULT, OLDER_ADULT",NA,220,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-10-01,2025-09-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Abemaciclib|DRUG: Niraparib Tosylate Monohydrate,ALL,"ADULT, OLDER_ADULT",PHASE1,8,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-07,2025-06-30
UNKNOWN,NO,DRUG: Pacritinib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,74,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-13,2023-07
RECRUITING,NO,PROCEDURE: Vacuum assisted biopsy (VAB),ALL,"ADULT, OLDER_ADULT",NA,420,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-08-17,2025-06
RECRUITING,NO,OTHER: Cognitive interview,ALL,"ADULT, OLDER_ADULT",NA,625,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-11-16,2026-08-31
COMPLETED,YES,DRUG: Abemaciclib|DRUG: Nonsteroidal Aromatase Inhibitor (NSAI)|DRUG: Fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE4,200,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-22,2023-01-09
RECRUITING,NO,DRUG: HS-10352 combined with fulvestrant (Stage 1)|DRUG: HS-10352 combined with fulvestrant (Stage 2),ALL,"ADULT, OLDER_ADULT",PHASE1,224,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-12,2025-12-31
WITHDRAWN,NO,DRUG: ZOLADEX 10.8 mg|DRUG: ZOLADEX 3.6mg,FEMALE,ADULT,PHASE3,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-31,2021-11-04
RECRUITING,NO,BEHAVIORAL: Nutrition and physical activity counseling program,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-01-06,2024-06-01
RECRUITING,NO,DRUG: MRG002|DRUG: Trastuzumab Emtansine for Injection,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,350,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-30,2023-10
ACTIVE_NOT_RECRUITING,NO,DRUG: TTX-080|DRUG: TTX-080|DRUG: pembrolizumab|DRUG: cetuximab,ALL,"ADULT, OLDER_ADULT",PHASE1,240,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-14,2024-06-01
RECRUITING,NO,DIAGNOSTIC_TEST: 68Ga-FAPI-46 PET/CT,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-02-04,2022-12
RECRUITING,NO,DEVICE: Activity tracker,FEMALE,OLDER_ADULT,NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-02-17,2024-11-13
COMPLETED,NO,DRUG: Fulvestrant injection,FEMALE,ADULT,PHASE1,48,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-01,2023-10-01
RECRUITING,NO,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Gemcitabine|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Naxitamab|BIOLOGICAL: Universal Donor Expanded TGF-beta-imprinted NK Cells,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,42,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-03-01,2024-12-31
RECRUITING,NO,"PROCEDURE: Surgery for harvesting tumor-draining lymph nodes|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Tumor-draining lymph node-derived lymphocyte (LNL)|BIOLOGICAL: Interleukin-2|BIOLOGICAL: Camrelizumab|DRUG: Chemotherapeutic drug, ADC or PARP inhibitor",FEMALE,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-01,2031-12-31
RECRUITING,NO,PROCEDURE: Breast surgery omission,FEMALE,"ADULT, OLDER_ADULT",NA,533,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-22,2031-03
RECRUITING,NO,DRUG: Camizestrant|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane|DRUG: Abemaciclib,ALL,"ADULT, OLDER_ADULT",PHASE3,5500,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-05,2037-05-06
RECRUITING,NO,DIAGNOSTIC_TEST: Functional Magnetic Resonance Imaging at rest and in activation with attentional task,FEMALE,"ADULT, OLDER_ADULT",NA,75,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-03-20,2027-09
COMPLETED,NO,DRUG: ZN-c5,ALL,"ADULT, OLDER_ADULT",PHASE1,35,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-03,2021-05-25
RECRUITING,NO,BEHAVIORAL: PeACE|BEHAVIORAL: Community peer coaching,ALL,"ADULT, OLDER_ADULT",NA,560,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-07-15,2025-12
COMPLETED,NO,"BEHAVIORAL: ""My Guide"" (psychoeducation & self-management program)",FEMALE,"ADULT, OLDER_ADULT",NA,58,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-04-01,2023-11-07
TERMINATED,NO,"BIOLOGICAL: ISB 1302 250 ng/kg|BIOLOGICAL: ISB 1302 325 ng/kg|BIOLOGICAL: ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|BIOLOGICAL: ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|BIOLOGICAL: ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|BIOLOGICAL: ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22|BIOLOGICAL: ISB 1302 escalating doses,1200 ng/kg D15,22|BIOLOGICAL: ISB 1302 at the MTD and/or RP2D dose",FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,1,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-08,2020-07-24
RECRUITING,NO,OTHER: Survey|BEHAVIORAL: Education Session,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2022-03-15,2024-04
RECRUITING,NO,OTHER: FES PET,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-10-18,2025-10-18
RECRUITING,NO,DRUG: Everolimus 10 mg|DRUG: CDK4/6 Inhibitor SHR6390|DRUG: Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors,FEMALE,"ADULT, OLDER_ADULT",PHASE2,265,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-26,2028-01
UNKNOWN,NO,DRUG: Cipterbin Combined With Vinorelbine,FEMALE,"ADULT, OLDER_ADULT",PHASE4,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-04,2022-12-30
COMPLETED,NO,DRUG: Pembrolizumab|DRUG: Trastuzumab Biosimilar ABP 980|DRUG: Pertuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,46,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-18,2022-05-31
COMPLETED,NO,DRUG: Bupivacaine + Fentanyl,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-27,2023-05-25
NOT_YET_RECRUITING,NO,"DRUG: Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab",FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-04,2024-08-01
NOT_YET_RECRUITING,NO,DEVICE: ciNPT|OTHER: Conventional Tape Dressings|PROCEDURE: DIEP Breast Reconstruction,FEMALE,"ADULT, OLDER_ADULT",NA,114,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-07,2026-03
ACTIVE_NOT_RECRUITING,NO,DRUG: Zanidatamab|DRUG: Letrozole|DRUG: Tamoxifen,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-16,2024-12-29
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Biospecimen Collection|DRUG: Cabozantinib S-malate|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab,ALL,"ADULT, OLDER_ADULT",PHASE1,18,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-22,2025-11-02
RECRUITING,NO,"DRUG: CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)",FEMALE,"ADULT, OLDER_ADULT",PHASE2,94,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-25,2024-12-25
SUSPENDED,NO,PROCEDURE: Biospecimen Collection|DRUG: Letrozole|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",PHASE4,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-23,2024-12-31
COMPLETED,NO,OTHER: Ga-As Laser|OTHER: Microcurrent Electrical Stimulation|OTHER: traditional therapy,FEMALE,ADULT,NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-05-25,2023-09-30
UNKNOWN,NO,DRUG: SG001|DRUG: Nab-paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE2,79,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-01,2023-10-01
RECRUITING,NO,OTHER: Survey,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-09-01,2023-08
RECRUITING,NO,DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Epirubicin|DRUG: Cyclophosphamide,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1736,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-01,2028-06
RECRUITING,NO,DRUG: Ovarian function suppression with endocrine treatments,FEMALE,ADULT,PHASE4,418,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-06,2033-01
NOT_YET_RECRUITING,NO,DIETARY_SUPPLEMENT: Curcumin|DRUG: Paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-08-30,2024-03-10
RECRUITING,NO,DEVICE: Frozen glove and sock|DRUG: ddEC-ddT,FEMALE,"ADULT, OLDER_ADULT",NA,102,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-06-10,2026-11
RECRUITING,NO,DRUG: DB-1303/BNT323|DRUG: T-DM1,ALL,"ADULT, OLDER_ADULT",PHASE3,224,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-29,2026-02
RECRUITING,NO,DRUG: Chemotherapy|PROCEDURE: Computed Tomography|OTHER: Fludeoxyglucose F-18|PROCEDURE: Positron Emission Tomography|PROCEDURE: Surgical Procedure,ALL,"ADULT, OLDER_ADULT",PHASE2,235,NETWORK,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-05-10,2025-03-31
NOT_YET_RECRUITING,NO,PROCEDURE: sentinle lymphnode biopsy,FEMALE,ADULT,NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-30,2025-04-01
NOT_YET_RECRUITING,NO,BEHAVIORAL: Endocrine Therapy Education Program,FEMALE,"ADULT, OLDER_ADULT",NA,76,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-07,2024-12-31
COMPLETED,NO,BEHAVIORAL: Mindful attention|BEHAVIORAL: Decentering|BEHAVIORAL: Value-based action,FEMALE,"ADULT, OLDER_ADULT",NA,31,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2021-08-01
RECRUITING,NO,DIAGNOSTIC_TEST: TCHP,ALL,"ADULT, OLDER_ADULT",NA,94,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-04-21,2030-04-30
RECRUITING,NO,BEHAVIORAL: ADA|BEHAVIORAL: Usual Care,FEMALE,"ADULT, OLDER_ADULT",NA,160,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2023-11-06,2025-11
RECRUITING,NO,DRUG: Tislelizumab|DRUG: capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,460,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-03,2032-08
RECRUITING,NO,DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Nab paclitaxel|DRUG: Pyrotinib|DRUG: Capecitabine|DRUG: T-DM1|DRUG: Everolimus|DRUG: CDK4/6 inhibitor|DRUG: AI|DRUG: Anti-PD-1 monoclonal antibody,FEMALE,"ADULT, OLDER_ADULT",PHASE3,120,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-01,2024-02-28
RECRUITING,NO,DRUG: Benralizumab|DRUG: fulvestrant or AIs) and PI3K inhibition (alpelisib),ALL,"ADULT, OLDER_ADULT",PHASE2,63,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-06,2026-07
RECRUITING,NO,PROCEDURE: Real Acupuncture|OTHER: Sham Acupuncture,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-07-11,2025-07
NOT_YET_RECRUITING,NO,DRUG: Injection of A166,ALL,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-01,2024-12-31
RECRUITING,NO,BEHAVIORAL: Fear-focused Self-Compassion Therapy,FEMALE,ADULT,NA,160,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-09-15,2023-12
NOT_YET_RECRUITING,NO,DRUG: Capecitabine Pill,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-04,2028-12
TERMINATED,YES,DRUG: SBT6050|DRUG: trastuzumab deruxtecan|DRUG: tucatinib|DRUG: trastuzumab|DRUG: capecitabine|DRUG: trastuzumab deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,2,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-08,2022-07-07
NOT_YET_RECRUITING,NO,BEHAVIORAL: Practice Led Intervention,ALL,"ADULT, OLDER_ADULT",NA,910,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-12,2025-12
RECRUITING,NO,DRUG: Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE4,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-13,2025-09
ACTIVE_NOT_RECRUITING,NO,OTHER: Cognitive stimulation,FEMALE,OLDER_ADULT,NA,55,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-06-05,2023-12
RECRUITING,NO,DRUG: Hydrogen Peroxide,ALL,"ADULT, OLDER_ADULT",PHASE2,184,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-16,2026-12-31
RECRUITING,NO,DRUG: （Carrelizumab + TCb） regimen|DRUG: TCb regimen,FEMALE,"ADULT, OLDER_ADULT",PHASE2,369,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-20,2029-12-31
RECRUITING,NO,DEVICE: Acellular Dermal Matrix|PROCEDURE: Reconstruction without ADM,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-10-20,2025-03-31
RECRUITING,NO,RADIATION: Proton versus photon radiation therapy,ALL,"ADULT, OLDER_ADULT",NA,1502,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2037-06-01
RECRUITING,NO,PROCEDURE: Opioid-free anesthesia|PROCEDURE: Conventional opioid-based anesthesia,FEMALE,"ADULT, OLDER_ADULT",PHASE3,230,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-12-16,2025-10-31
COMPLETED,YES,DEVICE: Imagio,ALL,"ADULT, OLDER_ADULT",NA,38,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-08-19,2022-02-17
ACTIVE_NOT_RECRUITING,NO,DRUG: TQB3616 capsule|DRUG: Placebo|DRUG: Fulvestrant injection,FEMALE,"ADULT, OLDER_ADULT",PHASE3,432,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-07-01,2026-06
RECRUITING,NO,BIOLOGICAL: pembrolizumab|DRUG: paclitaxel|DRUG: nab-paclitaxel|DRUG: liposomal doxorubicin|DRUG: capecitabine|DRUG: normal saline|DRUG: dextrose,ALL,"ADULT, OLDER_ADULT",PHASE3,800,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-06-18,2028-07-21
NOT_YET_RECRUITING,NO,BEHAVIORAL: ICOgnition,FEMALE,"ADULT, OLDER_ADULT",NA,176,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-12-14,2025-09-07
UNKNOWN,NO,PROCEDURE: Mini-flap|PROCEDURE: Conventional flap,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-24,2023-12-01
NOT_YET_RECRUITING,NO,"OTHER: Adequate and balanced healthy diet program (CHO: 45-60%, protein:10-20%, fat:20-35%)|OTHER: Ketogenic diet program (CHO: 6%, protein:19%, fat:75%)",FEMALE,ADULT,NA,56,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-01-30,2025-01-30
RECRUITING,NO,DRUG: Disitamab vedotin,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05-04,2026-08
ENROLLING_BY_INVITATION,NO,DIAGNOSTIC_TEST: Shared decision making|DIAGNOSTIC_TEST: Usual care,FEMALE,"ADULT, OLDER_ADULT",NA,368,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-07-06,2024-01-31
SUSPENDED,NO,RADIATION: MRIdian Radiation Treatment Unit,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-16,2031-01
RECRUITING,NO,DRUG: VIO-01,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,165,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-10,2028-12-28
COMPLETED,NO,BEHAVIORAL: Integrated intervention of smoking cessation and breastfeeding|BEHAVIORAL: Attention placebo control,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-01-01,2023-10-30
NOT_YET_RECRUITING,NO,DRUG: Trastuzumab-Deruxtecan (T-DXd),ALL,"ADULT, OLDER_ADULT",PHASE2,27,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-04,2026-07
RECRUITING,NO,RADIATION: Group 1 (preoperative radiation hypofractionated)|OTHER: Group 2 (preoperative radiation conventionally fractionated),ALL,"ADULT, OLDER_ADULT",PHASE3,126,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-04-05,2028-11-01
UNKNOWN,NO,OTHER: Video information about mammography screening|OTHER: Video information about smart energy systems,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2020-06-16,2020-07-30
COMPLETED,NO,"DRUG: Combination, Palbociclib + Binimetinib",FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,24,NETWORK,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-18,2023-12-14
RECRUITING,NO,DRUG: Trastuzumab and Pertuzumab (FDC SC) and T-DM1,ALL,"ADULT, OLDER_ADULT",PHASE2,393,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-05,2028-03
NOT_YET_RECRUITING,NO,DEVICE: Diffusing Alpha Radiation Emitters Therapy (DaRT),ALL,OLDER_ADULT,NA,10,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02,2026-06
ACTIVE_NOT_RECRUITING,NO,DRUG: Trastuzumab Emtansine|DRUG: Atezolizumab|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,96,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-06-07,2024-04-30
ENROLLING_BY_INVITATION,NO,BEHAVIORAL: WATSOCPAP,FEMALE,"ADULT, OLDER_ADULT",NA,84,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2024-03-01,2024-10-01
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Home-based exercise intervention,FEMALE,"ADULT, OLDER_ADULT",NA,49,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2021-09-01,2024-01-31
WITHDRAWN,NO,BIOLOGICAL: Adipose SVF cell|BIOLOGICAL: Normal saline,FEMALE,ADULT,NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2020-12-01,2021-12-30
RECRUITING,NO,DEVICE: Fixed positions of arm down and arm up,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-15,2024-07-30
RECRUITING,NO,BEHAVIORAL: Online Pain Coping Skills Training|OTHER: Education,FEMALE,"ADULT, OLDER_ADULT",PHASE3,452,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-01-19,2026-11-30
NOT_YET_RECRUITING,NO,DRUG: Trastuzumab deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE2,72,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-10-01,2034-10-01
RECRUITING,NO,BEHAVIORAL: general exercise,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2023-09-20,2024-06-30
COMPLETED,NO,BEHAVIORAL: Postcard|BEHAVIORAL: Small Gift|BEHAVIORAL: Loss Frame and Fear Appeals,FEMALE,ADULT,NA,1342,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: SCREENING",2020-10-02,2021-10-05
RECRUITING,NO,BEHAVIORAL: Patient Navigation|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-11-14,2023-12-31
RECRUITING,NO,DRUG: ARX788,ALL,"ADULT, OLDER_ADULT",PHASE2,32,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07-14,2023-06-30
NOT_YET_RECRUITING,NO,DIAGNOSTIC_TEST: Contrast Enhanced Mammography,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-03-01,2027-01-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Famitinib|DRUG: SHR6390|DRUG: Fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,65,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-08,2026-01-30
RECRUITING,NO,RADIATION: Axillary Radiotherapy|PROCEDURE: Lymphadenectomy,ALL,"ADULT, OLDER_ADULT",NA,1660,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-01,2026-12-31
RECRUITING,NO,BIOLOGICAL: Blood sampling,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-04-01,2024-12-31
COMPLETED,NO,OTHER: Focus Group Discussion,FEMALE,"ADULT, OLDER_ADULT",NA,10,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-11-08,2023-02-12
RECRUITING,NO,DIAGNOSTIC_TEST: Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD),FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-03-02,2024-05-30
RECRUITING,NO,BEHAVIORAL: MAAT-G|BEHAVIORAL: Supportive therapy (time and attention control),ALL,OLDER_ADULT,NA,85,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-04-02,2024-09-01
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Nature based exercise,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-06-21,2024-05
RECRUITING,NO,BIOLOGICAL: Platelet-rich plasma (PRP),FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-09-26,2026-09-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Abemaciclib|DRUG: Abiraterone|DRUG: Afatinib|BIOLOGICAL: Bevacizumab|DRUG: Bicalutamide|PROCEDURE: Biospecimen Collection|DRUG: Bortezomib|DRUG: Cabazitaxel|DRUG: Cabozantinib|DRUG: Capecitabine|DRUG: Carboplatin|DRUG: Celecoxib|DRUG: Cobimetinib|DRUG: Copanlisib|DRUG: Dabrafenib|DRUG: Dacomitinib|DRUG: Darolutamide|DRUG: Dasatinib|DRUG: Doxorubicin|BIOLOGICAL: Durvalumab|DRUG: Enasidenib|DRUG: Entrectinib|DRUG: Enzalutamide|DRUG: Erlotinib|DRUG: Everolimus|DRUG: Fluorouracil|DRUG: Idelalisib|DRUG: Imatinib|BIOLOGICAL: Ipilimumab|DRUG: Lenvatinib|DRUG: Leucovorin|DRUG: Lorlatinib|DRUG: Losartan|DRUG: Nab-paclitaxel|DRUG: Neratinib|BIOLOGICAL: Nivolumab|DRUG: Olaparib|DRUG: Oxaliplatin|DRUG: Palbociclib|DRUG: Panobinostat|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Pertuzumab|DRUG: Ponatinib|OTHER: Quality-of-Life Assessment|DRUG: Regorafenib|DRUG: Ruxolitinib|DRUG: Sirolimus|DRUG: Sorafenib|DRUG: Sunitinib|DRUG: Trametinib|BIOLOGICAL: Trastuzumab Emtansine|DRUG: Tretinoin|DRUG: Vemurafenib|DRUG: Venetoclax|DRUG: Vismodegib|DRUG: Vorinostat,ALL,"ADULT, OLDER_ADULT",PHASE1,2,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-01,2027-06-30
WITHDRAWN,NO,OTHER: Best Practice|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|OTHER: Laboratory Biomarker Analysis,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-07-03,2023-01-26
RECRUITING,NO,PROCEDURE: Surgery for harvesting tumor-draining lymph nodes|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Tumor-draining lymph node-derived lymphocyte (LNL)|BIOLOGICAL: Interleukin-2|BIOLOGICAL: Camrelizumab|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,170,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-01,2035-04-30
RECRUITING,NO,DRUG: Trastuzumab deruxtecan|DRUG: Durvalumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,63,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-04,2032-12-01
RECRUITING,NO,DEVICE: MATTISSE TEC,FEMALE,"ADULT, OLDER_ADULT",NA,50,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-07-01,2028-12-31
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health|OTHER: Diet-Exercise|OTHER: Exercise-Diet|OTHER: Combined Diet and Exercise,ALL,"ADULT, OLDER_ADULT",NA,603,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-03-04,2024-08-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Eribulin Mesylate|DRUG: Grapiprant,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-04,2025-12-31
RECRUITING,NO,DRUG: Utidelone|DRUG: Tirelizumab|DRUG: Bevacizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,78,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-10-30,2026-10-30
NOT_YET_RECRUITING,NO,DRUG: Eribulin Mesylate,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06,2024-06
RECRUITING,NO,DRUG: Tucidinostat|DRUG: Capecitabine|DRUG: Endocrine Therapy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,73,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10-03,2025-04-01
RECRUITING,NO,PROCEDURE: Prepectoral Breast Reconstruction with Acellular Dermal Matrix (ADM)|PROCEDURE: Prepectoral Breast Reconstruction without Acellular Dermal Matrix (ADM),FEMALE,"ADULT, OLDER_ADULT",PHASE3,352,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-23,2024-03
RECRUITING,NO,OTHER: Fulvestrant Run-In|OTHER: No Fulvestrant Run-In,FEMALE,"ADULT, OLDER_ADULT",PHASE2,56,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-25,2026-12-01
RECRUITING,NO,DRUG: Sacituzumab govitecan,ALL,"ADULT, OLDER_ADULT",PHASE3,96,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-10-05,2026-05-01
COMPLETED,NO,DIAGNOSTIC_TEST: ultrasonographic measurement,FEMALE,"ADULT, OLDER_ADULT",NA,34,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-01-02,2020-01-31
RECRUITING,NO,DIAGNOSTIC_TEST: pHLIP® ICG NIRF imaging,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,55,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-11-19,2026-11
RECRUITING,NO,DRUG: 89Zr-TLX250 PET/CT,ALL,"ADULT, OLDER_ADULT",PHASE2,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-09-21,2024-06
NOT_YET_RECRUITING,NO,DRUG: SNB-101,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-06-21,2025-06-30
NOT_YET_RECRUITING,NO,BEHAVIORAL: Salud en Mis Manos - Dissemination and Implementation Assistance|BEHAVIORAL: Salud en Mis Manos- Usual Implementation Practice,FEMALE,"ADULT, OLDER_ADULT",NA,2000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2024-02-02,2024-09-30
ACTIVE_NOT_RECRUITING,NO,DRUG: tucatinib|DRUG: trastuzumab|DRUG: fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE2,217,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-11,2025-05-31
RECRUITING,NO,RADIATION: Fractionated Stereotatic Radiation Therapy,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,120,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-01,2026-12-31
NOT_YET_RECRUITING,NO,DRUG: Olaparib|DRUG: Lenvatinib|DRUG: Sunitinib|DRUG: Palbociclib|DRUG: Pazopanib|DRUG: Olaparib|DRUG: Lenvatinib|DRUG: Sunitinib|DRUG: Palbociclib|DRUG: Pazopanib,ALL,OLDER_ADULT,PHASE4,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-05,2025-03
NOT_YET_RECRUITING,NO,DRUG: Tucidinostat|DRUG: Fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE2,73,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-01,2024-12-30
UNKNOWN,NO,PROCEDURE: specimen sample collection,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-09-08,2023-09
COMPLETED,NO,DEVICE: Imagio OA/US,ALL,"ADULT, OLDER_ADULT",NA,20,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2021-03-30,2023-01-04
RECRUITING,NO,DRUG: sintilimab|DRUG: bevacizumab biosimilar|DRUG: pegylated liposomal doxorubicin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,41,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-15,2025-03-15
RECRUITING,NO,DRUG: Morphine Sulfate|DRUG: Lidocaine Hcl 2% Jelly,ALL,"ADULT, OLDER_ADULT",PHASE2,106,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-09-12,2024-04
ACTIVE_NOT_RECRUITING,NO,DIETARY_SUPPLEMENT: Omega-3 fatty acid supplement,FEMALE,"ADULT, OLDER_ADULT",PHASE2,77,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-07-28,2023-12-30
COMPLETED,NO,DRUG: regional nerve block with local anesthesia of bupivacaine with steroid|OTHER: Placebo regional nerveblock with normal saline,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,21,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-07-06,2021-11-25
RECRUITING,NO,OTHER: Receive technology-based supportive cancer care|BEHAVIORAL: Receive redesigned team-based supportive cancer care,ALL,"ADULT, OLDER_ADULT",NA,2996,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-06-24,2026-10-15
RECRUITING,NO,DEVICE: iBreast device|OTHER: Clinical Breast Examination|DIAGNOSTIC_TEST: Breast ultrasound|DIAGNOSTIC_TEST: Mammography,FEMALE,"ADULT, OLDER_ADULT",NA,4100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-12-08,2023-10-31
NOT_YET_RECRUITING,NO,DRUG: pyrotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-02-20,2024-12-20
NOT_YET_RECRUITING,NO,"DEVICE: Intervention group with the IV and V LED board|DEVICE: Intervention group with the IV, V and Violet LED board|DEVICE: Control group with LED board without emitting light",FEMALE,"ADULT, OLDER_ADULT",NA,186,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-01-10,2024-12-30
NOT_YET_RECRUITING,NO,OTHER: mobile application with breathing instructions and a sensor to attach around the chest. To be able to train at home before radiotherapy with DIBH starts.,FEMALE,"ADULT, OLDER_ADULT",NA,160,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-09-01,2029-03-30
RECRUITING,NO,BEHAVIORAL: Cognitive remediation,FEMALE,ADULT,NA,164,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-02-01,2024-12-01
TERMINATED,YES,DRUG: Abemaciclib|DRUG: Fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE2,1,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-23,2022-02-16
RECRUITING,NO,OTHER: exercises using virtual reality technology,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-09-15,2024-07-30
RECRUITING,NO,DRUG: Samuraciclib|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE2,60,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-14,2025-06-16
NOT_YET_RECRUITING,NO,DRUG: Olaparib|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE2,64,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-31,2025-12-31
NOT_YET_RECRUITING,NO,BEHAVIORAL: Counseling to preserve fertility,FEMALE,ADULT,NA,4100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2021-12,2028-12
RECRUITING,NO,DRUG: Bazedoxifene and Conjugated Estrogens,FEMALE,ADULT,PHASE2,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-12-14,2027-07-31
COMPLETED,YES,BEHAVIORAL: MAAT-G,ALL,OLDER_ADULT,NA,4,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-06-12,2022-02-01
COMPLETED,NO,PROCEDURE: total mastectomy,FEMALE,"ADULT, OLDER_ADULT",NA,1,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-01,2023-09-12
COMPLETED,NO,BIOLOGICAL: CDK-002,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,27,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-15,2022-12-23
COMPLETED,NO,DRUG: Elacestrant,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,23,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-09,2022-02-25
COMPLETED,NO,BEHAVIORAL: Shared decision making supported by an in-consultation patient decision aid,FEMALE,"ADULT, OLDER_ADULT",NA,678,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-03-04,2023-07-31
RECRUITING,NO,DRUG: Inavolisib|DRUG: PHESGO|DRUG: Endocrine therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,170,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-02,2027-01
NOT_YET_RECRUITING,NO,DRUG: Temozolomide|DRUG: Olaparib,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-07-01,2028-07-01
NOT_YET_RECRUITING,NO,DRUG: Niraparib + Elacestrant|DRUG: Niraparib,ALL,"ADULT, OLDER_ADULT",PHASE2,176,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-03-31,2028-03-31
NOT_YET_RECRUITING,NO,PROCEDURE: Bariatric Surgery with Sleeve Gastrectomy|BEHAVIORAL: Lifestyle Intervention,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2024-01,2025-02
RECRUITING,NO,DRUG: Capecitabine+endocrine therapy|DRUG: Placebo+endocrine therapy,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1979,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2021-09-28,2028-09
RECRUITING,NO,BEHAVIORAL: Self-Administered Hypnosis|BEHAVIORAL: Self-Administered White Noise Hypnosis,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2023-09-08,2024-07-31
RECRUITING,NO,BEHAVIORAL: Exercise Intervention,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-04-26,2027-12
RECRUITING,NO,BIOLOGICAL: XmAb®808|BIOLOGICAL: Keytruda® (pembrolizumab),ALL,"ADULT, OLDER_ADULT",PHASE1,220,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-14,2027-12
TERMINATED,NO,OTHER: cryotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,14,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-08-04,2021-02-03
RECRUITING,NO,DRUG: Durvalumab|DRUG: Trastuzumab|DRUG: Pertuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,39,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-03,2025-02
RECRUITING,NO,BEHAVIORAL: Time-Restricted Eating (TRE)|BEHAVIORAL: Control,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-01,2026-12-31
NOT_YET_RECRUITING,NO,PROCEDURE: 3D printed technology,FEMALE,"ADULT, OLDER_ADULT",NA,126,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-10-08,2025-12-30
NOT_YET_RECRUITING,NO,DRUG: Dalpiciclib|DRUG: Chidamide,FEMALE,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-01,2025-11-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Sacituzumab govitecan|DRUG: Loperamide|DRUG: Granulocyte Colony-Stimulating Factor,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-07,2025-12-14
RECRUITING,NO,DRUG: Abemaciclib|OTHER: Questionnaire Administration,ALL,OLDER_ADULT,PHASE2,43,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-25,2024-08-21
RECRUITING,NO,BEHAVIORAL: Nurse-practitioner led intervention,ALL,"ADULT, OLDER_ADULT",NA,76,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-02-28,2026-12
RECRUITING,NO,BEHAVIORAL: Mindfulness Relaxation|PROCEDURE: Functional Magnetic Resonance Imaging|PROCEDURE: Biospecimen Collection|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-11-13,2024-12
RECRUITING,NO,PROCEDURE: Wire-guided localization and marker clip localization|PROCEDURE: marker clip localization,FEMALE,"ADULT, OLDER_ADULT",NA,110,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-16,2025-12-01
RECRUITING,NO,DRUG: 68Ga-RM26-RGD|DRUG: 18F-FDG|DRUG: 68Ga-RM26|DRUG: 68Ga-RGD,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,90,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-08-16,2023-12-31
RECRUITING,NO,DRUG: Organoid-guided treatment|DRUG: Taxane|DRUG: Capecitabine|DRUG: Gemcitabine|DRUG: Vinorelbine|DRUG: Eribulin|DRUG: Anthracycline|DRUG: Carboplatin|DRUG: Utidelone|DRUG: Trastuzumab deruxtecan|DRUG: Sacituzumab govitecan,ALL,"ADULT, OLDER_ADULT",PHASE2,252,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-20,2028-06-30
RECRUITING,NO,BEHAVIORAL: In-person supervised cardiac rehabilitation|BEHAVIORAL: Virtual cardiac rehabilitation,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-03-21,2024-12
RECRUITING,NO,DRUG: letrozole,FEMALE,"ADULT, OLDER_ADULT",PHASE4,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-01,2026-03-25
RECRUITING,NO,DRUG: HLX11|DRUG: EU-Perjeta®,ALL,"ADULT, OLDER_ADULT",PHASE3,900,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-04-25,2025-12-30
ACTIVE_NOT_RECRUITING,NO,OTHER: Enhanced Consultation|OTHER: Standard of Care Consultation|PROCEDURE: Conventional Imaging|OTHER: Educational Intervention|OTHER: Questionnaire Administration,ALL,"ADULT, OLDER_ADULT",NA,35,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-10-13,2027-02-02
COMPLETED,NO,BEHAVIORAL: Education,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,81,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2022-06-01,2022-12-01
RECRUITING,NO,DRUG: JK08,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,149,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-17,2026-02-20
RECRUITING,NO,DRUG: Dexrazoxane,FEMALE,"ADULT, OLDER_ADULT",PHASE1,25,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-09-14,2025-10-31
ACTIVE_NOT_RECRUITING,NO,DRUG: BPI-16350|DRUG: placebo|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE3,274,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-25,2025-07-31
UNKNOWN,NO,DRUG: Serabelisib|DRUG: Canagliflozin 300mg,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-01,2021-12-30
WITHDRAWN,NO,DRUG: Niraparib|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Pegfilgrastim|DRUG: Carboplatin,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-01,2026-01
RECRUITING,NO,DRUG: Trastuzumab deruxtecan (DS-8201a)|DRUG: Trastuzumab deruxtecan (DS-8201a)|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,115,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-10,2024-03-01
ACTIVE_NOT_RECRUITING,NO,DEVICE: Scalp cooling,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-01-08,2025-12-31
COMPLETED,NO,OTHER: training and counseling supported guided imagery application,FEMALE,"ADULT, OLDER_ADULT",NA,68,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-02-01,2022-11-15
UNKNOWN,NO,OTHER: The personalized telephone based intervention,FEMALE,"ADULT, OLDER_ADULT",NA,220,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-06-17,2023-03
NOT_YET_RECRUITING,NO,DRUG: Experimental: chemotheyapy|DRUG: Active Comparator: endocrine therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,240,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-20,2026-12-20
ACTIVE_NOT_RECRUITING,NO,DRUG: Standard of Care (SOC) gadolinium Breast MRI|DRUG: reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.,FEMALE,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-07-14,2024-03-31
NOT_YET_RECRUITING,NO,DRUG: Dalpiciclib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-10,2024-08-10
RECRUITING,NO,DRUG: Trastuzumab Emtansine (T-DM1),FEMALE,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-01,2026-05-31
ACTIVE_NOT_RECRUITING,NO,"DRUG: tamoxifen, letrozole, anastrozole, or exemestane|BEHAVIORAL: Patient reported outcomes",FEMALE,OLDER_ADULT,PHASE2,83,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-07,2025-06-07
RECRUITING,NO,DIAGNOSTIC_TEST: PET scan,FEMALE,ADULT,NA,210,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-04-26,2024-05-24
NOT_YET_RECRUITING,NO,OTHER: State-Trait Anxiety Inventory (STAI),FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2024-03,2026-03
NOT_YET_RECRUITING,NO,OTHER: MARVIN|OTHER: MARVIN-Pharma|OTHER: MARVINA|OTHER: MARVIN-CHAMP,ALL,"CHILD, ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2024-01-01,2034-12-31
ACTIVE_NOT_RECRUITING,NO,OTHER: Base intervention-Fitbit with EHR integration|OTHER: Coaching Calls|OTHER: Online Gym,FEMALE,"ADULT, OLDER_ADULT",NA,323,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2020-11-09,2026-01-31
RECRUITING,NO,DEVICE: Neoadjuvant Chemotherapy by CDSS (MedicBK)|DRUG: General practice,ALL,"ADULT, OLDER_ADULT",NA,1200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-12,2024-03-30
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction|PROCEDURE: Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction|OTHER: quality-of-life questionnaires|OTHER: measured by arm volume,FEMALE,"ADULT, OLDER_ADULT",PHASE3,180,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-22,2026-01
NOT_YET_RECRUITING,NO,DRUG: CVL237 tablets,ALL,"ADULT, OLDER_ADULT",PHASE2,98,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-20,2027-06-30
RECRUITING,NO,DIAGNOSTIC_TEST: Aerobic Training|DIAGNOSTIC_TEST: Progressive Resistance Training,FEMALE,"ADULT, OLDER_ADULT",NA,74,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-04-01,2023-08-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Camrelizumab|DRUG: Apatinib|DRUG: Eribulin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,46,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-25,2023-08-31
NOT_YET_RECRUITING,NO,DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Aldesleukin|BIOLOGICAL: Sleeping Beauty Transposed PBL,ALL,"ADULT, OLDER_ADULT",PHASE2,210,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02-22,2029-12-31
COMPLETED,NO,PROCEDURE: Microwave Ablation|DRUG: Camrelizumab|PROCEDURE: Breast Surgery,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-25,2023-04-30
RECRUITING,NO,OTHER: Myocardial Probe Temperature Screen|OTHER: Data Collection,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-09-29,2024-02
NOT_YET_RECRUITING,NO,OTHER: conventional physiotherapy|OTHER: Manual lymphatic drainage|OTHER: Myofascial relasing,FEMALE,ADULT,NA,48,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-15,2024-02-15
RECRUITING,NO,DRUG: Neratinib|DRUG: Capmatinib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,56,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-18,2028-12-31
RECRUITING,NO,PROCEDURE: Neurotization Procedure|OTHER: Questionnaire Administration|PROCEDURE: Subcutaneous Mastectomy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,14,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-05,2025-11-10
ACTIVE_NOT_RECRUITING,NO,DRUG: SKB264,ALL,"ADULT, OLDER_ADULT",PHASE3,254,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-10,2024-12-31
UNKNOWN,NO,BIOLOGICAL: Next Generation Sequencing and Network Analysis,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2022-01,2023-12
RECRUITING,NO,DRUG: Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide,FEMALE,"ADULT, OLDER_ADULT",PHASE4,402,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-01,2024-12-30
NOT_YET_RECRUITING,NO,BEHAVIORAL: Exercise training,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2023-11,2024-05
TERMINATED,YES,BIOLOGICAL: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,48,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-15,2021-10-29
NOT_YET_RECRUITING,NO,BEHAVIORAL: mindfulness yoga,FEMALE,"ADULT, OLDER_ADULT",NA,78,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-08-01,2024-08-01
RECRUITING,NO,"PROCEDURE: Consultation|PROCEDURE: Cerebral and medullary MRI, lumbar puncture, CSF sampling|BIOLOGICAL: biological test",FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-01-04,2026-12
RECRUITING,NO,PROCEDURE: Surgery for unilateral breast reconstruction,FEMALE,"ADULT, OLDER_ADULT",NA,32,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-25,2025-05-25
RECRUITING,NO,RADIATION: F-DOPA PET/CT,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-12-03,2024-02
RECRUITING,NO,DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide,ALL,"ADULT, OLDER_ADULT",PHASE2,26,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-02-01,2024-06-01
RECRUITING,NO,PROCEDURE: Transversus thoracis plane block combined with serratus anterior plane block|PROCEDURE: Serratus anterior plan block,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-07-12,2024-06
RECRUITING,NO,DRUG: Talazoparib|DRUG: ASTX727,ALL,"ADULT, OLDER_ADULT",PHASE1,38,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-01,2025-07-01
RECRUITING,NO,DRUG: XB002|DRUG: Nivolumab,ALL,"ADULT, OLDER_ADULT",PHASE1,573,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-07,2024-10-07
NOT_YET_RECRUITING,NO,BIOLOGICAL: Aldesleukin|BIOLOGICAL: Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|PROCEDURE: Echocardiography|DRUG: Fludarabine|PROCEDURE: Leukapheresis|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Mammogram|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Ultrasound Imaging,FEMALE,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-04-01,2027-04-01
NOT_YET_RECRUITING,NO,DRUG: Surufatinib|DRUG: Tislelizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,45,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-04,2025-08
RECRUITING,NO,DRUG: ARV-471|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE3,560,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-03,2028-05-15
COMPLETED,NO,OTHER: messages,FEMALE,OLDER_ADULT,NA,4173,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-05-12,2023-06-19
NOT_YET_RECRUITING,NO,DRUG: BLEX 404 Oral Liquid,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,44,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-03-01,2025-08-28
RECRUITING,NO,BEHAVIORAL: Weekly Survey,ALL,"ADULT, OLDER_ADULT",NA,240,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-11-06,2026-05
RECRUITING,NO,BEHAVIORAL: Video Education|BEHAVIORAL: Genetic Counseling,ALL,"ADULT, OLDER_ADULT",NA,1020,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-08-04,2026-09-01
RECRUITING,NO,DRUG: Abemaciclib|DRUG: Elacestrant,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,44,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-21,2025-01
ACTIVE_NOT_RECRUITING,NO,DRUG: U3 1402|DRUG: U3 1402,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,80,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-22,2023-09-30
ACTIVE_NOT_RECRUITING,NO,DRUG: ARV-471,ALL,"ADULT, OLDER_ADULT",PHASE1,9,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-20,2024-11-07
ACTIVE_NOT_RECRUITING,NO,"DEVICE: Compression sleeve, worn during exercise|DEVICE: Adjustable Compression (AC) garment, worn during exercise|DEVICE: Compression sleeve, daytime wear|BEHAVIORAL: Decongestive Progressive Resistance Exercise program|BEHAVIORAL: Home exercise program",FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-06-29,2024-05-31
ACTIVE_NOT_RECRUITING,NO,OTHER: Personalized Coaching (Arm A)|OTHER: Standard supportive approach (Arm B),FEMALE,"ADULT, OLDER_ADULT",NA,1133,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-12-18,2024-12
TERMINATED,NO,BIOLOGICAL: N-803|BIOLOGICAL: PD-L1 t-haNK|DRUG: Sacituzumab Govitecan-Hziy|DRUG: Cyclophosphamide,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,3,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-27,2023-01-04
ACTIVE_NOT_RECRUITING,NO,DRUG: Albumin paclitaxel+trastuzumab+pyrrolitinib|DRUG: Docetaxel+Carboplatin+trastuzumab+Parstuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,610,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-03,2026-05-03
RECRUITING,NO,DRUG: DB-1310,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,287,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-10,2026-08-31
NOT_YET_RECRUITING,NO,DRUG: Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg,FEMALE,ADULT,PHASE2,124,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-15,2030-12
UNKNOWN,NO,DRUG: PYRROTINI|RADIATION: Brain radiation therapy,FEMALE,"ADULT, OLDER_ADULT",PHASE4,43,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-01,2022-06
RECRUITING,NO,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Multigated Acquisition Scan|BIOLOGICAL: Trastuzumab Deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE1,63,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-01,2024-12-31
NOT_YET_RECRUITING,NO,OTHER: Music therapy,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2024-01-20,2024-05-30
RECRUITING,NO,DRUG: Standard of care administration of Endocrine therapy|DRUG: Dose-frequency escalation administration of Endocrine therapy,ALL,"ADULT, OLDER_ADULT",PHASE4,240,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-28,2029-07
UNKNOWN,NO,DIETARY_SUPPLEMENT: grape juice|OTHER: control,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-05-08,2021-07-15
NOT_YET_RECRUITING,NO,DIAGNOSTIC_TEST: Gradient and pulse imaging,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-05-11,2023-07-01
COMPLETED,NO,DEVICE: OnLume Imaging System|DRUG: Indocyanine green,FEMALE,"ADULT, OLDER_ADULT",NA,9,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-05,2023-04-27
NOT_YET_RECRUITING,NO,DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Fulvestrant|DRUG: Capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE3,493,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-01,2026-04-30
ENROLLING_BY_INVITATION,NO,OTHER: Educational video series,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-12-05,2025-08-01
NOT_YET_RECRUITING,NO,BEHAVIORAL: Education Intervention,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SCREENING,2023-11-30,2024-06-30
TERMINATED,YES,DEVICE: Philips Sonalleve® MR-HIFU Breast Therapy System,FEMALE,"ADULT, OLDER_ADULT",NA,1,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-13,2020-02-05
RECRUITING,NO,BEHAVIORAL: Cognitive Behavioral Therapy for Insomnia,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-03-01,2025-09-30
TERMINATED,NO,DRUG: ALRN-6924|DRUG: TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2),ALL,"ADULT, OLDER_ADULT",PHASE1,6,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-01-09,2023-02-22
COMPLETED,NO,RADIATION: Curative radiotherapy|OTHER: Paleolithic lifestyle intervention,FEMALE,"ADULT, OLDER_ADULT",NA,13,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-19,2020-07-16
COMPLETED,NO,DEVICE: Easy Dew MD Regen Cream,ALL,"ADULT, OLDER_ADULT",NA,30,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-11-11,2023-07-28
RECRUITING,NO,DEVICE: Continuous Positive Airway Pressure|OTHER: Deep inspiratory breath hold|OTHER: Free Breath,ALL,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-10-19,2025-06-30
RECRUITING,NO,DRUG: HC-5404-FU,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-08,2024-03-08
RECRUITING,NO,DRUG: Famitinib|DRUG: Camrelizumab|DRUG: nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin,FEMALE,"ADULT, OLDER_ADULT",PHASE3,223,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-17,2027-01-01
NOT_YET_RECRUITING,NO,BEHAVIORAL: Emotional Disclosure|BEHAVIORAL: Non-Emotional Writing,FEMALE,ADULT,NA,64,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-01-01,2024-12-30
RECRUITING,NO,PROCEDURE: Contrast-Enhanced Ultrasound|DRUG: Perflutren Lipid Microspheres,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-12-07,2024-04-01
NOT_YET_RECRUITING,NO,PROCEDURE: Negative pressure therapy (NPT)|PROCEDURE: Dressing,FEMALE,"ADULT, OLDER_ADULT",NA,256,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-06,2027-02
RECRUITING,NO,BIOLOGICAL: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|BIOLOGICAL: Sargramostim,ALL,"ADULT, OLDER_ADULT",PHASE2,33,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-11-17,2024-04-30
RECRUITING,NO,DEVICE: CT-100-D-004-A|DEVICE: CT-100-D-004-B,ALL,"ADULT, OLDER_ADULT",NA,180,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2023-10-19,2023-12-23
RECRUITING,NO,DRUG: CPO-100,ALL,"ADULT, OLDER_ADULT",PHASE1,126,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-24,2025-03-01
TERMINATED,NO,DRUG: Copanlisib|BIOLOGICAL: Pertuzumab|BIOLOGICAL: Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,2,NIH,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-20,2022-04-29
UNKNOWN,NO,BEHAVIORAL: Elly Mobile Phone Application,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-12-02,2022-07-08
ACTIVE_NOT_RECRUITING,NO,OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|BIOLOGICAL: Therapeutic Autologous Platelet-rich Plasma,FEMALE,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-09-23,2024-12-31
COMPLETED,NO,BEHAVIORAL: Mindfulness open and circular program,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-09-01,2022-07-13
RECRUITING,NO,PROCEDURE: axillary lymph node dissection with vein branches reservation|PROCEDURE: axillary lymph node dissection without vein branches reservation,ALL,"ADULT, OLDER_ADULT",NA,261,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-03,2025-03
RECRUITING,NO,DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Pembrolizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,139,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-05,2025-12
RECRUITING,NO,OTHER: Hand Mobility and Grip Strengthening Exercises|OTHER: Usual Care,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-10-01,2024-04-30
RECRUITING,NO,DRUG: [18F]fluoroestradiol (FES),ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-08-10,2024-12-31
ENROLLING_BY_INVITATION,NO,DIAGNOSTIC_TEST: Total-body PET imaging,ALL,"ADULT, OLDER_ADULT",NA,9,OTHER,Allocation: NA|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2024-03,2025-03-01
RECRUITING,NO,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Ipatasertib|PROCEDURE: Magnetic Resonance Imaging|DRUG: Paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE2,33,NIH,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09-22,2025-08-31
RECRUITING,NO,DRUG: INX-315,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,81,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-28,2026-06
RECRUITING,NO,DRUG: Continuation of CDK4/6 inhibitor Palbociclib|DRUG: Discontinuation of CDK4/6 inhibitor Palbociclib|DRUG: Continuation of CDK4/6 inhibitor -Palbociclib|DRUG: Discontinuation of CDK4/6 inhibitor -Palbociclib|DRUG: Continuation of CDK4/6 inhibitor Abemaciclib|DRUG: Discontinuation of CDK4/6 inhibitor Abemaciclib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-17,2028-07-10
NOT_YET_RECRUITING,NO,DRUG: A1:SG with SHR3680|DRUG: A2:SG|DRUG: B1:SG with SHR1210|DRUG: B2:SG|DRUG: C1:SG with SHR3162|DRUG: C2:SG|DRUG: D1:SG with VEGFRI|DRUG: D2:SG,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,125,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-01,2025-09-01
RECRUITING,NO,BEHAVIORAL: Education and counseling|BEHAVIORAL: Education,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-07-01,2025-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: ART4215|DRUG: Talazoparib|DRUG: Niraparib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,390,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-13,2026-01
RECRUITING,NO,RADIATION: Standard of Care Adjuvant Breast Radiation|DRUG: Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation,ALL,"ADULT, OLDER_ADULT",PHASE3,1300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-13,2037-02-01
COMPLETED,NO,BEHAVIORAL: Culturally-Targeted Video|OTHER: FORCE Fact Sheet,ALL,"ADULT, OLDER_ADULT",NA,61,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-02-24,2022-01-31
RECRUITING,NO,DRUG: Tucatinib|DRUG: Doxil,ALL,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-24,2026-07
RECRUITING,NO,OTHER: Best Practice|OTHER: Medical Device Usage and Evaluation|PROCEDURE: Respiratory Muscle Training|OTHER: Survey Administration,ALL,"ADULT, OLDER_ADULT",NA,130,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-10-16,2029-10-16
NOT_YET_RECRUITING,NO,PROCEDURE: Erector spinae plane block|PROCEDURE: Placebo Block,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-09,2024-12
RECRUITING,NO,OTHER: alternative medicine education consultation,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-09-28,2024-08
RECRUITING,NO,"DRUG: Mecapegfilgrastim|DRUG: dalpiciclib|DRUG: exemestane, fulvestrant, letrozole, tamoxifen",ALL,"ADULT, OLDER_ADULT",PHASE2,132,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-08-01,2024-12-01
WITHDRAWN,NO,DRUG: Reparixin|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-04-19,2024-07
NOT_YET_RECRUITING,NO,OTHER: Whatsapp reminder,FEMALE,"ADULT, OLDER_ADULT",NA,600,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SCREENING,2022-06-01,2024-05-31
RECRUITING,NO,DRUG: MT-302 (A),ALL,"ADULT, OLDER_ADULT",PHASE1,48,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-08-02,2028-08-31
RECRUITING,NO,DRUG: Palbociclib|DRUG: Avelumab,ALL,"ADULT, OLDER_ADULT",PHASE1,45,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-08-11,2025-12-31
UNKNOWN,NO,BEHAVIORAL: Vacuum-Assisted Biopsy|BEHAVIORAL: Core Needle Biopsy|BEHAVIORAL: Intraoperative Excisional Biopsy,FEMALE,"ADULT, OLDER_ADULT",NA,600,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-01,2021-06-01
RECRUITING,NO,DRUG: Tamoxifen Oral Product|DIAGNOSTIC_TEST: Assessment of Ki-67|PROCEDURE: Surgery,FEMALE,ADULT,PHASE2,238,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-21,2028-12-31
ENROLLING_BY_INVITATION,NO,DRUG: TOL2506|DRUG: Tamoxifen|DRUG: Letrozole tablets|DRUG: Anastrozole Tablets|DRUG: Exemestane Tablets,ALL,ADULT,PHASE3,250,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-28,2028-06
COMPLETED,NO,DRUG: Trilaciclib|DRUG: Cylophosphamide|DRUG: Doxorubicin|DRUG: Paclitaxel|DRUG: Carboplatin (Investigator discretion)|BIOLOGICAL: Pembrolizumab (Investigator discretion),FEMALE,"ADULT, OLDER_ADULT",PHASE2,24,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-19,2023-03-13
RECRUITING,NO,BEHAVIORAL: Search only for masses|BEHAVIORAL: Search only for calcifications|BEHAVIORAL: Search for both together|BEHAVIORAL: Search for one after the other,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-09-01,2028-09-01
WITHDRAWN,NO,DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-15,2028-04-13
ACTIVE_NOT_RECRUITING,NO,OTHER: Cardiac Aggressive Risk MitigAtion Plan,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-10-07,2024-08-31
RECRUITING,NO,DRUG: ZN-A-1041 50mg BID|DRUG: ZN-A-1041 100mg BID|DRUG: ZN-A-1041 200mg BID|DRUG: ZN-A-1041 400mg BID|DRUG: ZN-A-1041 600mg BID|DRUG: ZN-A-1041 800mg BID|DRUG: ZN-A-1041 1000mg BID|DRUG: ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|DRUG: ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|DRUG: ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|DRUG: ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle,ALL,"ADULT, OLDER_ADULT",PHASE1,84,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-15,2024-06-30
NOT_YET_RECRUITING,NO,PROCEDURE: Reiki,FEMALE,"ADULT, OLDER_ADULT",NA,52,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2023-02-01,2023-08-31
COMPLETED,NO,BEHAVIORAL: Communciation intervention,FEMALE,"ADULT, OLDER_ADULT",NA,27,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2022-06-05,2023-09-01
RECRUITING,NO,DEVICE: CBBCT Imaging|DEVICE: Digital Mammography,FEMALE,"ADULT, OLDER_ADULT",NA,1024,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-10-30,2024-12-30
RECRUITING,NO,DRUG: XMT-1660,ALL,"ADULT, OLDER_ADULT",PHASE1,166,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-15,2026-01
TERMINATED,NO,DEVICE: Attune™|DEVICE: Cerena™,ALL,"ADULT, OLDER_ADULT",NA,31,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-05-15,2022-09-01
NOT_YET_RECRUITING,NO,DRUG: Olaparib|DRUG: 17b-estradiol,FEMALE,"ADULT, OLDER_ADULT",PHASE1,6,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-02,2028-12
NOT_YET_RECRUITING,NO,DRUG: Imatinib 400 MG Oral Tablet,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-02-06,2024-12-31
RECRUITING,NO,BEHAVIORAL: Art Therapy|BEHAVIORAL: Music Therapy,ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-04-21,2024-06-01
RECRUITING,NO,DRUG: Pemigatinib Pill,ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-08,2025-09-08
UNKNOWN,NO,PROCEDURE: Music therapy,ALL,"ADULT, OLDER_ADULT",NA,304,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-09-21,2021-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Cannabidiol|OTHER: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-01-19,2024-07-18
UNKNOWN,NO,BEHAVIORAL: Ice water immersion,ALL,"ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-02,2022-12
WITHDRAWN,NO,BEHAVIORAL: Navigator Phone Calls|BEHAVIORAL: Exit Interview,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-08-25,2023-10-17
COMPLETED,NO,DRUG: Ipatasertib|DRUG: Capecitabine|DRUG: Eribulin|DRUG: Carboplatin|DRUG: Gemcitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,54,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-08,2023-11-10
NOT_YET_RECRUITING,NO,OTHER: ePRO application and proactive clinical care with nurses.,FEMALE,"ADULT, OLDER_ADULT",PHASE2,410,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-01-15,2025-03-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Paclitaxel + bevacizumab therapy|DRUG: Paclitaxel + bevacizumab + atezolizumab,ALL,"ADULT, OLDER_ADULT",PHASE3,280,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-21,2025-09-30
RECRUITING,NO,"RADIATION: Breast irradiation (RT)|DRUG: Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen",FEMALE,OLDER_ADULT,PHASE3,926,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-02-08,2030-02-08
RECRUITING,NO,DRUG: Cephalexin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-09-28,2025-12-31
COMPLETED,NO,DRUG: Trastuzumab deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE2,41,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-25,2023-04-04
RECRUITING,NO,DRUG: Palbociclib Oral Product|DRUG: TAS-116|DRUG: TAS-116|DRUG: TAS-116,ALL,"ADULT, OLDER_ADULT",PHASE1,27,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09-12,2025-08
RECRUITING,NO,PROCEDURE: Contrast Enhanced Digital Mammography|PROCEDURE: Digital Tomosynthesis Mammography|DRUG: Iodinated Contrast Agent|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",NA,66,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-04-15,2024-04-30
NOT_YET_RECRUITING,NO,DRUG: Camrelizumab|DRUG: Nab-Paclitaxel|DRUG: Carboplatin,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,420,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-15,2025-06-30
RECRUITING,NO,DRUG: ORM-5029,ALL,"ADULT, OLDER_ADULT",PHASE1,87,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-03,2025-10
NOT_YET_RECRUITING,NO,DIETARY_SUPPLEMENT: Probiotic|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",NA,100,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2024-04-01,2026-04-01
UNKNOWN,NO,DRUG: Camrelizumab Plus Chemotherapy|DRUG: placebo+chemotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE3,581,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-09,2024-01-30
RECRUITING,NO,DRUG: Abemaciclib|DRUG: Hydroxychloroquine,ALL,"ADULT, OLDER_ADULT",PHASE2,66,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-01,2028-12
NOT_YET_RECRUITING,NO,PROCEDURE: Prospective data and sample collection|DRUG: Ketorolac 10 Mg Oral Tablet|DRUG: Pregabalin 75mg,FEMALE,"ADULT, OLDER_ADULT",PHASE2,112,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2024-02-20,2026-12
UNKNOWN,NO,BEHAVIORAL: Mindfulness Based-Cognitive Therapy (MBCT)|BEHAVIORAL: Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|OTHER: Treatment as usual (no intervention),ALL,"ADULT, OLDER_ADULT",NA,108,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-09-01,2021-09
COMPLETED,NO,DRUG: AZD9833,FEMALE,"ADULT, OLDER_ADULT",PHASE2,135,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-02,2023-06-19
RECRUITING,NO,DRUG: Albumin-Bound Paclitaxel|DRUG: Apatinib Mesylate|DRUG: Bevacizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,128,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-14,2024-06-01
COMPLETED,NO,DEVICE: Scalp cooling system 2,FEMALE,"ADULT, OLDER_ADULT",NA,170,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2020-12-23,2022-08-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Anastrozole|DRUG: Exemestane|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Paclitaxel|BIOLOGICAL: Talimogene Laherparepvec|DRUG: Tamoxifen|DRUG: Nab paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-05,2025-04-30
ACTIVE_NOT_RECRUITING,NO,DIETARY_SUPPLEMENT: Fasting-mimicking diet|DRUG: Metformin|DRUG: Preoperative chemotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-05,2024-05-01
ACTIVE_NOT_RECRUITING,NO,DEVICE: Device: Attune™|DEVICE: Device: Cerena™,ALL,"ADULT, OLDER_ADULT",NA,352,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-03-10,2022-12-15
RECRUITING,NO,"DRUG: Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel|DRUG: Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,160,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-01-17,2031-12-31
RECRUITING,NO,DEVICE: Compression therapy using surgical gloves,FEMALE,"ADULT, OLDER_ADULT",NA,104,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-06-13,2026-02
WITHDRAWN,NO,DRUG: Metabolic treatment,ALL,"ADULT, OLDER_ADULT",PHASE3,0,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-23,2027-09-23
RECRUITING,NO,DRUG: Ipatasertib|DRUG: Fulvestrant|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,250,NETWORK,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-01-27,2026-12-31
RECRUITING,NO,DEVICE: Decision Support System,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-05-03,2023-12-30
NOT_YET_RECRUITING,NO,OTHER: Internet-based Intervention,FEMALE,"ADULT, OLDER_ADULT",NA,320,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE,2024-02,2027-08
WITHDRAWN,NO,DEVICE: Negative Pressure Wound Therapy,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2023-09,2025-10
COMPLETED,NO,OTHER: Breathing exercise,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-01-01,2023-08-12
NOT_YET_RECRUITING,NO,BEHAVIORAL: Core Intervention|BEHAVIORAL: E-Coach|BEHAVIORAL: Buddy|BEHAVIORAL: General Mindfulness Training|BEHAVIORAL: MVPA-Specific Mindfulness Training,FEMALE,"ADULT, OLDER_ADULT",NA,304,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-01-08,2026-08-31
SUSPENDED,NO,DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Trastuzumab emtansine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-08-11,2026-06-01
NOT_YET_RECRUITING,NO,DRUG: Pyrotinib|DRUG: Trastuzumab|DRUG: Paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE3,876,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-06,2033-05-06
RECRUITING,NO,DIAGNOSTIC_TEST: Mammograms,FEMALE,"ADULT, OLDER_ADULT",NA,27000,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-03-01,2024-02
RECRUITING,NO,DRUG: ARX788,ALL,"ADULT, OLDER_ADULT",PHASE2,54,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-10-20,2023-06-30
WITHDRAWN,NO,RADIATION: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|DRUG: Letrozole 2.5Mg Tab|DRUG: Palbociclib 125mg,FEMALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-04,2028-12-31
ACTIVE_NOT_RECRUITING,NO,OTHER: Telerehabilitation with virtual game,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-02,2022-12-02
RECRUITING,NO,BEHAVIORAL: Informational brochure for patients and brief training for oncologists,FEMALE,ADULT,NA,750,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2022-06-01,2026-12
RECRUITING,NO,DEVICE: HiToP 191 PNP|DEVICE: Placebo device,ALL,"ADULT, OLDER_ADULT",NA,160,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-03,2024-12-31
ACTIVE_NOT_RECRUITING,NO,OTHER: Physiotherapeutic treatment and medical care|OTHER: medical care,FEMALE,"ADULT, OLDER_ADULT",NA,111,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-14,2024-03-30
NOT_YET_RECRUITING,NO,RADIATION: Hypofractionation|RADIATION: Conventional Fractionation,FEMALE,"ADULT, OLDER_ADULT",PHASE3,622,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-04-01,2032-12-31
RECRUITING,NO,DIAGNOSTIC_TEST: 18F-FES PET/CT scan,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-05-01,2024-12-31
RECRUITING,NO,DRUG: NPX267,ALL,"ADULT, OLDER_ADULT",PHASE1,131,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-21,2026-01
RECRUITING,NO,DEVICE: transauricular Vagus Nerve Stimulation,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09-26,2024-12-31
RECRUITING,NO,DRUG: CP-506|DRUG: Carboplatin|DRUG: Immune checkpoint inhibitor,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,126,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-25,2026-05
SUSPENDED,NO,OTHER: Educational Intervention|OTHER: Text Message-based Navigation Intervention|BEHAVIORAL: Motivational Interviewing|OTHER: Best Practice|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1180,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-02-15,2025-10
UNKNOWN,NO,DRUG: Eribulin Mesylate|DRUG: Anlotinib hydrochloride,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2022-12
NOT_YET_RECRUITING,NO,DRUG: DP303c|DRUG: Trastuzumab|DRUG: Vinorelbine Tartrate|DRUG: Capecitabine tablets,ALL,"ADULT, OLDER_ADULT",PHASE3,420,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07,2028-07
UNKNOWN,NO,"OTHER: waiting room enriched with music, paintings and artificial plants",FEMALE,"ADULT, OLDER_ADULT",NA,106,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2020-11-01,2022-03-03
ENROLLING_BY_INVITATION,NO,OTHER: Aromatherapy with Essential Oils,ALL,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-07-19,2024-12-31
RECRUITING,NO,DRUG: Metarrestin,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,98,NIH,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-27,2024-12-31
NOT_YET_RECRUITING,NO,BEHAVIORAL: Digital Peer Navigation,ALL,ADULT,NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-05,2025-12
UNKNOWN,NO,DRUG: Dapagliflozin 10Mg Tab,ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-25,2023-07
TERMINATED,NO,DRUG: FT538|DRUG: Cyclophosphamide|DRUG: Fludarabine|COMBINATION_PRODUCT: Monoclonal antibody - Dose Escalation|COMBINATION_PRODUCT: Monoclonal antibody - Dose Expansion,ALL,"ADULT, OLDER_ADULT",PHASE1,16,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-15,2023-08-11
ACTIVE_NOT_RECRUITING,NO,DRUG: Elacestrant|DRUG: Onapristone,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,67,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-02,2026-04-30
COMPLETED,NO,DEVICE: Transcutaneous vagus nerve stimulation,ALL,"ADULT, OLDER_ADULT",NA,288,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-03,2022-05-30
COMPLETED,NO,DEVICE: cryoablation,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-09-01,2023-01-27
ACTIVE_NOT_RECRUITING,NO,DRUG: Afuresertib,ALL,"ADULT, OLDER_ADULT",PHASE1,20,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-02-18,2024-12-30
RECRUITING,NO,BEHAVIORAL: Health Education|OTHER: Questionnaire Administration,ALL,"ADULT, OLDER_ADULT",NA,225,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-03-30,2025-12-31
RECRUITING,NO,"OTHER: Education, compression and exercise therapy|OTHER: Education, compression and exercise therapy manual lymph drainage",FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-21,2024-07-15
NOT_YET_RECRUITING,NO,DRUG: OnLife®|OTHER: Placebo,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2024-03-31,2026-06-30
NOT_YET_RECRUITING,NO,DRUG: Irinotecan Liposome Injection,FEMALE,"ADULT, OLDER_ADULT",PHASE1,136,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04,2024-04
RECRUITING,NO,DRUG: HMBD-001,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,135,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-10,2026-09
COMPLETED,NO,DRUG: honey based (HB) syrup,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-06-15,2020-10-05
ACTIVE_NOT_RECRUITING,NO,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE3,405,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-10-14,2026-12-04
ACTIVE_NOT_RECRUITING,NO,DRUG: Fulvestrant|DRUG: Capivasertib|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,818,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-16,2024-06-07
RECRUITING,NO,DRUG: Alpelisib|DRUG: Ribociclib,ALL,"ADULT, OLDER_ADULT",PHASE2,162,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-19,2030-06
RECRUITING,NO,DRUG: SPH4336 Tablets 400mg|DRUG: SPH4336 Tablets Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,374,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04-24,2024-12-16
NOT_YET_RECRUITING,NO,DRUG: PHESGO,FEMALE,"ADULT, OLDER_ADULT",PHASE2,63,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02,2031-07
NOT_YET_RECRUITING,NO,DRUG: Human Interleukin-2 (IL-2) (Proleukin),FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-01-02,2025-04
ACTIVE_NOT_RECRUITING,NO,DRUG: Sacituzumab Govitecan-hziy|DRUG: Eribulin Mesylate Injection|DRUG: Capecitabine Oral Product|DRUG: Gemcitabine Injection|DRUG: Vinorelbine injection,ALL,"ADULT, OLDER_ADULT",PHASE3,331,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-23,2024-03
RECRUITING,NO,DRUG: Tc99m sestamibi,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-12-13,2024-12-31
RECRUITING,NO,DRUG: CTS2190 capsules,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,224,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-26,2025-10-31
ACTIVE_NOT_RECRUITING,NO,GENETIC: Receive an adult-onset result|GENETIC: Receive a pediatric-onset result|GENETIC: Control - No Result,ALL,"CHILD, ADULT, OLDER_ADULT",EARLY_PHASE1,427,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-11-25,2024-06-30
RECRUITING,NO,PROCEDURE: Margin shaving,FEMALE,"ADULT, OLDER_ADULT",NA,234,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-07,2025-10-16
NOT_YET_RECRUITING,NO,DEVICE: Breast Exam with Bexa,FEMALE,"ADULT, OLDER_ADULT",NA,700,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2023-05,2023-12
TERMINATED,NO,BEHAVIORAL: Combined aerobic and resistance exercise,FEMALE,ADULT,NA,3,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-06-05,2021-09-20
ACTIVE_NOT_RECRUITING,NO,DRUG: INCB106385|DRUG: INCMGA00012,ALL,"ADULT, OLDER_ADULT",PHASE1,54,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-03,2024-01-30
RECRUITING,NO,BEHAVIORAL: CST-PSP|BEHAVIORAL: General health education,ALL,"ADULT, OLDER_ADULT",NA,307,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-06-08,2025-04-30
TERMINATED,NO,OTHER: Physical Therapy,ALL,"ADULT, OLDER_ADULT",NA,3,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-04-01,2023-03-31
WITHDRAWN,NO,DRUG: Alpelisib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Olaparib|PROCEDURE: Positron Emission Tomography,ALL,"ADULT, OLDER_ADULT",PHASE2,0,NIH,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-23,2025-04-30
COMPLETED,NO,BEHAVIORAL: Physical Activity|BEHAVIORAL: Attentional Control,FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-01-15,2022-07-07
NOT_YET_RECRUITING,NO,DRUG: Hetrombopag|DRUG: rh-TPO,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-28,2024-06-28
RECRUITING,NO,DRUG: nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1),FEMALE,"ADULT, OLDER_ADULT",PHASE2,90,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-25,2023-10-15
RECRUITING,NO,OTHER: Prescreening|OTHER: Screening and Enrollment|BEHAVIORAL: Baseline|BEHAVIORAL: Interpret BMI|OTHER: Interpret HbA1c|OTHER: Interpret lipid panel and assess other risk factors|BEHAVIORAL: Assess 10 year risk of cardiovascular event|BEHAVIORAL: Recommendations|BEHAVIORAL: Follow-Up,ALL,"ADULT, OLDER_ADULT",NA,450,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2022-06-03,2027-06-01
RECRUITING,NO,"BEHAVIORAL: Exercise, Problem-Solving Session and Education",ALL,"ADULT, OLDER_ADULT",NA,32,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-03-01,2024-04-30
RECRUITING,NO,DRUG: BL-M02D1,ALL,"ADULT, OLDER_ADULT",PHASE1,26,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-20,2024-05
RECRUITING,NO,PROCEDURE: Lymphatic Bypass Supermicrosurgery,ALL,"ADULT, OLDER_ADULT",NA,140,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2022-10-06,2024-07
UNKNOWN,NO,DRUG: OMT-111,ALL,"ADULT, OLDER_ADULT",PHASE2,78,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10,2022-10
NOT_YET_RECRUITING,NO,DRUG: Thero2-01S22|DRUG: Placebo|DRUG: Thero2-01S22|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE3,320,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-15,2027-05-15
RECRUITING,NO,DRUG: YL202 should be intravenously infused,ALL,"ADULT, OLDER_ADULT",PHASE2,200,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-15,2028-11
WITHDRAWN,NO,DRUG: Epidiferphane|DRUG: Taxane Chemotherapy,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,OTHER,Allocation: |Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-03,2023-03
ACTIVE_NOT_RECRUITING,NO,OTHER: Exercise Treatment|OTHER: Plant-Based Diet|OTHER: Physical activity|OTHER: Nutrition counseling|OTHER: Replication Exercise Test,FEMALE,"ADULT, OLDER_ADULT",PHASE2,43,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-04,2025-03
RECRUITING,NO,PROCEDURE: Ovarian biopsy via laparoscopy|PROCEDURE: Transvaginal oocyte retrieval,FEMALE,ADULT,NA,41,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-11-01,2024-12-31
WITHDRAWN,NO,COMBINATION_PRODUCT: Implantable Microdevice (IMD),ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05,2028-09-01
RECRUITING,NO,DRUG: ZB716|DRUG: Palbociclib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,106,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-07-26,2024-01-31
RECRUITING,NO,DEVICE: Breast Cancer Locator (BCL) guided partial mastectomy|DEVICE: Wire Localized (WL) partial mastectomy,FEMALE,"ADULT, OLDER_ADULT",NA,448,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-12-23,2024-09
NOT_YET_RECRUITING,NO,DRUG: Cyclosporin A,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-03,2027-03
NOT_YET_RECRUITING,NO,DRUG: LACUDY,FEMALE,ADULT,NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-20,2023-02-28
UNKNOWN,NO,PROCEDURE: microwave ablation|PROCEDURE: breast conserving surgery,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-18,2023-05-30
UNKNOWN,NO,DRUG: Loperamide|DRUG: Loperamide and golden bifid|DRUG: Loperamide and montmorillonite powder,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,470,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-05-16,2023-04-30
COMPLETED,NO,DRUG: TJ004309,ALL,"ADULT, OLDER_ADULT",PHASE2,25,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-02,2023-02-08
SUSPENDED,NO,OTHER: Referrals Recommendations,FEMALE,OLDER_ADULT,NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-03-12,2026-06-15
RECRUITING,NO,OTHER: Exercise,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-07,2024-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Cemiplimab|DRUG: Capecitabine,ALL,"ADULT, OLDER_ADULT",PHASE1,13,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-12,2025-12-09
NOT_YET_RECRUITING,NO,OTHER: Timing of pegfilgrastim administration,FEMALE,"ADULT, OLDER_ADULT",PHASE2,84,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-01,2025-05-31
NOT_YET_RECRUITING,NO,BEHAVIORAL: mindfulness-based self-compassion will be applied,FEMALE,ADULT,NA,70,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-05-15,2022-11-15
RECRUITING,NO,PROCEDURE: Delayed-immediate reconstruction|PROCEDURE: Delayed reconstruction,FEMALE,"ADULT, OLDER_ADULT",NA,590,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-01,2035-11
ACTIVE_NOT_RECRUITING,NO,DRUG: AZD9833,FEMALE,"ADULT, OLDER_ADULT",PHASE1,10,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-29,2025-12-31
RECRUITING,NO,OTHER: Patient navigator support,FEMALE,"ADULT, OLDER_ADULT",NA,196,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2022-07-18,2024-06
RECRUITING,NO,BEHAVIORAL: Taking Charge during Treatment (TCT) Intervention,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-03-01,2026-07-01
NOT_YET_RECRUITING,NO,OTHER: Adapted motor activity,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-02-01,2026-06-01
COMPLETED,NO,DIAGNOSTIC_TEST: Sorbstar®|DIAGNOSTIC_TEST: Dog Detection,FEMALE,"ADULT, OLDER_ADULT",NA,35,OTHER,"Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2021-01-25,2021-12-20
COMPLETED,NO,"DRUG: Olaparib tablets, 150 mg|DRUG: Lynparza® (olaparib) tablets 150 mg",FEMALE,"ADULT, OLDER_ADULT",PHASE1,70,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2022-04-07,2022-10-20
UNKNOWN,NO,DRUG: Albumin-bound paclitaxel plus capecitabine|DRUG: capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,92,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-15,2023-02-25
NOT_YET_RECRUITING,NO,DRUG: PVX-410,ALL,"ADULT, OLDER_ADULT",PHASE2,53,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04-30,2025-04-01
RECRUITING,NO,DRUG: Reduced dose intensity of IO,ALL,"ADULT, OLDER_ADULT",PHASE3,646,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-08,2025-03-07
RECRUITING,NO,OTHER: Acupuncture,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-11-25,2024-12-25
NOT_YET_RECRUITING,NO,COMBINATION_PRODUCT: Neoadjuvant therapy: TCbHPy|COMBINATION_PRODUCT: Neoadjuvant therapy: TCbHP,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-15,2025-09-30
RECRUITING,NO,RADIATION: SABR,ALL,"ADULT, OLDER_ADULT",NA,345,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-19,2027-12-31
RECRUITING,NO,BEHAVIORAL: Hybrid lifestyle educational multidisciplinary intervention.|BEHAVIORAL: Hybrid lifestyle personalized multidisciplinary intervention.,FEMALE,ADULT,NA,146,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-09,2028-12-31
COMPLETED,NO,DIETARY_SUPPLEMENT: Red Bull Energy Drink|OTHER: Still water,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-11,2023-01-01
RECRUITING,NO,BEHAVIORAL: Telehealth Blood Pressure Monitoring and Food Insecurity,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-02-01,2023-05-31
RECRUITING,NO,"DRUG: Disitamb Vedotin ,pyrotinib",ALL,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-01,2026-12-31
WITHDRAWN,NO,BEHAVIORAL: Sleep Hygiene Training,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-15,2020-07
COMPLETED,NO,DRUG: CDX-527,ALL,"ADULT, OLDER_ADULT",PHASE1,27,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-04,2023-04-06
RECRUITING,NO,OTHER: Xemio mobile application,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-12-01,2023-06-30
RECRUITING,NO,DEVICE: Light Glasses (Experimental)|DEVICE: Light Glasses (Comparison),FEMALE,"ADULT, OLDER_ADULT",NA,240,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-08,2024-07
TERMINATED,NO,DRUG: Enobosarm|DRUG: Exemestane,ALL,"ADULT, OLDER_ADULT",PHASE3,52,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-12,2024-01-09
NOT_YET_RECRUITING,NO,DRUG: (CDK)4/6 inhibitor,FEMALE,"ADULT, OLDER_ADULT",NA,500,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-12-10,2024-01-01
RECRUITING,NO,DRUG: LS301-IT 0.025 mg/kg|DRUG: LS301-IT 0.05 mg/kg|DRUG: LS301-IT 0.075 mg/kg|DRUG: LS301-IT 0.1 mg/kg,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,100,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-14,2024-06
NOT_YET_RECRUITING,NO,DIETARY_SUPPLEMENT: Tart Cherry|DIETARY_SUPPLEMENT: Omega 3 FA (Fish Oil),FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-03,2026-01
RECRUITING,NO,DIETARY_SUPPLEMENT: Silibinin|OTHER: Placebo,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-09-01,2027-09-01
ACTIVE_NOT_RECRUITING,YES,DRUG: Trastuzumab deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE2,102,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-30,2026-07-14
COMPLETED,NO,DRUG: ZN-c5,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-31,2022-06-23
UNKNOWN,NO,DRUG: Navelbine|DRUG: Docetaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE3,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-01,2023-02-28
RECRUITING,NO,DRUG: Sacituzumab Govitecan-hziy|DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: nab-Paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin,ALL,"ADULT, OLDER_ADULT",PHASE3,440,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-25,2027-02
ACTIVE_NOT_RECRUITING,NO,DRUG: DS-8201a|DRUG: T-DM1,ALL,"ADULT, OLDER_ADULT",PHASE3,1600,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-04,2030-12-31
RECRUITING,NO,PROCEDURE: SLNB|PROCEDURE: pALND|PROCEDURE: ALND,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-01,2028-10-31
RECRUITING,NO,DRUG: Palbociclib 125Mg Tab|DRUG: Fulvestrant injection|DRUG: Tamoxifen|DRUG: Letrozole|DRUG: Exemestane|DRUG: Anastrozole,ALL,"ADULT, OLDER_ADULT",PHASE2,1100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-30,2030-09-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Trilaciclib|DRUG: Sacituzumab Govitecan-hziy,ALL,"ADULT, OLDER_ADULT",PHASE2,30,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-22,2024-07
COMPLETED,NO,DEVICE: Clinical investigation device class IIa not marked CE,FEMALE,"ADULT, OLDER_ADULT",NA,353,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-09-16,2021-08-20
NOT_YET_RECRUITING,NO,DRUG: Adebrelimab plus Fluzoparib,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-04-16,2028-12-31
RECRUITING,NO,DRUG: crocin|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-03-29,2023-09-25
WITHDRAWN,NO,"BEHAVIORAL: Change in knowledge, motivation, skills, and resources",ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-07-01,2024-12-31
RECRUITING,NO,RADIATION: External Beam radiotherapy using IMRT technique,ALL,"ADULT, OLDER_ADULT",NA,197,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-01,2026-12-30
RECRUITING,NO,DRUG: HCQ|DRUG: Avelumab|DRUG: Palbociclib,ALL,"ADULT, OLDER_ADULT",PHASE2,96,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-01,2028-05
NOT_YET_RECRUITING,NO,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|RADIATION: Radiation Therapy|PROCEDURE: Resection|DRUG: Trotabresib|DRUG: Vinorelbine,ALL,"ADULT, OLDER_ADULT",PHASE1,34,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-31,2031-12-31
RECRUITING,NO,BEHAVIORAL: Group Exercise Classes,ALL,"ADULT, OLDER_ADULT",NA,1500,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-09-02,2027-12-31
NOT_YET_RECRUITING,NO,OTHER: Fasting,FEMALE,"ADULT, OLDER_ADULT",NA,54,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-15,2025-09-30
COMPLETED,NO,OTHER: Multidisciplinary collaborative care arm,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-03-01,2022-07-20
NOT_YET_RECRUITING,NO,PROCEDURE: Biofeedback device and other group control group|PROCEDURE: Control group,FEMALE,ADULT,NA,54,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-02-27,2024-04-17
RECRUITING,NO,DRUG: Apatinib|DRUG: Dalpiciclib|DRUG: Fulvestrant/AI,FEMALE,"ADULT, OLDER_ADULT",PHASE2,145,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-01,2027-06-01
RECRUITING,NO,DRUG: huCART-meso cells|DEVICE: Mesothelin Expression Testing,ALL,"ADULT, OLDER_ADULT",PHASE1,12,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-06,2038-02
RECRUITING,NO,BEHAVIORAL: Strength After Breast Cancer,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2024-01-02,2025-03
RECRUITING,NO,DRUG: SHR-A1811 for injection ; capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,116,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-25,2025-12-31
NOT_YET_RECRUITING,NO,DEVICE: Convertible Plasma Jet,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2024-03,2025-07
ACTIVE_NOT_RECRUITING,NO,OTHER: online cancer risk assessment|OTHER: Usual care,ALL,"ADULT, OLDER_ADULT",NA,18623,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-07-01,2025-08-31
RECRUITING,NO,DRUG: Parecoxib + paracetamol|DRUG: Normal saline,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-03-28,2023-05-10
COMPLETED,NO,PROCEDURE: the combination of transversus thoracic muscle plane and pectoral nerves blocks|PROCEDURE: the pectoral nerves block only,FEMALE,"ADULT, OLDER_ADULT",NA,116,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-07-12,2023-08-05
COMPLETED,NO,PROCEDURE: Bilevel erector spinae plane block|PROCEDURE: Single level erector spinae plane block|DRUG: Intravenous morphine,FEMALE,"ADULT, OLDER_ADULT",NA,126,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-06-27,2024-01-10
NOT_YET_RECRUITING,NO,OTHER: Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening,ALL,"ADULT, OLDER_ADULT",NA,2500,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2024-01-01,2025-01-01
COMPLETED,NO,OTHER: Hand and foot exercise,FEMALE,"ADULT, OLDER_ADULT",NA,79,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2023-06-01,2024-02-16
COMPLETED,NO,DRUG: BYON5667 & SYD985|DRUG: Placebo & SYD985,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,48,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-01-10,2023-06-26
NOT_YET_RECRUITING,NO,BEHAVIORAL: ONLOOP program,ALL,"ADULT, OLDER_ADULT",NA,900,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SCREENING,2024-01,2027-06
NOT_YET_RECRUITING,NO,DEVICE: FreeStyle Libre Pro,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-12,2024-03
RECRUITING,NO,DRUG: [18F]FMISO PET/MRI imaging,FEMALE,"ADULT, OLDER_ADULT",PHASE1,25,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-12,2027-08
RECRUITING,NO,DRUG: OP-1250|DRUG: Fulvestrant|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane,ALL,"ADULT, OLDER_ADULT",PHASE3,510,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-16,2027-09-30
RECRUITING,NO,RADIATION: Stereotactic body radiotherapy,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-06,2025-09-06
UNKNOWN,NO,OTHER: exercise intervention|OTHER: routine radiotherapy protokol,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-10,2021-04-10
ACTIVE_NOT_RECRUITING,NO,DRUG: AC682,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-12,2024-02-29
NOT_YET_RECRUITING,NO,PROCEDURE: DIEP-flap|PROCEDURE: Implant,FEMALE,"ADULT, OLDER_ADULT",NA,250,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-01,2032-12-31
RECRUITING,NO,DRUG: Talazoparib Tosylate,ALL,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-23,2024-03
NOT_YET_RECRUITING,NO,DRUG: SYHX2011|DRUG: Paclitaxel for injection (albumin-bound),ALL,"ADULT, OLDER_ADULT",PHASE3,454,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-01,2024-09-01
RECRUITING,NO,DRUG: Capecitabine|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Sacituzumab govitecan,ALL,"ADULT, OLDER_ADULT",PHASE3,1332,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-28,2029-03-30
RECRUITING,NO,RADIATION: Stereotactic Radiosurgery (SRS)|DRUG: Abemaciclib|DRUG: Endocrine therapy,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,31,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-30,2024-12-31
RECRUITING,NO,DRUG: ESG401,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,177,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-14,2025-04
RECRUITING,NO,DRUG: Lumason,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-09-01,2031-09-01
RECRUITING,NO,DRUG: AMXI-5001:Dose Escalation Phase I|DRUG: AMXI-5001:Dose Expansion Phase II,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,122,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-12,2025-01
RECRUITING,NO,DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE2,135,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-20,2028-06-24
NOT_YET_RECRUITING,NO,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Pembrolizumab|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Olaparib|DRUG: Capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-02,2030-06
RECRUITING,NO,BIOLOGICAL: BT-001|DRUG: Pembrolizumab [Keytruda],ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,48,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-25,2025-04-30
RECRUITING,NO,DRUG: Cyclophosphamide|DRUG: Methotrexate|DRUG: Capecitabine,ALL,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-22,2034-09
RECRUITING,NO,RADIATION: Accelerated Proton Beam Radiation Therapy (PBT)|RADIATION: Accelerated Photon Radiation Therapy (XRT),FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-15,2025-09-17
NOT_YET_RECRUITING,NO,"DRUG: Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy",FEMALE,"ADULT, OLDER_ADULT",PHASE2,52,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10-20,2024-10-20
ACTIVE_NOT_RECRUITING,NO,OTHER: Biomarker Guided Intervention,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,101,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-03-18,2025-05
RECRUITING,NO,DRUG: Carboplatin|DRUG: Tocilizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,168,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01,2027-12
RECRUITING,NO,DRUG: Telmisartan tablets,FEMALE,"ADULT, OLDER_ADULT",PHASE2,35,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-04-09,2023-06
RECRUITING,NO,COMBINATION_PRODUCT: 89Zr-ss-pertuzumab PET/CT,ALL,"ADULT, OLDER_ADULT",PHASE1,60,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-11-30,2024-11-30
RECRUITING,NO,BEHAVIORAL: Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|BEHAVIORAL: Positive Psychology - online|BEHAVIORAL: Autogenic Training - online,FEMALE,"ADULT, OLDER_ADULT",NA,440,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-06-06,2025-06
RECRUITING,NO,RADIATION: Ultra-fractionated WBI|RADIATION: Ultra-fractionated PBI,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-01,2033-05-31
RECRUITING,NO,DEVICE: contrast enhanced mammography|DRUG: Iodinated Contrast Media (ICM),FEMALE,"ADULT, OLDER_ADULT",PHASE4,1855,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-02-01,2026-11
COMPLETED,NO,RADIATION: 16α-18F-fluor-17β-estradiol,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,8,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-10-23,2023-06-28
ENROLLING_BY_INVITATION,NO,OTHER: Clinician Nudge Email|OTHER: Patient Nudge Letter and Share questionaire,ALL,"ADULT, OLDER_ADULT",NA,800,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: OTHER,2022-11-28,2025-12-31
NOT_YET_RECRUITING,NO,DRUG: Tranexamic acid|DRUG: Normal Saline,FEMALE,"ADULT, OLDER_ADULT",PHASE3,106,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2022-08,2024-08
ACTIVE_NOT_RECRUITING,NO,"DRUG: Palbociclib (75, 100, 125 milligram [mg])|DRUG: H3B-6545 (150, 300, 450 mg)",FEMALE,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-01,2024-03-31
COMPLETED,NO,OTHER: Cognitive stimulation sessions coupled with Adapted Physical Activity sessions.,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-01-24,2022-02-11
RECRUITING,NO,OTHER: Multidisciplinary vocational rehabilitation intervention,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-05-09,2024-05
RECRUITING,NO,DRUG: SHR6390,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-12-18,2023-09-28
ACTIVE_NOT_RECRUITING,NO,"DRUG: A1: Pyrotinib with nab-paclitaxel|DRUG: A2: nab-paclitaxel|DRUG: B1: everolimus with nab-paclitaxel|DRUG: B2: nab-paclitaxel|DRUG: C1: PD-1 with nab-paclitaxel and famitinib|DRUG: C2: nab-paclitaxel|DRUG: D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|DRUG: D2: nab-paclitaxel, with maintenance of capecitabine|DRUG: E1: everolimus with nab-paclitaxel|DRUG: E2: nab-paclitaxel",FEMALE,"ADULT, OLDER_ADULT",PHASE2,139,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-28,2024-12-31
ACTIVE_NOT_RECRUITING,NO,OTHER: Mother tongue and Norwegian,FEMALE,"ADULT, OLDER_ADULT",NA,11355,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-04-15,2030-12-31
RECRUITING,NO,DRUG: Vericiguat|OTHER: Optimal medical therapy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-17,2028-07-17
COMPLETED,NO,DIAGNOSTIC_TEST: whole body study and SPECT with 99mTc-RM26,ALL,"ADULT, OLDER_ADULT",PHASE1,10,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2021-02-01,2023-06-01
NOT_YET_RECRUITING,NO,DRUG: SHR-A1921 + Bevacizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02-01,2026-06-30
NOT_YET_RECRUITING,NO,DRUG: CBD Oral|OTHER: Control,ALL,"ADULT, OLDER_ADULT",PHASE1,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2024-01-31,2026-09-30
RECRUITING,NO,OTHER: Kombucha,ALL,ADULT,NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-12-12,2025-12-12
COMPLETED,NO,RADIATION: Curative radiotherapy|BEHAVIORAL: 5:2 intermittent fasting,FEMALE,"ADULT, OLDER_ADULT",NA,13,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-06-01,2022-11-17
RECRUITING,NO,DRUG: VLS-1488,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,120,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-18,2026-06
WITHDRAWN,NO,DRUG: ARX788,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-05,2022-04-20
RECRUITING,NO,DRUG: dalpiciclib; fluvestrant; compound gossypol acetate tablets,FEMALE,"ADULT, OLDER_ADULT",PHASE2,53,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-08-01,2025-08-31
NOT_YET_RECRUITING,NO,DRUG: Indocyanine green,FEMALE,"ADULT, OLDER_ADULT",NA,250,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-01,2026-01-01
NOT_YET_RECRUITING,NO,DEVICE: QPOP|DEVICE: CURATE.AI|DRUG: Azacitidine + docetaxel|DRUG: Azacitidine + paclitaxel|DRUG: Azacitidine + irinotecan,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,10,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-06,2027-04-04
RECRUITING,NO,DRUG: Ceralasertib|DRUG: Durvalumab|DRUG: Nab-paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE2,37,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-15,2025-11
RECRUITING,NO,DRUG: 18F-labeled DPA-714 PET scan,FEMALE,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2025-06-01,2026-07-01
NOT_YET_RECRUITING,NO,DEVICE: VTM examination and breast biopsy,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-10-01,2024-05-01
NOT_YET_RECRUITING,NO,"COMBINATION_PRODUCT: quercetin, EGCG, metformin , zinc",FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,200,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-01-01,2024-01-31
UNKNOWN,NO,DRUG: HS-10342,ALL,"ADULT, OLDER_ADULT",PHASE2,20,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-30,2023-12-31
RECRUITING,NO,DRUG: HMBD-002|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,240,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-01,2025-01
RECRUITING,NO,PROCEDURE: DIEP Flap Neurotization,FEMALE,"ADULT, OLDER_ADULT",NA,156,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-01,2025-12-31
RECRUITING,NO,DRUG: Alpelisib|DRUG: Tucatinib|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-25,2025-06-30
RECRUITING,NO,DRUG: XL309 (ISM3091),ALL,"ADULT, OLDER_ADULT",PHASE1,66,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-17,2025-12-09
RECRUITING,NO,DRUG: Ribociclib (neoadjuvant)|DRUG: Chemotherapy (adjuvant)|DRUG: Ribociclib (adjuvant),ALL,"ADULT, OLDER_ADULT",PHASE2,1100,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-03,2030-07-01
RECRUITING,NO,RADIATION: Stereotactic Ablative Radiation Therapy|PROCEDURE: Locoregional treatment|OTHER: Standard of Care,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-20,2028-09-20
COMPLETED,NO,"OTHER: Wearable Sensor|OTHER: Blue-blocking glasses|OTHER: Clear glasses|OTHER: Full SYNC app|OTHER: ""Dummy"" SYNC app",ALL,"ADULT, OLDER_ADULT",NA,139,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2021-07-15,2023-03-09
RECRUITING,NO,PROCEDURE: ALND Group,FEMALE,"ADULT, OLDER_ADULT",NA,500,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-03-01,2027-08-31
NOT_YET_RECRUITING,NO,DRUG: SHR-A1811 & Dalpiciclib Isethionate Tablets|DRUG: SHR-A1811 & Fulvestrant|DRUG: SHR-A1811 & Bevacizumab injection,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,300,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-04,2025-02-27
RECRUITING,NO,DEVICE: Clip-on electrode with fiber optics,FEMALE,"ADULT, OLDER_ADULT",NA,24,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09-26,2024-04-30
WITHDRAWN,NO,DRUG: Sabizabulin|DRUG: Sacituzumab Govitecan-hziy|DRUG: Sabizabulin/Sacituzumab govitecan-hziy Combo,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-12-30,2023-06-30
RECRUITING,NO,DRUG: PF-07248144|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Palbociclib|DRUG: PF-07220060,ALL,"ADULT, OLDER_ADULT",PHASE1,186,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-16,2026-11-08
COMPLETED,NO,DRUG: pyrotinib tablet|DRUG: Montmorillonite Power|DRUG: Loperamide,ALL,ADULT,PHASE1,36,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-08,2022-08-02
NOT_YET_RECRUITING,NO,PROCEDURE: Fluorescence guided detection of tumor positive margins.,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,70,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-12-01,2024-07-01
RECRUITING,NO,PROCEDURE: Lymphoscintigraphy,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-06-02,2027-12-01
RECRUITING,NO,"BEHAVIORAL: Breast, Colorectal, and Cervical Cancer Screening Interventions",ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SCREENING,2021-06-01,2024-12-31
RECRUITING,NO,DRUG: Tucatinib|DRUG: Trastuzumab|DRUG: Vinorelbine,ALL,"ADULT, OLDER_ADULT",PHASE2,49,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-08,2026-08
ACTIVE_NOT_RECRUITING,NO,DRUG: Trastuzumab deruxtecan|DRUG: Durvalumab|DRUG: Paclitaxel|DRUG: Capivasertib|DRUG: Anastrozole|DRUG: Fulvestrant|DRUG: Capecitabine,ALL,"ADULT, OLDER_ADULT",PHASE1,139,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-17,2025-11-28
RECRUITING,NO,DRUG: Agent Affecting Integumentary System|OTHER: Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",PHASE1,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-06-21,2024-06-21
WITHDRAWN,NO,DRUG: Letrozole|DRUG: Atezolizumab,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-02,2025-01-31
RECRUITING,NO,PROCEDURE: Biospecimen Collection|DRUG: Letrozole,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-07-21,2025-06-15
COMPLETED,NO,DRUG: ADAPT6-SPECT,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-05-01,2022-12-31
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Computed Tomography|DRUG: Fluciclovine F18|DRUG: Gallium Ga 68 Gozetotide|PROCEDURE: Positron Emission Tomography,ALL,"ADULT, OLDER_ADULT",PHASE1,22,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-07-16,2024-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Seribantumab,ALL,"ADULT, OLDER_ADULT",PHASE2,75,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-29,2025-03
COMPLETED,NO,DRUG: (CARBAMIDE®)|DRUG: (VOLTAREN®) Emulgel 1%,FEMALE,"ADULT, OLDER_ADULT",PHASE2,86,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2022-12-08,2023-12-08
RECRUITING,NO,DRUG: Dalpiciclib|DRUG: Aromatase inhibitor|DRUG: Docetaxel injection|DRUG: Epirubicin Hydrochloride Injection|DRUG: Cyclophosphamide injection,FEMALE,"ADULT, OLDER_ADULT",PHASE2,144,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-09-30,2025-12-01
RECRUITING,NO,BEHAVIORAL: TRE|BEHAVIORAL: MedTRE,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-01,2026-03-01
RECRUITING,NO,DEVICE: ClearEdge device,FEMALE,"ADULT, OLDER_ADULT",NA,288,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-10,2024-12-31
UNKNOWN,NO,OTHER: accompanied and adapted water polo program,FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-03-15,2021-12-31
RECRUITING,NO,DRUG: Chidamide|DRUG: Abemaciclib|DRUG: endocrinotherapy（doctor's choice）,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,44,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-01,2025-05-01
NOT_YET_RECRUITING,NO,OTHER: MEDISKIN cream|OTHER: Panthenol cream,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-12,2023-06
RECRUITING,NO,DRUG: Fluzoparib|DRUG: Dalpiciclib|DRUG: Fulvestrant/AI,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-01,2027-06-01
RECRUITING,NO,DRUG: 1-(2-[18F]FLUOROETHYL)-L-Tryptophan,ALL,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-09-29,2024-12-31
COMPLETED,NO,"PROCEDURE: PECS block, SAP block",FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2022-04-01,2022-07-30
RECRUITING,NO,DRUG: Palbociclib|DRUG: Ribociclib|DRUG: Abemaciclib|DRUG: Letrozole,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-09-16,2026-09-30
NOT_YET_RECRUITING,NO,DRUG: Trilaciclib plus chemotherapy|DRUG: Chemotherapy,ALL,"ADULT, OLDER_ADULT",PHASE2,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-30,2027-06-30
RECRUITING,NO,DEVICE: NovaGray RILA Breast® test,MALE,"ADULT, OLDER_ADULT",NA,250,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-12-11,2027-06
RECRUITING,NO,DEVICE: NACgraft,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-28,2024-04-15
NOT_YET_RECRUITING,NO,DRUG: DP303c,ALL,"ADULT, OLDER_ADULT",PHASE2,191,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-01,2023-12-31
RECRUITING,NO,DRUG: Memantine|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|RADIATION: Stereotactic Radiosurgery|RADIATION: Whole-Brain Radiotherapy,ALL,"ADULT, OLDER_ADULT",PHASE3,350,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-12-15,2030-01-31
RECRUITING,NO,BEHAVIORAL: Comprehensive Oncology Rehabilitation and Exercise (CORE) Program,ALL,"ADULT, OLDER_ADULT",NA,72,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-03-24,2024-01-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Sitravatinib|DRUG: Tislelizumab|DRUG: Nab-paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE2,98,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-01,2024-06-30
ACTIVE_NOT_RECRUITING,NO,DIETARY_SUPPLEMENT: High Dose Vitamin D|DIETARY_SUPPLEMENT: Standard of Care Vitamin D,FEMALE,ADULT,NA,7,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-16,2024-12
RECRUITING,NO,DRUG: SHR-A1811|DRUG: Pyrotinib|DRUG: Bevacizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-31,2026-04-30
TERMINATED,NO,BEHAVIORAL: High-Intensity Interval Training|BEHAVIORAL: Moderate-Intensity Exercise,FEMALE,"ADULT, OLDER_ADULT",NA,7,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-03-28,2022-07-15
COMPLETED,NO,BEHAVIORAL: Laughter therapy,FEMALE,"ADULT, OLDER_ADULT",NA,42,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2022-02-17,2022-06-12
RECRUITING,NO,DRUG: Prevention therapy|DRUG: Rescue therapy,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-05-05,2025-12-31
NOT_YET_RECRUITING,NO,DRUG: SHR-A1811 Injection|DRUG: SHR-A1811 Injection ； Pertuzumab Injection|DRUG: Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection,FEMALE,"ADULT, OLDER_ADULT",PHASE3,864,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10,2032-10
UNKNOWN,NO,DRUG: Trastuzumab|DRUG: QL1209|DRUG: Pertuzumab|DRUG: Docetaxel|PROCEDURE: surgery,ALL,"ADULT, OLDER_ADULT",PHASE3,544,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11,2022-12
NOT_YET_RECRUITING,NO,DRUG: Inetetamab|DRUG: Toripalimab|DRUG: Albumin-Bound Paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE4,70,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-12,2025-12-31
RECRUITING,NO,OTHER: Ice Plant Intensive Cream plus Standard Care|OTHER: Standard Care,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2023-03-10,2024-02-28
NOT_YET_RECRUITING,NO,OTHER: GERONTE,ALL,OLDER_ADULT,NA,720,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-04,2026-01
COMPLETED,NO,COMBINATION_PRODUCT: LAE005 + Afuresertib + Nab-Paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE1,21,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-12,2023-12-11
RECRUITING,NO,PROCEDURE: Craniosacral therapy|PROCEDURE: Craniosacral self-help group training|PROCEDURE: Treatment as usal / wait list,FEMALE,"ADULT, OLDER_ADULT",NA,102,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-09-18,2025-12
COMPLETED,NO,BEHAVIORAL: Cognitive Behavioural Therapy (CBT)|BEHAVIORAL: Education and Mindfulness,FEMALE,"ADULT, OLDER_ADULT",NA,48,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-05-31,2023-03-02
WITHDRAWN,NO,PROCEDURE: Angiography|PROCEDURE: MRI-Based Angiogram|OTHER: Quality-of-Life Assessment,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2023-01-01,2024-12-31
RECRUITING,NO,BIOLOGICAL: Neoantigen Peptide Vaccine|BIOLOGICAL: Nivolumab|DRUG: Poly ICLC,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-09,2025-11-01
RECRUITING,NO,DRUG: Melphalan|DRUG: BCNU|DRUG: Vitamin B12B|DRUG: Vitamin C|DRUG: Ethanol|DEVICE: Autologous Hematopoietic Stem Cells,ALL,"ADULT, OLDER_ADULT",PHASE1,10,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-13,2025-12
RECRUITING,NO,DRUG: Everolimus|DRUG: Investigator's Choice of Chemotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE3,203,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-13,2026-08
NOT_YET_RECRUITING,NO,"OTHER: In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women|OTHER: Online In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women",FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-11,2025-12
RECRUITING,NO,BEHAVIORAL: simulation-based breast health education,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2023-10-01,2024-09-01
NOT_YET_RECRUITING,NO,PROCEDURE: Lipidomic analysis for breast cancer patients,FEMALE,"ADULT, OLDER_ADULT",NA,65,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-09-30,2024-08-10
TERMINATED,NO,DRUG: pudexacianinium chloride,ALL,"ADULT, OLDER_ADULT",PHASE2,1,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-08-10,2022-09-20
RECRUITING,NO,DEVICE: Apollo Armband,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-02-01,2026-03
RECRUITING,NO,BEHAVIORAL: Exercise,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: OTHER,2022-12-22,2026-06-01
TERMINATED,YES,BIOLOGICAL: Brachyury-TRICOM|DRUG: Entinostat|BIOLOGICAL: M7824|BIOLOGICAL: Ado-trastuzumab emtansine,ALL,"ADULT, OLDER_ADULT",PHASE1,1,NIH,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-04,2021-10-22
TERMINATED,YES,DRUG: Infigratinib|DRUG: Tamoxifen|DRUG: Omnipaque 350|DRUG: Iopamidol|DIAGNOSTIC_TEST: Computed tomography (CT),ALL,"ADULT, OLDER_ADULT",PHASE1,4,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-13,2021-10-22
ACTIVE_NOT_RECRUITING,NO,DRUG: Trastuzumab deruxtecan|DRUG: Durvalumab|DRUG: Paclitaxel|DRUG: Pertuzumab|DRUG: Tucatinib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,245,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-28,2025-07-02
RECRUITING,NO,BIOLOGICAL: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|DRUG: Paclitaxel|BIOLOGICAL: Trastuzumab|BIOLOGICAL: Pertuzumab,ALL,"ADULT, OLDER_ADULT",PHASE2,16,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04-20,2027-06-30
RECRUITING,NO,RADIATION: Whole breast / chest wall & regional lymph node irradiation|RADIATION: Internal mammary or supraclavicular lymph node boost,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-16,2030-03-16
RECRUITING,NO,DRUG: BMS-986449|DRUG: Nivolumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,100,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-06,2027-07-01
UNKNOWN,NO,DRUG: FCN-437c+Fulvestrant|DRUG: FCN-437c+Letrozole+Goserelin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-30,2023-06-30
RECRUITING,NO,DRUG: 99mTc-ABH2,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-03-20,2024-01-30
WITHDRAWN,NO,DRUG: Margetuximab|DRUG: Tucatinib|DRUG: Capecitabine,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-15,2024-10
NOT_YET_RECRUITING,NO,DRUG: Cannabidiol|DRUG: Delta-8-Tetrahydrocannabinol|DRUG: Placebo Administration|OTHER: Questionnaire Administration,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,120,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-03-06,2024-10-31
RECRUITING,NO,DRUG: Pyrotinib+Trastuzumab+Capecitabine|DRUG: Trastuzumab+Pertuzumab/Trastuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,206,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-07-02,2027-12-31
WITHDRAWN,NO,DIAGNOSTIC_TEST: single arm,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-07-07,2024-03
NOT_YET_RECRUITING,NO,DEVICE: Juzo Compression Sleeve and Glove|DEVICE: Compression Sleeve Sensor,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-05,2025-06-30
NOT_YET_RECRUITING,NO,BIOLOGICAL: Alpha-type-1 Polarized Dendritic Cells|PROCEDURE: Biopsy|PROCEDURE: Computed Tomography|PROCEDURE: Leukapheresis|BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment,ALL,"ADULT, OLDER_ADULT",PHASE2,19,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-03-07,2026-03-07
RECRUITING,NO,DRUG: XC|DRUG: TPC,FEMALE,"ADULT, OLDER_ADULT",NA,86,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-01,2027-02
RECRUITING,NO,BIOLOGICAL: ST-067|BIOLOGICAL: Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]|BIOLOGICAL: pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,316,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-06,2025-01-30
RECRUITING,NO,"BEHAVIORAL: Exercise-based multi-phasic, multi-modal intervention",FEMALE,"ADULT, OLDER_ADULT",NA,34,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-16,2024-06
RECRUITING,NO,DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Trastuzumab emtansine,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,130,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-07-01,2025-12-01
RECRUITING,NO,DRUG: Fluzoparib|DRUG: Fluzoparib+Camrelizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-23,2026-12-31
RECRUITING,NO,DRUG: Darcilide +AI (letrozole/anastrozole/Exemestane) + pyrrotinib,FEMALE,OLDER_ADULT,NA,34,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02-01,2026-12-01
RECRUITING,NO,OTHER: liquid biopsy,FEMALE,"ADULT, OLDER_ADULT",NA,1100,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-05-31,2029-05
UNKNOWN,NO,DEVICE: neuromuscular bandage,FEMALE,"ADULT, OLDER_ADULT",NA,270,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-11-08,2023-03-30
RECRUITING,NO,DRUG: QBS72S,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-16,2026-08
WITHDRAWN,NO,DRUG: GNC-035,ALL,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-15,2023-06
COMPLETED,NO,OTHER: control group|BEHAVIORAL: tai chi group,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2020-05-04,2021-04-06
NOT_YET_RECRUITING,NO,DRUG: Sacubitril-valsartan,FEMALE,"ADULT, OLDER_ADULT",PHASE4,600,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-02,2028-02
COMPLETED,NO,DRUG: QBS10072S,ALL,"ADULT, OLDER_ADULT",PHASE1,15,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-20,2022-12-22
NOT_YET_RECRUITING,NO,OTHER: Tele-monitoring through mobile application,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-06,2024-05
ACTIVE_NOT_RECRUITING,NO,DRUG: Pembrolizumab|DRUG: IRX 2,ALL,"ADULT, OLDER_ADULT",PHASE2,12,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-30,2025-06
RECRUITING,NO,OTHER: Physical Activity Intervention,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-05-11,2024-11-30
NOT_YET_RECRUITING,NO,DRUG: Monosialotetrahexose ganglioside sodium injection,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,150,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-04-20,2025-12-31
RECRUITING,NO,DRUG: Tucatinib|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Hormone therapy|DRUG: Pertuzumab/ Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-17,2026-03-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Cisplatin|DRUG: Elimusertib|DRUG: Gemcitabine Hydrochloride,ALL,"ADULT, OLDER_ADULT",PHASE1,74,NIH,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-25,2024-12-31
RECRUITING,NO,DEVICE: Large-area low-level laser therapy(Venusure)|DEVICE: Conventional low-level laser therapy,FEMALE,"ADULT, OLDER_ADULT",NA,54,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-24,2024-10-31
UNKNOWN,NO,DRUG: SHR6390|DRUG: Anastrozole|DRUG: Pyrotinib|DRUG: Trastuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,37,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-15,2022-12-31
RECRUITING,NO,BEHAVIORAL: Physical Activity|OTHER: Usual Care,FEMALE,OLDER_ADULT,NA,56,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-11-22,2024-11
RECRUITING,NO,DRUG: BT8009|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,329,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-17,2025-12
RECRUITING,NO,DRUG: Abemaciclib|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane|DRUG: LHRH Agonist,FEMALE,"ADULT, OLDER_ADULT",PHASE2,90,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02,2027-01-01
UNKNOWN,NO,OTHER: Ture self-acupressure|OTHER: Sham self-acupressure|OTHER: Usual care,FEMALE,"ADULT, OLDER_ADULT",NA,51,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-06-05,2022-03-29
ACTIVE_NOT_RECRUITING,NO,DRUG: Hemp-based CBD|OTHER: Placebo oral tablet,ALL,"ADULT, OLDER_ADULT",PHASE2,56,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-05-27,2023-04-01
RECRUITING,NO,BEHAVIORAL: Arm 1: Computerized Cognitive Training-Global Stimulation Games|BEHAVIORAL: Arm 2: Computerized Cognitive Training-Neuroplasticity Games,ALL,"ADULT, OLDER_ADULT",NA,386,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2024-02-02,2027-11-30
COMPLETED,NO,OTHER: Cardiac coherence,FEMALE,"ADULT, OLDER_ADULT",NA,53,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-02-14,2022-01-14
RECRUITING,NO,"DRUG: FCN-437c,Fulvestrant,Goserelin acetate|DRUG: Placebo,Fulvestrant,Goserelin acetate",FEMALE,"ADULT, OLDER_ADULT",PHASE3,312,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-18,2024-05-18
RECRUITING,NO,OTHER: Adapted Family Gene Toolkit|OTHER: Targeted intervention,ALL,"ADULT, OLDER_ADULT",NA,228,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING",2022-04-15,2024-12-31
RECRUITING,NO,DRUG: MBQ-167,ALL,"ADULT, OLDER_ADULT",PHASE1,48,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-09,2024-10-31
UNKNOWN,NO,DEVICE: Silver and copper IUD (TCu380Ag)|DEVICE: Copper IUD (TCu380A),FEMALE,ADULT,NA,90,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-06,2022-12-31
UNKNOWN,NO,RADIATION: Hypofractionation Schedules for Breast Cancer patients after mastecomy,FEMALE,"ADULT, OLDER_ADULT",NA,166,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: OTHER",2020-01-01,2022-02-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Paclitaxel|BIOLOGICAL: Pelareorep|DRUG: Avelumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,48,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-10,2024-07
RECRUITING,NO,DRUG: Letrozole|DRUG: Simvastatin,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-09-02,2025-04-15
COMPLETED,NO,DRUG: Digoxin,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,58,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-08,2023-12-01
RECRUITING,NO,"PROCEDURE: Acupuncture|DRUG: treatment of physician choice, according to the standard of care",FEMALE,"ADULT, OLDER_ADULT",NA,102,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-01,2023-12
RECRUITING,NO,DRUG: Inavolisib|DRUG: Fulvestrant|DRUG: Alpelisib,ALL,"ADULT, OLDER_ADULT",PHASE3,400,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-07,2029-03-30
UNKNOWN,NO,PROCEDURE: LYMPHA(LYmphatic Microsurgical Preventive Healing Approach) technique,ALL,"ADULT, OLDER_ADULT",NA,34,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-03-05,2022-02-28
WITHDRAWN,NO,BIOLOGICAL: radiolabeled DPTA-omburtamab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,0,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-31,2024-12-31
COMPLETED,NO,OTHER: Complete Decongestive Therapy|OTHER: Upper extremity exercises combined with diaphragmatic breathing exercises,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-03-20,2023-12-01
RECRUITING,NO,OTHER: Publicly available genetic testing resources|BEHAVIORAL: Virtual genetics navigator|BEHAVIORAL: Motivational interviewing (MI),ALL,"ADULT, OLDER_ADULT",NA,759,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-04-21,2026-05
RECRUITING,NO,DEVICE: Acupuncture,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04-01,2023-10-31
NOT_YET_RECRUITING,NO,PROCEDURE: Complete decongestive treatment program|PROCEDURE: Balance exercises,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-01-01,2025-07-01
WITHDRAWN,NO,BIOLOGICAL: CodaLytic,ALL,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-15,2025-01-30
COMPLETED,NO,OTHER: regional anesthesia,FEMALE,"ADULT, OLDER_ADULT",PHASE3,13,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-01,2022-10-31
RECRUITING,NO,DRUG: Standard of Care Neoadjuvant Chemotherapy|DIETARY_SUPPLEMENT: Vitamin D3|OTHER: Drug Diary,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-22,2024-10
RECRUITING,NO,DRUG: Fluzoparib|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane|DRUG: Tamoxifen|DRUG: Toremifene|DRUG: Abemaciclib|DRUG: LHRH agonist,FEMALE,"ADULT, OLDER_ADULT",PHASE3,766,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-01,2031-05-31
TERMINATED,NO,DRUG: Microbiota-based Formulation RBX7455,FEMALE,"ADULT, OLDER_ADULT",PHASE1,3,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-31,2023-01-11
COMPLETED,NO,BEHAVIORAL: Medication adherence eHealth intervention,FEMALE,"ADULT, OLDER_ADULT",NA,3,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-10-04,2022-11-30
RECRUITING,NO,BEHAVIORAL: Education|BEHAVIORAL: Navigation to clinic,FEMALE,"ADULT, OLDER_ADULT",NA,8000,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-02-20,2024-07-30
RECRUITING,NO,DRUG: PeptiCRAd-1|DRUG: Cyclophosphamide|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,15,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-02,2025-09
ACTIVE_NOT_RECRUITING,NO,OTHER: interactive 3D tool|OTHER: BREAST-Q Reconstruction Module|OTHER: DQI|OTHER: Ottawa Decision Regret Scale,FEMALE,"ADULT, OLDER_ADULT",NA,88,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-08-23,2024-08
NOT_YET_RECRUITING,NO,DRUG: Acolbifene Hydrochloride|PROCEDURE: Biospecimen Collection|PROCEDURE: Mammography|PROCEDURE: Random Periareolar Fine-Needle Aspiration|DRUG: Tamoxifen,FEMALE,"ADULT, OLDER_ADULT",PHASE2,80,NIH,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2024-03-01,2028-09-01
WITHDRAWN,NO,COMBINATION_PRODUCT: surgery combined with systemic therapy|OTHER: systemic therapy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-15,2022-05-01
RECRUITING,NO,DRUG: Palbociclib|DRUG: Fulvestrant|DRUG: Adjuvant Therapy,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,100,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-09,2026-12-15
RECRUITING,NO,OTHER: Overcome,FEMALE,"ADULT, OLDER_ADULT",NA,58,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-02-07,2025-06
COMPLETED,NO,DRUG: Zilovertamab vedotin,ALL,"ADULT, OLDER_ADULT",PHASE2,102,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-07,2023-06-12
RECRUITING,NO,DRUG: Atorvastatin 80 Mg Oral Tablet|DRUG: Placebo oral tablet,FEMALE,"ADULT, OLDER_ADULT",PHASE3,3360,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-04,2035-01-01
RECRUITING,NO,PROCEDURE: Arm 1 Partial mastectomy with Savi Scout® localization and shave margins.|PROCEDURE: Arm 2 Partial mastectomy with Savi Scout® localization and selective shave margins.,FEMALE,"ADULT, OLDER_ADULT",NA,204,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-17,2026-11
RECRUITING,NO,DRUG: Estradiol,FEMALE,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05-04,2027-05
COMPLETED,NO,DRUG: Day 7 regimen|DRUG: Day 3 regimen,FEMALE,"ADULT, OLDER_ADULT",PHASE2,160,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-07-13,2022-11-06
RECRUITING,NO,PROCEDURE: Axillary Dissection,ALL,"ADULT, OLDER_ADULT",NA,45,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-01,2025-03
ACTIVE_NOT_RECRUITING,NO,DRUG: Rosuvastatin|DRUG: Rosuvastatin (Inhibitor arm)|DRUG: Eltrombopag,ALL,ADULT,PHASE1,20,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-02-01,2024-12
NOT_YET_RECRUITING,NO,BEHAVIORAL: Behavioral: Core Exercise Promotion Intervention,ALL,"ADULT, OLDER_ADULT",NA,85,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-02-15,2026-04-01
NOT_YET_RECRUITING,NO,BEHAVIORAL: Nutritional intervention|BEHAVIORAL: Physical exercise intervention,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE,2023-01,2023-09
NOT_YET_RECRUITING,NO,DRUG: AK105|DRUG: Anlotinib hydrochloride|DRUG: Albumin Paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE2,42,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07,2024-03
RECRUITING,NO,DRUG: AZD8205,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,248,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-18,2025-06-30
COMPLETED,NO,DEVICE: Steri-strip,ALL,"ADULT, OLDER_ADULT",NA,94,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2020-11-01,2023-07-15
RECRUITING,NO,COMBINATION_PRODUCT: Chidamide,FEMALE,"ADULT, OLDER_ADULT",PHASE2,59,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-23,2024-05-23
NOT_YET_RECRUITING,NO,DRUG: chidamide，fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05-01,2024-09-01
RECRUITING,NO,OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|RADIATION: Radiation Boost|PROCEDURE: Therapeutic Surgical Procedure|RADIATION: Whole Breast Irradiation|OTHER: Breast MRI,ALL,"ADULT, OLDER_ADULT",NA,55,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-05-18,2024-01-31
RECRUITING,NO,DRUG: Tamoxifen|DIAGNOSTIC_TEST: FES PET/CT,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-20,2025-12
COMPLETED,NO,BEHAVIORAL: Breast cancer decision aid,FEMALE,OLDER_ADULT,NA,22,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-05-12,2023-09-14
COMPLETED,YES,BEHAVIORAL: Core Exercise Promotion Intervention,ALL,"ADULT, OLDER_ADULT",NA,37,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-08-10,2022-06-13
RECRUITING,NO,DRUG: Adagrasib|DRUG: Eltrombopag + adagrasib,ALL,ADULT,PHASE1,16,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2023-06-29,2024-08-17
RECRUITING,NO,DRUG: Cyclophosphamide|DRUG: Trastuzumab|DRUG: Pertuzumab|BIOLOGICAL: NK cells|DRUG: Interleukin-2,FEMALE,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-11,2025-04-11
NOT_YET_RECRUITING,NO,COMBINATION_PRODUCT: Meritup oral solution,FEMALE,"ADULT, OLDER_ADULT",PHASE2,32,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-12-01,2025-11-30
NOT_YET_RECRUITING,NO,DRUG: Aprepitant|DRUG: Palonosetron|DRUG: Fosaprepitant,FEMALE,"ADULT, OLDER_ADULT",PHASE4,1028,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-07,2029-07
WITHDRAWN,NO,DRUG: PICS (Reconstitution Method 1 or 2),ALL,"ADULT, OLDER_ADULT",PHASE1,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2020-04-27,2021-01-28
RECRUITING,NO,DRUG: Accelerated partial breast irradiation,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-12,2033-01-31
COMPLETED,NO,DRUG: Pyrotinib Maleate|DRUG: Vinorelbine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-01,2022-02-06
NOT_YET_RECRUITING,NO,DRUG: ILB-2109|DRUG: Toripalimab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,200,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-25,2026-07-24
RECRUITING,NO,DRUG: Vaginal Lactobacillus capsules,FEMALE,ADULT,PHASE2,60,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2023-08-24,2024-12-30
ENROLLING_BY_INVITATION,NO,BEHAVIORAL: Patient nudge|BEHAVIORAL: Provider nudge,FEMALE,"ADULT, OLDER_ADULT",NA,1600,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: SCREENING,2023-10-04,2024-09
RECRUITING,NO,DIAGNOSTIC_TEST: Brain imaging|DIAGNOSTIC_TEST: Analysis of circulating tumor DNA|BEHAVIORAL: Testing Morbidities Index,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2023-11-29,2028-06-01
TERMINATED,YES,DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Metformin XR|DRUG: Dapagliflozin + metformin XR|DRUG: Dapagliflozin,ALL,"ADULT, OLDER_ADULT",PHASE2,2,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-04-06,2023-05-10
RECRUITING,NO,OTHER: Home based exercise training,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04-07,2023-12-30
NOT_YET_RECRUITING,NO,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|DRUG: Immunotherapy|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography|RADIATION: Stereotactic Body Radiation Therapy,ALL,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-06-12,2026-10-22
RECRUITING,NO,DRUG: Huaier Granule,ALL,"ADULT, OLDER_ADULT",PHASE4,1072,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-18,2028-07-28
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Rhythmic Auditory Stimulation|BEHAVIORAL: Evidence-Based Exercise,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-08-15,2024-08-14
RECRUITING,NO,DRUG: PF-07220060|COMBINATION_PRODUCT: Letrozole|COMBINATION_PRODUCT: Fulvestrant|DRUG: Midazolam|COMBINATION_PRODUCT: Enzalutamide,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,337,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-23,2027-10-19
RECRUITING,NO,DRUG: Dexmedetomidine,FEMALE,"ADULT, OLDER_ADULT",PHASE3,158,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-12-07,2026-03-15
RECRUITING,NO,DRUG: RLY-5836|DRUG: Fulvestrant|DRUG: Palbociclib|DRUG: Ribociclib|DRUG: Abemaciclib,ALL,"ADULT, OLDER_ADULT",PHASE1,265,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-29,2026-01-13
COMPLETED,YES,BEHAVIORAL: Active video game teleconference support group|BEHAVIORAL: Standard support group + pedometer,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2020-05-11,2022-03-29
TERMINATED,NO,DRUG: [225Ac]-FPI-1966|DRUG: [111In]-FPI-1967|BIOLOGICAL: vofatamab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,6,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-20,2023-09-08
COMPLETED,YES,DIAGNOSTIC_TEST: Reader Group X - Session 1|DIAGNOSTIC_TEST: Reader Group Y - Session 1|DIAGNOSTIC_TEST: Reader Group X - Session 2|DIAGNOSTIC_TEST: Reader Group Y - Session 2,FEMALE,"ADULT, OLDER_ADULT",NA,16,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-08-15,2020-11-01
RECRUITING,NO,DRUG: Iohexol 350 Mg/mL Injectable Solution,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-03-13,2024-10
RECRUITING,NO,BEHAVIORAL: Inspiratory muscle training|BEHAVIORAL: Exercise training,FEMALE,"ADULT, OLDER_ADULT",NA,78,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-11-13,2029-06-30
RECRUITING,NO,DRUG: Docetaxel|PROCEDURE: Lumpectomy|PROCEDURE: Mastectomy|DRUG: Nab-paclitaxel|DRUG: Paclitaxel|BIOLOGICAL: Pertuzumab|RADIATION: Radiation Therapy|BIOLOGICAL: Trastuzumab|BIOLOGICAL: Trastuzumab Emtansine,ALL,"ADULT, OLDER_ADULT",PHASE2,2156,NETWORK,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-13,2038-12-31
RECRUITING,NO,DRUG: Paclitaxel|DRUG: Paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE4,22,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-28,2024-05
RECRUITING,NO,BEHAVIORAL: Supervised Home-Based Exercise|BEHAVIORAL: Unsupervised Home-Based Exercise|BEHAVIORAL: Attention Control,ALL,"ADULT, OLDER_ADULT",NA,135,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-10-31,2025-01-31
COMPLETED,NO,BEHAVIORAL: You-Tube Video: Elissa's EE song|BEHAVIORAL: Active Comparator: Standard of Care,FEMALE,"ADULT, OLDER_ADULT",NA,240,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2022-02-10,2022-03-14
RECRUITING,NO,OTHER: Coaching sessions,FEMALE,ADULT,NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-10-05,2024-04-05
RECRUITING,NO,DRUG: Docetaxel|DRUG: carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Epirubicin|DRUG: cyclophosphamide,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1406,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-07,2031-07-01
COMPLETED,NO,"DRUG: Combination, Rogaratinib + palbociclib + fulvestrant",FEMALE,"ADULT, OLDER_ADULT",PHASE1,9,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-11-25,2023-04-04
RECRUITING,NO,DRUG: BDC-3042|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,167,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-11,2028-03
RECRUITING,NO,DIETARY_SUPPLEMENT: QISENG|DIETARY_SUPPLEMENT: PLACEBO,FEMALE,"ADULT, OLDER_ADULT",NA,354,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-09-27,2025-09
RECRUITING,NO,DRUG: sulforaphane|DRUG: Placebo Oral Tablet,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,70,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-06-01,2026-06-01
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: TC-510|DRUG: Fludarabine|DRUG: Cyclophosphamide,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,6,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-21,2027-12
COMPLETED,NO,DRUG: amcenestrant|DRUG: [14C]-SAR439859 microtracer|DRUG: [14C]-SAR439859,FEMALE,"ADULT, OLDER_ADULT",PHASE1,6,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-06-15,2021-08-19
RECRUITING,NO,"OTHER: End-of-life conversation game called ""Hello""",ALL,"ADULT, OLDER_ADULT",NA,16,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-10-31,2024-11
COMPLETED,YES,DRUG: PF-06946860|DRUG: Placebo for PF-06946860,ALL,"ADULT, OLDER_ADULT",PHASE1,18,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-05-11,2022-08-09
UNKNOWN,NO,BIOLOGICAL: CD44v6-specific CAR gene-engineered T cells,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2023-12-31
RECRUITING,NO,DEVICE: contrast-enhanced mammography,FEMALE,"ADULT, OLDER_ADULT",NA,1500,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2023-11-08,2031-04
RECRUITING,NO,OTHER: Potlako intervention|OTHER: Enhanced care,ALL,"ADULT, OLDER_ADULT",PHASE2,1500,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-11-18,2025-09-30
NOT_YET_RECRUITING,NO,BEHAVIORAL: I-Can-Manage-Pain after cancer (Pain Management Program),ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-01,2024-07-30
RECRUITING,NO,DRUG: XZP-3287+Fulvestrant|DRUG: Placebo + Fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE3,300,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-16,2029-11
WITHDRAWN,NO,BIOLOGICAL: Recombinant human IL-7-hyFc (NT-I7)|BIOLOGICAL: Vaccine sequence 1|BIOLOGICAL: Vaccine sequence 2,ALL,"ADULT, OLDER_ADULT",PHASE1,0,NIH,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-30,2023-11-01
UNKNOWN,NO,DRUG: TQB2450|DRUG: Anlotinib|DRUG: Paclitaxel for Injection (albumin bound),ALL,"ADULT, OLDER_ADULT",PHASE3,332,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2022-07-01
RECRUITING,NO,DRUG: Neratinib,ALL,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-06,2025-07
ACTIVE_NOT_RECRUITING,NO,DRUG: QL1701|DRUG: Herceptin®|DRUG: Docetaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE3,474,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-04-29,2023-10
RECRUITING,NO,BEHAVIORAL: Self-administered acupressure|BEHAVIORAL: Aerobic exercise,ALL,"ADULT, OLDER_ADULT",NA,138,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2022-06-01,2025-05
RECRUITING,NO,DRUG: Pembrolizumab|RADIATION: Radiation Therapy|DRUG: Axatilimab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,35,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-01,2025-12-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Trilaciclib|DRUG: Placebo|DRUG: Gemcitabine|DRUG: Carboplatin,ALL,"ADULT, OLDER_ADULT",PHASE3,194,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-04-15,2024-10-25
UNKNOWN,NO,DRUG: OP-1250|DRUG: Palbociclib,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-10,2023-12
RECRUITING,NO,DEVICE: acupuncture|DRUG: Guizhi-Shaoyao-Zhimu decoction,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-05-05,2023-03-03
WITHDRAWN,NO,COMBINATION_PRODUCT: PAI Tool and Exercise Coaching,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-04-12,2022-04-12
RECRUITING,NO,BIOLOGICAL: ESR1 peptide vaccine,ALL,"ADULT, OLDER_ADULT",PHASE1,18,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-09-01,2026-02-01
RECRUITING,NO,BEHAVIORAL: Faith in Action! Church-based Navigation Model|OTHER: Control,FEMALE,"ADULT, OLDER_ADULT",NA,320,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-07-16,2024-12-01
RECRUITING,NO,PROCEDURE: Surgical intervention|DRUG: Control,ALL,"ADULT, OLDER_ADULT",PHASE3,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-01,2029-12-31
COMPLETED,NO,BEHAVIORAL: Information about hypothetical mammography screening without benefits,FEMALE,ADULT,NA,768,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-11-06,2021-01-04
NOT_YET_RECRUITING,NO,"OTHER: Leaflet ""decidons ensemble"" (making a decision together)",FEMALE,"ADULT, OLDER_ADULT",NA,66000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2023-01-01,2025-01-01
RECRUITING,NO,RADIATION: No PMRT for mastectomy / No regional RT for BCS|RADIATION: PMRT for mastectomy / WBI + Regional RT for BCS,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1106,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-01,2033-12-31
ACTIVE_NOT_RECRUITING,NO,DEVICE: da Vinci SPⓇ Single-port System,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-30,2023-08-01
TERMINATED,YES,DIETARY_SUPPLEMENT: probiotic plus prebiotic supplement|DIETARY_SUPPLEMENT: placebo,FEMALE,"ADULT, OLDER_ADULT",NA,3,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-07-20,2022-05-01
RECRUITING,NO,DEVICE: Surface Guided Radiation Therapy (SGRT),FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,556,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-01,2027-04-01
NOT_YET_RECRUITING,NO,DRUG: palbociclib and exemestane plus trastuzumab and pyrotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,57,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-30,2025-04-30
ACTIVE_NOT_RECRUITING,NO,OTHER: Best Practice|OTHER: Educational Intervention|OTHER: Educational Intervention|PROCEDURE: Genomic Profile|OTHER: Survey Administration,ALL,"ADULT, OLDER_ADULT",NA,465,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-12-30,2024-06-30
COMPLETED,NO,BEHAVIORAL: alcohol brief intervention|BEHAVIORAL: lifestyle health promotion,FEMALE,"ADULT, OLDER_ADULT",NA,558,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2021-02-05,2021-12-02
RECRUITING,NO,COMBINATION_PRODUCT: Study Device Arm,FEMALE,"ADULT, OLDER_ADULT",PHASE2,323,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: OTHER,2020-09-01,2025-12
WITHDRAWN,NO,BEHAVIORAL: Energy Conservation Work Simplification Education,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-27,2020-09-01
RECRUITING,NO,DEVICE: Phi-Bra prototype measurements,FEMALE,"ADULT, OLDER_ADULT",NA,41,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-03-30,2023-08-30
RECRUITING,NO,DRUG: Avapritinib,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-20,2025-02-03
UNKNOWN,NO,BEHAVIORAL: Physical exercise,FEMALE,"ADULT, OLDER_ADULT",NA,248,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2022-01-01,2023-12-30
RECRUITING,NO,BEHAVIORAL: Self-Guided PEPP Intervention Workbook|BEHAVIORAL: Self-Guided PEPP Education Workbook,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2024-02-01,2024-09-30
RECRUITING,NO,DRUG: Albumin-bound paclitaxel combined with carboplatin|DRUG: Epirubicin combined with docetaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE4,110,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-07-19,2026-11-30
RECRUITING,NO,BIOLOGICAL: Intratumoral administration of Stimotimagene copolymerplasmid|DRUG: Intravenous administration of Ganciclovir (Cymeven®),ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-01,2023-12
RECRUITING,NO,PROCEDURE: Acupuncture|PROCEDURE: Sham Acupuncture|OTHER: Wait-List Control (WLC)|OTHER: Questionnaires,FEMALE,"ADULT, OLDER_ADULT",PHASE2,260,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-06,2025-04
SUSPENDED,NO,DIAGNOSTIC_TEST: Zenith FLIM Diagnostics,FEMALE,"ADULT, OLDER_ADULT",NA,100,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-12-15,2022-11-02
RECRUITING,NO,DRUG: standard adjuvant chemotherapy plus moxifloxacin|DRUG: standard adjuvant chemotherapy plus placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE3,520,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-11,2028-12
ENROLLING_BY_INVITATION,NO,DEVICE: Magnetic Resonance Imaging (MRI),FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-09-01,2024-09-01
WITHDRAWN,NO,DRUG: ZN-c3|DRUG: Bevacizumab|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-14,2022-12-14
RECRUITING,NO,DRUG: Letrozole 2.5mg,FEMALE,"ADULT, OLDER_ADULT",PHASE2,28,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-13,2024-09
NOT_YET_RECRUITING,NO,BEHAVIORAL: Geriatric Assessment and Promotora Coaching,ALL,OLDER_ADULT,NA,49,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-02-07,2025-08-06
TERMINATED,YES,DRUG: Atezolizumab|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|BIOLOGICAL: PD1 Inhibitor,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,1,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07-19,2022-08-16
RECRUITING,NO,DIAGNOSTIC_TEST: Breast MRI for Breast Cancer Detection,FEMALE,"ADULT, OLDER_ADULT",NA,1464,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SCREENING,2023-04-23,2028-05-28
RECRUITING,NO,BEHAVIORAL: CO-OP Procedures|BEHAVIORAL: Attention Control Procedures,FEMALE,"ADULT, OLDER_ADULT",NA,44,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-10-11,2024-02-15
RECRUITING,NO,DRUG: Choline|DRUG: anti-PD-1 antibody and chemotherapy|DRUG: Sodium Cromoglicate|DRUG: Efavirenz,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-30,2023-03
RECRUITING,NO,DRUG: Tucatinib|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Combination product: Trastuzumab + Pertuzumab|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,650,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-07,2027-06-30
COMPLETED,NO,BEHAVIORAL: Standard Genetic Counseling|BEHAVIORAL: Educational Video,ALL,"ADULT, OLDER_ADULT",NA,269,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-12-01,2023-12-31
RECRUITING,NO,DEVICE: BRA CONNECT device,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2022-04-13,2024-11-28
RECRUITING,NO,BEHAVIORAL: Prehabilitation and rehabilitation,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-01,2024-01-01
ENROLLING_BY_INVITATION,NO,DRUG: [99mTc]Tc-G3-(G3S)3C,FEMALE,"ADULT, OLDER_ADULT",NA,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-06-04,2024-06-15
RECRUITING,NO,DRUG: Paclitaxel|DRUG: Monosialotetrahexosylganglioside|OTHER: Questionnaire Administration|OTHER: Quality-of-life assessment|DRUG: Placebo Administration,ALL,"ADULT, OLDER_ADULT",PHASE2,98,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2023-05-31,2030-05-31
RECRUITING,NO,DRUG: BL-M07D1,ALL,"ADULT, OLDER_ADULT",PHASE1,26,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-09,2024-08
ACTIVE_NOT_RECRUITING,NO,DRUG: CAM-H2,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,13,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-14,2024-01-31
RECRUITING,NO,DRUG: Recombinant oncolytic herpes simplex virus type 1 (R130),ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,24,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-30,2025-03
RECRUITING,NO,BIOLOGICAL: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells|BIOLOGICAL: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D,ALL,"ADULT, OLDER_ADULT",PHASE1,69,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-15,2035-01-15
NOT_YET_RECRUITING,NO,PROCEDURE: Vacuum-assisted percutaneous excision|PROCEDURE: Open surgical excision,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-01,2028-01-01
RECRUITING,NO,RADIATION: Per-Operative Radiotherapy technique by Papillon +TM,FEMALE,OLDER_ADULT,NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07-16,2028-06
ACTIVE_NOT_RECRUITING,NO,DRUG: Contrave|BEHAVIORAL: Behavioral Weight Loss,FEMALE,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2021-02-08,2023-12-31
RECRUITING,NO,DEVICE: medidux™ app,ALL,"ADULT, OLDER_ADULT",NA,585,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-08-29,2024-05-31
RECRUITING,NO,OTHER: Exercise,ALL,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-10-02,2024-10-02
RECRUITING,NO,PROCEDURE: Intraoperative Imaging|DEVICE: Lumpectomy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-11-28,2024-07-01
COMPLETED,NO,OTHER: Whole body vibration group|OTHER: Weight bearing exercises|DRUG: vitamin D supplements and calcium,ALL,ADULT,NA,45,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-01-20,2022-07-20
RECRUITING,NO,BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL),ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,50,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-19,2024-12-20
UNKNOWN,NO,OTHER: Acupuncture,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11,2023-03
RECRUITING,NO,DRUG: TTP488|DRUG: ddAC/ddT|DRUG: TC|DRUG: TCHP|DRUG: Chemotherapy regimen that includes ddAC,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,48,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-06,2024-11
RECRUITING,NO,DEVICE: Breast MRI|DIAGNOSTIC_TEST: standard breast imaging,FEMALE,"ADULT, OLDER_ADULT",NA,440,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-02-01,2026-08-31
RECRUITING,NO,BEHAVIORAL: Combined Aerobic and Resistance Exercise,FEMALE,"ADULT, OLDER_ADULT",NA,86,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-07-31,2026-08-01
RECRUITING,NO,OTHER: Acupuncture; based on Tradidtional Chinese Medicine,FEMALE,"ADULT, OLDER_ADULT",NA,250,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-09-01,2024-12-01
RECRUITING,NO,DRUG: Simvastatin 40mg|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,26,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-19,2025-02
RECRUITING,NO,DRUG: ARTISS 4mL Fibrin Sealant Topical Solution (Frozen)|OTHER: no ARTISS,FEMALE,"ADULT, OLDER_ADULT",PHASE4,138,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-02-01,2024-01-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Trastuzumab deruxtecan|DRUG: Placebo|DRUG: Taxane|DRUG: Pertuzumab|DRUG: Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE3,1157,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-26,2029-12-30
COMPLETED,NO,PROCEDURE: physitherapy follow-up|OTHER: control,FEMALE,"ADULT, OLDER_ADULT",NA,63,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-07-01,2022-01-19
ACTIVE_NOT_RECRUITING,NO,DRUG: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)|DRUG: Pertuzumab IV|DRUG: Trastuzumab IV|DRUG: Trastuzumab Emtansine|DRUG: Investigator's Choice of Chemotherapy|PROCEDURE: Surgery|RADIATION: Radiotherapy,ALL,"ADULT, OLDER_ADULT",PHASE3,346,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-05,2025-09-25
RECRUITING,NO,COMBINATION_PRODUCT: REM-001 photodynamic therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,15,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02-12,2024-12-31
COMPLETED,NO,BEHAVIORAL: App Promoting Healthy Behaviours,FEMALE,ADULT,NA,35,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-11-03,2023-03-10
RECRUITING,NO,DRUG: dose-dense nab-paclitaxel followed by EC,FEMALE,"ADULT, OLDER_ADULT",PHASE2,64,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-01,2024-12-30
ACTIVE_NOT_RECRUITING,NO,OTHER: Specific supervised exercise and weight loss program,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-17,2024-05-17
RECRUITING,NO,PROCEDURE: Biospecimen Collection|OTHER: Genetic Counseling|OTHER: Genetic Testing|OTHER: Survey Administration,ALL,"ADULT, OLDER_ADULT",NA,27500,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-03-09,2030-06-10
TERMINATED,YES,DRUG: Alectinib,ALL,"ADULT, OLDER_ADULT",PHASE2,1,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-05-24,2022-05-16
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Platelet Rich Plasma system,ALL,ADULT,EARLY_PHASE1,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-23,2024-06
RECRUITING,NO,DRUG: Pembrolizumab|DEVICE: Cryoablation,ALL,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-29,2027-01-29
ACTIVE_NOT_RECRUITING,NO,OTHER: Pyrotinib Plus Capecitabine combined with brain radiotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,39,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-02,2023-08-12
RECRUITING,NO,DRUG: carbon dye,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-01,2023-03-31
ACTIVE_NOT_RECRUITING,NO,OTHER: Low AGE diet|PROCEDURE: Research blood draw,FEMALE,"ADULT, OLDER_ADULT",NA,14,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-10-14,2023-12-10
UNKNOWN,NO,PROCEDURE: Modified pectoralis block (PEC II) and pecto-intercostal fascial plane block (PIFB),FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-01,2023-12-01
RECRUITING,NO,DRUG: PC14586|DRUG: pembrolizumab,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,230,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-29,2026-07-14
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Enhanced Usual Care|BEHAVIORAL: Acceptance Commitment Therapy|BEHAVIORAL: Cognitive Behavioral Therapy,FEMALE,"ADULT, OLDER_ADULT",NA,390,OTHER,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2021-07-17,2025-01-01
WITHDRAWN,NO,DRUG: Placebo|DRUG: NBP Softgel Capsules,ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-06-30,2025-01-30
RECRUITING,NO,BEHAVIORAL: In-person rehabilitaiton group|BEHAVIORAL: Virtual rehabilitation group,ALL,"ADULT, OLDER_ADULT",NA,117,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-12-02,2024-04-30
NOT_YET_RECRUITING,NO,OTHER: Acupressure|OTHER: Acupressure,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2024-03,2026-05
NOT_YET_RECRUITING,NO,DRUG: Trastuzumab Deruxtecan,FEMALE,"ADULT, OLDER_ADULT",PHASE2,69,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-08,2026-08
RECRUITING,NO,DRUG: S-ketamine (low dose)|DRUG: Placebo|DRUG: S-ketamine (high dose),FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,352,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-10-07,2024-07-07
RECRUITING,NO,PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Paclitaxel|BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|PROCEDURE: Surgical Procedure,ALL,"ADULT, OLDER_ADULT",PHASE3,2400,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-15,2033-04
RECRUITING,NO,OTHER: Aquatic Training Plus Health Education|OTHER: Land Training Plus Health Education|OTHER: Health Education,FEMALE,"ADULT, OLDER_ADULT",NA,48,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-12-19,2025-08-30
NOT_YET_RECRUITING,NO,BEHAVIORAL: Mental Exercises and Temporal Alteration,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2024-01-30,2024-09-01
UNKNOWN,NO,OTHER: Complementary and alternative medicines,ALL,"ADULT, OLDER_ADULT",PHASE1,250,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2020-07-01,2021-10-30
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Immediate lymphatic reconstruction,FEMALE,"ADULT, OLDER_ADULT",NA,240,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-02-14,2028-08
RECRUITING,NO,DEVICE: extra corporeal shock wave therapy device,FEMALE,ADULT,NA,68,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-11,2023-12
RECRUITING,NO,PROCEDURE: Omit SLNB,FEMALE,"ADULT, OLDER_ADULT",NA,311,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-21,2027-10-01
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Trigger point injection|PROCEDURE: Subcutaneous saline injection|OTHER: Comprehensive Rehabilitation program,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,72,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-01-03,2024-02-15
RECRUITING,NO,DRUG: GNC-035,ALL,"ADULT, OLDER_ADULT",PHASE1,29,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-26,2024-06
RECRUITING,NO,OTHER: Prospective data and sample collection,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-09-01,2024-10-31
NOT_YET_RECRUITING,NO,DRUG: Talazoparib|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,206,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03,2024-03-01
RECRUITING,NO,DRUG: IMP7068,ALL,"ADULT, OLDER_ADULT",PHASE1,350,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-25,2023-08-30
RECRUITING,NO,DRUG: Trilaciclib|DRUG: Pembrolizumab|DRUG: Gemcitabine|DRUG: Carboplatin,ALL,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-01-10,2027-03
NOT_YET_RECRUITING,NO,DRUG: Pyrotinib|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Taxanes|BIOLOGICAL: Trastuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,280,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-01,2024-03-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Taxane|DRUG: Letrozole|DRUG: Abemaciclib|DRUG: LHRH Analogue,FEMALE,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-02,2033-02-28
ACTIVE_NOT_RECRUITING,NO,OTHER: phone consultation|OTHER: e-PRO self-completed via connected objects (tablet/phone)|OTHER: phone consultation|OTHER: visit,FEMALE,"ADULT, OLDER_ADULT",NA,197,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-02-09,2024-03
RECRUITING,NO,DRUG: Fluzoparib+Paclitaxel|DRUG: Epirubicin+Cyclophosphamide,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-04-08,2026-06-01
COMPLETED,NO,DRUG: SHR6390+anatrozole,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-02,2023-03-31
RECRUITING,NO,BEHAVIORAL: Adaptive Aerobic Training/AT Dosing|BEHAVIORAL: Standard (fixed) Aerobic Training/AT dosing,FEMALE,"ADULT, OLDER_ADULT",PHASE2,140,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-30,2028-01-30
NOT_YET_RECRUITING,NO,DRUG: Taletrectinib,ALL,"ADULT, OLDER_ADULT",PHASE2,61,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-04,2030-01-01
UNKNOWN,NO,DRUG: TQ-B3525|DRUG: Fulvestrant injection,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,42,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07,2021-09
NOT_YET_RECRUITING,NO,DRUG: SZ011 CAR-NK,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,12,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-01,2024-06-01
RECRUITING,NO,BEHAVIORAL: Physical training,ALL,"ADULT, OLDER_ADULT",NA,712,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-09,2027-12
RECRUITING,NO,OTHER: Functional Precision Oncology,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-06,2027-09-30
NOT_YET_RECRUITING,NO,DRUG: Gemcitabine combined with eribulin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,58,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03,2024-09
ACTIVE_NOT_RECRUITING,NO,BIOLOGICAL: ZW25|DRUG: Docetaxel|BIOLOGICAL: Tislelizumab|DRUG: Capecitabine|DRUG: Oxaliplatin,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,71,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-26,2026-12-31
RECRUITING,NO,DRUG: Talazoparib|DRUG: Belinostat,ALL,"ADULT, OLDER_ADULT",PHASE1,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-04,2024-07
NOT_YET_RECRUITING,NO,BIOLOGICAL: EOC202|DRUG: albumin-bound paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-04,2025-05
RECRUITING,NO,BEHAVIORAL: Physical activity program,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-03-29,2023-12
RECRUITING,NO,PROCEDURE: Modified radical mastectomy for breast cancer|PROCEDURE: neoadjuvant therapy|PROCEDURE: Systematic treatment,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-08,2026-08-01
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: Al18F-NOTA-FAPI-04 PET/CT scan,ALL,"ADULT, OLDER_ADULT",NA,88,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-05-10,2024-02-01
WITHDRAWN,NO,DRUG: Abexinostat Tosylate|DRUG: Fulvestrant|DRUG: Palbociclib,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-31,2025-06-30
COMPLETED,NO,DIAGNOSTIC_TEST: patient-derived tumor-like cell clusters drug sensitivity test,FEMALE,"ADULT, OLDER_ADULT",PHASE2,86,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-11-01,2023-12-10
RECRUITING,NO,DRUG: AZD8421|DRUG: Camizestrant|DRUG: Ribociclib|DRUG: Palbociclib|DRUG: Abemaciclib,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,204,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-05,2025-06-18
RECRUITING,NO,DRUG: Elacestrant|DRUG: Triptorelin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-03,2025-01
COMPLETED,NO,OTHER: Tai Chi|DEVICE: FitBit|OTHER: Support Group Therapy|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment,FEMALE,"ADULT, OLDER_ADULT",NA,39,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-03-11,2021-12-23
COMPLETED,NO,PROCEDURE: Intra-articular steroid injection,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,28,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-26,2021-12-31
COMPLETED,NO,DRUG: [14C]GB491,MALE,ADULT,PHASE1,6,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-14,2022-11-14
RECRUITING,NO,DRUG: Talazoparib Oral Capsule,FEMALE,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-05-25,2025-05-10
RECRUITING,NO,DRUG: Elacestrant|DRUG: Alpelisib|DRUG: Everolimus|DRUG: Ribociclib|DRUG: Palbociclib|DRUG: Capivasertib|DRUG: Abemaciclib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,400,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-24,2026-08-31
ACTIVE_NOT_RECRUITING,NO,OTHER: AH-HA Tool in the EPIC EHR,ALL,"ADULT, OLDER_ADULT",NA,645,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-10-01,2024-03-07
UNKNOWN,NO,BIOLOGICAL: Tislelizumab|DRUG: Nab paclitaxel|DRUG: Doxorubicin|DRUG: Epirubicin|DEVICE: Cyclophosphamide,ALL,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09,2022-12
NOT_YET_RECRUITING,NO,DRUG: Dalpiciclib combined with Letrozole,FEMALE,"ADULT, OLDER_ADULT",PHASE2,178,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-01,2028-06-30
WITHDRAWN,NO,DEVICE: Cold Cap Therapy|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-12-14,2023-11-14
COMPLETED,NO,DEVICE: LifeExtend-AI,ALL,"ADULT, OLDER_ADULT",NA,62,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-02-17,2022-08-09
RECRUITING,NO,DRUG: Olinvacimab,ALL,"ADULT, OLDER_ADULT",PHASE2,30,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-30,2026-08-30
RECRUITING,NO,DRUG: YL202,ALL,"ADULT, OLDER_ADULT",PHASE1,80,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-20,2025-12
TERMINATED,NO,DRUG: FT536|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: IL-2|COMBINATION_PRODUCT: Avelumab|COMBINATION_PRODUCT: Pembrolizumab|COMBINATION_PRODUCT: Nivolumab|COMBINATION_PRODUCT: Atezolizumab|COMBINATION_PRODUCT: Trastuzumab|COMBINATION_PRODUCT: Cetuximab|COMBINATION_PRODUCT: Amivantamab|DRUG: IL-2,ALL,"ADULT, OLDER_ADULT",PHASE1,5,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-31,2023-08-11
RECRUITING,NO,DRUG: Ontruzant|DRUG: Chemotherapy|DRUG: Pertuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE4,108,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-07-11,2023-07
RECRUITING,NO,"DRUG: LOXO-783|DRUG: Fulvestrant|DRUG: Imlunestrant|DRUG: Abemaciclib|DRUG: Anastrozole, Exemestane, or Letrozole|DRUG: Paclitaxel",ALL,"ADULT, OLDER_ADULT",PHASE1,400,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-11,2025-05
NOT_YET_RECRUITING,NO,DRUG: AB-201|DRUG: Cyclophosphamide|DRUG: Fludarabine,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,133,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-01,2027-04
WITHDRAWN,NO,DRUG: Durvalumab|RADIATION: Radiation Therapy|DRUG: Carboplatin|DRUG: Paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07,2027-07
ACTIVE_NOT_RECRUITING,NO,DEVICE: EMBr Wave|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-10-07,2024-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: ARV-471,ALL,"ADULT, OLDER_ADULT",PHASE1,6,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-16,2024-03-31
COMPLETED,NO,DEVICE: Research Marker,FEMALE,"ADULT, OLDER_ADULT",NA,8,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2020-11-02,2022-04-07
RECRUITING,NO,DRUG: VS-6766|DRUG: Abemaciclib|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,63,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-23,2028-12-31
NOT_YET_RECRUITING,NO,DIAGNOSTIC_TEST: ctDNA monitoring|DIAGNOSTIC_TEST: 68Ga-FAPI-46-PET-CT,FEMALE,"ADULT, OLDER_ADULT",PHASE2,450,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: OTHER",2024-03-01,2028-09-15
UNKNOWN,NO,PROCEDURE: DIEP Breast Reconstruction|DEVICE: ciNPT|OTHER: Conventional Tape Dressings,FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-10,2022-10
RECRUITING,NO,RADIATION: Stereotactic Body Radiation Therapy,FEMALE,OLDER_ADULT,NA,30,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-01,2023-11
ENROLLING_BY_INVITATION,NO,OTHER: Sequential EHR Communications,FEMALE,"ADULT, OLDER_ADULT",NA,450,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-05-01,2024-06-01
ACTIVE_NOT_RECRUITING,NO,DRUG: ARV-471|DRUG: Anastrozole|PROCEDURE: Surgical resection of breast tumor,FEMALE,"ADULT, OLDER_ADULT",PHASE2,152,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-15,2024-08-15
RECRUITING,NO,DIAGNOSTIC_TEST: ThermoBreast - AI-based evaluation of dynamic breast thermography imaging,FEMALE,"ADULT, OLDER_ADULT",NA,28000,INDUSTRY,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: DIAGNOSTIC",2023-12-11,2029-12
WITHDRAWN,NO,DRUG: Bintrafusp Alfa|BIOLOGICAL: Immunocytokine NHS-IL12|RADIATION: Radiation Therapy,ALL,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-07,2022-02-16
COMPLETED,NO,BEHAVIORAL: Gratitude Intervention,FEMALE,"ADULT, OLDER_ADULT",NA,26,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2022-11-08,2023-07-25
RECRUITING,NO,DRUG: Anastrozole 1mg|DRUG: Letrozole 2.5mg|DRUG: Exemestane 25 mg|DRUG: Tamoxifen,FEMALE,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-18,2036-10
COMPLETED,NO,OTHER: Lavender Aromatherapy Tablet,FEMALE,"ADULT, OLDER_ADULT",NA,135,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-07-01,2023-03-01
RECRUITING,NO,OTHER: ALECSAT,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-21,2023-05-21
NOT_YET_RECRUITING,NO,DRUG: Dalpiciclib+ letrozole +capecitabine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-10,2024-08
RECRUITING,NO,DEVICE: Mobile Application with Interactive Nurse Support,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-07-15,2024-02-15
RECRUITING,NO,DIAGNOSTIC_TEST: Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS),FEMALE,"ADULT, OLDER_ADULT",NA,74,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-04-26,2024-10-01
NOT_YET_RECRUITING,NO,OTHER: Aerobic dance|OTHER: Fast-walking,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-02-01,2027-01-01
UNKNOWN,NO,BEHAVIORAL: SMS reminders to enhance colorectal cancer screening|BEHAVIORAL: SMS reminders to return the fecal immunochemical test at the pharmacy in CRC screening:|BEHAVIORAL: Invitation by SMS to previous participants in breast cancer screening:,ALL,"ADULT, OLDER_ADULT",NA,20000,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-09-15,2022-12-31
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: Define Standard of Truth (SOT) by Taihao Breast Cancer Diagnostic Software,FEMALE,"ADULT, OLDER_ADULT",NA,3,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-01-30,2023-11-30
RECRUITING,NO,DRUG: Pyrotinib 320mg + Vinorelbine|DRUG: Pyrotinib 400mg + Vinorelbine|DRUG: Pyrotinib plus Vinorelbine,ALL,"ADULT, OLDER_ADULT",PHASE2,208,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-22,2023-12-01
RECRUITING,NO,OTHER: Questionnaires|OTHER: back to work coaching,FEMALE,"ADULT, OLDER_ADULT",NA,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-09-13,2023-08-22
NOT_YET_RECRUITING,NO,DRUG: Pertuzumab and trastuzumab FDC subcutaneous|DRUG: Paclitaxel|DRUG: TDM1|DRUG: Endocrine therapy|PROCEDURE: Omission surgery,FEMALE,"ADULT, OLDER_ADULT",PHASE2,27,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-15,2027-07-15
NOT_YET_RECRUITING,NO,DRUG: Neratinib Oral Tablet|DRUG: Ruxolitinib Oral Tablet,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-11,2025-12
ACTIVE_NOT_RECRUITING,NO,DRUG: PY314|DRUG: Combination Therapy: PY314 + Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,288,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-29,2023-10-28
COMPLETED,NO,BEHAVIORAL: Sleep Coach App,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-05-12,2022-08-08
RECRUITING,NO,DEVICE: Novilase Laser ablation,FEMALE,"ADULT, OLDER_ADULT",NA,122,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-08-09,2025-09-30
RECRUITING,NO,DRUG: Binimetinib|PROCEDURE: Biopsy|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|DRUG: Fulvestrant|PROCEDURE: Magnetic Resonance Imaging,ALL,"ADULT, OLDER_ADULT",PHASE2,95,NIH,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-29,2026-11-01
RECRUITING,NO,BEHAVIORAL: Pain Neuroscience Education (PNE)|BEHAVIORAL: Motivational Interviewing (MI)|BEHAVIORAL: Biomedically-focused education,FEMALE,"ADULT, OLDER_ADULT",NA,156,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-01,2025-12
NOT_YET_RECRUITING,NO,DRUG: GEH121224 (18F) Injection|DIAGNOSTIC_TEST: Dynamic and Static - PET/CT Scan|DIAGNOSTIC_TEST: Static - PET/CT Scan,FEMALE,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-12,2024-12
NOT_YET_RECRUITING,NO,RADIATION: Arm I (No PMRT)|RADIATION: Arm II (PMRT),ALL,"ADULT, OLDER_ADULT",PHASE3,1314,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-11-11,2031-07-10
RECRUITING,NO,DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Nab paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Nab paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE4,1576,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-10,2027-12-20
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: MoviS Training,ALL,"ADULT, OLDER_ADULT",NA,172,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-01-07,2025-12-31
RECRUITING,NO,DRUG: TNG348|DRUG: Olaparib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,140,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-08,2026-06
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Prehabilitation program,FEMALE,"ADULT, OLDER_ADULT",NA,102,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-06-23,2034-03-15
COMPLETED,NO,DIETARY_SUPPLEMENT: Creatine,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-09-30,2023-03-07
COMPLETED,NO,BEHAVIORAL: YouTube Video Arm,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-11-01,2023-06-01
RECRUITING,NO,DRUG: Adagrasib|DRUG: Olaparib,ALL,"ADULT, OLDER_ADULT",PHASE1,52,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-01-30,2030-08-25
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Discussion|OTHER: Exercise Intervention|OTHER: Exercise Intervention|OTHER: Informational Intervention|OTHER: Informational Intervention|OTHER: Medical Device Usage and Evaluation|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,FEMALE,OLDER_ADULT,NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-12-03,2023-12-31
NOT_YET_RECRUITING,NO,DRUG: Disitamab Vedotin Injection|DRUG: Pertuzumab Injection|DRUG: Toripalimab,ALL,"ADULT, OLDER_ADULT",PHASE2,80,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12,2025-06
RECRUITING,NO,DRUG: ASTX660|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,48,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-03-02,2026-03-16
NOT_YET_RECRUITING,NO,DEVICE: Microwave ablation,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-01,2024-06-01
WITHDRAWN,NO,DRUG: Neratinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-24,2021-11-24
NOT_YET_RECRUITING,NO,DRUG: Tetrathiomolybdate|DRUG: Capecitabine|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,204,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-03,2034-03
NOT_YET_RECRUITING,NO,DRUG: Hydroxychloroquine,FEMALE,"ADULT, OLDER_ADULT",PHASE2,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-06,2025-12-01
COMPLETED,NO,OTHER: Application of CDSS to provide nutritional care in breast cancer patients from home|OTHER: General lifestyle advice to breast cancer patients by phone,FEMALE,"ADULT, OLDER_ADULT",NA,44,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2020-03-11,2021-04-15
RECRUITING,NO,BEHAVIORAL: Multicomponent Adherence Intervention|OTHER: Usual Care,ALL,"ADULT, OLDER_ADULT",NA,350,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-03-02,2027-03-31
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Prolonged Nightly Fasting|BEHAVIORAL: Exercise,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-01-15,2024-07-31
RECRUITING,NO,OTHER: myocardial perfusion SPECT,FEMALE,"ADULT, OLDER_ADULT",NA,58,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-10-27,2024-10-27
RECRUITING,NO,DRUG: nab-Paclitaxel+carboplatin|DRUG: Paclitaxel+carboplatin,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1498,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-07-19,2026-11-30
RECRUITING,NO,OTHER: The MRD strategy for high risk or MRD+ TNBC patients|OTHER: The MRD strategy for high risk or MRD+ HER2+ patients|OTHER: The MRD strategy for high risk or MRD+ ER+ patients|OTHER: The MRD strategy for low risk and MRD- TNBC patients|OTHER: The MRD strategy for low risk and MRD- HER2+ patients|OTHER: The MRD strategy for low risk and MRD- ER+ patients,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-24,2027-03-24
NOT_YET_RECRUITING,NO,DRUG: olaparib|DRUG: Durvalumab,ALL,"ADULT, OLDER_ADULT",PHASE2,152,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-01,2030-02-18
COMPLETED,NO,DRUG: TALZENNA capsule|DRUG: Talazoparib soft gel capsule|DRUG: Talazoparib soft gel capsule,ALL,"ADULT, OLDER_ADULT",PHASE1,73,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2020-12-21,2022-07-22
TERMINATED,NO,DRUG: Enzalutamide,ALL,"ADULT, OLDER_ADULT",PHASE2,34,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-01,2022-10-10
TERMINATED,YES,DRUG: Nivolumab|DRUG: Ipilimumab,ALL,"ADULT, OLDER_ADULT",PHASE2,1,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-04,2021-06-17
NOT_YET_RECRUITING,NO,DEVICE: Laser Therapy|DEVICE: Sham Intervention|OTHER: Questionnaire Administration|OTHER: Quality of Life Assessment,FEMALE,"ADULT, OLDER_ADULT",PHASE3,250,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2024-04,2027-05
RECRUITING,NO,DRUG: Seviteronel-D (Seivteronel in combination with dexamethasone)|DRUG: Docetaxel,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,65,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-01,2024-12
RECRUITING,NO,DRUG: VIP236,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-24,2024-12
RECRUITING,NO,DRUG: SPH4336 Tablets|DRUG: SPH4336 Tablets Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,254,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-09-08,2025-08-30
RECRUITING,NO,OTHER: Placebo|DRUG: Montelukast,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-03-01,2024-05-01
NOT_YET_RECRUITING,NO,DRUG: Ezabenlimab + BI907828,ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-01,2027-01-01
RECRUITING,NO,DIETARY_SUPPLEMENT: Chinese Herbs,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04-22,2024-04
RECRUITING,NO,RADIATION: De-escalation,ALL,"ADULT, OLDER_ADULT",NA,1350,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-17,2033-12-31
UNKNOWN,NO,DRUG: Pembrolizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,44,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-03,2023-12-01
ACTIVE_NOT_RECRUITING,YES,DRUG: Pertuzumab IV|DRUG: Trastuzumab IV|DRUG: Pertuzumab and Trastuzumab FDC SC|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel|PROCEDURE: Surgery|RADIATION: Post-Operative Radiotherapy|DRUG: Hormone Therapy,ALL,"ADULT, OLDER_ADULT",PHASE3,200,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-05,2025-11-11
RECRUITING,NO,DRUG: PRO1107,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,214,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-01-29,2027-02
TERMINATED,NO,DRUG: PF-07260437|DIAGNOSTIC_TEST: B7-H4 IHC,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-07,2023-10-17
RECRUITING,NO,BIOLOGICAL: CEA CAR-T cells|BIOLOGICAL: CEA CAR-T cells,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-30,2026-09-30
WITHDRAWN,NO,PROCEDURE: ESP BLOCK|PROCEDURE: PECS BLOCK,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-01,2023-01
RECRUITING,NO,PROCEDURE: LAG-3 expression / immune checkpoint protein expression,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,128,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2022-11-18,2027-12-31
NOT_YET_RECRUITING,NO,DRUG: NKT3447,ALL,"ADULT, OLDER_ADULT",PHASE1,90,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-02,2027-05
RECRUITING,NO,DRUG: Pyrotinib|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Docetaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-03,2024-05-31
COMPLETED,NO,DRUG: Metformin|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,76,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-04-12,2022-10-30
RECRUITING,NO,DRUG: 68Ga-FF58,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,80,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-10-14,2024-07-23
RECRUITING,NO,OTHER: Yoga,FEMALE,"ADULT, OLDER_ADULT",NA,34,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-05-04,2024-07-30
COMPLETED,NO,PROCEDURE: Double-point SAPB|PROCEDURE: Single-point SAPB,FEMALE,"ADULT, OLDER_ADULT",NA,57,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-01,2023-12-08
RECRUITING,NO,DRUG: Combination of liposomal doxorubicin,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-10-07,2027-09-30
WITHDRAWN,NO,DRUG: Alectinib|DRUG: Alpelisib|DRUG: Anastrozole|BIOLOGICAL: Atezolizumab|BIOLOGICAL: Bevacizumab|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Capecitabine|DRUG: Carboplatin|DRUG: Cobimetinib|DRUG: Entrectinib|DRUG: Eribulin|DRUG: Fulvestrant|BIOLOGICAL: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|DRUG: Irinotecan|DRUG: Letrozole|DRUG: Nab-paclitaxel|DRUG: Niraparib|DRUG: Olaparib|DRUG: Paclitaxel|DRUG: Palbociclib|BIOLOGICAL: Pertuzumab|OTHER: Quality-of-Life Assessment|BIOLOGICAL: Trastuzumab|BIOLOGICAL: Trastuzumab Emtansine|DRUG: Vemurafenib|DRUG: Vinorelbine|DRUG: Vismodegib,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-01-30,2026-05-31
NOT_YET_RECRUITING,NO,DRUG: Trastuzumab|DRUG: Taxanes|DRUG: Pertuzumab|DRUG: Tyrosine kinase inhibitor,FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-10-01,2025-09-30
RECRUITING,NO,DRUG: BPI-1178|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: BPI-1178,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,224,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-15,2024-03-15
RECRUITING,NO,DRUG: Sintilimab|DRUG: Anlotinib|DRUG: Nab paclitaxel|DRUG: Carboplatin|DRUG: Epirubicin|DRUG: Cyclophosphamide,FEMALE,"ADULT, OLDER_ADULT",PHASE2,31,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-15,2025-12-31
ACTIVE_NOT_RECRUITING,NO,RADIATION: intraoperative radiotherapy|RADIATION: postoperative radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2025-02-28
SUSPENDED,NO,DRUG: Docetaxel|DRUG: Pembrolizumab|DRUG: IL-12 gene therapy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-17,2024-08
NOT_YET_RECRUITING,NO,DRUG: Inetetamab|DRUG: Rapamycin|DRUG: Pyrotinib|DRUG: Chemotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE3,270,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-02,2027-02-02
RECRUITING,NO,BEHAVIORAL: CaRE@Home intervention,ALL,"ADULT, OLDER_ADULT",NA,388,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-07-07,2025-02
RECRUITING,NO,BEHAVIORAL: AI Opinion,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2023-03-01,2028-09-01
ACTIVE_NOT_RECRUITING,YES,DRUG: AZD9833|DRUG: Fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE2,240,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-22,2024-03-29
UNKNOWN,NO,DRUG: Pyrotinib|DRUG: Temozolomide Injection|DRUG: SHR-1316|DRUG: Bevacizumab|DRUG: Cisplatin/Carboplatin,ALL,"ADULT, OLDER_ADULT",PHASE2,59,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-30,2022-01-30
RECRUITING,NO,DRUG: vepdegestrant|DRUG: Samuraciclib,ALL,"ADULT, OLDER_ADULT",PHASE2,67,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-01-10,2027-02-02
RECRUITING,NO,OTHER: assessment for upper limb dysfunction|OTHER: retest assessment,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2022-04-26,2025-02
UNKNOWN,NO,PROCEDURE: Intercostobrachial Nerve Preserving Axillary Lymph Node Dissection|PROCEDURE: Intercostobrachial Nerve Sacrificing Axillary Lymph Node Dissection,FEMALE,"ADULT, OLDER_ADULT",NA,182,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-01-30,2022-10-01
RECRUITING,NO,RADIATION: Radiation Therapy,ALL,"ADULT, OLDER_ADULT",PHASE2,55,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-30,2029-08-09
RECRUITING,NO,DRUG: SPH4336 Tablets,FEMALE,"ADULT, OLDER_ADULT",PHASE2,52,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09-19,2025-12-31
NOT_YET_RECRUITING,NO,DRUG: Dapagliflozin 10mg,FEMALE,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2024-04,2025-12
RECRUITING,NO,DIAGNOSTIC_TEST: Injection of contrast enhancing agent Gadovist for MRI investigation|DIAGNOSTIC_TEST: Injection of contrast enhancing agent Imeron for B-CT investigation,FEMALE,"ADULT, OLDER_ADULT",NA,428,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-11-24,2024-12
RECRUITING,NO,BIOLOGICAL: Anti-HER2/HER3 Dendritic Cell Vaccine|BIOLOGICAL: Pembrolizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,23,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-19,2026-12-15
RECRUITING,NO,DRUG: Afatinib|DRUG: T-DM1,FEMALE,"ADULT, OLDER_ADULT",PHASE2,130,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-10,2024-03-31
UNKNOWN,NO,BEHAVIORAL: Breast Cancer Risk Reduction Household Intervention,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,90,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2020-01-25,2021-01-25
RECRUITING,NO,DRUG: AG-01 Compound,ALL,"ADULT, OLDER_ADULT",PHASE1,77,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-14,2026-11
RECRUITING,NO,PROCEDURE: Clinical Encounter|OTHER: Home Health Encounter|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-08-23,2025-01-01
NOT_YET_RECRUITING,NO,DRUG: Abemaciclib 150 MG + Giredestrant 30 MG,FEMALE,"ADULT, OLDER_ADULT",PHASE2,51,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-04-01,2027-04-01
RECRUITING,NO,DRUG: MRG002,ALL,"ADULT, OLDER_ADULT",PHASE2,66,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-05-13,2023-02
COMPLETED,NO,DRUG: Ramosetron Hydrochloride,ALL,"ADULT, OLDER_ADULT",PHASE4,144,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-12-17,2021-10-31
RECRUITING,NO,OTHER: Hypnotic Relaxation Intervention (HRI)|DEVICE: Vulvovaginal Atrophy (VVA),FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-11-22,2024-09-30
RECRUITING,NO,DRUG: Goserelin|DRUG: Fulvestrant|DRUG: Capivasertib|DRUG: Durvalumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,56,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-17,2025-12-31
RECRUITING,NO,DRUG: Dermaprazole 1%|DRUG: Dermaprazole 2%,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,57,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-04-24,2027-01
RECRUITING,NO,DEVICE: Individual decision aid (iDA),ALL,"ADULT, OLDER_ADULT",NA,220,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2023-03-01,2024-12-31
RECRUITING,NO,PROCEDURE: Lymphaticovenous anastomosis surgery combined with near infrared spectroscopy imaging,FEMALE,"ADULT, OLDER_ADULT",NA,64,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-13,2024-04
RECRUITING,NO,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Pembrolizumab|DRUG: Pertuzumab/Trastuzumab/Hyaluronidase-zzxf,ALL,"ADULT, OLDER_ADULT",PHASE2,185,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-04-18,2029-11
RECRUITING,NO,DRUG: Olaparib|DRUG: Chemotherapy drug,ALL,"ADULT, OLDER_ADULT",PHASE2,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-02-07,2025-12-31
RECRUITING,NO,BEHAVIORAL: Guided physical exercise|DRUG: Atorvastatin|OTHER: Independent exercise,ALL,"ADULT, OLDER_ADULT",PHASE3,240,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-31,2027-12-31
UNKNOWN,NO,DRUG: Vinorelbine 40mg|BIOLOGICAL: Toripalimab 240mg|BIOLOGICAL: Bevacizumab 5 mg/kg|DRUG: Cyclophosphamide 50 mg|DRUG: Capecitabine 500Mg Oral Tablet|DRUG: Cisplatin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,138,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-01,2023-12-31
COMPLETED,NO,DRUG: Rosuvastatin|DRUG: ALXN2040,ALL,ADULT,PHASE1,20,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-01,2023-04-05
RECRUITING,NO,DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Fulvestrant|BIOLOGICAL: Pertuzumab|OTHER: Quality-of-Life Assessment|DRUG: Ribociclib|BIOLOGICAL: Trastuzumab|DRUG: Tucatinib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,18,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-07,2025-04-01
ACTIVE_NOT_RECRUITING,NO,DIAGNOSTIC_TEST: Blood and urine molecular analysis (Timing 0)|DIAGNOSTIC_TEST: Blood and urine molecular analysis (Timing 1),FEMALE,"ADULT, OLDER_ADULT",NA,367,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-01-19,2024-12
RECRUITING,NO,DRUG: SGN-PDL1V|DRUG: pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,322,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-25,2026-12-31
RECRUITING,NO,DRUG: Carboplatin|DRUG: Gemcitabine|DRUG: Nadunolimab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,116,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-11,2026-08
RECRUITING,NO,DRUG: Paclitaxel injection|DRUG: Capecitabine tablets|DRUG: Letrozole 2.5mg|DRUG: Anastrozole 1mg|DRUG: Fulvestrant Prefilled Syringe|DRUG: Abemaciclib,FEMALE,"ADULT, OLDER_ADULT",PHASE3,180,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-11,2028-06
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Questionnaires|BEHAVIORAL: Semi-structured individual interviews|OTHER: Focus Group|OTHER: DELPHI Consensus Method,ALL,"ADULT, OLDER_ADULT",NA,190,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: OTHER,2021-02-02,2024-05-26
RECRUITING,NO,DRUG: TH1902,ALL,"ADULT, OLDER_ADULT",PHASE1,70,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-04,2024-12
UNKNOWN,NO,DEVICE: Acupuncture,FEMALE,"ADULT, OLDER_ADULT",NA,54,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-01,2023-12-01
NOT_YET_RECRUITING,NO,DRUG: Dexmedetomidine|DRUG: Liposomal bupivacaine,ALL,"ADULT, OLDER_ADULT",PHASE4,200,FED,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2024-04,2025-07
RECRUITING,NO,DRUG: RGT-419B|DRUG: RGT-419B in combination with hormonal therapy,ALL,"ADULT, OLDER_ADULT",PHASE1,18,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-04,2024-08-28
NOT_YET_RECRUITING,NO,BEHAVIORAL: Prolonged Overnight Fasting|BEHAVIORAL: Moderate-Intensity Exercise|BEHAVIORAL: General Health Education Sessions,FEMALE,"ADULT, OLDER_ADULT",NA,260,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2024-03-31,2029-03-31
RECRUITING,NO,COMBINATION_PRODUCT: Cryoablation Combined with Tirelizumab and Bevacizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-01,2024-04-01
RECRUITING,NO,GENETIC: Pre-treatment biopsy|GENETIC: Post treatment biopsy|GENETIC: Pre treatment blood sampling|GENETIC: Post treatment blood sampling,FEMALE,"ADULT, OLDER_ADULT",NA,241,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-06-20,2027-10-01
ACTIVE_NOT_RECRUITING,NO,DRUG: tucatinib|DRUG: trastuzumab deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE2,70,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-01,2025-10-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Alpelisib|DRUG: Nab-paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE2,8,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-05,2025-12-31
RECRUITING,NO,DRUG: Atezolizumab|DRUG: Trastuzumab Emtansine|DRUG: Placebo|DRUG: Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE3,1700,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-05-04,2035-06-29
RECRUITING,NO,DEVICE: biofeedback-based music program|OTHER: Control,FEMALE,"ADULT, OLDER_ADULT",NA,68,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-08-21,2024-01-30
RECRUITING,NO,DEVICE: Breast Tissue Expander,FEMALE,"ADULT, OLDER_ADULT",NA,136,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-12-14,2026-07-15
RECRUITING,NO,OTHER: psychological-clinical intervention with three days of expressive writing by Pennebaker,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-10-26,2024-01-30
RECRUITING,NO,RADIATION: rPBI,ALL,"ADULT, OLDER_ADULT",NA,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-27,2027-06-27
COMPLETED,NO,DRUG: SPECT,FEMALE,"ADULT, OLDER_ADULT",PHASE1,30,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2020-02-10,2021-10-04
COMPLETED,NO,OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|OTHER: Supportive Care,FEMALE,"ADULT, OLDER_ADULT",PHASE1,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-08-20,2023-05-17
RECRUITING,NO,"DIAGNOSTIC_TEST: Determination of tumormarkers (CA27.29, CEA, CA125)|DIAGNOSTIC_TEST: Determination of CTC levels|DIAGNOSTIC_TEST: Determination of ctDNA levels|OTHER: Biobanking of blood samples",ALL,"ADULT, OLDER_ADULT",NA,3500,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2022-12-07,2035-12
RECRUITING,NO,DRUG: Rosuvastatin|DRUG: Digoxin|DRUG: Metformin hydrochlorid|DRUG: Furosemide,ALL,"ADULT, OLDER_ADULT",NA,30,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-04-25,2025-01-27
RECRUITING,NO,DRUG: [18F]SF-DEVD-2|DRUG: [18F]-FDG,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-01,2024-01
ACTIVE_NOT_RECRUITING,NO,DRUG: PRT3645,ALL,"ADULT, OLDER_ADULT",PHASE1,22,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-27,2024-12
RECRUITING,NO,DRUG: SGN-B7H4V,ALL,"ADULT, OLDER_ADULT",PHASE1,430,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-12,2027-01-31
RECRUITING,NO,DRUG: Superparamagnetic Iron Oxide|DEVICE: Technetium99,ALL,"ADULT, OLDER_ADULT",PHASE2,220,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-01-01,2027-07-01
RECRUITING,NO,OTHER: gp-multitool.de,ALL,OLDER_ADULT,NA,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-02,2024-05-31
NOT_YET_RECRUITING,NO,DEVICE: Bone@BC app,FEMALE,"ADULT, OLDER_ADULT",NA,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-05-01,2025-10-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Atezolizumab 840 MG in 14 ML Injection|DRUG: Atezolizumab 1200 MG in 20 ML Injection|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide|PROCEDURE: Biopsy Arm A|PROCEDURE: Biopsy Arm B|PROCEDURE: Surgery,ALL,"ADULT, OLDER_ADULT",PHASE2,416,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2024-08-31
NOT_YET_RECRUITING,NO,DRUG: Definity|DEVICE: Sonalleve Focused Ultrasound Device,ALL,"ADULT, OLDER_ADULT",PHASE2,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02-01,2029-02-01
RECRUITING,NO,OTHER: Best Practice|PROCEDURE: Biospecimen Collection|PROCEDURE: Endocrine Drug Therapy|BEHAVIORAL: Health Education|OTHER: Questionnaire Administration|OTHER: Symptom Specific Assessment Tool,FEMALE,"ADULT, OLDER_ADULT",NA,540,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-03-29,2028-05-01
RECRUITING,NO,DRUG: Lidocaine 20mg/ml|DRUG: Placebo,ALL,"ADULT, OLDER_ADULT",PHASE3,1150,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-09-22,2024-12-01
RECRUITING,NO,OTHER: Risk stratified arm|OTHER: Control arm,FEMALE,"ADULT, OLDER_ADULT",NA,962,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-09-28,2034-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: CBX-12,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,130,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-03,2024-09
RECRUITING,NO,DRUG: JAB-2485 (Aurora A inhibitor)|DRUG: JAB-2485 (Aurora A inhibitor),ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,102,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-20,2026-08
COMPLETED,NO,OTHER: Best Practice|OTHER: Informational Intervention|OTHER: Questionnaire Administration|OTHER: Survey Administration,ALL,OLDER_ADULT,NA,75,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-08-24,2022-06-30
RECRUITING,NO,DRUG: Neratinib|DRUG: Loperamide|DRUG: Colesevelam,ALL,"ADULT, OLDER_ADULT",PHASE2,315,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-08-31,2030-01
ACTIVE_NOT_RECRUITING,NO,OTHER: Best Practice|BEHAVIORAL: Health Education|OTHER: Interview|OTHER: Planned Notification|OTHER: Survey Administration,FEMALE,"ADULT, OLDER_ADULT",NA,140,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SCREENING,2022-09-05,2025-03-31
RECRUITING,NO,DRUG: SI-B003,ALL,"ADULT, OLDER_ADULT",PHASE1,159,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-10,2024-05
RECRUITING,NO,DRUG: A1: SHR-A1811|DRUG: A2: SHR-A1811 with Camrelizumab|DRUG: B1: TROP2 ADC|DRUG: B2: TROP2 ADC with Camrelizumab|DRUG: C1: SHR-A1811|DRUG: C2: SHR-A1811 with BP102|DRUG: D1: TROP2 ADC|DRUG: D2: TROP2 ADC with BP102|DRUG: E1: SHR-A1811|DRUG: F1: TROP2 ADC|DRUG: G1: SHR-A1811|DRUG: H1: TROP2 ADC,FEMALE,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-30,2026-06
NOT_YET_RECRUITING,NO,PROCEDURE: Paravertebral nerve block (PVB)|PROCEDURE: Pectoralis and Serratus Plane Nerve Blocks (PECS 2)|DEVICE: Regional anesthetic technique with ultrasound guidance|DEVICE: Regional anesthetic technique with peripheral nerve stimulation.|DRUG: Levobupivacaine 0.5%|PROCEDURE: General anesthesia,FEMALE,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: BASIC_SCIENCE,2023-04,2025-12
COMPLETED,YES,DRUG: Rosuvastatin|DRUG: Sotorasib,ALL,ADULT,PHASE1,13,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-08-20,2021-10-10
NOT_YET_RECRUITING,NO,DRUG: CA9hu-1,ALL,"ADULT, OLDER_ADULT",PHASE1,50,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-01,2027-01
RECRUITING,NO,OTHER: survey,ALL,"ADULT, OLDER_ADULT",NA,100,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-10-06,2023-12-06
RECRUITING,NO,DRUG: Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-10-15,2024-12-01
NOT_YET_RECRUITING,NO,DRUG: Trastuzumab|DRUG: pyrotinib|DRUG: Dalpiciclib|DRUG: fulvestrant,FEMALE,"ADULT, OLDER_ADULT",PHASE2,126,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-01,2026-03-01
NOT_YET_RECRUITING,NO,DIAGNOSTIC_TEST: 3D printed model,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-04-30,2028-02-28
COMPLETED,NO,OTHER: Radiation Care Gel,ALL,"ADULT, OLDER_ADULT",NA,23,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-08-03,2022-10-07
RECRUITING,NO,OTHER: Transcutaneous Electrical Nerve Stimulation,ALL,"ADULT, OLDER_ADULT",NA,27,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-10-19,2025-03-31
UNKNOWN,NO,DRUG: Niraparib|DRUG: Anlotinib,ALL,"ADULT, OLDER_ADULT",PHASE1,52,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-01,2023-02-28
COMPLETED,NO,OTHER: Training|OTHER: Control,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-08-10,2021-09-23
RECRUITING,NO,DRUG: Fulvestrant|DRUG: Anastrozole|DRUG: Abemaciclib,ALL,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-31,2028-12-31
RECRUITING,NO,DRUG: [68Ga]GA-NeoB,FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-02-20,2025-02-23
RECRUITING,NO,DRUG: Rosuvastatin 20mg,FEMALE,"ADULT, OLDER_ADULT",PHASE3,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-09-15,2023-09-15
RECRUITING,NO,RADIATION: Hypofractionated radiotherapy|DRUG: Pembrolizumab infusion|PROCEDURE: Blood and tissue sampling,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,27,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-07,2024-08
RECRUITING,NO,BEHAVIORAL: Health Education|OTHER: Health Promotion and Education|BEHAVIORAL: Patient Navigation|OTHER: Survey Administration,ALL,"ADULT, OLDER_ADULT",NA,800,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2023-07-28,2029-09-30
COMPLETED,NO,"OTHER: Manuel Lymphatic Drainage(MLD), Exercises",FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2021-09-01,2023-06-01
TERMINATED,YES,DEVICE: Flexitouch Plus|DEVICE: Flexitouch Plus FT with software modification,FEMALE,"ADULT, OLDER_ADULT",NA,2,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-01-23,2020-02-08
RECRUITING,NO,DRUG: PD1+ TILs (NUMARZU-001) product infusion,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07-20,2027-09-30
RECRUITING,NO,DRUG: AO-252,ALL,"ADULT, OLDER_ADULT",PHASE1,144,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-02,2027-01-27
ACTIVE_NOT_RECRUITING,NO,DRUG: ENV-101 (taladegib),ALL,"ADULT, OLDER_ADULT",PHASE2,44,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-24,2024-05
NOT_YET_RECRUITING,NO,DRUG: Pembrolizumab 25 mg/ml|DRUG: Paclitaxel injection,ALL,"ADULT, OLDER_ADULT",PHASE2,354,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-01,2031-12-01
RECRUITING,NO,PROCEDURE: Vacuum-assisted excisional biopsy|PROCEDURE: Not excisional biopsy,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-01-17,2025-07-31
ACTIVE_NOT_RECRUITING,NO,RADIATION: Whole breast radiotherapy|RADIATION: Intra Operative Radiotherapy,FEMALE,OLDER_ADULT,NA,104,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-01,2025-09
COMPLETED,NO,DEVICE: Oculus Go Virtual Reality Goggles,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-09-15,2022-01-07
TERMINATED,NO,DRUG: NBE-002,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,12,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-19,2023-08-14
ENROLLING_BY_INVITATION,NO,DRUG: HRS-1358,FEMALE,"ADULT, OLDER_ADULT",PHASE1,102,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-07,2025-06-30
COMPLETED,NO,OTHER: Digital Delivery of Pre-Genetic Testing Information via the BRCA-DIRECT Platform|OTHER: Digital Delivery of Genetic Test Results via the BRCA-DIRECT Platform,FEMALE,"ADULT, OLDER_ADULT",NA,1140,OTHER,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: OTHER,2021-07-05,2023-01-16
RECRUITING,NO,DRUG: MEN1611|DRUG: Eribulin,ALL,"ADULT, OLDER_ADULT",PHASE2,28,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-24,2027-07
WITHDRAWN,NO,DRUG: NERATINIB|DRUG: FULVESTRANT,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07,2025-07-01
RECRUITING,NO,"BIOLOGICAL: Autologous, engineered T Cells targeting TP53 R175H",ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-27,2039-08
RECRUITING,NO,DRUG: Anastrozole|PROCEDURE: Therapeutic Conventional Surgery|BIOLOGICAL: Trastuzumab Deruxtecan,ALL,"ADULT, OLDER_ADULT",PHASE2,88,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-09,2025-09-30
COMPLETED,NO,BEHAVIORAL: Screening status,FEMALE,"ADULT, OLDER_ADULT",NA,27099,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-09-01,2023-09-01
RECRUITING,NO,DRUG: PLD Chemotherapy|DRUG: CDX-1140|DRUG: CDX-301,ALL,"ADULT, OLDER_ADULT",PHASE1,45,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-20,2025-04-20
COMPLETED,NO,BEHAVIORAL: Mindfulness-based stress reduction intervention,FEMALE,"CHILD, ADULT, OLDER_ADULT",NA,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: SUPPORTIVE_CARE",2023-08-24,2023-12-06
SUSPENDED,NO,PROCEDURE: axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)|PROCEDURE: Axillary lymphadenetomy alone,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-09-10,2030-06-01
NOT_YET_RECRUITING,NO,DRUG: letrozole,FEMALE,"ADULT, OLDER_ADULT",PHASE2,70,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-08-30,2025-05-31
RECRUITING,NO,"DEVICE: Fitness tracker based activity training for Arm A and B. Booklet ""physical training, exercise and cancer"" and an introduction about physical activity during cancer therapy for Arm A, B, C",FEMALE,"ADULT, OLDER_ADULT",NA,201,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-08-01,2025-08-01
WITHDRAWN,NO,BEHAVIORAL: Intermittent Fasting,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-12-02,2023-08
RECRUITING,NO,DRUG: SKB264,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,430,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-28,2025-12
RECRUITING,NO,DRUG: ART6043|DRUG: Olaparib|DRUG: Talazoparib|DRUG: Olaparib|DRUG: Talazoparib,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,250,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-30,2026-12-14
COMPLETED,NO,DRUG: Doxorubicin hydrochloride liposome injection,FEMALE,"ADULT, OLDER_ADULT",PHASE1,48,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2022-05-17,2023-02-09
COMPLETED,NO,DRUG: LY01005|DRUG: ZOLADEX® 3.6 mg,FEMALE,ADULT,PHASE3,188,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10-15,2022-06-24
RECRUITING,NO,DRUG: Spartalizumab|DRUG: Tislelizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,184,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-12,2027-03-31
RECRUITING,NO,DRUG: Capecitabine|DRUG: Tucidinostat,FEMALE,"ADULT, OLDER_ADULT",PHASE2,126,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-01,2024-12-01
RECRUITING,NO,DRUG: Fulvestrant|DRUG: Neratinib|DRUG: Alpelisib|DRUG: Everolimus|DRUG: Abemaciclib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,135,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-10,2031-10
UNKNOWN,NO,DRUG: oral etoposide + anlotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-23,2023-07-11
RECRUITING,NO,DIAGNOSTIC_TEST: 18F-FDG PET/CT|DIAGNOSTIC_TEST: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging|DRUG: 18F-FDHT,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-10-24,2026-10-24
ACTIVE_NOT_RECRUITING,NO,DEVICE: Mepitel Film,ALL,"ADULT, OLDER_ADULT",PHASE3,216,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-01-30,2024-12
COMPLETED,NO,OTHER: Pain neuroscience education and therapeutic exercise,FEMALE,"ADULT, OLDER_ADULT",NA,26,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-05,2023-01-09
RECRUITING,NO,PROCEDURE: Biospecimen Collection|DRUG: Fisetin|DRUG: Placebo Administration|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,FEMALE,OLDER_ADULT,PHASE2,88,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-03-27,2025-05-15
RECRUITING,NO,DRUG: Tucatinib in Combination of Oral VP16 and trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE2,66,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-19,2027-12-19
SUSPENDED,NO,"DRUG: Enobosarm & Abemaciclib Combo|DRUG: non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant",ALL,"ADULT, OLDER_ADULT",PHASE3,186,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-04-11,2025-12-31
RECRUITING,NO,"BEHAVIORAL: With Love, Grandma (""Con Cariño, Abuelita"")",FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-02-22,2024-05-31
RECRUITING,NO,"DRUG: FCN-437c, Letrozole or anastrozole, Goserelin acetate|DRUG: Placebo, Letrozole or anastrozole, Goserelin acetate",FEMALE,"ADULT, OLDER_ADULT",PHASE3,434,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-02,2025-03-02
NOT_YET_RECRUITING,NO,DRUG: CVL218,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,96,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-10,2026-06
NOT_YET_RECRUITING,NO,OTHER: yoga,ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-07-24,2024-06-06
ACTIVE_NOT_RECRUITING,NO,"DRUG: Pyrotinib maleate, SHR6390, letrozole",FEMALE,"ADULT, OLDER_ADULT",PHASE2,89,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-27,2026-12-30
RECRUITING,NO,DRUG: Sulfasalazine|DRUG: Placebos,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-05-03,2025-05-01
RECRUITING,NO,DRUG: Triamcinolone Acetonide|DRUG: Oleogel-S10,ALL,"ADULT, OLDER_ADULT",PHASE2,50,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-12-15,2026-12-15
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Standard Genetic Counseling|BEHAVIORAL: Quantitative Genetic Counseling,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-01-31,2024-12-01
RECRUITING,NO,DRUG: utidelone|DRUG: docetaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE3,349,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-21,2027-06-01
RECRUITING,NO,DEVICE: REGENERA breast implant implantation,FEMALE,"ADULT, OLDER_ADULT",NA,92,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-09-29,2029-12-30
NOT_YET_RECRUITING,NO,DRUG: Sindilimab|DRUG: Nab-paclitaxel|DRUG: Lenvatinib,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,58,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-30,2026-12-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Pyrotinib|DRUG: SHR6390,FEMALE,"ADULT, OLDER_ADULT",PHASE2,41,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-01,2023-05
COMPLETED,NO,DEVICE: Photobiomodulation therapy (PBMT)|DEVICE: Sham laser,FEMALE,"ADULT, OLDER_ADULT",NA,71,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-01,2021-06-01
COMPLETED,NO,PROCEDURE: pectoral nerve block,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-07-08,2021-10-10
COMPLETED,NO,DEVICE: electric stimulation therapy,FEMALE,ADULT,NA,198,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-06-10,2023-05-02
COMPLETED,NO,DEVICE: Wearable device,FEMALE,"ADULT, OLDER_ADULT",NA,99,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-02-24,2023-03-24
RECRUITING,NO,DRUG: Pyrrolidine、trastuzumab、AI,FEMALE,"ADULT, OLDER_ADULT",PHASE2,48,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-13,2025-09-30
RECRUITING,NO,BEHAVIORAL: Online modality|BEHAVIORAL: Genetic counselor follow-up,FEMALE,"ADULT, OLDER_ADULT",NA,2275,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2023-03-06,2024-06
RECRUITING,NO,DRUG: Tranexamic acid|DRUG: Normal saline,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2022-07-12,2024-12
NOT_YET_RECRUITING,NO,DRUG: [14C] TQB3616,MALE,ADULT,PHASE1,8,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-01,2024-12
NOT_YET_RECRUITING,NO,DRUG: pyrotinib + trastuzumab + nab-paclitaxel|DRUG: pertuzumab + trastuzumab + nab-paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE2,490,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05,2025-12
ACTIVE_NOT_RECRUITING,NO,DRUG: Patritumab deruxtecan|DRUG: Chemotherapy|DRUG: Letrozole,ALL,"ADULT, OLDER_ADULT",PHASE2,120,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-25,2030-07-31
ACTIVE_NOT_RECRUITING,NO,"DRUG: Liposomal bupivacaine|DRUG: Bupivacaine, epinephrine, dexamethasone, and clonidine",ALL,"ADULT, OLDER_ADULT",PHASE2,75,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2020-12-04,2023-12
RECRUITING,NO,OTHER: Educational Intervention|OTHER: Interview|OTHER: Survey Administration|OTHER: Telemedicine,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-03-15,2024-04-30
RECRUITING,NO,DRUG: Recombinant oncolytic herpes simplex virus type 1 (R130),ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-24,2026-06
RECRUITING,NO,DRUG: Dalpiciclib|DRUG: Pyrotinib|DRUG: SHR-A1811|DRUG: SHR-1316|DRUG: Camrelizumab|DRUG: Trophoblast cell-surface antigen 2 (TROP2) ADC|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Goserelin|DRUG: Letrozole|DRUG: Nab paclitaxel|DRUG: Carboplatin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Fluzoparib|DRUG: HER2 ADC,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,716,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-11-01,2025-09
ACTIVE_NOT_RECRUITING,NO,DRUG: CyPep-1|DRUG: Pembrolizumab 25 MG/ML [KEYTRUDA®],ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,90,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-21,2025-02
RECRUITING,NO,BEHAVIORAL: High-Intensity Intervals Training|OTHER: Attention Control,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-07-14,2025-06-15
COMPLETED,NO,"DRUG: REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|DRUG: Flumazenil|DRUG: Propofol",FEMALE,"ADULT, OLDER_ADULT",NA,66,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-02,2022-12-21
RECRUITING,NO,BEHAVIORAL: Exercise,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-01-11,2024-11
RECRUITING,NO,DRUG: Atezolizumab|DRUG: Bevacizumab|DRUG: Gemcitabine|DRUG: Carboplatin,ALL,"ADULT, OLDER_ADULT",PHASE2,31,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2025-09-30
WITHDRAWN,NO,DRUG: [11C]Martinostat|DEVICE: MR-PET scanner,FEMALE,"ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-02-01,2024-10-31
RECRUITING,NO,PROCEDURE: Wire-guided surgery|PROCEDURE: Radioactive seed localization|PROCEDURE: Intraoperative ultrasound localization,FEMALE,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-04,2025-10
RECRUITING,NO,DRUG: Fluzoparib; Apatinib|DRUG: Fluzoparib|DRUG: Physician's choice chemotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE3,474,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-13,2025-06-30
RECRUITING,NO,DRUG: Inetetamab|DRUG: Pyrotinib|DRUG: Capecitabine|DRUG: Gemcitabine|DRUG: Vinorelbine|DRUG: Carboplatin|DRUG: Albumin paclitaxel|DRUG: Eribulin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,71,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-09,2024-09-09
RECRUITING,NO,OTHER: Whole-body cryotherapy|OTHER: Placebo cryotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2023-05-05,2026-02-04
COMPLETED,NO,DIAGNOSTIC_TEST: contrast-enhanced breast MRI,ALL,"ADULT, OLDER_ADULT",NA,113,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-07-13,2021-08-15
NOT_YET_RECRUITING,NO,BIOLOGICAL: Cadonilimab|DRUG: Eribulin,FEMALE,"ADULT, OLDER_ADULT",PHASE2,128,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-02-10,2028-12-30
RECRUITING,NO,PROCEDURE: omission of SLNB in SentiOMIT or omission of ALND in SentiMACRO,FEMALE,"ADULT, OLDER_ADULT",NA,350,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-02-06,2033-12-31
RECRUITING,NO,DRUG: Mecobalamin 5 MG Disintegrating Oral Tablet|DRUG: placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE3,234,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-01-01,2030-12-31
NOT_YET_RECRUITING,NO,DEVICE: Amma Portable Scalp Cooling System (PSCS)|OTHER: Questionnaires,ALL,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-02-01,2025-07-31
NOT_YET_RECRUITING,NO,DRUG: Disitamab Vedotin plus pyrotinib or naratinib,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09,2027-04
RECRUITING,NO,DRUG: UTD1 combined with capecitabine,MALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-01,2025-07
RECRUITING,NO,OTHER: Electronic Health Record Review|OTHER: Health Promotion and Education|PROCEDURE: Health Telemonitoring|OTHER: Interview|BEHAVIORAL: Patient Navigation|OTHER: Survey Administration|OTHER: Text Message-Based Navigation Intervention,ALL,"ADULT, OLDER_ADULT",NA,410,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-10-31,2027-01-31
NOT_YET_RECRUITING,NO,PROCEDURE: Mechanical ischemic preconditioning of diep-type flap,FEMALE,"ADULT, OLDER_ADULT",NA,35,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05,2024-05
RECRUITING,NO,PROCEDURE: True acupuncture + standard antiemetic treatment|PROCEDURE: Sham acupuncture + standard antiemetic treatment,FEMALE,"ADULT, OLDER_ADULT",NA,234,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-15,2024-12-31
RECRUITING,NO,DRUG: Eribulin Injection [Halaven]|DRUG: Paclitaxel injection,FEMALE,"ADULT, OLDER_ADULT",PHASE4,82,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-11,2023-09-15
RECRUITING,NO,DRUG: Chidamide,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-01,2023-12-31
COMPLETED,NO,OTHER: active release group|OTHER: active control group,FEMALE,ADULT,NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-08-10,2023-01-15
RECRUITING,NO,DRUG: CX-5461,ALL,"ADULT, OLDER_ADULT",PHASE1,52,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-08,2025-06
COMPLETED,YES,BEHAVIORAL: Decision Support Tool with Active Monitoring|BEHAVIORAL: Decision Support Tool without Active Monitoring,FEMALE,"ADULT, OLDER_ADULT",NA,322,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2021-10-12,2022-01-31
COMPLETED,NO,PROCEDURE: erector spinae block with bupivacaine|PROCEDURE: erector spinae block with bupivacaine + dexmedetomidine,FEMALE,"ADULT, OLDER_ADULT",NA,58,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-07-01,2021-09-30
COMPLETED,YES,DRUG: Neratinib|DRUG: Capecitabine|DRUG: Loperamide,ALL,"ADULT, OLDER_ADULT",PHASE2,6,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-06-30,2021-12-28
RECRUITING,NO,RADIATION: 600cGY x 5 fractions,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-30,2027-12-31
WITHDRAWN,NO,DIETARY_SUPPLEMENT: Soy isoflavones|DIETARY_SUPPLEMENT: Lignans|DIETARY_SUPPLEMENT: Placebo,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-03,2022-12
UNKNOWN,NO,DEVICE: GammaPod Tumour Bed Boost,FEMALE,ADULT,NA,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01,2022-01
ACTIVE_NOT_RECRUITING,NO,OTHER: Mindfulness-based stress reduction,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-09-23,2024-01
RECRUITING,NO,DRUG: Enzalutamide|DRUG: Mifepristone|DRUG: TPC,ALL,"ADULT, OLDER_ADULT",PHASE2,201,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2023-10-18,2027-10
RECRUITING,NO,OTHER: low-energy extracorporeal shockwave and a tailored exercise program|OTHER: low-energy extracorporeal shockwave|OTHER: tailored exercise program,FEMALE,"ADULT, OLDER_ADULT",NA,93,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04-15,2023-09-01
RECRUITING,NO,DRUG: HS-10352,ALL,"ADULT, OLDER_ADULT",PHASE1,54,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-08,2023-08-31
RECRUITING,NO,DRUG: SHR-A1811|DRUG: Pyrotinib in combination with Capecitabine.,FEMALE,"ADULT, OLDER_ADULT",PHASE3,269,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-29,2024-12-31
RECRUITING,NO,BIOLOGICAL: E-602|BIOLOGICAL: Cemiplimab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,273,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-11,2025-06
ACTIVE_NOT_RECRUITING,NO,PROCEDURE: Flap fixation technique,FEMALE,"ADULT, OLDER_ADULT",NA,68,OTHER_GOV,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-12-01,2024-06-30
NOT_YET_RECRUITING,NO,PROCEDURE: Breast surgery|DEVICE: Suturing of surgical incision,ALL,"ADULT, OLDER_ADULT",NA,180,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2023-12,2024-11
COMPLETED,NO,PROCEDURE: Combined Modified Pectoralis and Transversus Plane Blocks|PROCEDURE: Erector Spinae block,FEMALE,ADULT,NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: PREVENTION,2021-02-08,2023-11-01
WITHDRAWN,NO,DIAGNOSTIC_TEST: Low-dose Imaging,FEMALE,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-08-24,2020-08-24
RECRUITING,NO,OTHER: Water exercise group|OTHER: Land exercise group|OTHER: Control group,ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-04-01,2027-08-30
RECRUITING,NO,BEHAVIORAL: Opening the Conversation|BEHAVIORAL: Side by Side,ALL,"ADULT, OLDER_ADULT",NA,200,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-09-01,2024-12-31
RECRUITING,NO,OTHER: Ergospirometry,ALL,ADULT,NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-08-19,2027-09
COMPLETED,NO,OTHER: Training|OTHER: Cancer Screening intervention|OTHER: Survey Administration,ALL,"ADULT, OLDER_ADULT",NA,35,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-11-18,2022-06-30
ACTIVE_NOT_RECRUITING,NO,DRUG: Atezolizumab|DRUG: Sacituzumab govitecan,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-02,2027-12-30
RECRUITING,NO,DIAGNOSTIC_TEST: MRI|DIAGNOSTIC_TEST: Lumbar puncture,ALL,"ADULT, OLDER_ADULT",NA,20,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-07-13,2026-07
RECRUITING,NO,BEHAVIORAL: POINT Protocol|BEHAVIORAL: Usual care,ALL,"ADULT, OLDER_ADULT",NA,240,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-06-01,2024-01-01
COMPLETED,NO,DRUG: Bupivacaine Hydrochloride|DRUG: Bupivacaine Hydrochloride and dexmedetomedine|DRUG: Bupivacaine Hydrochloride and ketamine,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,75,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2023-01-01,2023-04-30
RECRUITING,NO,DEVICE: StrataXRT,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-10-13,2023-06-30
COMPLETED,YES,OTHER: Electronic Health Record Review|OTHER: Questionnaire Administration|BEHAVIORAL: Behavioral Intervention,ALL,"ADULT, OLDER_ADULT",NA,6,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-08-03,2021-12-31
COMPLETED,NO,DEVICE: Web-based oncofertility support tool,ALL,"ADULT, OLDER_ADULT",NA,54,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-01-01,2021-08-05
RECRUITING,NO,BIOLOGICAL: Eflapegrastim|BIOLOGICAL: Eflapegrastim|BIOLOGICAL: Eflapegrastim|BIOLOGICAL: Eflapegrastim|DRUG: Docetaxel|DRUG: Cyclophosphamide,ALL,ADULT,PHASE1,90,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-11,2025-06-30
NOT_YET_RECRUITING,NO,DRUG: Sacituzumab govitecan|DRUG: Pembrolizumab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,348,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12,2029-09
RECRUITING,NO,PROCEDURE: Cryoablation,FEMALE,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-01,2026-11-01
RECRUITING,NO,DRUG: BDC-1001|DRUG: Nivolumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,390,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-24,2026-10-31
RECRUITING,NO,DRUG: Camrelizumab|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-20,2024-11-01
RECRUITING,NO,RADIATION: Focal Radiation therapy|DRUG: Pembrolizumab (200mg IV for 30 minutes|BIOLOGICAL: CDX-301,FEMALE,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-03-17,2027-12
NOT_YET_RECRUITING,NO,DEVICE: Electroacupuncture|DEVICE: Sham acupuncture,ALL,"ADULT, OLDER_ADULT",PHASE2,100,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-08-01,2024-12-30
WITHDRAWN,NO,DEVICE: Tissue Glu|DEVICE: Drain|OTHER: Questionnaires,ALL,"ADULT, OLDER_ADULT",NA,0,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2020-11-01,2021-09-01
COMPLETED,NO,DRUG: 99mTc-ADAPT6|DRUG: 99mTc-DARPinG3,FEMALE,"ADULT, OLDER_ADULT",NA,15,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-05-01,2023-01-21
UNKNOWN,NO,DRUG: SHR-1210+Albumin-bound paclitaxel + epirubicin,FEMALE,ADULT,PHASE1|PHASE2,39,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01,2023-01
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Supervised exercise,ALL,"ADULT, OLDER_ADULT",NA,357,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-01-08,2027-07-01
RECRUITING,NO,DRUG: P2Et (Caesalpinia spinosa extract)|DRUG: Placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2,58,OTHER,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-01,2023-06-30
COMPLETED,NO,DIAGNOSTIC_TEST: ICG-SG incubation solution,FEMALE,"ADULT, OLDER_ADULT",NA,26,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-02-17,2023-10-30
NOT_YET_RECRUITING,NO,RADIATION: preoperative radiotherapy|RADIATION: postoperative radiotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1826,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-01,2030-12-31
NOT_YET_RECRUITING,NO,GENETIC: HTR2 T Cells|GENETIC: HTR2 T Cells,ALL,"ADULT, OLDER_ADULT",PHASE1,27,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-03,2033-06
NOT_YET_RECRUITING,NO,BEHAVIORAL: Text message nudge,ALL,"ADULT, OLDER_ADULT",NA,30000,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2023-09,2024-02
ACTIVE_NOT_RECRUITING,NO,DRUG: Dalpiciclib|DRUG: Fulvestrant|DRUG: Pertuzumab|DRUG: Trastuzumab,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,72,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-01,2024-01-01
NOT_YET_RECRUITING,NO,DIETARY_SUPPLEMENT: Supplement|DIETARY_SUPPLEMENT: AI diet|DIETARY_SUPPLEMENT: Placebo,FEMALE,"ADULT, OLDER_ADULT",NA,90,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-03-01,2026-11-30
RECRUITING,NO,DRUG: pyrotinib,ALL,"ADULT, OLDER_ADULT",PHASE3,488,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-06-01,2030-08
RECRUITING,NO,DRUG: Atorvastatin 80mg|OTHER: placebo,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-10-30,2024-12-30
COMPLETED,YES,DRUG: Giredestrant|DRUG: Anastrozole|DRUG: Palbociclib|PROCEDURE: Surgery,FEMALE,"ADULT, OLDER_ADULT",PHASE2,221,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-04,2021-11-24
ACTIVE_NOT_RECRUITING,NO,DRUG: Neoadjuvant chemotherapy administered before surgical extraction of a tumor|OTHER: Observational,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,34,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-04-06,2027-11-28
RECRUITING,NO,RADIATION: Hypofractionated radiotherapy,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-26,2026-06-30
WITHDRAWN,NO,DRUG: Disulfiram|DRUG: Vinorelbin|DRUG: Cisplatin|DRUG: Copper,FEMALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER_GOV,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-01,2023-01-01
RECRUITING,NO,BEHAVIORAL: Exercise Timing Groups,FEMALE,"ADULT, OLDER_ADULT",NA,40,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-07-05,2023-12-31
RECRUITING,NO,PROCEDURE: ICG guided sentinel lymph node biopsy,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-01,2026-04-30
NOT_YET_RECRUITING,NO,"DRUG: Intuzumab, pyrrolidone, nab-paclitaxel",FEMALE,"ADULT, OLDER_ADULT",PHASE2,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-01,2023-12-31
RECRUITING,NO,OTHER: Questionnaires,ALL,ADULT,NA,400,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-11-10,2024-11-01
ACTIVE_NOT_RECRUITING,NO,OTHER: Skin and thickness measurement/breast MRI,FEMALE,"ADULT, OLDER_ADULT",NA,200,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-03-31,2023-12-01
NOT_YET_RECRUITING,NO,"DRUG: Placebo, metformin and atorvastatin",FEMALE,"ADULT, OLDER_ADULT",PHASE4,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-10,2023-09
UNKNOWN,NO,DRUG: Doxorubicin Hydrochloride Liposome Injection,FEMALE,"ADULT, OLDER_ADULT",PHASE1,80,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2021-07-28,2022-04-30
RECRUITING,NO,BIOLOGICAL: RAPA-201 Rapamycin Resistant T Cells|DRUG: Chemotherapy Prior to RAPA-201 Therapy,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,22,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-01,2024-12-31
UNKNOWN,NO,DRUG: GB491+Letrozole,FEMALE,"ADULT, OLDER_ADULT",PHASE1,10,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-02,2024-02-01
COMPLETED,NO,OTHER: Questionnaire Administration|BEHAVIORAL: Telephone-Based Intervention|OTHER: Virtual Technology Intervention,ALL,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-04-20,2023-09-28
RECRUITING,NO,DEVICE: Quiremspheres™,FEMALE,"ADULT, OLDER_ADULT",NA,13,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-10-19,2026-01-19
TERMINATED,NO,OTHER: 2 FES-PET Imaging will be performed:,FEMALE,"ADULT, OLDER_ADULT",NA,4,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-08-28,2021-07-09
RECRUITING,NO,DRUG: ABBV-400,ALL,"ADULT, OLDER_ADULT",PHASE1,220,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-09,2026-07-20
RECRUITING,NO,BIOLOGICAL: Pelareorep|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|BIOLOGICAL: Retifanlimab,FEMALE,"ADULT, OLDER_ADULT",PHASE2,25,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-13,2024-09-30
WITHDRAWN,NO,DRUG: Trifluridine/Tipiracil,ALL,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02,2020-06-09
RECRUITING,NO,"DRUG: Fosaprepitant , Tropisetron and Olanzapine|DRUG: Fosaprepitant , Tropisetron, Dexamethasone and Olanzapine",ALL,"ADULT, OLDER_ADULT",PHASE3,403,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-01,2024-06-01
RECRUITING,NO,DRUG: Afimoxifene|PROCEDURE: Core Biopsy|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",PHASE2,156,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-17,2024-06-25
RECRUITING,NO,BIOLOGICAL: GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,500,INDUSTRY,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-13,2025-08-12
RECRUITING,NO,DRUG: Cyclophosphamide|BIOLOGICAL: Neoantigen Peptide Vaccine|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Sargramostim,ALL,"ADULT, OLDER_ADULT",PHASE1,36,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-31,2026-02-24
RECRUITING,NO,COMBINATION_PRODUCT: X-PACT,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-08,2025-08
RECRUITING,NO,DRUG: Tranexamic Acid|OTHER: Saline,FEMALE,"ADULT, OLDER_ADULT",PHASE4,150,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-04-20,2024-09-30
RECRUITING,NO,DRUG: NX-1607|DRUG: Paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE1,345,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-29,2026-02-28
NOT_YET_RECRUITING,NO,DRUG: ANG1005|DRUG: Physician's Best Choice,ALL,"ADULT, OLDER_ADULT",PHASE3,150,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12,2024-12
RECRUITING,NO,RADIATION: adjuvant hypofractionated intensity-modulated proton radiotherapy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,67,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-01-10,2028-09-01
ACTIVE_NOT_RECRUITING,NO,DRUG: Tamoxifen 20 mg,FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04-04,2023-03-01
UNKNOWN,NO,DEVICE: IPC NET,ALL,OLDER_ADULT,NA,119,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-12-30,2023-12-30
COMPLETED,NO,OTHER: Ultrasound guided bi-level erector spinae plane block|OTHER: Ultrasound guided modified pectoral nerve block,FEMALE,"ADULT, OLDER_ADULT",NA,70,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2020-01-01,2021-01-15
RECRUITING,NO,OTHER: Educational Intervention|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|OTHER: Control Intervention,FEMALE,ADULT,NA,30,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-08-01,2023-09-30
RECRUITING,NO,OTHER: Availability of clinical decision support based on pharmacogenomic results.,ALL,"ADULT, OLDER_ADULT",NA,860,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2022-02-07,2028-03-31
COMPLETED,NO,OTHER: Video + Chatbot|OTHER: Video + Paper|OTHER: Paper + Chatbot|OTHER: Paper + Paper,FEMALE,"ADULT, OLDER_ADULT",NA,148,OTHER,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2022-04-18,2023-04-18
COMPLETED,NO,DRUG: Definity Suspension for Injection,ALL,"ADULT, OLDER_ADULT",PHASE1,20,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-07-22,2023-06-21
RECRUITING,NO,DRUG: Sacituzumab Govitecan|DRUG: Trastuzumab|DRUG: Trastuzumab and Hyaluronidase-oysk,ALL,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-04,2027-11-30
RECRUITING,NO,RADIATION: Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients),FEMALE,"ADULT, OLDER_ADULT",NA,148,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-15,2026-09-15
COMPLETED,NO,DRUG: Mirdametinib|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,6,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-14,2023-10-26
ENROLLING_BY_INVITATION,NO,DEVICE: Mobile Mammography Unit,FEMALE,"ADULT, OLDER_ADULT",NA,91982,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2022-02-14,2024-09
COMPLETED,YES,OTHER: Aerobic Exercise Intervention|OTHER: Resistance Exercise Intervention|OTHER: Exercise Intervention: Digital copies and outline of sessions|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment,FEMALE,"ADULT, OLDER_ADULT",NA,27,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2022-01-05,2022-11-10
RECRUITING,NO,DRUG: SNS-101 (anti-VISTA)|DRUG: Cemiplimab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,169,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-31,2027-06
NOT_YET_RECRUITING,NO,DRUG: Lutetium Lu 177 Dotatate,ALL,"ADULT, OLDER_ADULT",PHASE2,10,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-01,2023-12-20
RECRUITING,NO,DRUG: Tucatinib|DRUG: Eribulin|DRUG: Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE2,30,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-17,2025-05-26
COMPLETED,NO,DRUG: IFNα-2a,FEMALE,"ADULT, OLDER_ADULT",PHASE1,21,OTHER,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-06,2021-07-14
NOT_YET_RECRUITING,NO,DRUG: Letrozole|DRUG: Anastrozole|DRUG: Exemestane|DRUG: Tamoxifen,FEMALE,"ADULT, OLDER_ADULT",PHASE3,3832,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-05-02,2035-05-02
WITHDRAWN,NO,DRUG: Bevacizumab-IRDye800CW,MALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06,2023-03
RECRUITING,NO,BEHAVIORAL: Cognitive remediation program,FEMALE,"ADULT, OLDER_ADULT",NA,24,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-17,2025-07-17
RECRUITING,NO,DRUG: Trastuzumab Pyrotinib Exemestane Dalpiciclib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-01,2024-12
RECRUITING,NO,RADIATION: Ten-fraction hypofractionated breast radiotherapy with 40 Gy simultaneous integrated bed boost|RADIATION: Ten-fraction hypofractionated breast radiotherapy with 43 Gy simultaneous integrated bed boost,FEMALE,"ADULT, OLDER_ADULT",PHASE2,180,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-01,2025-01-01
RECRUITING,NO,BIOLOGICAL: CRX100 suspension for infusion|COMBINATION_PRODUCT: Fludarabine|COMBINATION_PRODUCT: Cyclophosphamide,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-01-08,2026-10
RECRUITING,NO,DRUG: Recombinant oncolytic herpes simplex virus type 1 (R130),ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,20,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-02,2026-03-02
RECRUITING,NO,PROCEDURE: Serratus Anterior Plane Block with local anesthetic|PROCEDURE: Serratus Anterior Plane Block with saline solution,FEMALE,"ADULT, OLDER_ADULT",NA,94,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-08-01,2023-07-31
RECRUITING,NO,DRUG: NGM831|DRUG: NGM831 plus pembrolizumab (KEYTRUDA®)|DRUG: NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®),ALL,"ADULT, OLDER_ADULT",PHASE1,130,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-31,2026-03
RECRUITING,NO,PROCEDURE: Surgery|RADIATION: Radiotherapy|OTHER: Radiofrequent ablation,ALL,"ADULT, OLDER_ADULT",PHASE2,118,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-04-17,2040-04-01
RECRUITING,NO,OTHER: Best Practice|RADIATION: Stereotactic Body Radiation Therapy|PROCEDURE: Sentinel Lymph Node Biopsy|OTHER: Questionnaire Administration|OTHER: Quality-of-Life Assessment|PROCEDURE: Resection|OTHER: Dietary Intervention,ALL,"ADULT, OLDER_ADULT",PHASE2,80,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-08-23,2026-01-01
NOT_YET_RECRUITING,NO,DRUG: Hormonal Antineoplastics|DRUG: Chemotherapy drug,FEMALE,"ADULT, OLDER_ADULT",PHASE1,100,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-04-01,2025-08-01
RECRUITING,NO,DRUG: Mitoxantrone Hydrochloride Liposome Injection,ALL,"ADULT, OLDER_ADULT",PHASE2,73,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-11,2024-05-30
NOT_YET_RECRUITING,NO,DRUG: Ribociclib|DRUG: Letrozole|DRUG: Ansastrozole|DRUG: Goserelin|DRUG: Leuprolide|DRUG: Exemestane,ALL,"ADULT, OLDER_ADULT",PHASE3,3100,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-04-10,2030-09-20
RECRUITING,NO,DRUG: Tamoxifen,FEMALE,"ADULT, OLDER_ADULT",PHASE4,100,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-01,2024-02-28
COMPLETED,NO,DRUG: Cannabidiol (CBD),FEMALE,"ADULT, OLDER_ADULT",PHASE2,40,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-04-16,2023-10-10
RECRUITING,NO,DRUG: Sacituzumab Govitecan-hziy|DRUG: Paclitaxel|DRUG: nab-Paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin,ALL,"ADULT, OLDER_ADULT",PHASE3,540,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-20,2027-05
RECRUITING,NO,DRUG: Camrelizumab|DRUG: Fluzoparib|DRUG: Nab-paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE2,66,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-05-06,2028-12-31
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Behavioral Intervention|BEHAVIORAL: Behavioral Intervention|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-11-01,2024-12-31
RECRUITING,NO,"OTHER: Manual Therapy, Physiotherapy, Kinesiology, Scar Massage|OTHER: Kinesiotherapy, Physiotherapy, Health Education",ALL,"ADULT, OLDER_ADULT",NA,46,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2021-12-01,2023-12-04
COMPLETED,NO,PROCEDURE: PECS II|PROCEDURE: Local anesthetic infiltration|PROCEDURE: Subcutaneus local anesthetic infiltration|DRUG: Ropivacaine|DEVICE: bk medical Flex Focus 500 Ultrasound Machine,FEMALE,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-02-19,2022-05-01
RECRUITING,NO,PROCEDURE: Sentinel Lymph Node Biopsy (SLNB)|DRUG: Doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Tumor-draining lymph node-derived lymphocyte (LNL)|BIOLOGICAL: Interleukin-2|DRUG: Nab-paclitaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE1,24,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-01,2031-08-31
NOT_YET_RECRUITING,NO,DEVICE: C02 microablative laser|COMBINATION_PRODUCT: Regenerative topical treatment,FEMALE,"ADULT, OLDER_ADULT",NA,98,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-12,2026-01
RECRUITING,NO,OTHER: antihypertensive medications|DIAGNOSTIC_TEST: Blood pressure measurement|DIAGNOSTIC_TEST: Echocardiogram|OTHER: Symptom-limited cardiopulmonary exercise test|OTHER: Quality of Life Measures|DIAGNOSTIC_TEST: Biomarkers,FEMALE,"ADULT, OLDER_ADULT",PHASE2,130,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-08-18,2027-08-18
NOT_YET_RECRUITING,NO,DRUG: Niraparib Oral Product,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,72,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03,2027-12
NOT_YET_RECRUITING,NO,DRUG: Nab-paclitaxel in combination with pyrotinib,FEMALE,"ADULT, OLDER_ADULT",PHASE2,261,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01,2025-06
ACTIVE_NOT_RECRUITING,NO,DRUG: Inavolisib|DRUG: Placebo|DRUG: Palbociclib|DRUG: Fulvestrant,ALL,"ADULT, OLDER_ADULT",PHASE3,325,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-01-29,2030-09-30
RECRUITING,NO,PROCEDURE: TiLoop Bra mesh in expander-implant breast reconstrution|PROCEDURE: sub-pectoral expander-implant breast reconstruction,FEMALE,"ADULT, OLDER_ADULT",NA,300,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-01,2026-08-01
COMPLETED,NO,BEHAVIORAL: Psychosexual Educational Partner Program (PEPP),FEMALE,"ADULT, OLDER_ADULT",NA,18,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-03-15,2022-08-29
WITHDRAWN,NO,DRUG: Abemaciclib|DRUG: Palbociclib|OTHER: Quality-of-Life Assessment|DRUG: Ribociclib,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,0,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-06-12,2021-09-13
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Telementoring with Practice Facilitation,ALL,"ADULT, OLDER_ADULT",NA,400,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-11-18,2024-07
RECRUITING,NO,DRUG: Ixabepilone Injection,ALL,"ADULT, OLDER_ADULT",PHASE2,60,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2025-11-01
RECRUITING,NO,DEVICE: BEAUTIFY application,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-07-25,2024-07
RECRUITING,NO,DRUG: Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)|DRUG: Eribulin Mesylate,FEMALE,"ADULT, OLDER_ADULT",PHASE2,180,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-18,2025-12-31
NOT_YET_RECRUITING,NO,DRUG: palbociclib combined with letrozole|DRUG: epirubicin combined with cyclophosphamide and sequential docetaxel,FEMALE,"ADULT, OLDER_ADULT",PHASE4,152,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-07-19,2026-05-31
COMPLETED,NO,OTHER: Somatic Acupressure|OTHER: Sham acupressure|OTHER: Usual care,FEMALE,"ADULT, OLDER_ADULT",NA,51,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-03-15,2022-07-20
TERMINATED,NO,DRUG: DUAVEE 0.45Mg-20Mg Tablet,FEMALE,ADULT,EARLY_PHASE1,11,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-06-01,2021-07-31
RECRUITING,NO,DRUG: SON-DP,ALL,"ADULT, OLDER_ADULT",PHASE1,150,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-09-19,2026-03
NOT_YET_RECRUITING,NO,DRUG: Trastuzumab deruxtecan (T-DXd) with pyrotinib,ALL,"ADULT, OLDER_ADULT",PHASE4,51,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-01-30,2026-12-01
RECRUITING,NO,DRUG: Herzuma,ALL,"ADULT, OLDER_ADULT",PHASE2,59,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-01,2027-03-30
RECRUITING,NO,DRUG: Olaparib|RADIATION: Stereotactic Radiosurgery|DRUG: Durvalumab|DRUG: Physicians Choice systemic chemotherapy,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,41,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-09,2026-09
RECRUITING,NO,DRUG: RP-6306|DRUG: Gemcitabine|OTHER: Observation|DRUG: Niraparib|DRUG: Fulvestrant,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,484,NETWORK,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-13,2028-06
NOT_YET_RECRUITING,NO,DEVICE: Transcutaneous Electrical Nerve Stimulation,ALL,"ADULT, OLDER_ADULT",NA,86,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-07-01,2024-04-22
RECRUITING,NO,OTHER: Audiovisual Intervention- Radiation Therapy Education|OTHER: ASTRO Radiation Therapy for Breast or Prostate Cancer Brochure|OTHER: Audiovisual Intervention- Cancer Clinical Trials Education|OTHER: NCI Taking Part in Cancer Research Studies Brochure,ALL,"ADULT, OLDER_ADULT",NA,240,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2022-05-03,2026-12-31
RECRUITING,NO,OTHER: ATENTO-B|OTHER: ATENTO-T,FEMALE,"ADULT, OLDER_ADULT",NA,56,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-09-30,2025-09-30
RECRUITING,NO,DRUG: Giredestrant|DRUG: Exemestane|DRUG: Fulvestrant|DRUG: Tamoxifen|DRUG: Everolimus|DRUG: LHRH Agonist|DRUG: Dexamethasone Mouth Rinse,ALL,"ADULT, OLDER_ADULT",PHASE3,320,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-03,2026-03-31
RECRUITING,NO,DEVICE: low-level light therapy,FEMALE,"ADULT, OLDER_ADULT",NA,106,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-17,2025-12-31
NOT_YET_RECRUITING,NO,DRUG: SHR-A1811|DRUG: Trastuzumab Emtansine,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1200,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11,2032-04
COMPLETED,NO,DRUG: Olaparib,FEMALE,"ADULT, OLDER_ADULT",PHASE4,162,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-30,2022-09-30
RECRUITING,NO,DRUG: ACE1702|DRUG: Cyclophosphamide|DRUG: Fludarabine,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-19,2024-06
UNKNOWN,NO,DEVICE: Treadmill|OTHER: resisted exercises,FEMALE,ADULT,NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-12-12,2021-04-01
RECRUITING,NO,DRUG: Intravenous injection of [99mTc]Tc-DB8,ALL,"ADULT, OLDER_ADULT",PHASE1,10,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2023-07-03,2024-02-01
RECRUITING,NO,DEVICE: Adjustable Compression Wrap|DEVICE: Compression Bandage,FEMALE,"ADULT, OLDER_ADULT",NA,72,OTHER_GOV,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-07-01,2023-12-31
COMPLETED,NO,PROCEDURE: paravertebral block|DRUG: opioid free anesthesia|PROCEDURE: sham block|PROCEDURE: opioid general anesthesia,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-01,2022-03-15
NOT_YET_RECRUITING,NO,DRUG: OB-002,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-01,2025-08
ACTIVE_NOT_RECRUITING,NO,DRUG: AN0025|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,63,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-20,2025-11-28
NOT_YET_RECRUITING,NO,"DRUG: elacestrant, palbociclib, abemaciclib, ribociclib",ALL,"ADULT, OLDER_ADULT",PHASE2,174,OTHER,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09-30,2025-07-01
NOT_YET_RECRUITING,NO,BIOLOGICAL: pharmacokinetics blood sample assessment,FEMALE,"ADULT, OLDER_ADULT",NA,48,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-05-30,2026-05-02
RECRUITING,NO,OTHER: num Vapocoolant,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-03-01,2025-04-30
RECRUITING,NO,DRUG: Phesgo|DRUG: Giredestrant|DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: LHRH Agonist|DRUG: Optional Endocrine Therapy of Investigator's Choice,ALL,"ADULT, OLDER_ADULT",PHASE3,812,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-04,2032-09-30
COMPLETED,NO,DRUG: MagTrace only|COMBINATION_PRODUCT: MagTrace and Magseed,FEMALE,"ADULT, OLDER_ADULT",NA,80,OTHER_GOV,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-10-01,2023-11-28
NOT_YET_RECRUITING,NO,OTHER: System implementation of patient-centered incidental findings report,ALL,"ADULT, OLDER_ADULT",NA,300,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2024-10,2029-03
RECRUITING,NO,DRUG: Pioglitazone,FEMALE,"ADULT, OLDER_ADULT",EARLY_PHASE1,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-25,2027-12-31
RECRUITING,NO,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|OTHER: Electronic Health Record Review|PROCEDURE: Magnetic Resonance Imaging|DRUG: Paclitaxel|RADIATION: Radium Ra 223 Dichloride|PROCEDURE: Single Photon Emission Computed Tomography,ALL,"ADULT, OLDER_ADULT",PHASE2,70,NIH,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-04,2024-06-30
RECRUITING,NO,BEHAVIORAL: Virtual Cancer and Mental Health Tumor Board,ALL,"ADULT, OLDER_ADULT",NA,30,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-05-31,2024-05-31
RECRUITING,NO,DRUG: Huangqi Guizhi Wuwu decoction (HGWD) infusion packs,FEMALE,"ADULT, OLDER_ADULT",PHASE2,92,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-01,2023-01-01
RECRUITING,NO,BEHAVIORAL: Mindful attention|BEHAVIORAL: Decentering|BEHAVIORAL: Values and committed action,FEMALE,"ADULT, OLDER_ADULT",NA,185,OTHER,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-01,2024-10-01
RECRUITING,NO,BEHAVIORAL: Swimming,ALL,"ADULT, OLDER_ADULT",NA,128,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-01,2025-12-31
RECRUITING,NO,PROCEDURE: Intraoperative CLI + FAR LightPath imaging,FEMALE,"ADULT, OLDER_ADULT",PHASE2,60,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-21,2024-12-31
NOT_YET_RECRUITING,NO,DRUG: Use of Bupivacaine in pectoral nerve block in mastectomy|DRUG: use of Ketamine as adjuvants to bupivacaine in pectoral nerve block in mastectomy|DRUG: Use of Magnesium Sulfate as adjuvants to bupivacaine in pectoral nerve block in mastectomy,FEMALE,"ADULT, OLDER_ADULT",PHASE2,72,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-02,2023-10-01
NOT_YET_RECRUITING,NO,DRUG: DOXIL/CAELYX,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2023-11-30,2024-04-01
RECRUITING,NO,DRUG: AZD9833|DRUG: AZD9833 Placebo|DRUG: Anastrozole|DRUG: Anastrozole placebo|DRUG: Letrozole|DRUG: Letrozole placebo|DRUG: Palbociclib|DRUG: Abemaciclib|DRUG: Luteinizing hormone-releasing hormone (LHRH) agonist|DRUG: Ribociclib,ALL,"ADULT, OLDER_ADULT",PHASE3,300,INDUSTRY,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-06-30,2027-11-26
ACTIVE_NOT_RECRUITING,NO,BEHAVIORAL: Yoga Breathing|BEHAVIORAL: Attention Control,FEMALE,"ADULT, OLDER_ADULT",NA,40,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2021-11-17,2023-06-30
RECRUITING,NO,DRUG: Epirubicin or Pirarubicin|DRUG: Cyclophosphamide,ALL,"ADULT, OLDER_ADULT",PHASE2,286,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02-01,2027-12
COMPLETED,NO,OTHER: Combined exercise training,FEMALE,"ADULT, OLDER_ADULT",NA,12,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-05-01,2021-09-30
RECRUITING,NO,DEVICE: PARASYM neuromodulation device|DEVICE: PARASYM neuromodulation device,ALL,"ADULT, OLDER_ADULT",NA,104,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: OTHER",2023-12-01,2026-09
TERMINATED,NO,DRUG: Niraparib combined with MGD013,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-03,2022-03-02
NOT_YET_RECRUITING,NO,PROCEDURE: implant exchange operation,FEMALE,"ADULT, OLDER_ADULT",NA,136,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12,2024-12
RECRUITING,NO,GENETIC: Polygenetic risk score,FEMALE,ADULT,NA,80,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2023-02,2035-11-11
WITHDRAWN,NO,OTHER: Omit breast radiation,FEMALE,"ADULT, OLDER_ADULT",PHASE2,0,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07,2028-10
WITHDRAWN,NO,"DRUG: Sabizabulin|DRUG: Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator",ALL,"ADULT, OLDER_ADULT",PHASE2,0,INDUSTRY,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-03-15,2024-05-26
RECRUITING,NO,BEHAVIORAL: CALM|BEHAVIORAL: Treatment as usual,ALL,"ADULT, OLDER_ADULT",NA,60,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-11-10,2025-07-31
COMPLETED,NO,DIETARY_SUPPLEMENT: Melatonin,FEMALE,"ADULT, OLDER_ADULT",NA,56,OTHER,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-01-01,2022-05-31
RECRUITING,NO,DRUG: TT-00420|DRUG: Combination Product: Atezolizumab|DRUG: Combination Product: Nab-Paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,114,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-13,2024-12
NOT_YET_RECRUITING,NO,DRUG: ARX788|PROCEDURE: Computed Tomography (CT)|PROCEDURE: Biospecimen Collection,ALL,"ADULT, OLDER_ADULT",PHASE2,36,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-03-01,2028-07-31
ACTIVE_NOT_RECRUITING,NO,DRUG: Tucatinib,ALL,"ADULT, OLDER_ADULT",PHASE1,25,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-29,2025-12-29
TERMINATED,YES,DRUG: SM-88,ALL,"ADULT, OLDER_ADULT",PHASE2,11,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-22,2023-02-10
RECRUITING,NO,BEHAVIORAL: Aerobic Training Group|BEHAVIORAL: Resistance Training Group|OTHER: Control group,FEMALE,"ADULT, OLDER_ADULT",NA,132,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-12-16,2024-04-30
RECRUITING,NO,DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: PRGN-3007,ALL,"ADULT, OLDER_ADULT",PHASE1,88,OTHER,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-01-25,2026-01
RECRUITING,NO,DRUG: AK117|DRUG: AK112|DRUG: Nab paclitaxel|DRUG: paclitaxel,ALL,"ADULT, OLDER_ADULT",PHASE2,80,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-23,2023-10-30
RECRUITING,NO,DRUG: Elacestrant|DRUG: Tamoxifen|DRUG: Letrozole 2.5mg|DRUG: Anastrozole 1mg|DRUG: Exemestane 25 MG,ALL,"ADULT, OLDER_ADULT",PHASE3,220,NETWORK,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-12-15,2030-05-01
RECRUITING,NO,BIOLOGICAL: Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein,ALL,"ADULT, OLDER_ADULT",PHASE1,33,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-23,2024-08-15
UNKNOWN,NO,DIAGNOSTIC_TEST: self-rating scale for severity of sleep disorders|DIAGNOSTIC_TEST: self-rating scale for distress caused by sleep disorders,FEMALE,"ADULT, OLDER_ADULT",NA,51,OTHER,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-06-01,2022-06-30
RECRUITING,NO,DRUG: Alpha-tocopheryloxyacetic Acid|BIOLOGICAL: Trastuzumab,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INDUSTRY,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-04-08,2025-02-01
RECRUITING,NO,RADIATION: Active Comparator: Standard|RADIATION: Experimental 1: Hypofractionated radiotherapy|RADIATION: Experimental 2: Accelerated Partial Breast Irradiation,FEMALE,"ADULT, OLDER_ADULT",NA,36,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-04,2026-12-31
RECRUITING,NO,DRUG: trifluridine/tipiracil,FEMALE,"ADULT, OLDER_ADULT",PHASE2,50,NETWORK,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-25,2024-07
RECRUITING,NO,RADIATION: Proton Beam Radiation Therapy|OTHER: Questionnaire Administration|RADIATION: X-ray Therapy,FEMALE,"ADULT, OLDER_ADULT",PHASE3,146,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-06-15,2024-06-01
ACTIVE_NOT_RECRUITING,NO,DRUG: AZD8701|BIOLOGICAL: Durvalumab,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INDUSTRY,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-18,2023-12-15
RECRUITING,NO,BEHAVIORAL: Health Education,FEMALE,"ADULT, OLDER_ADULT",NA,28,OTHER,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2023-07-01,2023-12-30
